Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,14667957,Css,"The mean (SD) Css of eptifibatide was essentially identical when it was coadministered with either UFH or enoxaparin (1640 [227] ng/mL and 1610 (229) ng/mL, respectively).",Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14667957/),[ng] / [ml],1640,1032,DB01109,Heparin
,14667957,Css,"The mean (SD) Css of eptifibatide was essentially identical when it was coadministered with either UFH or enoxaparin (1640 [227] ng/mL and 1610 (229) ng/mL, respectively).",Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14667957/),[ng] / [ml],1610,1033,DB01109,Heparin
,2847825,recovery,Low molecular weight heparin (Mr 8 kDa) was prepared from conventional heparin (Mr 18 kDa) by the chromatography on DEAE-sephadex with the recovery of 56%.,[Anticoagulant and antithrombotic effects of low molecular weight heparin]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2847825/),%,56,1733,DB01109,Heparin
,11680668,oral clearance (CL),"The population estimates and 90% confidence intervals (CI) for oral clearance (CL) and apparent volume of distribution of the plasma compartment (Vc) were 0.0176 l/h/kg (CI = 0.012-0.023) and 0.098 l/kg (CI = 0.088 - 0.109), respectively.",Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11680668/),[l] / [h·kg],0.0176,2486,DB01109,Heparin
,11680668,apparent volume of distribution of the plasma compartment (Vc),"The population estimates and 90% confidence intervals (CI) for oral clearance (CL) and apparent volume of distribution of the plasma compartment (Vc) were 0.0176 l/h/kg (CI = 0.012-0.023) and 0.098 l/kg (CI = 0.088 - 0.109), respectively.",Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11680668/),[l] / [kg],0.098,2487,DB01109,Heparin
,11680668,elimination half-life,The elimination half-life was 3.9 h (CI = 2.5-5.2).,Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11680668/),h,3.9,2488,DB01109,Heparin
,7495071,CL/F,The apparent total body clearance of enoxaparin doses (CL/F = 16.7 +/- 5.5 and 13.8 +/- 3.2 ml/min) is significantly smaller than those of nadroparin (CL/F = 21.4 +/- 7.0 ml/min; p < 0.01) and dalteparin (CL/F = 33.3 +/- 11.8 ml/min; p < 0.001) while dalteparin apparent clearance is about 1.5-fold greater (p < 0.001) than that of nadroparin.,"Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7495071/),[ml] / [min],16.7,3377,DB01109,Heparin
,7495071,CL/F,The apparent total body clearance of enoxaparin doses (CL/F = 16.7 +/- 5.5 and 13.8 +/- 3.2 ml/min) is significantly smaller than those of nadroparin (CL/F = 21.4 +/- 7.0 ml/min; p < 0.01) and dalteparin (CL/F = 33.3 +/- 11.8 ml/min; p < 0.001) while dalteparin apparent clearance is about 1.5-fold greater (p < 0.001) than that of nadroparin.,"Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7495071/),[ml] / [min],13.8,3378,DB01109,Heparin
,7495071,CL/F,The apparent total body clearance of enoxaparin doses (CL/F = 16.7 +/- 5.5 and 13.8 +/- 3.2 ml/min) is significantly smaller than those of nadroparin (CL/F = 21.4 +/- 7.0 ml/min; p < 0.01) and dalteparin (CL/F = 33.3 +/- 11.8 ml/min; p < 0.001) while dalteparin apparent clearance is about 1.5-fold greater (p < 0.001) than that of nadroparin.,"Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7495071/),[ml] / [min],21.4,3379,DB01109,Heparin
,7495071,CL/F,The apparent total body clearance of enoxaparin doses (CL/F = 16.7 +/- 5.5 and 13.8 +/- 3.2 ml/min) is significantly smaller than those of nadroparin (CL/F = 21.4 +/- 7.0 ml/min; p < 0.01) and dalteparin (CL/F = 33.3 +/- 11.8 ml/min; p < 0.001) while dalteparin apparent clearance is about 1.5-fold greater (p < 0.001) than that of nadroparin.,"Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7495071/),[ml] / [min],33.3,3380,DB01109,Heparin
,7495071,apparent elimination half life t1/2,These differences in the disposition profiles explain why the apparent elimination half life t1/2 values of the LMMHs compared here are different: dalteparin: 2.8 h; nadroparin: 3.7 h; and enoxaparin: 4.1 h.,"Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7495071/),h,2.8,3381,DB01109,Heparin
,7495071,apparent elimination half life t1/2,These differences in the disposition profiles explain why the apparent elimination half life t1/2 values of the LMMHs compared here are different: dalteparin: 2.8 h; nadroparin: 3.7 h; and enoxaparin: 4.1 h.,"Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7495071/),h,3.7,3382,DB01109,Heparin
,7495071,apparent elimination half life t1/2,These differences in the disposition profiles explain why the apparent elimination half life t1/2 values of the LMMHs compared here are different: dalteparin: 2.8 h; nadroparin: 3.7 h; and enoxaparin: 4.1 h.,"Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7495071/),h,4.1,3383,DB01109,Heparin
,28375032,T1/2,"The T1/2 of reference and test were 2.88 ± 1.21 h and 2.76 ± 0.97 h for Anti-Xa, 1.87 ± 0.62 h and 1.96 ± 1.52 h for Anti-IIa.",Pharmacodynamic properties and bioequivalence of dalteparin sodium subcutaneous injection in healthy Chinese male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375032/),h,2.88,4723,DB01109,Heparin
,28375032,T1/2,"The T1/2 of reference and test were 2.88 ± 1.21 h and 2.76 ± 0.97 h for Anti-Xa, 1.87 ± 0.62 h and 1.96 ± 1.52 h for Anti-IIa.",Pharmacodynamic properties and bioequivalence of dalteparin sodium subcutaneous injection in healthy Chinese male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375032/),h,2.76,4724,DB01109,Heparin
,28375032,T1/2,"The T1/2 of reference and test were 2.88 ± 1.21 h and 2.76 ± 0.97 h for Anti-Xa, 1.87 ± 0.62 h and 1.96 ± 1.52 h for Anti-IIa.",Pharmacodynamic properties and bioequivalence of dalteparin sodium subcutaneous injection in healthy Chinese male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375032/),h,1.87,4725,DB01109,Heparin
,28375032,T1/2,"The T1/2 of reference and test were 2.88 ± 1.21 h and 2.76 ± 0.97 h for Anti-Xa, 1.87 ± 0.62 h and 1.96 ± 1.52 h for Anti-IIa.",Pharmacodynamic properties and bioequivalence of dalteparin sodium subcutaneous injection in healthy Chinese male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375032/),h,1.96,4726,DB01109,Heparin
,17851145,recovery,The average recovery of gaboxadol was about 87% and the ion suppression was approximately 8%.,Development and validation of a selective and sensitive bioanalytical procedure for the quantitative determination of gaboxadol in human plasma employing mixed mode solid phase extraction and hydrophilic interaction liquid chromatography with tandem mass spectroscopic detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17851145/),%,87,4875,DB01109,Heparin
,17851145,ion suppression,The average recovery of gaboxadol was about 87% and the ion suppression was approximately 8%.,Development and validation of a selective and sensitive bioanalytical procedure for the quantitative determination of gaboxadol in human plasma employing mixed mode solid phase extraction and hydrophilic interaction liquid chromatography with tandem mass spectroscopic detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17851145/),%,8,4876,DB01109,Heparin
,28973394,half-life,"The HEP polysaccharide was stable with a long half-life (~8 days for 99-kDa chain) in the nonhuman primate bloodstream, but was efficiently degraded to very short oligosaccharides when internalized by cells, and then excreted into urine and feces.",Synthesis and characterization of heparosan-granulocyte-colony stimulating factor conjugates: a natural sugar-based drug delivery system to treat neutropenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28973394/),d,8,5189,DB01109,Heparin
,3710290,half-life,Unfractionated heparin was cleared after intravenous administration with a half-life of 35 min irrespective of assay method.,Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710290/),min,35,6050,DB01109,Heparin
,3710290,half-life,"However, the concentration of PK 10169 declined with the longer half-life of 60 min, and its anti-IIa and anti-Xa activities had half-lives of 40 and 275 min, respectively.",Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710290/),min,60,6051,DB01109,Heparin
,3710290,half-lives,"However, the concentration of PK 10169 declined with the longer half-life of 60 min, and its anti-IIa and anti-Xa activities had half-lives of 40 and 275 min, respectively.",Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710290/),min,40,6052,DB01109,Heparin
,3710290,half-lives,"However, the concentration of PK 10169 declined with the longer half-life of 60 min, and its anti-IIa and anti-Xa activities had half-lives of 40 and 275 min, respectively.",Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710290/),min,275,6053,DB01109,Heparin
,12357518,plasma anti-Xa activity,"Mean plasma anti-Xa activity (units/ml) 10 min and 2, 4, 6, and 8 hr after IV dose was 2.29 +/- 0.39, 0.99 +/- 0.29, 0.58 +/- 0.14, 0.36 +/- 0.13, 0.24 +/- 0.11, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),[units] / [ml],2.29,6705,DB01109,Heparin
,12357518,plasma anti-Xa activity,"Mean plasma anti-Xa activity (units/ml) 10 min and 2, 4, 6, and 8 hr after IV dose was 2.29 +/- 0.39, 0.99 +/- 0.29, 0.58 +/- 0.14, 0.36 +/- 0.13, 0.24 +/- 0.11, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),[units] / [ml],0.99,6706,DB01109,Heparin
,12357518,plasma anti-Xa activity,"Mean plasma anti-Xa activity (units/ml) 10 min and 2, 4, 6, and 8 hr after IV dose was 2.29 +/- 0.39, 0.99 +/- 0.29, 0.58 +/- 0.14, 0.36 +/- 0.13, 0.24 +/- 0.11, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),[units] / [ml],0.58,6707,DB01109,Heparin
,12357518,plasma anti-Xa activity,"Mean plasma anti-Xa activity (units/ml) 10 min and 2, 4, 6, and 8 hr after IV dose was 2.29 +/- 0.39, 0.99 +/- 0.29, 0.58 +/- 0.14, 0.36 +/- 0.13, 0.24 +/- 0.11, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),[units] / [ml],0.36,6708,DB01109,Heparin
,12357518,plasma anti-Xa activity,"Mean plasma anti-Xa activity (units/ml) 10 min and 2, 4, 6, and 8 hr after IV dose was 2.29 +/- 0.39, 0.99 +/- 0.29, 0.58 +/- 0.14, 0.36 +/- 0.13, 0.24 +/- 0.11, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),[units] / [ml],0.24,6709,DB01109,Heparin
,12357518,Plasma anti-Xa activity,"Mean Plasma anti-Xa activity 2, 4, 6, 8, 10, and 12 hr after SC dose was 1.01 +/- 0.22, 1.13 +/- 0.27, 1.1 +/- 0.41, 0.84 +/- 0.19, 0.62 +/- 0.24, and 0.46 +/- 0.21, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,1.01,6710,DB01109,Heparin
,12357518,Plasma anti-Xa activity,"Mean Plasma anti-Xa activity 2, 4, 6, 8, 10, and 12 hr after SC dose was 1.01 +/- 0.22, 1.13 +/- 0.27, 1.1 +/- 0.41, 0.84 +/- 0.19, 0.62 +/- 0.24, and 0.46 +/- 0.21, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,1.13,6711,DB01109,Heparin
,12357518,Plasma anti-Xa activity,"Mean Plasma anti-Xa activity 2, 4, 6, 8, 10, and 12 hr after SC dose was 1.01 +/- 0.22, 1.13 +/- 0.27, 1.1 +/- 0.41, 0.84 +/- 0.19, 0.62 +/- 0.24, and 0.46 +/- 0.21, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,1.1,6712,DB01109,Heparin
,12357518,Plasma anti-Xa activity,"Mean Plasma anti-Xa activity 2, 4, 6, 8, 10, and 12 hr after SC dose was 1.01 +/- 0.22, 1.13 +/- 0.27, 1.1 +/- 0.41, 0.84 +/- 0.19, 0.62 +/- 0.24, and 0.46 +/- 0.21, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,0.84,6713,DB01109,Heparin
,12357518,Plasma anti-Xa activity,"Mean Plasma anti-Xa activity 2, 4, 6, 8, 10, and 12 hr after SC dose was 1.01 +/- 0.22, 1.13 +/- 0.27, 1.1 +/- 0.41, 0.84 +/- 0.19, 0.62 +/- 0.24, and 0.46 +/- 0.21, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,0.62,6714,DB01109,Heparin
,12357518,Plasma anti-Xa activity,"Mean Plasma anti-Xa activity 2, 4, 6, 8, 10, and 12 hr after SC dose was 1.01 +/- 0.22, 1.13 +/- 0.27, 1.1 +/- 0.41, 0.84 +/- 0.19, 0.62 +/- 0.24, and 0.46 +/- 0.21, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,0.46,6715,DB01109,Heparin
,12357518,plasma anti-Xa activity,"Mean plasma anti-Xa activity at the start and end of PCI was 1.27 +/- 0.41 and 1.07 +/- 0.42, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,1.27,6716,DB01109,Heparin
,12357518,plasma anti-Xa activity,"Mean plasma anti-Xa activity at the start and end of PCI was 1.27 +/- 0.41 and 1.07 +/- 0.42, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,1.07,6717,DB01109,Heparin
,11979349,heart rate,"There was a declining trend for FBV (0.8 mL/h), heart rate (0.25 beats/min/h), and measured blood flow (0.33 mL/min/h; P < 0.05).",Dialyzer fiber bundle volume and kinetics of solute removal in continuous venovenous hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11979349/),[beats] / [h·min],0.25,6752,DB01109,Heparin
,11979349,blood flow,"There was a declining trend for FBV (0.8 mL/h), heart rate (0.25 beats/min/h), and measured blood flow (0.33 mL/min/h; P < 0.05).",Dialyzer fiber bundle volume and kinetics of solute removal in continuous venovenous hemodialysis. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11979349/),[ml] / [h·min],0.33,6753,DB01109,Heparin
,20563583,area under the plasma concentration versus time curve (AUC),"Glomerular filtration rate was considered to be 0, and the target area under the plasma concentration versus time curve (AUC) was 4 (carboplatin dose, 100 mg) for patient 1 and 5 (125 mg) for patient 2.",Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20563583/),,4,6985,DB01109,Heparin
,20563583,area under the plasma concentration versus time curve (AUC),"Glomerular filtration rate was considered to be 0, and the target area under the plasma concentration versus time curve (AUC) was 4 (carboplatin dose, 100 mg) for patient 1 and 5 (125 mg) for patient 2.",Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20563583/),,5,6986,DB01109,Heparin
,20563583,AUCs,"The AUCs in patients 1 and 2 were 4.7 and 6.1 (mg/ml min), which were about 20% higher than the target values (4 and 5 mg/ml min, respectively).",Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20563583/),[mg] / [min·ml],4.7,6987,DB01109,Heparin
,20563583,AUCs,"The AUCs in patients 1 and 2 were 4.7 and 6.1 (mg/ml min), which were about 20% higher than the target values (4 and 5 mg/ml min, respectively).",Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20563583/),[mg] / [min·ml],6.1,6988,DB01109,Heparin
,20563583,AUCs,"The AUCs in patients 1 and 2 were 4.7 and 6.1 (mg/ml min), which were about 20% higher than the target values (4 and 5 mg/ml min, respectively).",Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20563583/),[mg] / [min·ml],4,6989,DB01109,Heparin
,20563583,AUCs,"The AUCs in patients 1 and 2 were 4.7 and 6.1 (mg/ml min), which were about 20% higher than the target values (4 and 5 mg/ml min, respectively).",Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20563583/),[mg] / [min·ml],5,6990,DB01109,Heparin
,20563583,AUCs,"In the absence of hemodialysis, the hypothetical AUCs were 6.2 and 7.6 (mg/ml min), respectively.",Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20563583/),[mg] / [min·ml],6.2,6991,DB01109,Heparin
,20563583,AUCs,"In the absence of hemodialysis, the hypothetical AUCs were 6.2 and 7.6 (mg/ml min), respectively.",Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20563583/),[mg] / [min·ml],7.6,6992,DB01109,Heparin
,20563583,body clearances,"The pre-dialysis body clearances of carboplatin were 16.1 and 16.5 ml/min, with elimination half-lives of 17.5 and 13.8 h, respectively.",Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20563583/),[ml] / [min],16.1,6993,DB01109,Heparin
,20563583,body clearances,"The pre-dialysis body clearances of carboplatin were 16.1 and 16.5 ml/min, with elimination half-lives of 17.5 and 13.8 h, respectively.",Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20563583/),[ml] / [min],16.5,6994,DB01109,Heparin
,20563583,elimination half-lives,"The pre-dialysis body clearances of carboplatin were 16.1 and 16.5 ml/min, with elimination half-lives of 17.5 and 13.8 h, respectively.",Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20563583/),h,17.5,6995,DB01109,Heparin
,20563583,elimination half-lives,"The pre-dialysis body clearances of carboplatin were 16.1 and 16.5 ml/min, with elimination half-lives of 17.5 and 13.8 h, respectively.",Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20563583/),h,13.8,6996,DB01109,Heparin
,4024029,half-life,The half-life of heparin activity was about 1 hr for UFH and about 2 hr for LMWH.,A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024029/),h,1,7832,DB01109,Heparin
,4024029,half-life,The half-life of heparin activity was about 1 hr for UFH and about 2 hr for LMWH.,A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024029/),h,2,7833,DB01109,Heparin
,14668419,half-life,"It has a linear pharmacokinetic profile, and its half-life of approximately 17 h allows for once-daily dosing.",New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14668419/),h,17,8614,DB01109,Heparin
,11304894,distribution t1/2,rFGF-2 displayed biphasic elimination with a mean studywide distribution t1/2 of 21 minutes and a mean apparent terminal elimination t1/2 of 7.6 hours.,Pharmacokinetics and pharmacodynamics of recombinant FGF-2 in a phase I trial in coronary artery disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304894/),min,21,10111,DB01109,Heparin
,11304894,apparent terminal elimination t1/2,rFGF-2 displayed biphasic elimination with a mean studywide distribution t1/2 of 21 minutes and a mean apparent terminal elimination t1/2 of 7.6 hours.,Pharmacokinetics and pharmacodynamics of recombinant FGF-2 in a phase I trial in coronary artery disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304894/),h,7.6,10112,DB01109,Heparin
,9748709,elimination of half-life,The elimination of half-life of DAS was 9.90 h and was 6.0 times longer than that of DLS and 16.5 times longer than that of heparin.,"Pharmacokinetics of danaparoid sodium, dalteparin sodium and heparin determined by inhibitory effect on the activated coagulation factor X activity after single intravenous administration in rabbits. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748709/),h,9.90,10669,DB01109,Heparin
,9748709,area under the plasma concentration-time curve (AUC),The area under the plasma concentration-time curve (AUC) of DAS was 47.13 +/- 14.55 anti-Xa U.h/ml and was 2.4 times larger than that of DLS and 2.9 times larger than that of heparin.,"Pharmacokinetics of danaparoid sodium, dalteparin sodium and heparin determined by inhibitory effect on the activated coagulation factor X activity after single intravenous administration in rabbits. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748709/),[h·u] / [ml],47.13,10670,DB01109,Heparin
,9748709,urinary cumulative excretion,"The urinary cumulative excretion of anti-Xa activity of DAS and DLS was 42.6 +/- 6.4% and 16.4 +/- 0.8% of dose, respectively, in 24 h after dosing, respectively.","Pharmacokinetics of danaparoid sodium, dalteparin sodium and heparin determined by inhibitory effect on the activated coagulation factor X activity after single intravenous administration in rabbits. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748709/),%,42.6,10671,DB01109,Heparin
,9748709,urinary cumulative excretion,"The urinary cumulative excretion of anti-Xa activity of DAS and DLS was 42.6 +/- 6.4% and 16.4 +/- 0.8% of dose, respectively, in 24 h after dosing, respectively.","Pharmacokinetics of danaparoid sodium, dalteparin sodium and heparin determined by inhibitory effect on the activated coagulation factor X activity after single intravenous administration in rabbits. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748709/),%,16.4,10672,DB01109,Heparin
,17395544,t(1/2beta),"The mean+/-S.E. values of t(1/2beta), MRT, AUC and Cl(B) in sheep were 10.85+/-1.21 h, 15.13+/-1.67 h, 31.88+/-2.97 microg h mL(-1) and 0.016+/-0.002 L h(-1) kg(-1), respectively whereas the respective values in goats were 6.73+/-0.58 h, 9.37+/-0.83 h, 19.23+/-2.23 microg h mL(-1) and 0.03+/-0.01 L h(-1) kg(-1).",Comparative plasma pharmacokinetics of meloxicam in sheep and goats following intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17395544/),h,10.85,10900,DB01109,Heparin
,17395544,MRT,"The mean+/-S.E. values of t(1/2beta), MRT, AUC and Cl(B) in sheep were 10.85+/-1.21 h, 15.13+/-1.67 h, 31.88+/-2.97 microg h mL(-1) and 0.016+/-0.002 L h(-1) kg(-1), respectively whereas the respective values in goats were 6.73+/-0.58 h, 9.37+/-0.83 h, 19.23+/-2.23 microg h mL(-1) and 0.03+/-0.01 L h(-1) kg(-1).",Comparative plasma pharmacokinetics of meloxicam in sheep and goats following intravenous administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17395544/),h,15.13,10901,DB01109,Heparin
,17395544,AUC,"The mean+/-S.E. values of t(1/2beta), MRT, AUC and Cl(B) in sheep were 10.85+/-1.21 h, 15.13+/-1.67 h, 31.88+/-2.97 microg h mL(-1) and 0.016+/-0.002 L h(-1) kg(-1), respectively whereas the respective values in goats were 6.73+/-0.58 h, 9.37+/-0.83 h, 19.23+/-2.23 microg h mL(-1) and 0.03+/-0.01 L h(-1) kg(-1).",Comparative plasma pharmacokinetics of meloxicam in sheep and goats following intravenous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17395544/),h,15.13,10902,DB01109,Heparin
,17395544,Cl(B),"The mean+/-S.E. values of t(1/2beta), MRT, AUC and Cl(B) in sheep were 10.85+/-1.21 h, 15.13+/-1.67 h, 31.88+/-2.97 microg h mL(-1) and 0.016+/-0.002 L h(-1) kg(-1), respectively whereas the respective values in goats were 6.73+/-0.58 h, 9.37+/-0.83 h, 19.23+/-2.23 microg h mL(-1) and 0.03+/-0.01 L h(-1) kg(-1).",Comparative plasma pharmacokinetics of meloxicam in sheep and goats following intravenous administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17395544/),[l] / [h·kg],0.016,10903,DB01109,Heparin
,17395544,Cl(B),"The mean+/-S.E. values of t(1/2beta), MRT, AUC and Cl(B) in sheep were 10.85+/-1.21 h, 15.13+/-1.67 h, 31.88+/-2.97 microg h mL(-1) and 0.016+/-0.002 L h(-1) kg(-1), respectively whereas the respective values in goats were 6.73+/-0.58 h, 9.37+/-0.83 h, 19.23+/-2.23 microg h mL(-1) and 0.03+/-0.01 L h(-1) kg(-1).",Comparative plasma pharmacokinetics of meloxicam in sheep and goats following intravenous administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17395544/),h,9.37,10904,DB01109,Heparin
,21162606,bioavailability,The bioavailability of bemiparin was estimated at 96% and the apparent volume of distribution was 5.1 L.,Bemiparin: pharmacological profile. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21162606/),%,96,10989,DB01109,Heparin
,21162606,apparent volume of distribution,The bioavailability of bemiparin was estimated at 96% and the apparent volume of distribution was 5.1 L.,Bemiparin: pharmacological profile. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21162606/),l,5.1,10990,DB01109,Heparin
,21162606,half-life,Bemiparin has the longest half-life of all LMWH at 5.3 h compared with 0.5-1.0 h for unfractionated heparin.,Bemiparin: pharmacological profile. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21162606/),h,5.3,10991,DB01109,Heparin
,21162606,half-life,Bemiparin has the longest half-life of all LMWH at 5.3 h compared with 0.5-1.0 h for unfractionated heparin.,Bemiparin: pharmacological profile. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21162606/),h,0.5-1.0,10992,DB01109,Heparin
over,21162606,mean residence time,"Elimination is linear, with a mean residence time of over 7 h and total clearance of 0.9 L/h.",Bemiparin: pharmacological profile. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21162606/),h,7,10993,DB01109,Heparin
,21162606,total clearance,"Elimination is linear, with a mean residence time of over 7 h and total clearance of 0.9 L/h.",Bemiparin: pharmacological profile. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21162606/),[l] / [h],0.9,10994,DB01109,Heparin
,2465247,t0.5 alpha,"The bulk of injected 99mTc-heparin or LMWH fraction was rapidly distributed to the tissular compartment (t0.5 alpha = 13 min), whereas the radiocomplex remaining in the circulation was slowly eliminated with a half-time (t0.5 beta) of an average 320 min.","Kinetics of radiolabelled (99mTc) heparin and low molecular weight heparin fractions CY 216, CY 222 in patients with uncomplicated myocardial infarction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2465247/),min,13,11539,DB01109,Heparin
,2465247,half-time (t0.5 beta),"The bulk of injected 99mTc-heparin or LMWH fraction was rapidly distributed to the tissular compartment (t0.5 alpha = 13 min), whereas the radiocomplex remaining in the circulation was slowly eliminated with a half-time (t0.5 beta) of an average 320 min.","Kinetics of radiolabelled (99mTc) heparin and low molecular weight heparin fractions CY 216, CY 222 in patients with uncomplicated myocardial infarction. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2465247/),min,320,11540,DB01109,Heparin
,2829379,recovery of radioactivity,"The recovery of radioactivity in urine within three hours was 5 and 35 per cent of the dose, respectively, for 3H-heparin and 3H-Fragmin.",Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2829379/),%,5,11566,DB01109,Heparin
,2829379,recovery of radioactivity,"The recovery of radioactivity in urine within three hours was 5 and 35 per cent of the dose, respectively, for 3H-heparin and 3H-Fragmin.",Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2829379/),%,35,11567,DB01109,Heparin
,2829379,t1/2,It is concluded from the present study that the rapid plasma elimination of heparin in the rabbit (t1/2 = 17 minutes) is mainly due to a high tissue distribution (liver and kidney) while the plasma elimination of Fragmin (t1/2 = 28 minutes) is mainly caused by renal excretion.,Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2829379/),min,17,11568,DB01109,Heparin
,2829379,t1/2,It is concluded from the present study that the rapid plasma elimination of heparin in the rabbit (t1/2 = 17 minutes) is mainly due to a high tissue distribution (liver and kidney) while the plasma elimination of Fragmin (t1/2 = 28 minutes) is mainly caused by renal excretion.,Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2829379/),min,28,11569,DB01109,Heparin
,6495266,half-life in the second phase,In semilogarithmic plots 125I-antithrombin III disappeared according to a double exponential curve with a half-life in the second phase of 56.8 hr in the absence of heparin and of 33.7 hr in the presence of heparin.,Elimination of intravenously administered radiolabelled antithrombin III and heparin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6495266/),h,56.8,13735,DB01109,Heparin
,6495266,half-life in the second phase,In semilogarithmic plots 125I-antithrombin III disappeared according to a double exponential curve with a half-life in the second phase of 56.8 hr in the absence of heparin and of 33.7 hr in the presence of heparin.,Elimination of intravenously administered radiolabelled antithrombin III and heparin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6495266/),h,33.7,13736,DB01109,Heparin
,11251329,plasma anti-factor Xa levels,"The plasma anti-factor Xa levels in the 6 healthy volunteers who received a microenema containing 25,000 U of LMWH with 20 mg/ml of Sch were 0.38 U/ml at 15 min and 0.1 U/ml at 240 min.",Intestinal absorption of low molecular weight heparin in animals and human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11251329/),[u] / [ml],0.38,14587,DB01109,Heparin
,11251329,plasma anti-factor Xa levels,"The plasma anti-factor Xa levels in the 6 healthy volunteers who received a microenema containing 25,000 U of LMWH with 20 mg/ml of Sch were 0.38 U/ml at 15 min and 0.1 U/ml at 240 min.",Intestinal absorption of low molecular weight heparin in animals and human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11251329/),[u] / [ml],0.1,14588,DB01109,Heparin
,32827160,CL/F,"The estimates of CL/F and Vd/F in the full model were 929 mL/h and 7180 mL, respectively, for a reference female patient aged 12 years with body weight of 43 kg.",Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32827160/),[ml] / [h],929,15430,DB01109,Heparin
,32827160,Vd/F,"The estimates of CL/F and Vd/F in the full model were 929 mL/h and 7180 mL, respectively, for a reference female patient aged 12 years with body weight of 43 kg.",Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32827160/),ml,7180,15431,DB01109,Heparin
,8533979,Total clearance,"Total clearance of heparin was similar after the 40 and 80 IU/kg of body weight dosages, averaging 0.45 and 0.36 IU/kg/min, respectively.",Pharmacokinetics of heparin and its pharmacodynamic effect on plasma lipoprotein lipase activity and coagulation in healthy horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533979/),[iu] / [kg·min],0.45,15703,DB01109,Heparin
,8533979,Total clearance,"Total clearance of heparin was similar after the 40 and 80 IU/kg of body weight dosages, averaging 0.45 and 0.36 IU/kg/min, respectively.",Pharmacokinetics of heparin and its pharmacodynamic effect on plasma lipoprotein lipase activity and coagulation in healthy horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533979/),[iu] / [kg·min],0.36,15704,DB01109,Heparin
,8533979,half-life,"The half-life of heparin averaged 53, 70, and 136 minutes after 40, 80, and 120 IU/kg, respectively, with significant differences observed between the low and high doses.",Pharmacokinetics of heparin and its pharmacodynamic effect on plasma lipoprotein lipase activity and coagulation in healthy horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533979/),min,53,15705,DB01109,Heparin
,8533979,half-life,"The half-life of heparin averaged 53, 70, and 136 minutes after 40, 80, and 120 IU/kg, respectively, with significant differences observed between the low and high doses.",Pharmacokinetics of heparin and its pharmacodynamic effect on plasma lipoprotein lipase activity and coagulation in healthy horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533979/),min,70,15706,DB01109,Heparin
,8533979,half-life,"The half-life of heparin averaged 53, 70, and 136 minutes after 40, 80, and 120 IU/kg, respectively, with significant differences observed between the low and high doses.",Pharmacokinetics of heparin and its pharmacodynamic effect on plasma lipoprotein lipase activity and coagulation in healthy horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533979/),min,136,15707,DB01109,Heparin
,8533979,Maximal LPL activity,"Maximal LPL activity observed was independent of dose, averaging 4.8 mumol of free fatty acids/ml/h.",Pharmacokinetics of heparin and its pharmacodynamic effect on plasma lipoprotein lipase activity and coagulation in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533979/),μM,4.8,15708,DB01109,Heparin
,9134637,half-life,"Hirudin half-life was > 30 times longer in hemodialysis patients (51.8 +/- 15.6 vs. 1.7 +/- 1.5 h, p < 0.001), whereas area under the curve was > 60 times higher (34,669 +/- 14,898 vs. 545 +/- 205 ng/ml x h, p < 0.001).",Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9134637/),h,51.8,18302,DB01109,Heparin
,9134637,half-life,"Hirudin half-life was > 30 times longer in hemodialysis patients (51.8 +/- 15.6 vs. 1.7 +/- 1.5 h, p < 0.001), whereas area under the curve was > 60 times higher (34,669 +/- 14,898 vs. 545 +/- 205 ng/ml x h, p < 0.001).",Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9134637/),h,1.7,18303,DB01109,Heparin
,9134637,area under the curve,"Hirudin half-life was > 30 times longer in hemodialysis patients (51.8 +/- 15.6 vs. 1.7 +/- 1.5 h, p < 0.001), whereas area under the curve was > 60 times higher (34,669 +/- 14,898 vs. 545 +/- 205 ng/ml x h, p < 0.001).",Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9134637/),[ng] / [h·ml],"34,669",18304,DB01109,Heparin
,9134637,area under the curve,"Hirudin half-life was > 30 times longer in hemodialysis patients (51.8 +/- 15.6 vs. 1.7 +/- 1.5 h, p < 0.001), whereas area under the curve was > 60 times higher (34,669 +/- 14,898 vs. 545 +/- 205 ng/ml x h, p < 0.001).",Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9134637/),[ng] / [h·ml],545,18305,DB01109,Heparin
,9134637,Distribution volume,"Distribution volume was lower in hemodialysis patients (11.0 +/- 3.1 vs. 14.1 +/- 2.01, p < 0.05).",Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9134637/),,11.0,18306,DB01109,Heparin
,9134637,Distribution volume,"Distribution volume was lower in hemodialysis patients (11.0 +/- 3.1 vs. 14.1 +/- 2.01, p < 0.05).",Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9134637/),,14.1,18307,DB01109,Heparin
,3379667,Peak concentrations,"Peak concentrations 4 h after administration were 0.021 +/- 0.016 (mean +/- SD) units of heparin/ml of plasma (U/ml) after 60 U/kg, 0.035 +/- 0.025 U/ml after 80 U/kg, 0.023 +/- 0.004 U/ml after 100 U/kg, 0.034 +/- 0.019 U/ml after 125 U/kg, and 0.053 +/- 0.019 U/ml after 150 U/kg.",Dose-dependent plasma elimination of subcutaneously administered calcium heparin in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379667/),units,0.021,18325,DB01109,Heparin
,3379667,Peak concentrations,"Peak concentrations 4 h after administration were 0.021 +/- 0.016 (mean +/- SD) units of heparin/ml of plasma (U/ml) after 60 U/kg, 0.035 +/- 0.025 U/ml after 80 U/kg, 0.023 +/- 0.004 U/ml after 100 U/kg, 0.034 +/- 0.019 U/ml after 125 U/kg, and 0.053 +/- 0.019 U/ml after 150 U/kg.",Dose-dependent plasma elimination of subcutaneously administered calcium heparin in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379667/),[u] / [ml],0.035,18326,DB01109,Heparin
,3379667,Peak concentrations,"Peak concentrations 4 h after administration were 0.021 +/- 0.016 (mean +/- SD) units of heparin/ml of plasma (U/ml) after 60 U/kg, 0.035 +/- 0.025 U/ml after 80 U/kg, 0.023 +/- 0.004 U/ml after 100 U/kg, 0.034 +/- 0.019 U/ml after 125 U/kg, and 0.053 +/- 0.019 U/ml after 150 U/kg.",Dose-dependent plasma elimination of subcutaneously administered calcium heparin in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379667/),[u] / [ml],0.023,18327,DB01109,Heparin
,3379667,Peak concentrations,"Peak concentrations 4 h after administration were 0.021 +/- 0.016 (mean +/- SD) units of heparin/ml of plasma (U/ml) after 60 U/kg, 0.035 +/- 0.025 U/ml after 80 U/kg, 0.023 +/- 0.004 U/ml after 100 U/kg, 0.034 +/- 0.019 U/ml after 125 U/kg, and 0.053 +/- 0.019 U/ml after 150 U/kg.",Dose-dependent plasma elimination of subcutaneously administered calcium heparin in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379667/),[u] / [ml],0.034,18328,DB01109,Heparin
,3379667,Peak concentrations,"Peak concentrations 4 h after administration were 0.021 +/- 0.016 (mean +/- SD) units of heparin/ml of plasma (U/ml) after 60 U/kg, 0.035 +/- 0.025 U/ml after 80 U/kg, 0.023 +/- 0.004 U/ml after 100 U/kg, 0.034 +/- 0.019 U/ml after 125 U/kg, and 0.053 +/- 0.019 U/ml after 150 U/kg.",Dose-dependent plasma elimination of subcutaneously administered calcium heparin in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379667/),[u] / [ml],0.053,18329,DB01109,Heparin
,3379667,Elimination constant,"Elimination constant (l/h), elimination half-life (h), and elimination time (h) calculated to reach base-line values after 80 U/kg were 0.182 +/- 0.041 l/h, 3.8 +/- 0.9 h, and 9.7 +/- 2.2 h.",Dose-dependent plasma elimination of subcutaneously administered calcium heparin in horses. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379667/),[l] / [h],0.182,18330,DB01109,Heparin
,3379667,elimination half-life,"Elimination constant (l/h), elimination half-life (h), and elimination time (h) calculated to reach base-line values after 80 U/kg were 0.182 +/- 0.041 l/h, 3.8 +/- 0.9 h, and 9.7 +/- 2.2 h.",Dose-dependent plasma elimination of subcutaneously administered calcium heparin in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379667/),[l] / [h],0.182,18331,DB01109,Heparin
,3379667,elimination half-life,"Elimination constant (l/h), elimination half-life (h), and elimination time (h) calculated to reach base-line values after 80 U/kg were 0.182 +/- 0.041 l/h, 3.8 +/- 0.9 h, and 9.7 +/- 2.2 h.",Dose-dependent plasma elimination of subcutaneously administered calcium heparin in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379667/),h,3.8,18332,DB01109,Heparin
,3379667,elimination time (h),"Elimination constant (l/h), elimination half-life (h), and elimination time (h) calculated to reach base-line values after 80 U/kg were 0.182 +/- 0.041 l/h, 3.8 +/- 0.9 h, and 9.7 +/- 2.2 h.",Dose-dependent plasma elimination of subcutaneously administered calcium heparin in horses. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379667/),h,9.7,18333,DB01109,Heparin
>,19175499,bioaccumulation,No bioaccumulation>30% could be found up to day 10 even in patients with severe RI.,Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19175499/),%,30,19178,DB01109,Heparin
>,19175499,bioaccumulation,"The use of dalteparin at a prophylactic dose was not associated with a bioaccumulation>30% even in patients with severe renal insufficiency during a median follow-up of 10 days (IQR 4-13, range 1-20).",Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19175499/),%,30,19179,DB01109,Heparin
,29376194,concentrations,Rivaroxaban concentrations ranged from <LLOQ to 300.6 ng/ml at the time of admission to hospital and from <LLOQ to 55.5 ng/ml at the beginning of the procedure.,Residual rivaroxaban exposure after discontinuation of anticoagulant therapy in patients undergoing cardiac catheterization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29376194/),ng,300,21279,DB01109,Heparin
,29376194,concentrations,Rivaroxaban concentrations ranged from <LLOQ to 300.6 ng/ml at the time of admission to hospital and from <LLOQ to 55.5 ng/ml at the beginning of the procedure.,Residual rivaroxaban exposure after discontinuation of anticoagulant therapy in patients undergoing cardiac catheterization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29376194/),ng,55,21280,DB01109,Heparin
,29376194,Times,Times since last rivaroxaban intake were (mean ± SD) 51.0 ± 31.7 h (admission) and 85.5 ± 36.8 h (start catheterization).,Residual rivaroxaban exposure after discontinuation of anticoagulant therapy in patients undergoing cardiac catheterization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29376194/),h,51.0,21281,DB01109,Heparin
,29376194,Times,Times since last rivaroxaban intake were (mean ± SD) 51.0 ± 31.7 h (admission) and 85.5 ± 36.8 h (start catheterization).,Residual rivaroxaban exposure after discontinuation of anticoagulant therapy in patients undergoing cardiac catheterization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29376194/),h,85.5,21282,DB01109,Heparin
,2363120,half-life,Plasmatic elimination of rHV2-Lys47 from rat plasma after i.v. injection had a fast distribution phase with a half-life of 3 min during which 90% of injected rHV2-Lys47 was lost and was followed by a slower elimination phase.,Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363120/),min,3,22246,DB01109,Heparin
,8845462,elimination half-lives (T1/2 el),Using the HC II assay the elimination half-lives (T1/2 el) increased from 1.9 h to 3.3 h with increasing doses of LMW-dermatan sulfate.,"Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845462/),h,1.9,22983,DB01109,Heparin
,8845462,elimination half-lives (T1/2 el),Using the HC II assay the elimination half-lives (T1/2 el) increased from 1.9 h to 3.3 h with increasing doses of LMW-dermatan sulfate.,"Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845462/),h,3.3,22984,DB01109,Heparin
,8845462,T1/2 el,"T1/2 el were 4.3 and 6.9 h with the Heptest assay and 3.3 and 5.1 with the aXa method, respectively.","Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845462/),h,4.3,22985,DB01109,Heparin
,8845462,T1/2 el,"T1/2 el were 4.3 and 6.9 h with the Heptest assay and 3.3 and 5.1 with the aXa method, respectively.","Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845462/),h,6.9,22986,DB01109,Heparin
,8845462,T1/2 el,"T1/2 el were 4.3 and 6.9 h with the Heptest assay and 3.3 and 5.1 with the aXa method, respectively.","Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845462/),,3.3,22987,DB01109,Heparin
,8845462,T1/2 el,"T1/2 el were 4.3 and 6.9 h with the Heptest assay and 3.3 and 5.1 with the aXa method, respectively.","Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845462/),,5.1,22988,DB01109,Heparin
,8845462,T1/2 el,"T1/2 el was 5.6 h using HC II method, 11.1 h using Heptest and 7.8 h with the aXa activity.","Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845462/),h,5.6,22989,DB01109,Heparin
,8845462,T1/2 el,"T1/2 el was 5.6 h using HC II method, 11.1 h using Heptest and 7.8 h with the aXa activity.","Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845462/),h,11.1,22990,DB01109,Heparin
,8845462,T1/2 el,"T1/2 el was 5.6 h using HC II method, 11.1 h using Heptest and 7.8 h with the aXa activity.","Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845462/),h,7.8,22991,DB01109,Heparin
,12845386,clearance,"Values for clearance, volume of distribution, volume of distribution at steady state, and elimination rate constant were on the order of 10 mL/h/kg, 48 mL/kg, 45 mL/kg, and 0.22/h, respectively.",Pharmacokinetics of enoxaparin in patients undergoing percutaneous coronary intervention with and without glycoprotein IIb/IIIa therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845386/),[ml] / [h·kg],10,24529,DB01109,Heparin
,12845386,volume of distribution at steady state,"Values for clearance, volume of distribution, volume of distribution at steady state, and elimination rate constant were on the order of 10 mL/h/kg, 48 mL/kg, 45 mL/kg, and 0.22/h, respectively.",Pharmacokinetics of enoxaparin in patients undergoing percutaneous coronary intervention with and without glycoprotein IIb/IIIa therapy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845386/),[ml] / [kg],48,24530,DB01109,Heparin
,12845386,volume of distribution at steady state,"Values for clearance, volume of distribution, volume of distribution at steady state, and elimination rate constant were on the order of 10 mL/h/kg, 48 mL/kg, 45 mL/kg, and 0.22/h, respectively.",Pharmacokinetics of enoxaparin in patients undergoing percutaneous coronary intervention with and without glycoprotein IIb/IIIa therapy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845386/),[ml] / [kg],45,24531,DB01109,Heparin
,12845386,elimination rate constant,"Values for clearance, volume of distribution, volume of distribution at steady state, and elimination rate constant were on the order of 10 mL/h/kg, 48 mL/kg, 45 mL/kg, and 0.22/h, respectively.",Pharmacokinetics of enoxaparin in patients undergoing percutaneous coronary intervention with and without glycoprotein IIb/IIIa therapy. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845386/),1/[h],0.22,24532,DB01109,Heparin
,11228340,Oral bioavailability,"Oral bioavailability, measured as melagatran in plasma, is about 20% after oral administration of H 376/95, which is 2.7-5.5 times higher than after oral administration of melagatran.","The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11228340/),%,20,24799,DB01109,Heparin
,11228340,inhibition constant (K(i)) ratio,"Pharmacodynamic properties: H 376/95 is inactive towards human alpha-thrombin compared with melagatran [inhibition constant (K(i)) ratio, 185 times], a potential advantage for patients with silent gastrointestinal bleeding.","The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11228340/),times,185,24800,DB01109,Heparin
,28846877,Cmax24h,"The median anti-FXa Cmax24h was 0.05 (interquartile range, IQR, 0.05-0.18) IU/ml in the CII group and 0.18 (IQR, 0.12-0.33) IU/ml in the SCB group (p=0.05).",Plasma anti-FXa concentration after continuous intravenous infusion and subcutaneous dosing of enoxaparin for thromboprophylaxis in critically ill patients. A randomized clinical trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28846877/),[iu] / [ml],0.05,24893,DB01109,Heparin
,28846877,Cmax24h,"The median anti-FXa Cmax24h was 0.05 (interquartile range, IQR, 0.05-0.18) IU/ml in the CII group and 0.18 (IQR, 0.12-0.33) IU/ml in the SCB group (p=0.05).",Plasma anti-FXa concentration after continuous intravenous infusion and subcutaneous dosing of enoxaparin for thromboprophylaxis in critically ill patients. A randomized clinical trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28846877/),[iu] / [ml],0.18,24894,DB01109,Heparin
,28846877,AUC(0-24h),"Median anti-FXa AUC(0-24h) was 1.20 (IQR, 0.98-2.88) in the CII and 1.54 (IQR, 1.22-4.12) in the SCB group (p=0.095).",Plasma anti-FXa concentration after continuous intravenous infusion and subcutaneous dosing of enoxaparin for thromboprophylaxis in critically ill patients. A randomized clinical trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28846877/),,1.20,24895,DB01109,Heparin
,28846877,AUC(0-24h),"Median anti-FXa AUC(0-24h) was 1.20 (IQR, 0.98-2.88) in the CII and 1.54 (IQR, 1.22-4.12) in the SCB group (p=0.095).",Plasma anti-FXa concentration after continuous intravenous infusion and subcutaneous dosing of enoxaparin for thromboprophylaxis in critically ill patients. A randomized clinical trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28846877/),,1.54,24896,DB01109,Heparin
>,28846877,detectable anti-FXa concentration,"After 72h, 66.7% of patients in the CII group had a detectable anti-FXa concentration of >0.1IU/ml, compared with 16.7% in the SCB group (p=0.019).",Plasma anti-FXa concentration after continuous intravenous infusion and subcutaneous dosing of enoxaparin for thromboprophylaxis in critically ill patients. A randomized clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28846877/),[iu] / [ml],0.1,24897,DB01109,Heparin
,9167016,dissociation constants (Kd),"The dissociation constants (Kd) for AT of the three species were in the range of 41-132, 1.4-6.2 and 2.8-4.6 nM for SP, 80027 and 32701, respectively.",Pharmacokinetic study of three synthetic AT-binding pentasaccharides in various animal species-extrapolation to humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167016/),nM,41-132,26002,DB01109,Heparin
,9167016,dissociation constants (Kd),"The dissociation constants (Kd) for AT of the three species were in the range of 41-132, 1.4-6.2 and 2.8-4.6 nM for SP, 80027 and 32701, respectively.",Pharmacokinetic study of three synthetic AT-binding pentasaccharides in various animal species-extrapolation to humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167016/),nM,1.4-6.2,26003,DB01109,Heparin
,9167016,dissociation constants (Kd),"The dissociation constants (Kd) for AT of the three species were in the range of 41-132, 1.4-6.2 and 2.8-4.6 nM for SP, 80027 and 32701, respectively.",Pharmacokinetic study of three synthetic AT-binding pentasaccharides in various animal species-extrapolation to humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167016/),nM,2.8-4.6,26004,DB01109,Heparin
,9167016,terminal half-lives,"The values obtained for the terminal half-lives of SP, 80027 and 32701 were 14.1, 88 and 6.5 h, respectively.",Pharmacokinetic study of three synthetic AT-binding pentasaccharides in various animal species-extrapolation to humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167016/),h,14.1,26005,DB01109,Heparin
,9167016,terminal half-lives,"The values obtained for the terminal half-lives of SP, 80027 and 32701 were 14.1, 88 and 6.5 h, respectively.",Pharmacokinetic study of three synthetic AT-binding pentasaccharides in various animal species-extrapolation to humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167016/),h,88,26006,DB01109,Heparin
,9167016,terminal half-lives,"The values obtained for the terminal half-lives of SP, 80027 and 32701 were 14.1, 88 and 6.5 h, respectively.",Pharmacokinetic study of three synthetic AT-binding pentasaccharides in various animal species-extrapolation to humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167016/),h,6.5,26007,DB01109,Heparin
,3091779,peak ulcers,"These doses produced peak ulcers of 0.15 to 0.22 cm2, respectively, one to five days after injection.",Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2,0.15,26156,DB01109,Heparin
,3091779,peak ulcers,"These doses produced peak ulcers of 0.15 to 0.22 cm2, respectively, one to five days after injection.",Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2,0.22,26157,DB01109,Heparin
,3091779,area X time,The integrated ulcer area X time values (area under the curve [AUC] ulceration) were 0.89 and 3.11 cm2 X d.,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2·d,0.89,26158,DB01109,Heparin
,3091779,area X time,The integrated ulcer area X time values (area under the curve [AUC] ulceration) were 0.89 and 3.11 cm2 X d.,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2·d,3.11,26159,DB01109,Heparin
,3091779,area under the curve [AUC],The integrated ulcer area X time values (area under the curve [AUC] ulceration) were 0.89 and 3.11 cm2 X d.,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2·d,0.89,26160,DB01109,Heparin
,3091779,area under the curve [AUC],The integrated ulcer area X time values (area under the curve [AUC] ulceration) were 0.89 and 3.11 cm2 X d.,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2·d,3.11,26161,DB01109,Heparin
,3091779,AUC,DMSO significantly increased the AUC for MMC in skin from 0.89 to 2.25 ng/h/mL of tissue (P less than .05).,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),[ng] / [h·ml],0.89,26162,DB01109,Heparin
,3091779,AUC,DMSO significantly increased the AUC for MMC in skin from 0.89 to 2.25 ng/h/mL of tissue (P less than .05).,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),[ng] / [h·ml],2,26163,DB01109,Heparin
,23041275,oral bioavailability,"Among all the compounds, 6ODS-LHbD showed the highest oral bioavailability in rats (19.3%).","Orally active desulfated low molecular weight heparin and deoxycholic acid conjugate, 6ODS-LHbD, suppresses neovascularization and bone destruction in arthritis. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23041275/),%,19.3,26293,DB01109,Heparin
,26612429,peak plasma concentrations,Mean peak plasma concentrations were greater (1.91 (SD 0.39) vs. 0.71 (SD 0.17) µg/mL) and the time to reach them shorter (3.20 (SD 1.64) vs. 14.33 (SD 2.19) hours) following S/C compared with oral administration (p<0.05).,"Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612429/),[μg] / [ml],1.91,26419,DB01109,Heparin
,26612429,peak plasma concentrations,Mean peak plasma concentrations were greater (1.91 (SD 0.39) vs. 0.71 (SD 0.17) µg/mL) and the time to reach them shorter (3.20 (SD 1.64) vs. 14.33 (SD 2.19) hours) following S/C compared with oral administration (p<0.05).,"Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612429/),[μg] / [ml],0.71,26420,DB01109,Heparin
,26612429,time to reach them,Mean peak plasma concentrations were greater (1.91 (SD 0.39) vs. 0.71 (SD 0.17) µg/mL) and the time to reach them shorter (3.20 (SD 1.64) vs. 14.33 (SD 2.19) hours) following S/C compared with oral administration (p<0.05).,"Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612429/),h,3.20,26421,DB01109,Heparin
,26612429,time to reach them,Mean peak plasma concentrations were greater (1.91 (SD 0.39) vs. 0.71 (SD 0.17) µg/mL) and the time to reach them shorter (3.20 (SD 1.64) vs. 14.33 (SD 2.19) hours) following S/C compared with oral administration (p<0.05).,"Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612429/),h,14.33,26422,DB01109,Heparin
,26612429,terminal half-life,"The terminal half-life was longer (15.16 (SD 4.74) vs. 10.69 (SD 1.49) hours) and the MRT was shorter (15.67 (SD 2.37) vs. 24.33 (SD 3.12) hours) following S/C than oral administration (p<0.05), but bioavailability was similar (98.24 (SD 9.62) vs. 96.49 (SD 10.71)%).","Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612429/),h,15.16,26423,DB01109,Heparin
,26612429,terminal half-life,"The terminal half-life was longer (15.16 (SD 4.74) vs. 10.69 (SD 1.49) hours) and the MRT was shorter (15.67 (SD 2.37) vs. 24.33 (SD 3.12) hours) following S/C than oral administration (p<0.05), but bioavailability was similar (98.24 (SD 9.62) vs. 96.49 (SD 10.71)%).","Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612429/),h,10.69,26424,DB01109,Heparin
,26612429,MRT,"The terminal half-life was longer (15.16 (SD 4.74) vs. 10.69 (SD 1.49) hours) and the MRT was shorter (15.67 (SD 2.37) vs. 24.33 (SD 3.12) hours) following S/C than oral administration (p<0.05), but bioavailability was similar (98.24 (SD 9.62) vs. 96.49 (SD 10.71)%).","Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612429/),h,15.67,26425,DB01109,Heparin
,26612429,MRT,"The terminal half-life was longer (15.16 (SD 4.74) vs. 10.69 (SD 1.49) hours) and the MRT was shorter (15.67 (SD 2.37) vs. 24.33 (SD 3.12) hours) following S/C than oral administration (p<0.05), but bioavailability was similar (98.24 (SD 9.62) vs. 96.49 (SD 10.71)%).","Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612429/),h,24.33,26426,DB01109,Heparin
,26612429,bioavailability,"The terminal half-life was longer (15.16 (SD 4.74) vs. 10.69 (SD 1.49) hours) and the MRT was shorter (15.67 (SD 2.37) vs. 24.33 (SD 3.12) hours) following S/C than oral administration (p<0.05), but bioavailability was similar (98.24 (SD 9.62) vs. 96.49 (SD 10.71)%).","Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612429/),%,98.24,26427,DB01109,Heparin
,26612429,bioavailability,"The terminal half-life was longer (15.16 (SD 4.74) vs. 10.69 (SD 1.49) hours) and the MRT was shorter (15.67 (SD 2.37) vs. 24.33 (SD 3.12) hours) following S/C than oral administration (p<0.05), but bioavailability was similar (98.24 (SD 9.62) vs. 96.49 (SD 10.71)%).","Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612429/),%,96.49,26428,DB01109,Heparin
below,15467910,peak anti-Xa,"Doses were adjusted when peak anti-Xa levels fell below 0.1 IU/ml and, in some cases, when levels at 10 and 18 hours post injection were undetectable (<0.05 IU/ml).",Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467910/),[iu] / [ml],0.1,26689,DB01109,Heparin
below,15467910,peak,Our results showed that women receiving tinzaparin (50 IU/kg) frequently had peak (4 hour) anti-Xa levels below 0.1IU/ml and that 46% of these patients required dose adjustment.,Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467910/),[iu] / [ml],0.1,26690,DB01109,Heparin
below,15467910,anti-Xa,Our results showed that women receiving tinzaparin (50 IU/kg) frequently had peak (4 hour) anti-Xa levels below 0.1IU/ml and that 46% of these patients required dose adjustment.,Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467910/),[iu] / [ml],0.1,26691,DB01109,Heparin
,9236430,peak delivered amount,"Mean peak delivered amount was 45 +/- 44 IU (236 +/- 228 micrograms), corresponding to an efficiency of delivery ranging from 1% to 8% of the totally infused dose.",Site-specific intracoronary heparin delivery in humans after balloon angioplasty. A radioisotopic assessment of regional pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9236430/),iu,45,28249,DB01109,Heparin
,9236430,peak delivered amount,"Mean peak delivered amount was 45 +/- 44 IU (236 +/- 228 micrograms), corresponding to an efficiency of delivery ranging from 1% to 8% of the totally infused dose.",Site-specific intracoronary heparin delivery in humans after balloon angioplasty. A radioisotopic assessment of regional pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9236430/),μg,236,28250,DB01109,Heparin
,9236430,Total regionally bioavailable he,Total regionally bioavailable heparin reached 244 +/- 194 IU.h (1.28 +/- 1.01 mg.h).,Site-specific intracoronary heparin delivery in humans after balloon angioplasty. A radioisotopic assessment of regional pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9236430/),h·iu,244,28251,DB01109,Heparin
,9236430,Total regionally bioavailable he,Total regionally bioavailable heparin reached 244 +/- 194 IU.h (1.28 +/- 1.01 mg.h).,Site-specific intracoronary heparin delivery in humans after balloon angioplasty. A radioisotopic assessment of regional pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9236430/),h·mg,1.28,28252,DB01109,Heparin
,9236430,Retention time,"Retention time varied from 12 to 90 hours (mean, 50:33 +/- 22:50 hours:minutes).",Site-specific intracoronary heparin delivery in humans after balloon angioplasty. A radioisotopic assessment of regional pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9236430/),hours:minutes,50:,28253,DB01109,Heparin
,9236430,Retention time,"Retention time varied from 12 to 90 hours (mean, 50:33 +/- 22:50 hours:minutes).",Site-specific intracoronary heparin delivery in humans after balloon angioplasty. A radioisotopic assessment of regional pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9236430/),hours:minutes,33,28254,DB01109,Heparin
,26777886,encapsulation efficiency,The encapsulation efficiency was 63-74%.,Development of PEG-PLGA based Intravenous Low Molecular Weight Heparin (LMWH) Nanoparticles Intended to Treat Venous Thrombosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26777886/),%,63-74,28255,DB01109,Heparin
,26777886,drug release,In vitro drug release was 57-75% for 48 hrs.,Development of PEG-PLGA based Intravenous Low Molecular Weight Heparin (LMWH) Nanoparticles Intended to Treat Venous Thrombosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26777886/),%,57-75,28256,DB01109,Heparin
>,23872204,m/z,"Octreotide and internal standard (triptorelin) were identified in positive electrospray ionization mode using ion transitions of m/z 512>120 and 890>249, respectively.",Validation of a rapid liquid chromatography-tandem mass spectrometric assay for the determination of octreotide plasma concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23872204/),,512,28295,DB01109,Heparin
>,23872204,m/z,"Octreotide and internal standard (triptorelin) were identified in positive electrospray ionization mode using ion transitions of m/z 512>120 and 890>249, respectively.",Validation of a rapid liquid chromatography-tandem mass spectrometric assay for the determination of octreotide plasma concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23872204/),,120,28296,DB01109,Heparin
>,23872204,m/z,"Octreotide and internal standard (triptorelin) were identified in positive electrospray ionization mode using ion transitions of m/z 512>120 and 890>249, respectively.",Validation of a rapid liquid chromatography-tandem mass spectrometric assay for the determination of octreotide plasma concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23872204/),,89,28297,DB01109,Heparin
>,23872204,m/z,"Octreotide and internal standard (triptorelin) were identified in positive electrospray ionization mode using ion transitions of m/z 512>120 and 890>249, respectively.",Validation of a rapid liquid chromatography-tandem mass spectrometric assay for the determination of octreotide plasma concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23872204/),,249,28298,DB01109,Heparin
,23872204,recovery,"The recovery and ion suppression effect ranged between 79.7 and 84.5% and between -8.1 and -21.3%, respectively.",Validation of a rapid liquid chromatography-tandem mass spectrometric assay for the determination of octreotide plasma concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23872204/),%,79.7 and 84.5,28299,DB01109,Heparin
,3258496,apparent half-life,Human heparin cofactor II cleared from the circulation of mice with an apparent half-life of 80 min while heparin cofactor II-thrombin complexes cleared with an apparent half-life of only 10 min.,In vivo catabolism of heparin cofactor II and its complex with thrombin: evidence for a common receptor-mediated clearance pathway for three serine proteinase inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3258496/),min,80,28571,DB01109,Heparin
,3258496,apparent half-life,Human heparin cofactor II cleared from the circulation of mice with an apparent half-life of 80 min while heparin cofactor II-thrombin complexes cleared with an apparent half-life of only 10 min.,In vivo catabolism of heparin cofactor II and its complex with thrombin: evidence for a common receptor-mediated clearance pathway for three serine proteinase inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3258496/),min,10,28572,DB01109,Heparin
,25563929,oral bioavailability,"The PK evaluation of NP046 showed low oral bioavailability (3.2% and 6% at 50 mg/kg and 10 mg/kg dose, respectively and a moderate mean half-life ranging from 3.1 to 4.4 hours.",Efficacy and pharmacokinetic evaluation of a novel anti-malarial compound (NP046) in a mouse model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25563929/),%,3.2,29021,DB01109,Heparin
,25563929,oral bioavailability,"The PK evaluation of NP046 showed low oral bioavailability (3.2% and 6% at 50 mg/kg and 10 mg/kg dose, respectively and a moderate mean half-life ranging from 3.1 to 4.4 hours.",Efficacy and pharmacokinetic evaluation of a novel anti-malarial compound (NP046) in a mouse model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25563929/),%,6,29022,DB01109,Heparin
,25563929,half-life,"The PK evaluation of NP046 showed low oral bioavailability (3.2% and 6% at 50 mg/kg and 10 mg/kg dose, respectively and a moderate mean half-life ranging from 3.1 to 4.4 hours.",Efficacy and pharmacokinetic evaluation of a novel anti-malarial compound (NP046) in a mouse model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25563929/),h,3.1 to 4.4,29023,DB01109,Heparin
,16697485,absolute bioavailabilities,Mean absolute bioavailabilities were 51% and 59% for the two tested doses.,Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16697485/),%,51,29171,DB01109,Heparin
,16697485,absolute bioavailabilities,Mean absolute bioavailabilities were 51% and 59% for the two tested doses.,Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16697485/),%,59,29172,DB01109,Heparin
,10595641,t1/2alpha,"After a single intravenous infusion of wild type rKPI into dogs, its elimination fit a two compartment model with a t1/2alpha and t1/2beta of 5 and 77 min, respectively.",Recombinant Kunitz protease inhibitory domain of the amyloid beta-protein precursor as an anticoagulant in venovenous extracorporeal circulation in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10595641/),min,5,29695,DB01109,Heparin
,10595641,t1/2beta,"After a single intravenous infusion of wild type rKPI into dogs, its elimination fit a two compartment model with a t1/2alpha and t1/2beta of 5 and 77 min, respectively.",Recombinant Kunitz protease inhibitory domain of the amyloid beta-protein precursor as an anticoagulant in venovenous extracorporeal circulation in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10595641/),min,77,29696,DB01109,Heparin
,10595641,Ki,"Further investigations determined if a variant form of rKPI with 178-fold more potent anti-factor Xa activity (rKPI-DD135, Ki = 0.9 nM) could serve as an anticoagulant in a rabbit model of extracorporeal circulation using a venovenous shunt.",Recombinant Kunitz protease inhibitory domain of the amyloid beta-protein precursor as an anticoagulant in venovenous extracorporeal circulation in rabbits. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10595641/),nM,0.9,29697,DB01109,Heparin
,3794520,half-lives,"There was, however, a noticeably faster disappearance from plasma of excess functional ATIII compared with that of ATIII antigen, with mean half-lives of 47.5 +/- 9 hours and 62.3 +/- 8 hours, respectively.",Catabolism and distribution of functionally heterogeneous human antithrombin III. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3794520/),h,47.5,29810,DB01109,Heparin
,3794520,half-lives,"There was, however, a noticeably faster disappearance from plasma of excess functional ATIII compared with that of ATIII antigen, with mean half-lives of 47.5 +/- 9 hours and 62.3 +/- 8 hours, respectively.",Catabolism and distribution of functionally heterogeneous human antithrombin III. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3794520/),h,62.3,29811,DB01109,Heparin
,7950784,polarization rate,Sixteen chitosan polymers with a polarization rate of 71 to 547 and substitution by sulfur from 0.62 to 1.86 which were intravenously injected showed heparin-like action.,[The relation between the physicochemical structure and the anticoagulant effects of polysulfated chitosan derivatives]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7950784/),,71 to 547,30689,DB01109,Heparin
,7950784,half-life,"The most active (30-52 U/mg) and long-acting (250-350 min) products had a polymerization in the range 180-240 and sulfation no less than 1.5, the half-life being 37-50 min, and the elimination constant being 1.38.10(-2) to 1.88.10(-2)min-1.",[The relation between the physicochemical structure and the anticoagulant effects of polysulfated chitosan derivatives]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7950784/),min,37-50,30690,DB01109,Heparin
,7950784,elimination constant,"The most active (30-52 U/mg) and long-acting (250-350 min) products had a polymerization in the range 180-240 and sulfation no less than 1.5, the half-life being 37-50 min, and the elimination constant being 1.38.10(-2) to 1.88.10(-2)min-1.",[The relation between the physicochemical structure and the anticoagulant effects of polysulfated chitosan derivatives]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7950784/),1/[min],1.38.10(-2),30691,DB01109,Heparin
,7950784,elimination constant,"The most active (30-52 U/mg) and long-acting (250-350 min) products had a polymerization in the range 180-240 and sulfation no less than 1.5, the half-life being 37-50 min, and the elimination constant being 1.38.10(-2) to 1.88.10(-2)min-1.",[The relation between the physicochemical structure and the anticoagulant effects of polysulfated chitosan derivatives]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7950784/),1/[min],1.88.10(-2),30692,DB01109,Heparin
,8656642,plasma clearance,TP-9201 had a plasma clearance of 9.9 +/- 2 ml/min/kg and a volume of distribution that was larger than plasma volume.,"Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8656642/),[ml] / [kg·min],9.9,31019,DB01109,Heparin
,8656642,half life (t1/2),"After discontinuation of TP-9201, recovery of platelet aggregation had a half life (t1/2) of 2-3 h and was complete < or = 24 h.","Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8656642/),h,2-3,31020,DB01109,Heparin
,8578550,beta-half-life time,"The beta-half-life time of the antifactor Xa (aXa) of ""endpoint-attached heparins"" was significantly prolonged: LMMH-tyr (125 min), LMMH-tyr-fitc (141 min) compared to LMMH (69 min).",N' alkylamine low molecular mass heparins (LMM-heparin-tyramine and LMM-heparin-tyramine-fitc) exhibit long lasting anticoagulant effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578550/),min,125,31322,DB01109,Heparin
,8578550,beta-half-life time,"The beta-half-life time of the antifactor Xa (aXa) of ""endpoint-attached heparins"" was significantly prolonged: LMMH-tyr (125 min), LMMH-tyr-fitc (141 min) compared to LMMH (69 min).",N' alkylamine low molecular mass heparins (LMM-heparin-tyramine and LMM-heparin-tyramine-fitc) exhibit long lasting anticoagulant effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578550/),min,141,31323,DB01109,Heparin
,8578550,beta-half-life time,"The beta-half-life time of the antifactor Xa (aXa) of ""endpoint-attached heparins"" was significantly prolonged: LMMH-tyr (125 min), LMMH-tyr-fitc (141 min) compared to LMMH (69 min).",N' alkylamine low molecular mass heparins (LMM-heparin-tyramine and LMM-heparin-tyramine-fitc) exhibit long lasting anticoagulant effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578550/),min,69,31324,DB01109,Heparin
,8578550,half-life time,It showed a decreased clearance and a prolonged half-life time (132 min).,N' alkylamine low molecular mass heparins (LMM-heparin-tyramine and LMM-heparin-tyramine-fitc) exhibit long lasting anticoagulant effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578550/),min,132,31325,DB01109,Heparin
,20110016,binding,"The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),%,6.0,31969,DB01109,Heparin
,20110016,binding,"The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),%,6.9,31970,DB01109,Heparin
,20110016,binding,"The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),%,9.3,31971,DB01109,Heparin
,20110016,t((1/2)),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),h,9.30,31972,DB01109,Heparin
,20110016,t((1/2)),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),h,10.37,31973,DB01109,Heparin
,20110016,t((1/2)),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),h,11.15,31974,DB01109,Heparin
,20110016,mean residence time (MRT(0-48)),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),h,12.06,31975,DB01109,Heparin
,20110016,mean residence time (MRT(0-48)),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),h,13.15,31976,DB01109,Heparin
,20110016,mean residence time (MRT(0-48)),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),h,13.00,31977,DB01109,Heparin
,20110016,elimination rate constant (k(e)),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),1/[hours],0.076,31978,DB01109,Heparin
,20110016,elimination rate constant (k(e)),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),1/[hours],0.067,31979,DB01109,Heparin
,20110016,elimination rate constant (k(e)),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),1/[hours],0.063,31980,DB01109,Heparin
,20110016,AUC(0-48),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),[μ] / [h·ml],1202.5,31981,DB01109,Heparin
,20110016,AUC(0-48),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),[μ] / [h·ml],1416.3,31982,DB01109,Heparin
,20110016,AUC(0-48),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),[μ] / [h·ml],1298.5,31983,DB01109,Heparin
,20110016,clearance (CL),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),[l] / [h·kg],1.01,31984,DB01109,Heparin
,20110016,clearance (CL),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),[l] / [h·kg],0.83,31985,DB01109,Heparin
,20110016,clearance (CL),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),[l] / [h·kg],0.92,31986,DB01109,Heparin
>,26529577,zeta potential,"On the other hand, nanocomplexes' dispersions, prepared at 1:1 heparin/chitosan mass ratio and in the concentration range 0.375-1.875mg/mL, demonstrated mean diameter <400nm and zeta potential >34mV.",Development and preclinical pharmacokinetics of a novel subcutaneous thermoresponsive system for prolonged delivery of heparin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26529577/),mv,34,32358,DB01109,Heparin
,27473996,peak remifentanil concentration,Mean peak remifentanil concentration was 7.14ηgmL(-1) at 50min after start of infusion.,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),1/[ηgml],7.14,33193,DB01109,Heparin
,27473996,volume of distribution,Mean volume of distribution was 268±40mLkg(-1) and mean half-life was 12.8min.,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),1/[mlkg],268,33194,DB01109,Heparin
,27473996,half-life,Mean volume of distribution was 268±40mLkg(-1) and mean half-life was 12.8min.,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),min,12.8,33195,DB01109,Heparin
,27473996,Limit of quantification,Limit of quantification was 0.2ηgmL(-1).,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),1/[ηgml],0.2,33196,DB01109,Heparin
<,23649851,F,"In vivo, oral Absorption at doses of 300 IU/kg was rather low (F < 2.5%) while dose increase resulted in a maximum at 600 IU/kg (FRL: 6.0 ± 1.2%; FRS: 5.8 ± 2.5%) and 1,200 IU/kg did not result in higher bioavailability (FRL: 4.6 ± 0.4%; FRS: 4.1 ± 0.8%).",Oral delivery of low molecular weight heparin by polyaminomethacrylate coacervates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649851/),%,2.5,33535,DB01109,Heparin
,23649851,bioavaila,"In vivo, oral Absorption at doses of 300 IU/kg was rather low (F < 2.5%) while dose increase resulted in a maximum at 600 IU/kg (FRL: 6.0 ± 1.2%; FRS: 5.8 ± 2.5%) and 1,200 IU/kg did not result in higher bioavailability (FRL: 4.6 ± 0.4%; FRS: 4.1 ± 0.8%).",Oral delivery of low molecular weight heparin by polyaminomethacrylate coacervates. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649851/),%,4.6,33536,DB01109,Heparin
,23649851,bioavaila,"In vivo, oral Absorption at doses of 300 IU/kg was rather low (F < 2.5%) while dose increase resulted in a maximum at 600 IU/kg (FRL: 6.0 ± 1.2%; FRS: 5.8 ± 2.5%) and 1,200 IU/kg did not result in higher bioavailability (FRL: 4.6 ± 0.4%; FRS: 4.1 ± 0.8%).",Oral delivery of low molecular weight heparin by polyaminomethacrylate coacervates. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649851/),%,4.1,33537,DB01109,Heparin
,23649851,FRL,"In vivo, oral Absorption at doses of 300 IU/kg was rather low (F < 2.5%) while dose increase resulted in a maximum at 600 IU/kg (FRL: 6.0 ± 1.2%; FRS: 5.8 ± 2.5%) and 1,200 IU/kg did not result in higher bioavailability (FRL: 4.6 ± 0.4%; FRS: 4.1 ± 0.8%).",Oral delivery of low molecular weight heparin by polyaminomethacrylate coacervates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649851/),%,4.6,33538,DB01109,Heparin
,7802862,anti Xa/anti IIa ratio,"The pharmacokinetic profile of Clivarin is characterized by a linear relationship between dose and absorption, relatively low clearance and a long elimination half-life, and a high anti Xa/anti IIa ratio of 5.3.",Pharmacokinetics of Clivarin a new low molecular weight heparin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7802862/),,5.3,34933,DB01109,Heparin
,7824963,plasmatic bioavailability,The estimated plasmatic bioavailability was about 18% for DS.,Human pharmacokinetics of glycosaminoglycans using deuterium-labeled and unlabeled substances: evidence for oral absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7824963/),%,18,34972,DB01109,Heparin
,12115833,absolute bioavailability,The absolute bioavailability of LMWH was increased from 4.0 +/- 0.4% in the absence of TDM to 19 +/- 0.3% in the presence of TDM.,Nasal administration of low molecular weight heparin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115833/),%,4.0,36681,DB01109,Heparin
,12115833,absolute bioavailability,The absolute bioavailability of LMWH was increased from 4.0 +/- 0.4% in the absence of TDM to 19 +/- 0.3% in the presence of TDM.,Nasal administration of low molecular weight heparin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115833/),%,19,36682,DB01109,Heparin
,10609418,plasma activity,"After intravenous application of 25, 50 and 100 I.U./kg body weight heparin plasma activity of 0.65 +/- 0.15 I.U./ml (mean +/- s), 0.91 +/- 0.10 I.U./ml and 1.94 +/- 0.22 I.U./ml was measured.",[Pharmacokinetics of an unfractionated heparin (Liquemin) in the dog after intravenous and subcutaneous application based on heparin activity]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10609418/),[i·u] / [ml],0.65,37860,DB01109,Heparin
,10609418,plasma activity,"After intravenous application of 25, 50 and 100 I.U./kg body weight heparin plasma activity of 0.65 +/- 0.15 I.U./ml (mean +/- s), 0.91 +/- 0.10 I.U./ml and 1.94 +/- 0.22 I.U./ml was measured.",[Pharmacokinetics of an unfractionated heparin (Liquemin) in the dog after intravenous and subcutaneous application based on heparin activity]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10609418/),[i·u] / [ml],0.91,37861,DB01109,Heparin
,10609418,plasma activity,"After intravenous application of 25, 50 and 100 I.U./kg body weight heparin plasma activity of 0.65 +/- 0.15 I.U./ml (mean +/- s), 0.91 +/- 0.10 I.U./ml and 1.94 +/- 0.22 I.U./ml was measured.",[Pharmacokinetics of an unfractionated heparin (Liquemin) in the dog after intravenous and subcutaneous application based on heparin activity]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10609418/),[i·u] / [ml],1.94,37862,DB01109,Heparin
,10609418,maximum plasma heparin activities,"Subcutaneous applications of 250, 500 or 750 I.U./kg revealed maximum plasma heparin activities of 0.25 +/- 0.10, 0.60 +/- 0.15 and 1.29 +/- 0.24 I.U./ml.",[Pharmacokinetics of an unfractionated heparin (Liquemin) in the dog after intravenous and subcutaneous application based on heparin activity]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10609418/),[i·u] / [ml],0.25,37863,DB01109,Heparin
,10609418,maximum plasma heparin activities,"Subcutaneous applications of 250, 500 or 750 I.U./kg revealed maximum plasma heparin activities of 0.25 +/- 0.10, 0.60 +/- 0.15 and 1.29 +/- 0.24 I.U./ml.",[Pharmacokinetics of an unfractionated heparin (Liquemin) in the dog after intravenous and subcutaneous application based on heparin activity]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10609418/),[i·u] / [ml],0.60,37864,DB01109,Heparin
,10609418,maximum plasma heparin activities,"Subcutaneous applications of 250, 500 or 750 I.U./kg revealed maximum plasma heparin activities of 0.25 +/- 0.10, 0.60 +/- 0.15 and 1.29 +/- 0.24 I.U./ml.",[Pharmacokinetics of an unfractionated heparin (Liquemin) in the dog after intravenous and subcutaneous application based on heparin activity]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10609418/),[i·u] / [ml],1.29,37865,DB01109,Heparin
,10609418,terminal half-life time (t50),Intravenously applicated heparin has a short terminal half-life time (t50) between 22 and 44 minutes.,[Pharmacokinetics of an unfractionated heparin (Liquemin) in the dog after intravenous and subcutaneous application based on heparin activity]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10609418/),min,22 and 44,37866,DB01109,Heparin
,10609418,t50,"After 250, 500 or 750 I.U./kg the t50 was 3.7 +/- 2.4, 3.5 +/- 1.2 or 5.3 +/- 2.4 hours.",[Pharmacokinetics of an unfractionated heparin (Liquemin) in the dog after intravenous and subcutaneous application based on heparin activity]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10609418/),h,3.7,37867,DB01109,Heparin
,10609418,t50,"After 250, 500 or 750 I.U./kg the t50 was 3.7 +/- 2.4, 3.5 +/- 1.2 or 5.3 +/- 2.4 hours.",[Pharmacokinetics of an unfractionated heparin (Liquemin) in the dog after intravenous and subcutaneous application based on heparin activity]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10609418/),h,3.5,37868,DB01109,Heparin
,10609418,t50,"After 250, 500 or 750 I.U./kg the t50 was 3.7 +/- 2.4, 3.5 +/- 1.2 or 5.3 +/- 2.4 hours.",[Pharmacokinetics of an unfractionated heparin (Liquemin) in the dog after intravenous and subcutaneous application based on heparin activity]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10609418/),h,5.3,37869,DB01109,Heparin
,10609418,Cltot,Especially the Cltot after subcutaneous injection decreased from 2.08 +/- 0.73 ml/min/kg (250 I.E./kg) to 0.83 +/- 0.27 ml/min/kg (750 I.E./kg).,[Pharmacokinetics of an unfractionated heparin (Liquemin) in the dog after intravenous and subcutaneous application based on heparin activity]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10609418/),[ml] / [kg·min],2.08,37870,DB01109,Heparin
,10609418,Cltot,Especially the Cltot after subcutaneous injection decreased from 2.08 +/- 0.73 ml/min/kg (250 I.E./kg) to 0.83 +/- 0.27 ml/min/kg (750 I.E./kg).,[Pharmacokinetics of an unfractionated heparin (Liquemin) in the dog after intravenous and subcutaneous application based on heparin activity]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10609418/),[ml] / [kg·min],0.83,37871,DB01109,Heparin
,10609418,total bioavailability,The total bioavailability of subcutaneously administered UFH was 53-100% depending on the dosage.,[Pharmacokinetics of an unfractionated heparin (Liquemin) in the dog after intravenous and subcutaneous application based on heparin activity]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10609418/),%,53-100,37872,DB01109,Heparin
,27536434,A max,"For anti-Xa activity, the means (SD) of A max (IU/mL) were 1.34 (0.25) [range = 0.59-2.03] and 1.39 (0.35) [range = 0.65-2.69]; AUC0- t (IU•h/mL) values were 11.4 (2.76) [range = 2.89-19.5] and 12.1 (2.87) [range = 2.52-21.30]; AUC0 - ∞ (IU•h/mL) values were 13.1 (3.59) [range = 3.15-28.2] and 14.5 (4.97) [range = 2.79-36.1] for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[iu] / [ml],1.34,38605,DB01109,Heparin
,27536434,A max,"For anti-Xa activity, the means (SD) of A max (IU/mL) were 1.34 (0.25) [range = 0.59-2.03] and 1.39 (0.35) [range = 0.65-2.69]; AUC0- t (IU•h/mL) values were 11.4 (2.76) [range = 2.89-19.5] and 12.1 (2.87) [range = 2.52-21.30]; AUC0 - ∞ (IU•h/mL) values were 13.1 (3.59) [range = 3.15-28.2] and 14.5 (4.97) [range = 2.79-36.1] for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[iu] / [ml],1.39,38606,DB01109,Heparin
,27536434,AUC0- t,"For anti-Xa activity, the means (SD) of A max (IU/mL) were 1.34 (0.25) [range = 0.59-2.03] and 1.39 (0.35) [range = 0.65-2.69]; AUC0- t (IU•h/mL) values were 11.4 (2.76) [range = 2.89-19.5] and 12.1 (2.87) [range = 2.52-21.30]; AUC0 - ∞ (IU•h/mL) values were 13.1 (3.59) [range = 3.15-28.2] and 14.5 (4.97) [range = 2.79-36.1] for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[h·iu] / [ml],11.4,38607,DB01109,Heparin
,27536434,AUC0- t,"For anti-Xa activity, the means (SD) of A max (IU/mL) were 1.34 (0.25) [range = 0.59-2.03] and 1.39 (0.35) [range = 0.65-2.69]; AUC0- t (IU•h/mL) values were 11.4 (2.76) [range = 2.89-19.5] and 12.1 (2.87) [range = 2.52-21.30]; AUC0 - ∞ (IU•h/mL) values were 13.1 (3.59) [range = 3.15-28.2] and 14.5 (4.97) [range = 2.79-36.1] for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[h·iu] / [ml],12.1,38608,DB01109,Heparin
,27536434,AUC0 - ∞,"For anti-Xa activity, the means (SD) of A max (IU/mL) were 1.34 (0.25) [range = 0.59-2.03] and 1.39 (0.35) [range = 0.65-2.69]; AUC0- t (IU•h/mL) values were 11.4 (2.76) [range = 2.89-19.5] and 12.1 (2.87) [range = 2.52-21.30]; AUC0 - ∞ (IU•h/mL) values were 13.1 (3.59) [range = 3.15-28.2] and 14.5 (4.97) [range = 2.79-36.1] for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[h·iu] / [ml],13.1,38609,DB01109,Heparin
,27536434,AUC0 - ∞,"For anti-Xa activity, the means (SD) of A max (IU/mL) were 1.34 (0.25) [range = 0.59-2.03] and 1.39 (0.35) [range = 0.65-2.69]; AUC0- t (IU•h/mL) values were 11.4 (2.76) [range = 2.89-19.5] and 12.1 (2.87) [range = 2.52-21.30]; AUC0 - ∞ (IU•h/mL) values were 13.1 (3.59) [range = 3.15-28.2] and 14.5 (4.97) [range = 2.79-36.1] for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[h·iu] / [ml],14.5,38610,DB01109,Heparin
,27536434,A max,"For anti-IIa activity, the means (SD) of A max (IU/mL) were 0.34 (0.12) [range = 0.14-0.72] and 0.34 (0.13) [range = 0.11-0.84]; AUC0- t (IU•h/mL) values were 2.05 (0.72) [range = 0.61-4.69] and 2.11 (0.76) [range = 0.84-4.80]; AUC0 - ∞ (IU•h/mL) values were 2.47 (0.80) [range = 0.76-6.29] and 2.61 (0.86) [range = 1.31-5.36], for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[iu] / [ml],0.34,38611,DB01109,Heparin
,27536434,A max,"For anti-IIa activity, the means (SD) of A max (IU/mL) were 0.34 (0.12) [range = 0.14-0.72] and 0.34 (0.13) [range = 0.11-0.84]; AUC0- t (IU•h/mL) values were 2.05 (0.72) [range = 0.61-4.69] and 2.11 (0.76) [range = 0.84-4.80]; AUC0 - ∞ (IU•h/mL) values were 2.47 (0.80) [range = 0.76-6.29] and 2.61 (0.86) [range = 1.31-5.36], for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[iu] / [ml],0.34,38612,DB01109,Heparin
,27536434,AUC0- t,"For anti-IIa activity, the means (SD) of A max (IU/mL) were 0.34 (0.12) [range = 0.14-0.72] and 0.34 (0.13) [range = 0.11-0.84]; AUC0- t (IU•h/mL) values were 2.05 (0.72) [range = 0.61-4.69] and 2.11 (0.76) [range = 0.84-4.80]; AUC0 - ∞ (IU•h/mL) values were 2.47 (0.80) [range = 0.76-6.29] and 2.61 (0.86) [range = 1.31-5.36], for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[h·iu] / [ml],2.05,38613,DB01109,Heparin
,27536434,AUC0- t,"For anti-IIa activity, the means (SD) of A max (IU/mL) were 0.34 (0.12) [range = 0.14-0.72] and 0.34 (0.13) [range = 0.11-0.84]; AUC0- t (IU•h/mL) values were 2.05 (0.72) [range = 0.61-4.69] and 2.11 (0.76) [range = 0.84-4.80]; AUC0 - ∞ (IU•h/mL) values were 2.47 (0.80) [range = 0.76-6.29] and 2.61 (0.86) [range = 1.31-5.36], for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[h·iu] / [ml],2.11,38614,DB01109,Heparin
,27536434,AUC0 - ∞,"For anti-IIa activity, the means (SD) of A max (IU/mL) were 0.34 (0.12) [range = 0.14-0.72] and 0.34 (0.13) [range = 0.11-0.84]; AUC0- t (IU•h/mL) values were 2.05 (0.72) [range = 0.61-4.69] and 2.11 (0.76) [range = 0.84-4.80]; AUC0 - ∞ (IU•h/mL) values were 2.47 (0.80) [range = 0.76-6.29] and 2.61 (0.86) [range = 1.31-5.36], for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[h·iu] / [ml],2.47,38615,DB01109,Heparin
,27536434,AUC0 - ∞,"For anti-IIa activity, the means (SD) of A max (IU/mL) were 0.34 (0.12) [range = 0.14-0.72] and 0.34 (0.13) [range = 0.11-0.84]; AUC0- t (IU•h/mL) values were 2.05 (0.72) [range = 0.61-4.69] and 2.11 (0.76) [range = 0.84-4.80]; AUC0 - ∞ (IU•h/mL) values were 2.47 (0.80) [range = 0.76-6.29] and 2.61 (0.86) [range = 1.31-5.36], for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[h·iu] / [ml],2.61,38616,DB01109,Heparin
,10691095,ED50,"Nevertheless, in a stasis-induced venous thrombosis model, intraduodenal UFH prevented thrombus formation in a dose-dependent way (ED50, 2000 IU/kg).",Absorption and antithrombotic activity of unfractioned heparin after intraduodenal administration in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691095/),[iu] / [kg],2000,38737,DB01109,Heparin
,24024964,maximum loading,DNPH showed a maximum loading of 22.9 μg of protamine/mg of Fe.,Long-circulating heparin-functionalized magnetic nanoparticles for potential application as a protein drug delivery platform. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24024964/),μg,22.9,38985,DB01109,Heparin
,24024964,long-circulating half-life,"In the pharmacokinetic study, DNPH displayed a long-circulating half-life of 9.37 h, 37.5-fold longer than that (0.15 h) of HP.",Long-circulating heparin-functionalized magnetic nanoparticles for potential application as a protein drug delivery platform. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24024964/),h,9.37,38986,DB01109,Heparin
,24024964,long-circulating half-life,"In the pharmacokinetic study, DNPH displayed a long-circulating half-life of 9.37 h, 37.5-fold longer than that (0.15 h) of HP.",Long-circulating heparin-functionalized magnetic nanoparticles for potential application as a protein drug delivery platform. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24024964/),h,0.15,38987,DB01109,Heparin
,1325682,bioavailability,"After subcutaneous administration, the bioavailability of C4-UH remained low (10%) at any dose while that of C4-CY 216 ranged from 42 to 120%.",Pharmacodynamic properties of long lasting butyryl heparin derivatives in the rabbit. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1325682/),%,10,39348,DB01109,Heparin
,1325682,bioavailability,"After subcutaneous administration, the bioavailability of C4-UH remained low (10%) at any dose while that of C4-CY 216 ranged from 42 to 120%.",Pharmacodynamic properties of long lasting butyryl heparin derivatives in the rabbit. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1325682/),%,42 to 120,39349,DB01109,Heparin
,15527497,TG,"TG increased from 2.14 mmol/L before, to 2.59 mmol/L after the dialysis (p < 0.01).","Lipoprotein lipase in hemodialysis patients: indications that low molecular weight heparin depletes functional stores, despite low plasma levels of the enzyme. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15527497/),[mM] / [l],2.14,39636,DB01109,Heparin
,15527497,TG,"TG increased from 2.14 mmol/L before, to 2.59 mmol/L after the dialysis (p < 0.01).","Lipoprotein lipase in hemodialysis patients: indications that low molecular weight heparin depletes functional stores, despite low plasma levels of the enzyme. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15527497/),[mM] / [l],2.59,39637,DB01109,Heparin
>,8707165,F,"Since they are mainly administered subcutaneously, then compared to UFH, they are almost completely absorbed (F > or = 90%) and, in contrast to UFH, those for which data are available in the literature exhibit linear pharmacokinetics with proportionality between anti-Xa (and anti-IIa in some cases) plasma concentration and dose, and stationary distribution volume and clearance processes when the dosage is increased.","Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8707165/),%,90,39903,DB01109,Heparin
,877532,half-life,The half-life is about 50 min and the distribution volume 3000 ml (factor Xa inhibition) and 3800 ml (radioactivity).,Pharmacokinetics of heparin after a single intravenous or subcutaneous injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/877532/),min,50,40808,DB01109,Heparin
,877532,distribution volume,The half-life is about 50 min and the distribution volume 3000 ml (factor Xa inhibition) and 3800 ml (radioactivity).,Pharmacokinetics of heparin after a single intravenous or subcutaneous injection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/877532/),ml,3000,40809,DB01109,Heparin
,877532,distribution volume,The half-life is about 50 min and the distribution volume 3000 ml (factor Xa inhibition) and 3800 ml (radioactivity).,Pharmacokinetics of heparin after a single intravenous or subcutaneous injection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/877532/),ml,3800,40810,DB01109,Heparin
above,877532,peak concentrations,"With subcutaneous injection peak concentrations above 0.2 IR heparin/ml were measured by both methods 2-4 h after administration; 9 h after administration, no further factor Xa inhibition was detectable in 2 probands.",Pharmacokinetics of heparin after a single intravenous or subcutaneous injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/877532/),[heparin·ir] / [ml],0.2,40811,DB01109,Heparin
,19446753,maximal plasma anti-Xa activities,"The highest maximal plasma anti-Xa activities and the highest bioavailabilities for enoxaparin granules (0.45+/-0.12IU/mL; 19.00+/-0.30%, respectively) and for bemiparin granules (0.54+/-0.08IU/mL; 29.02+/-4.12%, respectively) were found after oral administration of granules loaded with ERS alone at a dose of 600IU anti-Xa/kg to rabbits.",Granules in the improvement of oral heparin bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446753/),[iu] / [ml],0.45,40968,DB01109,Heparin
,19446753,maximal plasma anti-Xa activities,"The highest maximal plasma anti-Xa activities and the highest bioavailabilities for enoxaparin granules (0.45+/-0.12IU/mL; 19.00+/-0.30%, respectively) and for bemiparin granules (0.54+/-0.08IU/mL; 29.02+/-4.12%, respectively) were found after oral administration of granules loaded with ERS alone at a dose of 600IU anti-Xa/kg to rabbits.",Granules in the improvement of oral heparin bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446753/),[iu] / [ml],0.54,40969,DB01109,Heparin
,19446753,bioavailabilities,"The highest maximal plasma anti-Xa activities and the highest bioavailabilities for enoxaparin granules (0.45+/-0.12IU/mL; 19.00+/-0.30%, respectively) and for bemiparin granules (0.54+/-0.08IU/mL; 29.02+/-4.12%, respectively) were found after oral administration of granules loaded with ERS alone at a dose of 600IU anti-Xa/kg to rabbits.",Granules in the improvement of oral heparin bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446753/),%,19.00,40970,DB01109,Heparin
,19446753,bioavailabilities,"The highest maximal plasma anti-Xa activities and the highest bioavailabilities for enoxaparin granules (0.45+/-0.12IU/mL; 19.00+/-0.30%, respectively) and for bemiparin granules (0.54+/-0.08IU/mL; 29.02+/-4.12%, respectively) were found after oral administration of granules loaded with ERS alone at a dose of 600IU anti-Xa/kg to rabbits.",Granules in the improvement of oral heparin bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446753/),%,29.02,40971,DB01109,Heparin
,12200805,maximal anti-factor Xa (anti-Xa) activity,Mean maximal anti-factor Xa (anti-Xa) activity was 0.33 IU/mL 4.0 hours after SC administration and 1.33 IU/mL 0.25 hours after IV administration.,Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12200805/),[iu] / [ml],0.33,41242,DB01109,Heparin
,12200805,maximal anti-factor Xa (anti-Xa) activity,Mean maximal anti-factor Xa (anti-Xa) activity was 0.33 IU/mL 4.0 hours after SC administration and 1.33 IU/mL 0.25 hours after IV administration.,Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12200805/),[iu] / [ml],1.33,41243,DB01109,Heparin
,12200805,half-lives,"Anti-Xa half-lives were 3.89 and 2.31 hours, respectively.",Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12200805/),h,3.89,41244,DB01109,Heparin
,12200805,half-lives,"Anti-Xa half-lives were 3.89 and 2.31 hours, respectively.",Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12200805/),h,2.31,41245,DB01109,Heparin
,6883930,total amount,"The total amount of lidocaine removed was 8.9 and 12.5 mg for patients A and B, respectively.",Hemodialysis clearance of total and unbound lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883930/),,8.9,42254,DB01109,Heparin
,6883930,total amount,"The total amount of lidocaine removed was 8.9 and 12.5 mg for patients A and B, respectively.",Hemodialysis clearance of total and unbound lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883930/),,12.5,42255,DB01109,Heparin
,6883930,plasma dialysis clearance (Clp),"For patient A, the mean plasma dialysis clearance (Clp) was 28.2 +/- 6.3 ml/min for total lidocaine and 41.3 +/- 15.6 ml/min for unbound lidocaine.",Hemodialysis clearance of total and unbound lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883930/),[ml] / [min],28.2,42256,DB01109,Heparin
,6883930,plasma dialysis clearance (Clp),"For patient A, the mean plasma dialysis clearance (Clp) was 28.2 +/- 6.3 ml/min for total lidocaine and 41.3 +/- 15.6 ml/min for unbound lidocaine.",Hemodialysis clearance of total and unbound lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883930/),[ml] / [min],41.3,42257,DB01109,Heparin
,6883930,dial,"The mean dialysate clearance (Cld) of total lidocaine was 28.6 +/- 7.8 and 26.3 +/- 6.5 ml/min for patients A and B, respectively.",Hemodialysis clearance of total and unbound lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883930/),[ml] / [min],28.6,42258,DB01109,Heparin
,6883930,Cld,"The Cld of unbound lidocaine was 42.7 +/- 6.7 and 44.5 +/- 9.9 for patients A and B, respectively.",Hemodialysis clearance of total and unbound lidocaine. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883930/),,42.7,42259,DB01109,Heparin
,6883930,Cld,"The Cld of unbound lidocaine was 42.7 +/- 6.7 and 44.5 +/- 9.9 for patients A and B, respectively.",Hemodialysis clearance of total and unbound lidocaine. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883930/),,44.5,42260,DB01109,Heparin
,6883930,unbound fractions,"Although both patients A and B had substantial elevations in AAG concentrations (254 and 247 mg/dl, respectively), they exhibited high lidocaine unbound fractions of 0.55 and 0.68 before dialysis.",Hemodialysis clearance of total and unbound lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883930/),,0.55,42261,DB01109,Heparin
,6883930,unbound fractions,"Although both patients A and B had substantial elevations in AAG concentrations (254 and 247 mg/dl, respectively), they exhibited high lidocaine unbound fractions of 0.55 and 0.68 before dialysis.",Hemodialysis clearance of total and unbound lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883930/),,0.68,42262,DB01109,Heparin
,17523052,IC(50),Enalaprilat inhibited the hydrolysis of BIO1211 in a concentration-dependent manner with IC(50) values of 2 nM in human and sheep plasma and 10 nM in rat plasma.,Effect of enalapril on the in vitro and in vivo peptidyl cleavage of a potent VLA-4 antagonist. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523052/),nM,2,42375,DB01109,Heparin
,17523052,IC(50),Enalaprilat inhibited the hydrolysis of BIO1211 in a concentration-dependent manner with IC(50) values of 2 nM in human and sheep plasma and 10 nM in rat plasma.,Effect of enalapril on the in vitro and in vivo peptidyl cleavage of a potent VLA-4 antagonist. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523052/),nM,10,42376,DB01109,Heparin
,32097685,half-lives,"Pharmacokinetic profiles of DOPAC and 3-HPAA followed a two-compartment body model, with a fast distribution into peripheral tissues (half-lives of 3.27-5.26 min) and rapid elimination from the body (half-lives of 18.4-33.3 min).","Single dose pharmacokinetics of intravenous 3,4-dihydroxyphenylacetic acid and 3-hydroxyphenylacetic acid in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32097685/),min,3.27-5.26,42421,DB01109,Heparin
,32097685,half-lives,"Pharmacokinetic profiles of DOPAC and 3-HPAA followed a two-compartment body model, with a fast distribution into peripheral tissues (half-lives of 3.27-5.26 min) and rapid elimination from the body (half-lives of 18.4-33.3 min).","Single dose pharmacokinetics of intravenous 3,4-dihydroxyphenylacetic acid and 3-hydroxyphenylacetic acid in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32097685/),min,18.4-33.3,42422,DB01109,Heparin
,29378154,Maximum concentrations,"Maximum concentrations of IVM in plasma and mean residence time of IVM were lower after oral (10.2 (SD 7.2) ng/mL and 0.38 (SD 0.14) days, respectively) than after S/C (82.9 (SD 12.4) ng/mL and 1.05 (SD 0.24) days, respectively) administration (p<0.01).",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),[ng] / [ml],10.2,44382,DB01109,Heparin
,29378154,Maximum concentrations,"Maximum concentrations of IVM in plasma and mean residence time of IVM were lower after oral (10.2 (SD 7.2) ng/mL and 0.38 (SD 0.14) days, respectively) than after S/C (82.9 (SD 12.4) ng/mL and 1.05 (SD 0.24) days, respectively) administration (p<0.01).",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),[ng] / [ml],82.9,44383,DB01109,Heparin
,29378154,Maximum concentrations,"Maximum concentrations of IVM in plasma and mean residence time of IVM were lower after oral (10.2 (SD 7.2) ng/mL and 0.38 (SD 0.14) days, respectively) than after S/C (82.9 (SD 12.4) ng/mL and 1.05 (SD 0.24) days, respectively) administration (p<0.01).",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),d,1.05,44384,DB01109,Heparin
,29378154,mean residence time,"Maximum concentrations of IVM in plasma and mean residence time of IVM were lower after oral (10.2 (SD 7.2) ng/mL and 0.38 (SD 0.14) days, respectively) than after S/C (82.9 (SD 12.4) ng/mL and 1.05 (SD 0.24) days, respectively) administration (p<0.01).",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),d,0.38,44385,DB01109,Heparin
,29378154,mean residence time,"Maximum concentrations of IVM in plasma and mean residence time of IVM were lower after oral (10.2 (SD 7.2) ng/mL and 0.38 (SD 0.14) days, respectively) than after S/C (82.9 (SD 12.4) ng/mL and 1.05 (SD 0.24) days, respectively) administration (p<0.01).",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),d,1.05,44386,DB01109,Heparin
,29378154,time to maximum concentration,"The time to maximum concentration and elimination half-life were shorter following oral (0.14 (SD 0.04) and 0.23 (SD 0.11) days, respectively) than S/C (0.25 (SD 0.00) and 1.45 (SD 0.45) days, respectively) administration (p<0.01).",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),d,0.14,44387,DB01109,Heparin
,29378154,time to maximum concentration,"The time to maximum concentration and elimination half-life were shorter following oral (0.14 (SD 0.04) and 0.23 (SD 0.11) days, respectively) than S/C (0.25 (SD 0.00) and 1.45 (SD 0.45) days, respectively) administration (p<0.01).",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),d,0.25,44388,DB01109,Heparin
,29378154,elimination half-life,"The time to maximum concentration and elimination half-life were shorter following oral (0.14 (SD 0.04) and 0.23 (SD 0.11) days, respectively) than S/C (0.25 (SD 0.00) and 1.45 (SD 0.45) days, respectively) administration (p<0.01).",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),d,0.23,44389,DB01109,Heparin
,29378154,elimination half-life,"The time to maximum concentration and elimination half-life were shorter following oral (0.14 (SD 0.04) and 0.23 (SD 0.11) days, respectively) than S/C (0.25 (SD 0.00) and 1.45 (SD 0.45) days, respectively) administration (p<0.01).",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),d,1.45,44390,DB01109,Heparin
,29378154,Peak concentrations,"Peak concentrations of IVM were 15.7, 23.3 and 1.9 µg/kg, observed 2, 5 and 4 days after I/V, S/C and oral administration, respectively.",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),[μg] / [kg],15.7,44391,DB01109,Heparin
,29378154,Peak concentrations,"Peak concentrations of IVM were 15.7, 23.3 and 1.9 µg/kg, observed 2, 5 and 4 days after I/V, S/C and oral administration, respectively.",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),[μg] / [kg],23.3,44392,DB01109,Heparin
,29378154,Peak concentrations,"Peak concentrations of IVM were 15.7, 23.3 and 1.9 µg/kg, observed 2, 5 and 4 days after I/V, S/C and oral administration, respectively.",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),[μg] / [kg],1.9,44393,DB01109,Heparin
,29761517,peak drug concentration,"The peak drug concentration at 30 min after dosing (23.8 ± 2.1 vs. 26.1 ± 2 μg/ml, p = .043) and area under the curve (70.4 ± 10.5 vs. 90.4 ± 17.6 μg hr/ml, p = .015) were significantly lower in young-adult compared to aged alpacas.",Pharmacokinetics of intravenous gentamicin in healthy young-adult compared to aged alpacas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29761517/),[μg] / [ml],23.8,44456,DB01109,Heparin
,29761517,peak drug concentration,"The peak drug concentration at 30 min after dosing (23.8 ± 2.1 vs. 26.1 ± 2 μg/ml, p = .043) and area under the curve (70.4 ± 10.5 vs. 90.4 ± 17.6 μg hr/ml, p = .015) were significantly lower in young-adult compared to aged alpacas.",Pharmacokinetics of intravenous gentamicin in healthy young-adult compared to aged alpacas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29761517/),[μg] / [ml],26.1,44457,DB01109,Heparin
,29761517,area under the curve,"The peak drug concentration at 30 min after dosing (23.8 ± 2.1 vs. 26.1 ± 2 μg/ml, p = .043) and area under the curve (70.4 ± 10.5 vs. 90.4 ± 17.6 μg hr/ml, p = .015) were significantly lower in young-adult compared to aged alpacas.",Pharmacokinetics of intravenous gentamicin in healthy young-adult compared to aged alpacas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29761517/),[h·μg] / [ml],70.4,44458,DB01109,Heparin
,29761517,area under the curve,"The peak drug concentration at 30 min after dosing (23.8 ± 2.1 vs. 26.1 ± 2 μg/ml, p = .043) and area under the curve (70.4 ± 10.5 vs. 90.4 ± 17.6 μg hr/ml, p = .015) were significantly lower in young-adult compared to aged alpacas.",Pharmacokinetics of intravenous gentamicin in healthy young-adult compared to aged alpacas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29761517/),[h·μg] / [ml],90.4,44459,DB01109,Heparin
,29761517,systemic clearance,"Accordingly, young alpacas had a significantly greater systemic clearance than older animals (95.5 ± 14.4 and 75.6 ± 16.1 ml hr-1 kg-1 ; p = .018), respectively).",Pharmacokinetics of intravenous gentamicin in healthy young-adult compared to aged alpacas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29761517/),[ml] / [h·kg],95.5,44460,DB01109,Heparin
,29761517,systemic clearance,"Accordingly, young alpacas had a significantly greater systemic clearance than older animals (95.5 ± 14.4 and 75.6 ± 16.1 ml hr-1 kg-1 ; p = .018), respectively).",Pharmacokinetics of intravenous gentamicin in healthy young-adult compared to aged alpacas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29761517/),[ml] / [h·kg],75.6,44461,DB01109,Heparin
≤,29761517,MIC,"In conclusion, a single 6.6 mg/kg intravenous gentamicin injection achieves target blood concentrations of >10 times the MIC of gentamicin-susceptible pathogens with MIC levels ≤2 μg/ml, in both young-adult and geriatric alpacas.",Pharmacokinetics of intravenous gentamicin in healthy young-adult compared to aged alpacas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29761517/),[μg] / [ml],2,44462,DB01109,Heparin
,9200334,relative bioavailability,"The relative bioavailability of the aXa activity, aIIa activity, and the plasma concentrations ranged between 70 and 100%.",Comparison of the pharmacodynamic and pharmacokinetic profiles of two low-molecular-mass heparins in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9200334/),%,70 and 100,45896,DB01109,Heparin
,7485329,peak plasma heparin concentration,"However, the peak plasma heparin concentration in pregnant subjects was significantly lower than in controls (0.11 +/- 0.017 units/ml vs 0.23 +/- 0.036 units/ml) and the time to peak plasma heparin concentration was significantly shorter in the pregnant patients compared with the nonpregnant controls (113 +/- 20 minutes vs 222 +/- 20 minutes).",Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7485329/),[units] / [ml],0.11,45929,DB01109,Heparin
,7485329,peak plasma heparin concentration,"However, the peak plasma heparin concentration in pregnant subjects was significantly lower than in controls (0.11 +/- 0.017 units/ml vs 0.23 +/- 0.036 units/ml) and the time to peak plasma heparin concentration was significantly shorter in the pregnant patients compared with the nonpregnant controls (113 +/- 20 minutes vs 222 +/- 20 minutes).",Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7485329/),[units] / [ml],0.23,45930,DB01109,Heparin
,7485329,time to peak plasma heparin concentration,"However, the peak plasma heparin concentration in pregnant subjects was significantly lower than in controls (0.11 +/- 0.017 units/ml vs 0.23 +/- 0.036 units/ml) and the time to peak plasma heparin concentration was significantly shorter in the pregnant patients compared with the nonpregnant controls (113 +/- 20 minutes vs 222 +/- 20 minutes).",Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7485329/),min,113,45931,DB01109,Heparin
,7485329,time to peak plasma heparin concentration,"However, the peak plasma heparin concentration in pregnant subjects was significantly lower than in controls (0.11 +/- 0.017 units/ml vs 0.23 +/- 0.036 units/ml) and the time to peak plasma heparin concentration was significantly shorter in the pregnant patients compared with the nonpregnant controls (113 +/- 20 minutes vs 222 +/- 20 minutes).",Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7485329/),min,222,45932,DB01109,Heparin
,7485329,peak activated partial thromboplastin time,The peak activated partial thromboplastin time (30.3 +/- 1.7 seconds) was significantly lower and time to peak activated partial thromboplastin time (137 +/- 31 minutes) significantly shorter in the pregnant women compared with nonpregnant controls (50 +/- 4.0 seconds; 230 +/- 26 minutes).,Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7485329/),seconds,30.3,45933,DB01109,Heparin
,7485329,time to peak activated partial thromboplastin time,The peak activated partial thromboplastin time (30.3 +/- 1.7 seconds) was significantly lower and time to peak activated partial thromboplastin time (137 +/- 31 minutes) significantly shorter in the pregnant women compared with nonpregnant controls (50 +/- 4.0 seconds; 230 +/- 26 minutes).,Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7485329/),min,137,45934,DB01109,Heparin
,7485329,time to peak activated partial thromboplastin time,The peak activated partial thromboplastin time (30.3 +/- 1.7 seconds) was significantly lower and time to peak activated partial thromboplastin time (137 +/- 31 minutes) significantly shorter in the pregnant women compared with nonpregnant controls (50 +/- 4.0 seconds; 230 +/- 26 minutes).,Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7485329/),seconds,50,45935,DB01109,Heparin
,7485329,time to peak activated partial thromboplastin time,The peak activated partial thromboplastin time (30.3 +/- 1.7 seconds) was significantly lower and time to peak activated partial thromboplastin time (137 +/- 31 minutes) significantly shorter in the pregnant women compared with nonpregnant controls (50 +/- 4.0 seconds; 230 +/- 26 minutes).,Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7485329/),min,230,45936,DB01109,Heparin
approached,2468354,absolute bioavailability,"2. The absolute bioavailability of Org 10172 as measured by plasma anti-Xa activity, glycosaminoglycuronans with no affinity to antithrombin III (NoA-GAG) and thrombin generation inhibiting activity approached 100% in both sexes.",Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468354/),%,100,46688,DB01109,Heparin
,2468354,half-life of elimination,3. The half-life of elimination of its anti-Xa activity (19.2 +/- 6.1 h) was similar to that found previously in young volunteers.,Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468354/),h,19.2,46689,DB01109,Heparin
,2468354,t1/2,Org 10172 was further characterised by a rapid disappearance from the circulation of its anti-thrombin activity (t1/2 1.8 +/- 0.6 h) and of the NoA-GAG (t1/2 3.5 +/- 2.1 h).,Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468354/),h,1.8,46690,DB01109,Heparin
,2468354,t1/2,Org 10172 was further characterised by a rapid disappearance from the circulation of its anti-thrombin activity (t1/2 1.8 +/- 0.6 h) and of the NoA-GAG (t1/2 3.5 +/- 2.1 h).,Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468354/),h,3.5,46691,DB01109,Heparin
,2468354,t1/2,4. Its thrombin generation inhibiting activity was of intermediate duration (t1/2 elimination 6.2 +/- 4.0 h).,Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468354/),h,6.2,46692,DB01109,Heparin
,8663206,half-life (t1/2),"In vivo, IFN-gamma is eliminated from the bloodstream with a half-life (t1/2) of 1.1 min, due to binding to heparan sulfate.",Heparin decreases the blood clearance of interferon-gamma and increases its activity by limiting the processing of its carboxyl-terminal sequence. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8663206/),min,1.1,47804,DB01109,Heparin
,8663206,t1/2,"When bound to heparin, the plasma clearance of IFN-gamma is decreased greatly (t1/2 = 99 min), and the area under the curve obtained with IFN-gamma alone represented only 15% of that obtained with injected IFN-gamma bound to heparin.",Heparin decreases the blood clearance of interferon-gamma and increases its activity by limiting the processing of its carboxyl-terminal sequence. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8663206/),min,99,47805,DB01109,Heparin
,15657783,steady state,"Baseline NAC was on average 454 ng ml(-1); its concentration increased to 9,253 ng ml(-1) at the second infusion and attained a steady state between 14,000 ng ml(-1) and 17,000 ng ml(-1) at the fourth dose.",Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657783/),[ng] / [ml],"14,000",48595,DB01109,Heparin
,15657783,steady state,"Baseline NAC was on average 454 ng ml(-1); its concentration increased to 9,253 ng ml(-1) at the second infusion and attained a steady state between 14,000 ng ml(-1) and 17,000 ng ml(-1) at the fourth dose.",Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657783/),[ng] / [ml],"17,000",48596,DB01109,Heparin
,15657783,C (max),"We observed a C (max) of 53,458 ng ml(-1) with a t (max) of 3.0 h.",Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657783/),[ng] / [ml],"53,458",48597,DB01109,Heparin
,15657783,t (max),"We observed a C (max) of 53,458 ng ml(-1) with a t (max) of 3.0 h.",Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657783/),h,3.0,48598,DB01109,Heparin
,15657783,Plasma clearance,Plasma clearance was 1.25 l h(-1) and dialytic clearance 5.52 l h(-1).,Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657783/),[l] / [h],1.25,48599,DB01109,Heparin
,15657783,dialytic clearance,Plasma clearance was 1.25 l h(-1) and dialytic clearance 5.52 l h(-1).,Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657783/),[l] / [h],5.52,48600,DB01109,Heparin
,15657783,total body clearance,"The dialytic clearance is effective, the total body clearance being reduced to 1.25 l h(-1).",Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657783/),[l] / [h],1.25,48601,DB01109,Heparin
,18436089,Terminal half-life,Terminal half-life was 54 minutes.,Pharmacodynamics of unfractionated heparin during and after a hemodialysis session. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18436089/),min,54,49066,DB01109,Heparin
,18436089,anti-Xa activities,"Median anti-Xa activities were 0.55 IU/mL at peak, 0.25 IU/mL at end of the 4-hour session, and less than 0.1 IU/mL at 90 minutes after the session.",Pharmacodynamics of unfractionated heparin during and after a hemodialysis session. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18436089/),[iu] / [ml],0.55,49067,DB01109,Heparin
,18436089,anti-Xa activities,"Median anti-Xa activities were 0.55 IU/mL at peak, 0.25 IU/mL at end of the 4-hour session, and less than 0.1 IU/mL at 90 minutes after the session.",Pharmacodynamics of unfractionated heparin during and after a hemodialysis session. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18436089/),[iu] / [ml],0.25,49068,DB01109,Heparin
less,18436089,anti-Xa activities,"Median anti-Xa activities were 0.55 IU/mL at peak, 0.25 IU/mL at end of the 4-hour session, and less than 0.1 IU/mL at 90 minutes after the session.",Pharmacodynamics of unfractionated heparin during and after a hemodialysis session. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18436089/),[iu] / [ml],0.1,49069,DB01109,Heparin
,18436089,Peak,"Peak values were 1.1, 0.8, 0.6, and 0.5 IU/mL, respectively.",Pharmacodynamics of unfractionated heparin during and after a hemodialysis session. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18436089/),[iu] / [ml],1.1,49070,DB01109,Heparin
,18436089,Peak,"Peak values were 1.1, 0.8, 0.6, and 0.5 IU/mL, respectively.",Pharmacodynamics of unfractionated heparin during and after a hemodialysis session. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18436089/),[iu] / [ml],0.8,49071,DB01109,Heparin
,18436089,Peak,"Peak values were 1.1, 0.8, 0.6, and 0.5 IU/mL, respectively.",Pharmacodynamics of unfractionated heparin during and after a hemodialysis session. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18436089/),[iu] / [ml],0.6,49072,DB01109,Heparin
,18436089,Peak,"Peak values were 1.1, 0.8, 0.6, and 0.5 IU/mL, respectively.",Pharmacodynamics of unfractionated heparin during and after a hemodialysis session. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18436089/),[iu] / [ml],0.5,49073,DB01109,Heparin
over,2552603,bioavailability,After IV injection the clearance of the antifactor Xa activities was independent of the dose and the clearance of UH was significantly higher than that of CY 216; after SC injection the bioavailability estimated from the antifactor Xa effect was consistently over 100% for CY 216 while that of UH increased from 27% at the lowest dose to 93% at the highest dose.,Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2552603/),%,100,49624,DB01109,Heparin
,2552603,bioavailability,After IV injection the clearance of the antifactor Xa activities was independent of the dose and the clearance of UH was significantly higher than that of CY 216; after SC injection the bioavailability estimated from the antifactor Xa effect was consistently over 100% for CY 216 while that of UH increased from 27% at the lowest dose to 93% at the highest dose.,Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2552603/),%,27,49625,DB01109,Heparin
,2552603,bioavailability,After IV injection the clearance of the antifactor Xa activities was independent of the dose and the clearance of UH was significantly higher than that of CY 216; after SC injection the bioavailability estimated from the antifactor Xa effect was consistently over 100% for CY 216 while that of UH increased from 27% at the lowest dose to 93% at the highest dose.,Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2552603/),%,93,49626,DB01109,Heparin
,11144698,elimination half-life,"Pharmacokinetic parameters calculated from these concentrations using a one-compartment model were elimination half-life four hours, volume of distribution 0.13 L/kg, and clearance 0.022 L/kg/h.",Use of enoxaparin in a preterm infant. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144698/),h,four,49676,DB01109,Heparin
,11144698,volume of distribution,"Pharmacokinetic parameters calculated from these concentrations using a one-compartment model were elimination half-life four hours, volume of distribution 0.13 L/kg, and clearance 0.022 L/kg/h.",Use of enoxaparin in a preterm infant. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144698/),[l] / [kg],0.13,49677,DB01109,Heparin
,11144698,clearance,"Pharmacokinetic parameters calculated from these concentrations using a one-compartment model were elimination half-life four hours, volume of distribution 0.13 L/kg, and clearance 0.022 L/kg/h.",Use of enoxaparin in a preterm infant. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144698/),[l] / [h·kg],0.022,49678,DB01109,Heparin
,31232851,half-life,A 50 U/kg dose of antithrombin had a simulated half-life 13.2 ± 6.6 hours.,Antithrombin Population Pharmacokinetics in Pediatric Ventricular Assist Device Patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31232851/),h,13.2,49844,DB01109,Heparin
,17334516,ED(50),"In the prevention model, rivaroxaban reduced thrombus formation dose-dependently (calculated ED(50) 1.3 mg/kg).","Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17334516/),[mg] / [kg],1.3,50323,DB01109,Heparin
,9733364,half-life of,"The half-life of the initial phase was 4 min, and that of the terminal phase was 162-209 min.","Pharmacokinetics and pharmacodynamics of SM-20302, a GPIIb/IIIa receptor antagonist, in anesthetized dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9733364/),min,4,51264,DB01109,Heparin
,9733364,half-life of,"The half-life of the initial phase was 4 min, and that of the terminal phase was 162-209 min.","Pharmacokinetics and pharmacodynamics of SM-20302, a GPIIb/IIIa receptor antagonist, in anesthetized dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9733364/),min,162-209,51265,DB01109,Heparin
,9733364,Plasma clearance,Plasma clearance for SM-20302 ranged from 6.58 to 9.73 ml/min/kg.,"Pharmacokinetics and pharmacodynamics of SM-20302, a GPIIb/IIIa receptor antagonist, in anesthetized dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9733364/),[ml] / [kg·min],6.58 to 9.73,51266,DB01109,Heparin
,9733364,median,"By using a sigmoid Emax model, the in vivo median inhibitory concentration (IC50) for SM-20302 was estimated to be 14-19 ng/ml in cPRP and 79-89 ng/ml in hPRP.","Pharmacokinetics and pharmacodynamics of SM-20302, a GPIIb/IIIa receptor antagonist, in anesthetized dogs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9733364/),[ng] / [ml],14-19,51267,DB01109,Heparin
,9733364,inhibitory concentration (IC50),"By using a sigmoid Emax model, the in vivo median inhibitory concentration (IC50) for SM-20302 was estimated to be 14-19 ng/ml in cPRP and 79-89 ng/ml in hPRP.","Pharmacokinetics and pharmacodynamics of SM-20302, a GPIIb/IIIa receptor antagonist, in anesthetized dogs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9733364/),[ng] / [ml],14-19,51268,DB01109,Heparin
,9733364,inhibitory concentration (IC50),"By using a sigmoid Emax model, the in vivo median inhibitory concentration (IC50) for SM-20302 was estimated to be 14-19 ng/ml in cPRP and 79-89 ng/ml in hPRP.","Pharmacokinetics and pharmacodynamics of SM-20302, a GPIIb/IIIa receptor antagonist, in anesthetized dogs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9733364/),[ng] / [ml],79-89,51269,DB01109,Heparin
,17139369,maximum concentration (Cmax ),The mean (range) PK parameters determined after the 4th dose were as follows: i) maximum concentration (Cmax ) was 0.31 IU/ml (0.06 to 0.55 IU/ml); ii) time to Cmax was 3.55 hours (2.59 to 4.96 hr); iii) area under the curve was 3.24 IU*hr/ml (0.64 to 6.44 IU*hr/ml); iv) half-life was 3.82 hr (2.03 to 9.63 hr); and v) trough anti-factor Xa activity 0.04 IU/ml (0.02 to 0.08 IU/ml).,A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139369/),[iu] / [ml],0.31,52147,DB01109,Heparin
,17139369,time to Cmax,The mean (range) PK parameters determined after the 4th dose were as follows: i) maximum concentration (Cmax ) was 0.31 IU/ml (0.06 to 0.55 IU/ml); ii) time to Cmax was 3.55 hours (2.59 to 4.96 hr); iii) area under the curve was 3.24 IU*hr/ml (0.64 to 6.44 IU*hr/ml); iv) half-life was 3.82 hr (2.03 to 9.63 hr); and v) trough anti-factor Xa activity 0.04 IU/ml (0.02 to 0.08 IU/ml).,A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139369/),h,3.55,52148,DB01109,Heparin
,17139369,area under the curve,The mean (range) PK parameters determined after the 4th dose were as follows: i) maximum concentration (Cmax ) was 0.31 IU/ml (0.06 to 0.55 IU/ml); ii) time to Cmax was 3.55 hours (2.59 to 4.96 hr); iii) area under the curve was 3.24 IU*hr/ml (0.64 to 6.44 IU*hr/ml); iv) half-life was 3.82 hr (2.03 to 9.63 hr); and v) trough anti-factor Xa activity 0.04 IU/ml (0.02 to 0.08 IU/ml).,A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139369/),[h·iu] / [ml],3.24,52149,DB01109,Heparin
,17139369,half-life,The mean (range) PK parameters determined after the 4th dose were as follows: i) maximum concentration (Cmax ) was 0.31 IU/ml (0.06 to 0.55 IU/ml); ii) time to Cmax was 3.55 hours (2.59 to 4.96 hr); iii) area under the curve was 3.24 IU*hr/ml (0.64 to 6.44 IU*hr/ml); iv) half-life was 3.82 hr (2.03 to 9.63 hr); and v) trough anti-factor Xa activity 0.04 IU/ml (0.02 to 0.08 IU/ml).,A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139369/),h,3.82,52150,DB01109,Heparin
,17139369,trough anti-factor Xa activity,The mean (range) PK parameters determined after the 4th dose were as follows: i) maximum concentration (Cmax ) was 0.31 IU/ml (0.06 to 0.55 IU/ml); ii) time to Cmax was 3.55 hours (2.59 to 4.96 hr); iii) area under the curve was 3.24 IU*hr/ml (0.64 to 6.44 IU*hr/ml); iv) half-life was 3.82 hr (2.03 to 9.63 hr); and v) trough anti-factor Xa activity 0.04 IU/ml (0.02 to 0.08 IU/ml).,A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139369/),[iu] / [ml],0.04,52151,DB01109,Heparin
,29977164,terminal half-life,"Betrixaban has the longest half-life among the DOAC class, with a terminal half-life of 35-45 h and an effective half-life of 19-27 h.",Pharmacological properties of betrixaban. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29977164/),h,35-45,53299,DB01109,Heparin
,29977164,effective half-life,"Betrixaban has the longest half-life among the DOAC class, with a terminal half-life of 35-45 h and an effective half-life of 19-27 h.",Pharmacological properties of betrixaban. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29977164/),h,19-27,53300,DB01109,Heparin
,8212732,EC50,"The values of EC50 associated with the activation of a single 'receptor' and of a proposed additional 'receptor' were 3 and 13 micrograms/ml of heparin material, respectively.","Relationship between pharmacokinetics and pharmacodynamics of tinzaparin (logiparin), a low molecular weight heparin, in dogs. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8212732/),[μg] / [ml],3,54436,DB01109,Heparin
,8212732,EC50,"The values of EC50 associated with the activation of a single 'receptor' and of a proposed additional 'receptor' were 3 and 13 micrograms/ml of heparin material, respectively.","Relationship between pharmacokinetics and pharmacodynamics of tinzaparin (logiparin), a low molecular weight heparin, in dogs. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8212732/),[μg] / [ml],13,54437,DB01109,Heparin
,15961985,peak anti-Xa activities,kg(-1) x 12 h(-)1 in patients with severe renal impairment should avoid accumulation of enoxaparin and keep peak anti-Xa activities between 0.5 and 1.2 IU/mL for a large majority of patients.,Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15961985/),[iu] / [ml],0.5 and 1.2,54844,DB01109,Heparin
,2363243,elimination half-lives,"With respect to the long elimination half-lives (mean values 39-94 h), caution is needed in case of repeated doses (accumulation).",Age-dependent pharmacokinetics of phenylbutazone in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363243/),h,39-94,55556,DB01109,Heparin
,10560804,SCs,"The observed SCs and clearances differed significantly between F50 and Nephral 200 (0.60+/-0.17 and 21.0+/-5.9 ml/min, respectively, vs. 0.44+/-0.09 and 15.5+/-3.0 ml/min, respectively; P = 0.001).",Hirudin elimination by hemofiltration: a comparative in vitro study of different membranes. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10560804/),[ml] / [min],0.60,56250,DB01109,Heparin
,10560804,SCs,"The observed SCs and clearances differed significantly between F50 and Nephral 200 (0.60+/-0.17 and 21.0+/-5.9 ml/min, respectively, vs. 0.44+/-0.09 and 15.5+/-3.0 ml/min, respectively; P = 0.001).",Hirudin elimination by hemofiltration: a comparative in vitro study of different membranes. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10560804/),[ml] / [min],0.44,56251,DB01109,Heparin
,10560804,clearances,"The observed SCs and clearances differed significantly between F50 and Nephral 200 (0.60+/-0.17 and 21.0+/-5.9 ml/min, respectively, vs. 0.44+/-0.09 and 15.5+/-3.0 ml/min, respectively; P = 0.001).",Hirudin elimination by hemofiltration: a comparative in vitro study of different membranes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10560804/),[ml] / [min],21.0,56252,DB01109,Heparin
,10560804,clearances,"The observed SCs and clearances differed significantly between F50 and Nephral 200 (0.60+/-0.17 and 21.0+/-5.9 ml/min, respectively, vs. 0.44+/-0.09 and 15.5+/-3.0 ml/min, respectively; P = 0.001).",Hirudin elimination by hemofiltration: a comparative in vitro study of different membranes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10560804/),[ml] / [min],15.5,56253,DB01109,Heparin
,27347822,peak anti-Xa activity,"RESULTS 2 hours after the second injection, the target peak anti-Xa activity range of 0.5 to 1.0 U/mL was achieved in all cats, whereas median trough values remained below this range.",Assessment of the effects of dalteparin on coagulation variables and determination of a treatment schedule for use in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27347822/),[u] / [ml],0.5 to 1.0,56282,DB01109,Heparin
,10323789,activated partial thromboplastin time,This concentration prolonged the activated partial thromboplastin time from 32+/-1 seconds to 79+/-4 seconds (P<0.01).,Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10323789/),seconds,32,56772,DB01109,Heparin
,10323789,activated partial thromboplastin time,This concentration prolonged the activated partial thromboplastin time from 32+/-1 seconds to 79+/-4 seconds (P<0.01).,Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10323789/),seconds,79,56773,DB01109,Heparin
,10323789,activated,"PEG-hirudin in plasma concentrations of 0.5, 2.5, and 5 microg/mL prolonged the activated partial thromboplastin time to 48+/-2, 87+/-4, and 118+/-4 seconds, respectively.",Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10323789/),seconds,48,56774,DB01109,Heparin
,9430774,peak plasma concentrations,"The peak plasma concentrations of pentoxifylline and metabolite I occurred at 15 min after bolus injection and were 9.2 +/- 1.4 and 7.8 +/- 4.3 micrograms/mL, respectively.",The effects of pentoxifylline infusion on plasma 6-keto-prostaglandin F1 alpha and ex vivo endotoxin-induced tumour necrosis factor activity in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430774/),[μg] / [ml],9.2,56959,DB01109,Heparin
,9430774,peak plasma concentrations,"The peak plasma concentrations of pentoxifylline and metabolite I occurred at 15 min after bolus injection and were 9.2 +/- 1.4 and 7.8 +/- 4.3 micrograms/mL, respectively.",The effects of pentoxifylline infusion on plasma 6-keto-prostaglandin F1 alpha and ex vivo endotoxin-induced tumour necrosis factor activity in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430774/),[μg] / [ml],7.8,56960,DB01109,Heparin
,9430774,half-life of elimination (t1/2 beta),The half-life of elimination (t1/2 beta) of pentoxifylline was 1.44 h and volume of distribution (Vdarea) was 0.94 L/kg.,The effects of pentoxifylline infusion on plasma 6-keto-prostaglandin F1 alpha and ex vivo endotoxin-induced tumour necrosis factor activity in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430774/),h,1.44,56961,DB01109,Heparin
,9430774,volume of distribution (Vdarea),The half-life of elimination (t1/2 beta) of pentoxifylline was 1.44 h and volume of distribution (Vdarea) was 0.94 L/kg.,The effects of pentoxifylline infusion on plasma 6-keto-prostaglandin F1 alpha and ex vivo endotoxin-induced tumour necrosis factor activity in horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430774/),[l] / [kg],0.94,56962,DB01109,Heparin
>,9031463,half-life,The absorption and elimination were first-order processes and the long half-life (> 5 h) kept constant after increasing doses.,Pharmacokinetics and tolerability of a new low molecular mass heparin (RO-11) in healthy volunteers--a dose-finding study within the therapeutical range. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9031463/),h,5,58101,DB01109,Heparin
,2463884,time,This time was prolonged to 60 seconds when HBGF I was injected with heparin.,Pharmacokinetics and distribution of heparin-binding growth factor I (endothelial cell growth factor) in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2463884/),seconds,60,58732,DB01109,Heparin
,2463884,elimination half-life,The elimination half-life of HBGF I was 14 minutes in the presence of heparin.,Pharmacokinetics and distribution of heparin-binding growth factor I (endothelial cell growth factor) in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2463884/),min,14,58733,DB01109,Heparin
,27493093,protamine-to-heparin,"There was no difference in heparin administration (414±107 mg (CD) v 403±90 mg (PK); p = 0.54), whereas protamine dosing was considerably different with a protamine-to-heparin dosing ratio of 1.1±0.3 for the CD group and 0.5±0.1 for the PK group (p<0.001).",A Pharmacokinetic Model for Protamine Dosing After Cardiopulmonary Bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27493093/),,1.1,59569,DB01109,Heparin
,27493093,protamine-to-heparin,"There was no difference in heparin administration (414±107 mg (CD) v 403±90 mg (PK); p = 0.54), whereas protamine dosing was considerably different with a protamine-to-heparin dosing ratio of 1.1±0.3 for the CD group and 0.5±0.1 for the PK group (p<0.001).",A Pharmacokinetic Model for Protamine Dosing After Cardiopulmonary Bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27493093/),,0.5,59570,DB01109,Heparin
,27493093,dosing ratio,"There was no difference in heparin administration (414±107 mg (CD) v 403±90 mg (PK); p = 0.54), whereas protamine dosing was considerably different with a protamine-to-heparin dosing ratio of 1.1±0.3 for the CD group and 0.5±0.1 for the PK group (p<0.001).",A Pharmacokinetic Model for Protamine Dosing After Cardiopulmonary Bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27493093/),,1.1,59571,DB01109,Heparin
,27493093,dosing ratio,"There was no difference in heparin administration (414±107 mg (CD) v 403±90 mg (PK); p = 0.54), whereas protamine dosing was considerably different with a protamine-to-heparin dosing ratio of 1.1±0.3 for the CD group and 0.5±0.1 for the PK group (p<0.001).",A Pharmacokinetic Model for Protamine Dosing After Cardiopulmonary Bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27493093/),,0.5,59572,DB01109,Heparin
,27493093,activated coagulation time (ΔACT),The changes in activated coagulation time (ΔACT) values (ACT after protamine minus preoperative ACT;+17±77 s v+6±15 s; p = 0.31) were equal between groups.,A Pharmacokinetic Model for Protamine Dosing After Cardiopulmonary Bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27493093/),s,17,59573,DB01109,Heparin
,27493093,activated coagulation time (ΔACT),The changes in activated coagulation time (ΔACT) values (ACT after protamine minus preoperative ACT;+17±77 s v+6±15 s; p = 0.31) were equal between groups.,A Pharmacokinetic Model for Protamine Dosing After Cardiopulmonary Bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27493093/),s,6,59574,DB01109,Heparin
,27493093,clotting time (CT,"Yet, the thromboelastometric intrinsically activated coagulation test clotting time (CT; 250±76 s v 203±44 s; p<0.001) and intrinsically activated coagulation test without the heparin effect CT (275±105 v 198±32 s; p<0.001) were prolonged in the CD group.",A Pharmacokinetic Model for Protamine Dosing After Cardiopulmonary Bypass. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27493093/),s,250,59575,DB01109,Heparin
,27493093,clotting time (CT,"Yet, the thromboelastometric intrinsically activated coagulation test clotting time (CT; 250±76 s v 203±44 s; p<0.001) and intrinsically activated coagulation test without the heparin effect CT (275±105 v 198±32 s; p<0.001) were prolonged in the CD group.",A Pharmacokinetic Model for Protamine Dosing After Cardiopulmonary Bypass. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27493093/),s,203,59576,DB01109,Heparin
,27493093,CT,"Yet, the thromboelastometric intrinsically activated coagulation test clotting time (CT; 250±76 s v 203±44 s; p<0.001) and intrinsically activated coagulation test without the heparin effect CT (275±105 v 198±32 s; p<0.001) were prolonged in the CD group.",A Pharmacokinetic Model for Protamine Dosing After Cardiopulmonary Bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27493093/),s,275,59577,DB01109,Heparin
,27493093,CT,"Yet, the thromboelastometric intrinsically activated coagulation test clotting time (CT; 250±76 s v 203±44 s; p<0.001) and intrinsically activated coagulation test without the heparin effect CT (275±105 v 198±32 s; p<0.001) were prolonged in the CD group.",A Pharmacokinetic Model for Protamine Dosing After Cardiopulmonary Bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27493093/),s,198,59578,DB01109,Heparin
,23230876,half-life,"Using flow rates typical of adults receiving CVVHDF, we determined a median half-life for arterial magnesium concentration to decay to a new steady state of 4.73 hours (interquartile range [IQR], 3.73-7.32 hours).",Magnesium flux during continuous venovenous haemodiafiltration with heparin and citrate anticoagulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230876/),h,4.73,59905,DB01109,Heparin
,23230876,arterial magnesium concentration,"Median arterial magnesium concentration was 0.88mmol/L (IQR, 0.83-0.97mmol/L) in the heparin group and 0.79mmol/L (IQR, 0.69-0.91mmol/L) in the citrate group.",Magnesium flux during continuous venovenous haemodiafiltration with heparin and citrate anticoagulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230876/),[mM] / [l],0.88,59906,DB01109,Heparin
,23230876,arterial magnesium concentration,"Median arterial magnesium concentration was 0.88mmol/L (IQR, 0.83-0.97mmol/L) in the heparin group and 0.79mmol/L (IQR, 0.69-0.91mmol/L) in the citrate group.",Magnesium flux during continuous venovenous haemodiafiltration with heparin and citrate anticoagulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230876/),[mM] / [l],0.79,59907,DB01109,Heparin
,28267480,concentration,"The median concentration of betrixaban among subjects administered the 80-mg dose was higher than that of the 40-mg dose (19 ng/mL vs 11 ng/mL, P<.001).",The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28267480/),[ng] / [ml],11,60446,DB01109,Heparin
,26792118,plasma half-life,Median argatroban plasma half-life was 2.7 hours (interquartile range 1.8 to 7.3).,Argatroban pharmacokinetics and pharmacodynamics in critically ill cardiac surgical patients with suspected heparin-induced thrombocytopenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26792118/),h,2.7,60472,DB01109,Heparin
> or =,11504781,Apparent distribution volumes,Apparent distribution volumes were high (> or =1 l/kg).,"Pharmacokinetics and tissue distribution of SB-251353, a novel human CXC chemokine, after intravenous administration to mice. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504781/),[l] / [kg],1,60805,DB01109,Heparin
<,11504781,excretion,Limited excretion of SB-251353 in the urine (<2%) was consistent with catabolism of the chemokine in the tubules.,"Pharmacokinetics and tissue distribution of SB-251353, a novel human CXC chemokine, after intravenous administration to mice. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504781/),%,2,60806,DB01109,Heparin
,2764536,ff,"CPB markedly increased the in vitro ff, which was reversed by protamine post-CPB (ff pre-CPB, 0.15 +/- 0.01; during CPB, 0.53 +/- 0.20; post-CPB, 0.16 +/- 0.02).",Ceftriaxone disposition in open-heart surgery patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2764536/),,0.15,62072,DB01109,Heparin
,2764536,ff,"CPB markedly increased the in vitro ff, which was reversed by protamine post-CPB (ff pre-CPB, 0.15 +/- 0.01; during CPB, 0.53 +/- 0.20; post-CPB, 0.16 +/- 0.02).",Ceftriaxone disposition in open-heart surgery patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2764536/),,0.53,62073,DB01109,Heparin
,2764536,ff,"CPB markedly increased the in vitro ff, which was reversed by protamine post-CPB (ff pre-CPB, 0.15 +/- 0.01; during CPB, 0.53 +/- 0.20; post-CPB, 0.16 +/- 0.02).",Ceftriaxone disposition in open-heart surgery patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2764536/),,0.16,62074,DB01109,Heparin
,2764536,ff,"The in vitro ff exceeded the in vivo ff (0.53 +/- 0.20 versus 0.24 +/- 0.07), probably due to continued free fatty acid release caused by heparin during dialysis.",Ceftriaxone disposition in open-heart surgery patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2764536/),,0.53,62075,DB01109,Heparin
,2764536,ff,"The in vitro ff exceeded the in vivo ff (0.53 +/- 0.20 versus 0.24 +/- 0.07), probably due to continued free fatty acid release caused by heparin during dialysis.",Ceftriaxone disposition in open-heart surgery patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2764536/),,0.24,62076,DB01109,Heparin
,2764536,renal clearance due to filtration,"Clearances based on free drug decreased, and the renal clearance due to filtration increased (7.6 +/- 2.8 versus 15.0 +/- 4.5 ml/min) while the creatinine clearance decreased (114 +/- 29 versus 72 +/- 28 ml/min) during CPB.",Ceftriaxone disposition in open-heart surgery patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2764536/),[ml] / [min],7.6,62077,DB01109,Heparin
,2764536,renal clearance due to filtration,"Clearances based on free drug decreased, and the renal clearance due to filtration increased (7.6 +/- 2.8 versus 15.0 +/- 4.5 ml/min) while the creatinine clearance decreased (114 +/- 29 versus 72 +/- 28 ml/min) during CPB.",Ceftriaxone disposition in open-heart surgery patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2764536/),[ml] / [min],15.0,62078,DB01109,Heparin
,2764536,volume of distribution,Lower binding also increased the volume of distribution (154 +/- 41 ml/kg) and extended the half-life (15 +/- 6 h).,Ceftriaxone disposition in open-heart surgery patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2764536/),[ml] / [kg],154,62079,DB01109,Heparin
,2764536,half-life,Lower binding also increased the volume of distribution (154 +/- 41 ml/kg) and extended the half-life (15 +/- 6 h).,Ceftriaxone disposition in open-heart surgery patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2764536/),h,15,62080,DB01109,Heparin
,3142086,apparent Mr,"Using a combination of chromatography on Sephadex G25, Sephadex G75 and Heparin Sepharose CL6B we have isolated two fibrinolytically active species, which, under non-reduced SDS PAGE, have apparent Mr = 38,000 and 56,000.","Isolation, identification and pharmacokinetic properties of human tissue-type plasminogen activator species: possible localisation of a clearance recognition site. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142086/),,"38,000",62635,DB01109,Heparin
,3142086,apparent Mr,"Using a combination of chromatography on Sephadex G25, Sephadex G75 and Heparin Sepharose CL6B we have isolated two fibrinolytically active species, which, under non-reduced SDS PAGE, have apparent Mr = 38,000 and 56,000.","Isolation, identification and pharmacokinetic properties of human tissue-type plasminogen activator species: possible localisation of a clearance recognition site. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142086/),,"56,000",62636,DB01109,Heparin
,16497407,coupling ratio,"The calculated coupling ratio and bioactivity of LMWH-DOCA was 3.6 and 126.8 IU/mg, respectively.","Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16497407/),[iu] / [mg],3.6,63786,DB01109,Heparin
,16497407,bioactivity,"The calculated coupling ratio and bioactivity of LMWH-DOCA was 3.6 and 126.8 IU/mg, respectively.","Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16497407/),[iu] / [mg],126.8,63787,DB01109,Heparin
,16497407,maximum anti-factor Xa activity,"When 100 mg/kg (12,680 IU/kg) of LMWH-DOCA was administered to rats or mice, its maximum anti-factor Xa activity was 0.76+/-0.15 and 0.15+/-0.03 IU/ml, respectively.","Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16497407/),[iu] / [ml],0.76,63788,DB01109,Heparin
,16497407,maximum anti-factor Xa activity,"When 100 mg/kg (12,680 IU/kg) of LMWH-DOCA was administered to rats or mice, its maximum anti-factor Xa activity was 0.76+/-0.15 and 0.15+/-0.03 IU/ml, respectively.","Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16497407/),[iu] / [ml],0.15,63789,DB01109,Heparin
,16497407,anti-factor Xa activity,"On the other hand, when a single dose of 100 mg/kg LMWH-DOCA mixed with either a bile solution or 200 mg/kg free DOCA was administered to mice, the anti-factor Xa activity of LMWH-DOCA was 0.42-0.45 IU/ml.","Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16497407/),[iu] / [ml],0.42-0.45,63790,DB01109,Heparin
,16497407,bioavailability,"In the monkey experiments, the bioavailability of LMWH-DOCA after administering 200 mg/kg free DOCA orally was 6.8%, which was 8 times higher than that of LMWH (0.8%) and 4 times higher than that of LMWH-DOCA in the absence of free DOCA (1.7%).","Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16497407/),%,6.8,63791,DB01109,Heparin
,16497407,bioavailability,"In the monkey experiments, the bioavailability of LMWH-DOCA after administering 200 mg/kg free DOCA orally was 6.8%, which was 8 times higher than that of LMWH (0.8%) and 4 times higher than that of LMWH-DOCA in the absence of free DOCA (1.7%).","Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16497407/),%,0.8,63792,DB01109,Heparin
,16497407,bioavailability,"In the monkey experiments, the bioavailability of LMWH-DOCA after administering 200 mg/kg free DOCA orally was 6.8%, which was 8 times higher than that of LMWH (0.8%) and 4 times higher than that of LMWH-DOCA in the absence of free DOCA (1.7%).","Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16497407/),%,1.7,63793,DB01109,Heparin
,15850607,anti-Xa,"Mean (95% confidence interval (95% CI)) anti-Xa was equal to 1.14 IU/mL (1.07-1.21) and 1.14 IU/mL (1.08-1.20) among patients who received one (n=92) and two injections (n=122) per day, respectively.",Dosage of enoxaparin among obese and renal impairment patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15850607/),[iu] / [ml],1.14,64532,DB01109,Heparin
,15850607,anti-Xa,"Mean (95% confidence interval (95% CI)) anti-Xa was equal to 1.14 IU/mL (1.07-1.21) and 1.14 IU/mL (1.08-1.20) among patients who received one (n=92) and two injections (n=122) per day, respectively.",Dosage of enoxaparin among obese and renal impairment patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15850607/),[iu] / [ml],1.14,64533,DB01109,Heparin
,15850607,Anti,"Anti-Xa increases with body mass index (BMI) (0.01 IU/mL for each kg/m2; 95% CI: 0.002-0.017), but the increase is insufficient to reach supratherapeutic anti-Xa.",Dosage of enoxaparin among obese and renal impairment patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15850607/),[iu] / [ml],0.01,64534,DB01109,Heparin
,9815004,half-life,"The heparin-washable component of the hepatic uptake clearance of 125I-HGF was only slightly changed, whereas the heparin-resistant component was significantly reduced 30 min after injection of excess HGF, followed by gradual recovery with a half-life of 3.2 h.",Ligand-induced downregulation of receptor-mediated clearance of hepatocyte growth factor in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815004/),h,3.2,64742,DB01109,Heparin
,11028251,k,"Sensitivity analysis based on the literature produced estimates of the k at 1.39 to 2.77 h-1, the pool of binding sites of 50 units/kg, and the regeneration rate of 15 to 20 unit/kg/h--virtually identical to the empirically derived guidelines for the bolus size and infusion rate for unfractionated heparin.",The use of time step simulations and difference equations (TSSADEQ) in modeling heparin pharmacokinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028251/),1/[h],1.39 to 2.77,65005,DB01109,Heparin
,11028251,pool of binding sites,"Sensitivity analysis based on the literature produced estimates of the k at 1.39 to 2.77 h-1, the pool of binding sites of 50 units/kg, and the regeneration rate of 15 to 20 unit/kg/h--virtually identical to the empirically derived guidelines for the bolus size and infusion rate for unfractionated heparin.",The use of time step simulations and difference equations (TSSADEQ) in modeling heparin pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028251/),[units] / [kg],50,65006,DB01109,Heparin
,11028251,regeneration rate,"Sensitivity analysis based on the literature produced estimates of the k at 1.39 to 2.77 h-1, the pool of binding sites of 50 units/kg, and the regeneration rate of 15 to 20 unit/kg/h--virtually identical to the empirically derived guidelines for the bolus size and infusion rate for unfractionated heparin.",The use of time step simulations and difference equations (TSSADEQ) in modeling heparin pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028251/),[unit] / [h·kg],15 to 20,65007,DB01109,Heparin
,33245951,half-life,"GIP half-life following intravenous injection amounted to 93 ± 2 s, which was extended to 5 ± 0.6 min by inhibition of DPP-4.",Pharmacokinetics of exogenous GIP(1-42) in C57Bl/6 mice; Extremely rapid degradation but marked variation between available assays. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33245951/),s,93,66463,DB01109,Heparin
,33245951,half-life,"GIP half-life following intravenous injection amounted to 93 ± 2 s, which was extended to 5 ± 0.6 min by inhibition of DPP-4.",Pharmacokinetics of exogenous GIP(1-42) in C57Bl/6 mice; Extremely rapid degradation but marked variation between available assays. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33245951/),min,5,66464,DB01109,Heparin
,9167018,IC50,The IC50 on TG in PPP and in whole blood were 1.80 +/- 0.16 and 4.33 +/- 1.01 micrograms.,Long-term persistence of low-molecular-weight material with anti-factor Xa activity contributes to anticoagulant and antithrombotic effects after subcutaneous injection of CY 216 in the rabbit. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167018/),μg,1.80,67147,DB01109,Heparin
,9167018,IC50,The IC50 on TG in PPP and in whole blood were 1.80 +/- 0.16 and 4.33 +/- 1.01 micrograms.,Long-term persistence of low-molecular-weight material with anti-factor Xa activity contributes to anticoagulant and antithrombotic effects after subcutaneous injection of CY 216 in the rabbit. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167018/),μg,4.33,67148,DB01109,Heparin
,10386230,TERalb,"The mean (+/- SD) TERalb was increased by diabetes compared with values in normal rats (17.5 +/- 3 vs 14.1 +/- 3.3%/h, respectively).",Effects of heparin on vascular dysfunction in diabetic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10386230/),[%] / [h],17.5,67235,DB01109,Heparin
,10386230,TERalb,"The mean (+/- SD) TERalb was increased by diabetes compared with values in normal rats (17.5 +/- 3 vs 14.1 +/- 3.3%/h, respectively).",Effects of heparin on vascular dysfunction in diabetic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10386230/),[%] / [h],14.1,67236,DB01109,Heparin
,10386230,Album,"[131I]-Albumin clearance was significantly increased in diabetic rats in the eye, skin and skeletal muscle tissues compared with normal rats (0.17-0.40 vs 0.1-0.23 microL plasma/g per min).",Effects of heparin on vascular dysfunction in diabetic rats. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10386230/),[plasma·μl] / [g·min],0.17-0.40,67237,DB01109,Heparin
,10386230,clearance,"[131I]-Albumin clearance was significantly increased in diabetic rats in the eye, skin and skeletal muscle tissues compared with normal rats (0.17-0.40 vs 0.1-0.23 microL plasma/g per min).",Effects of heparin on vascular dysfunction in diabetic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10386230/),[plasma·μl] / [g·min],0.17-0.40,67238,DB01109,Heparin
,10386230,clearance,"[131I]-Albumin clearance was significantly increased in diabetic rats in the eye, skin and skeletal muscle tissues compared with normal rats (0.17-0.40 vs 0.1-0.23 microL plasma/g per min).",Effects of heparin on vascular dysfunction in diabetic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10386230/),[plasma·μl] / [g·min],0.1-0.23,67239,DB01109,Heparin
,16790078,Cmax,"The mean Cmax value was not different between ICU patients with and without subcutaneous oedema (0.15 +/- 0.02 versus 0.14 +/- 0.02 IU/ml, p = 0.34).",Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16790078/),[iu] / [ml],0.15,67308,DB01109,Heparin
,16790078,Cmax,"The mean Cmax value was not different between ICU patients with and without subcutaneous oedema (0.15 +/- 0.02 versus 0.14 +/- 0.02 IU/ml, p = 0.34).",Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16790078/),[iu] / [ml],0.14,67309,DB01109,Heparin
,16790078,AUC(0-24 h),"In the index group, the mean AUC(0-24 h) value was slightly higher compared with the reference group (1.50 +/- 0.31 versus 1.15 +/- 0.25 h.IU/ml, p = 0.31).",Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16790078/),[h·iu] / [ml],1.50,67310,DB01109,Heparin
,16790078,AUC(0-24 h),"In the index group, the mean AUC(0-24 h) value was slightly higher compared with the reference group (1.50 +/- 0.31 versus 1.15 +/- 0.25 h.IU/ml, p = 0.31).",Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16790078/),[h·iu] / [ml],1.15,67311,DB01109,Heparin
,25280062,anti,Six patients did not reach a therapeutic anti-Xa activity target (0.6-1.2 IU/ml) at 4 h after LMWH administration.,Pharmacokinetics of low molecular weight heparin in patients with malignant tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25280062/),[iu] / [ml],0.6-1.2,67623,DB01109,Heparin
,25280062,anti-factor Xa,Four patients did not reach anti-factor Xa values of 0.6 IU/ml throughout the trial.,Pharmacokinetics of low molecular weight heparin in patients with malignant tumors. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25280062/),[iu] / [ml],0.6,67624,DB01109,Heparin
,25280062,anti-Xa activity,"The median anti-Xa activity before LMWH injection was 0.24 IU/ml (range 0.07-0.7 IU/ml), as opposed to 0.52 IU/ml in historical controls.",Pharmacokinetics of low molecular weight heparin in patients with malignant tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25280062/),[iu] / [ml],0.24,67625,DB01109,Heparin
,25280062,anti-Xa activity,"The median anti-Xa activity before LMWH injection was 0.24 IU/ml (range 0.07-0.7 IU/ml), as opposed to 0.52 IU/ml in historical controls.",Pharmacokinetics of low molecular weight heparin in patients with malignant tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25280062/),[iu] / [ml],0.52,67626,DB01109,Heparin
,25280062,anti-Xa activity,"The median anti-Xa activity 4 h after LMWH injection was 0.58 IU/ml (range 0.22-1.23 IU/ml), as opposed to 1.2 IU/ml in historical controls.",Pharmacokinetics of low molecular weight heparin in patients with malignant tumors. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25280062/),[iu] / [ml],0.58,67627,DB01109,Heparin
,25280062,anti-Xa activity,"The median anti-Xa activity 4 h after LMWH injection was 0.58 IU/ml (range 0.22-1.23 IU/ml), as opposed to 1.2 IU/ml in historical controls.",Pharmacokinetics of low molecular weight heparin in patients with malignant tumors. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25280062/),[iu] / [ml],1.2,67628,DB01109,Heparin
,26171322,flow rate,The flow rate was 500 μl/min along with a 5 μl injection volume.,Bioanalytical Method for Carbocisteine in Human Plasma by Using LC-MS/MS: A Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26171322/),[μl] / [min],500,68064,DB01109,Heparin
,26171322,MR,The MRM mode of the ions for carbocisteine was 180.0 > 89.0 and for rosiglitazone it was 238.1 > 135.1.,Bioanalytical Method for Carbocisteine in Human Plasma by Using LC-MS/MS: A Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26171322/),,180.0,68065,DB01109,Heparin
,26171322,MR,The MRM mode of the ions for carbocisteine was 180.0 > 89.0 and for rosiglitazone it was 238.1 > 135.1.,Bioanalytical Method for Carbocisteine in Human Plasma by Using LC-MS/MS: A Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26171322/),,238.1,68066,DB01109,Heparin
,26171322,retention times,"The retention times of carbocisteine and the internal standard rosiglitazone were approximately 2.20 and 3.01 min, respectively.",Bioanalytical Method for Carbocisteine in Human Plasma by Using LC-MS/MS: A Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26171322/),min,2.20,68067,DB01109,Heparin
,26171322,retention times,"The retention times of carbocisteine and the internal standard rosiglitazone were approximately 2.20 and 3.01 min, respectively.",Bioanalytical Method for Carbocisteine in Human Plasma by Using LC-MS/MS: A Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26171322/),min,3.01,68068,DB01109,Heparin
,26171322,overall run time,The overall run time was 4.50 min.,Bioanalytical Method for Carbocisteine in Human Plasma by Using LC-MS/MS: A Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26171322/),min,4.50,68069,DB01109,Heparin
,9268354,second order rate constants,"Reaction with thrombin was rapid with bimolecular and second order rate constants of 1.3 x 10(9) M-1 s-1 and 3.1 x 10(9) M-1 s-1, respectively.","Covalent antithrombin-heparin complexes with high anticoagulant activity. Intravenous, subcutaneous, and intratracheal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9268354/),1/[M·s],1.3 x 10(9),71614,DB01109,Heparin
,9268354,second order rate constants,"Reaction with thrombin was rapid with bimolecular and second order rate constants of 1.3 x 10(9) M-1 s-1 and 3.1 x 10(9) M-1 s-1, respectively.","Covalent antithrombin-heparin complexes with high anticoagulant activity. Intravenous, subcutaneous, and intratracheal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9268354/),1/[M·s],3.1 x 10(9),71615,DB01109,Heparin
,9268354,half-life,The intravenous half-life of the complex in rabbits was 2.6 h as compared with 0.32 h for similar loads of heparin.,"Covalent antithrombin-heparin complexes with high anticoagulant activity. Intravenous, subcutaneous, and intratracheal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9268354/),h,2.6,71616,DB01109,Heparin
,9268354,half-life,The intravenous half-life of the complex in rabbits was 2.6 h as compared with 0.32 h for similar loads of heparin.,"Covalent antithrombin-heparin complexes with high anticoagulant activity. Intravenous, subcutaneous, and intratracheal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9268354/),h,0.32,71617,DB01109,Heparin
,27913481,clearance,"His creatinine at diagnosis is 1.4 mg/dL, with an estimated clearance of 63 mL/min.",Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27913481/),[ml] / [min],63,73184,DB01109,Heparin
,19767097,absolute bioavailability,"No significant anticoagulant activity was detected after oral administration of the free form heparin solution in a rat model, while administration of NPs orally was effective in the delivery of heparin into the blood stream; the absolute bioavailability was found to be 20.5%.","The characteristics, biodistribution and bioavailability of a chitosan-based nanoparticulate system for the oral delivery of heparin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19767097/),%,20.5,74232,DB01109,Heparin
,21306770,surface charge,NPs prepared by the ionic interaction between polymer and TRAIL showed uniform spherical structures of diameter 213.3 ± 9.7 nm and a surface charge of 5.33 ± 1.2 mV.,Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21306770/),m,5.33,74535,DB01109,Heparin
,17854496,anti-Xa levels,"Based on a mathematical model, a dosing scheme for danaparoid was designed, aiming at anti-Xa levels of 0.5 to 0.7 U/mL, with a maximum of 1.0 U/mL.",Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854496/),[u] / [ml],0.5 to 0.7,75054,DB01109,Heparin
,17854496,anti-Xa levels,"Based on a mathematical model, a dosing scheme for danaparoid was designed, aiming at anti-Xa levels of 0.5 to 0.7 U/mL, with a maximum of 1.0 U/mL.",Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854496/),[u] / [ml],1.0,75055,DB01109,Heparin
,17854496,blood flow rate,"CVVH with a blood flow rate of 150 mL/minute and a substitution rate of 2,000 mL/hour was performed with a cellulose triacetate membrane.",Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854496/),[ml] / [min],150,75056,DB01109,Heparin
,17854496,substitution rate,"CVVH with a blood flow rate of 150 mL/minute and a substitution rate of 2,000 mL/hour was performed with a cellulose triacetate membrane.",Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854496/),[ml] / [h],"2,000",75057,DB01109,Heparin
,17854496,anti-Xa activity,The median anti-Xa activity reached a maximum of 1.02 (0.66 to 1.31) anti-Xa-U/mL after 15 minutes and gradually declined to 0.40 (0.15 to 0.58) anti-Xa-U/mL over the span of 24 hours.,Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854496/),[a-u·anti-] / [ml],1.02,75058,DB01109,Heparin
,17854496,anti-Xa activity,The median anti-Xa activity reached a maximum of 1.02 (0.66 to 1.31) anti-Xa-U/mL after 15 minutes and gradually declined to 0.40 (0.15 to 0.58) anti-Xa-U/mL over the span of 24 hours.,Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854496/),[a-u·anti-] / [ml],0.40,75059,DB01109,Heparin
,17854496,fragment F1+2,Median prothrombin fragment F1+2 gradually decreased from 432 (200 to 768) to 262 (248 to 317) pmol/L after 24 hours.,Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854496/),[pM] / [l],432,75060,DB01109,Heparin
,17854496,fragment F1+2,Median prothrombin fragment F1+2 gradually decreased from 432 (200 to 768) to 262 (248 to 317) pmol/L after 24 hours.,Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854496/),[pM] / [l],262,75061,DB01109,Heparin
,15168087,peak concentration,Pharmacokinetics showed a mean peak concentration (12.7 ng/ml) 12 h after the first injection and a mean half-life of 18.1 h.,CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15168087/),[ng] / [ml],12.7,75316,DB01109,Heparin
,15168087,half-life,Pharmacokinetics showed a mean peak concentration (12.7 ng/ml) 12 h after the first injection and a mean half-life of 18.1 h.,CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15168087/),h,18.1,75317,DB01109,Heparin
,2851016,terminal half-lives,"The terminal half-lives of anti-IIa and anti-Xa activities were approximately 2 and 4 hours, respectively, with no significant variation between the different doses.","The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2851016/),h,2,75905,DB01109,Heparin
,2851016,terminal half-lives,"The terminal half-lives of anti-IIa and anti-Xa activities were approximately 2 and 4 hours, respectively, with no significant variation between the different doses.","The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2851016/),h,4,75906,DB01109,Heparin
,2851016,apparent volume of distribution,Enoxaparine displays a relatively small apparent volume of distribution (about 7.0 L) and its total body clearance is about 1.25 L/hr.,"The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2851016/),l,7.0,75907,DB01109,Heparin
,2851016,total body clearance,Enoxaparine displays a relatively small apparent volume of distribution (about 7.0 L) and its total body clearance is about 1.25 L/hr.,"The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2851016/),[l] / [h],1.25,75908,DB01109,Heparin
,2851016,mean residence time,The mean residence time ranges from 4.6 to 7.6 hours.,"The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2851016/),h,4.6 to 7.6,75909,DB01109,Heparin
,15225677,retention times,"Based on the present study, the retention times for CPA and CHA were 3.029 +/- 0.017 min and 5.07 +/- 0.031 min, respectively.",Clearance of cyclopentyladenosine and cyclohexyladenosine in rats following a single subcutaneous dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15225677/),min,3.029,77917,DB01109,Heparin
,15225677,retention times,"Based on the present study, the retention times for CPA and CHA were 3.029 +/- 0.017 min and 5.07 +/- 0.031 min, respectively.",Clearance of cyclopentyladenosine and cyclohexyladenosine in rats following a single subcutaneous dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15225677/),min,5.07,77918,DB01109,Heparin
,15225677,half-lives,"In addition, the maximum concentrations of CPA and CHA were measured 60 and 80 min after the administration, and the half-lives of these compounds in the circulation were approximately 48.5 +/- 4.4 min and 106.6 +/- 7.4 min, respectively.",Clearance of cyclopentyladenosine and cyclohexyladenosine in rats following a single subcutaneous dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15225677/),min,48.5,77919,DB01109,Heparin
,15225677,half-lives,"In addition, the maximum concentrations of CPA and CHA were measured 60 and 80 min after the administration, and the half-lives of these compounds in the circulation were approximately 48.5 +/- 4.4 min and 106.6 +/- 7.4 min, respectively.",Clearance of cyclopentyladenosine and cyclohexyladenosine in rats following a single subcutaneous dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15225677/),min,106.6,77920,DB01109,Heparin
,15225677,elimination half-life,"Moreover, in the present study, the elimination half-life was approximately sevenfold longer than that previously reported for CPA (48.5 +/- 4.4 min versus 6.9 +/- 0.5] min).",Clearance of cyclopentyladenosine and cyclohexyladenosine in rats following a single subcutaneous dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15225677/),min,48.5,77921,DB01109,Heparin
,15225677,elimination half-life,"Moreover, in the present study, the elimination half-life was approximately sevenfold longer than that previously reported for CPA (48.5 +/- 4.4 min versus 6.9 +/- 0.5] min).",Clearance of cyclopentyladenosine and cyclohexyladenosine in rats following a single subcutaneous dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15225677/),min,6.9,77922,DB01109,Heparin
,24401673,anti-Xa activity,The mean anti-Xa activity at the end of haemodialysis (Clast) was 0.15 IU/ml in group 1 and 0.60 IU/ml in group 2.,Pharmacokinetics of dalteparin during haemodialysis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24401673/),[iu] / [ml],0.15,78657,DB01109,Heparin
,24401673,anti-Xa activity,The mean anti-Xa activity at the end of haemodialysis (Clast) was 0.15 IU/ml in group 1 and 0.60 IU/ml in group 2.,Pharmacokinetics of dalteparin during haemodialysis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24401673/),[iu] / [ml],0.60,78658,DB01109,Heparin
,3433260,half-life,"Our present findings indicating a mean half-life of 3.0 days are quite comparable to studies by others on non-heat treated AT III, however.",Properties and catabolism of heat treated antithrombin III concentrate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433260/),d,3.0,79256,DB01109,Heparin
,22460596,protein binding,The protein binding was significantly higher in the native Tibetan group (70.5 %) compared to the native Han group (67.3 %) (p < 0.05).,Comparison of the pharmacokinetics of sulfamethoxazole in native Han and Tibetan male Chinese volunteers living at high altitude. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22460596/),%,70.5,80123,DB01109,Heparin
,22460596,protein binding,The protein binding was significantly higher in the native Tibetan group (70.5 %) compared to the native Han group (67.3 %) (p < 0.05).,Comparison of the pharmacokinetics of sulfamethoxazole in native Han and Tibetan male Chinese volunteers living at high altitude. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22460596/),%,67.3,80124,DB01109,Heparin
,22460596,binding,"The binding of sulfamethoxazole to red blood cells was 7.4 and 8.3 % in the native Han and native Tibetan groups, respectively.",Comparison of the pharmacokinetics of sulfamethoxazole in native Han and Tibetan male Chinese volunteers living at high altitude. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22460596/),%,7.4,80125,DB01109,Heparin
,22460596,binding,"The binding of sulfamethoxazole to red blood cells was 7.4 and 8.3 % in the native Han and native Tibetan groups, respectively.",Comparison of the pharmacokinetics of sulfamethoxazole in native Han and Tibetan male Chinese volunteers living at high altitude. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22460596/),%,8.3,80126,DB01109,Heparin
,17668298,Plasma AUCss,"Plasma AUCss of [125I] rhHB-EGF equivalents following IB administration for 7 days were 4.28+/-2.29, 7.75+/-2.70, and 7.11+/-1.42 ng ml(-1) h(-1) at doses of 3, 10, and 30 microg/kg, respectively.",Toxicokinetic study of recombinant human heparin-binding epidermal growth factor-like growth factor (rhHB-EGF) in female Sprague Dawley rats. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17668298/),[ng] / [h·ml],4.28,81069,DB01109,Heparin
,17668298,Plasma AUCss,"Plasma AUCss of [125I] rhHB-EGF equivalents following IB administration for 7 days were 4.28+/-2.29, 7.75+/-2.70, and 7.11+/-1.42 ng ml(-1) h(-1) at doses of 3, 10, and 30 microg/kg, respectively.",Toxicokinetic study of recombinant human heparin-binding epidermal growth factor-like growth factor (rhHB-EGF) in female Sprague Dawley rats. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17668298/),[ng] / [h·ml],7.75,81070,DB01109,Heparin
,17668298,Plasma AUCss,"Plasma AUCss of [125I] rhHB-EGF equivalents following IB administration for 7 days were 4.28+/-2.29, 7.75+/-2.70, and 7.11+/-1.42 ng ml(-1) h(-1) at doses of 3, 10, and 30 microg/kg, respectively.",Toxicokinetic study of recombinant human heparin-binding epidermal growth factor-like growth factor (rhHB-EGF) in female Sprague Dawley rats. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17668298/),[ng] / [h·ml],7.11,81071,DB01109,Heparin
,17668298,AUCss,"Following IV administration, the AUCss on day 7 increased from 27.0+/-2.66 to 124+/-5.09 and 385.11+/-7.57 ng ml(-1) h(-1) with increasing the dose from 3 to 10 and 30 microg/kg.",Toxicokinetic study of recombinant human heparin-binding epidermal growth factor-like growth factor (rhHB-EGF) in female Sprague Dawley rats. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17668298/),[ng] / [h·ml],27.0,81072,DB01109,Heparin
,17668298,AUCss,"Following IV administration, the AUCss on day 7 increased from 27.0+/-2.66 to 124+/-5.09 and 385.11+/-7.57 ng ml(-1) h(-1) with increasing the dose from 3 to 10 and 30 microg/kg.",Toxicokinetic study of recombinant human heparin-binding epidermal growth factor-like growth factor (rhHB-EGF) in female Sprague Dawley rats. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17668298/),[ng] / [h·ml],124,81073,DB01109,Heparin
,17668298,AUCss,"Following IV administration, the AUCss on day 7 increased from 27.0+/-2.66 to 124+/-5.09 and 385.11+/-7.57 ng ml(-1) h(-1) with increasing the dose from 3 to 10 and 30 microg/kg.",Toxicokinetic study of recombinant human heparin-binding epidermal growth factor-like growth factor (rhHB-EGF) in female Sprague Dawley rats. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17668298/),[ng] / [h·ml],385.11,81074,DB01109,Heparin
,1716644,clearance of anti-Xa activity,"Chlorthalidone produced a slight decrease in clearance of anti-Xa activity from 7.1 +/- 1.0 to 6.6 +/- 0.8 mL/min and a decrease of the volume of distribution from 0.20 +/- 0.05 to 0.16 +/- 0.04 L/kg, whereas the volume of distribution of antithrombin activity increased from 0.14 +/- 0.05 to 0.26 +/- 0.10 L/kg (all differences P less than .05).","Influence of chlorthalidone on the pharmacokinetics and pharmacodynamics of Org 10172 (Lomoparan), a low molecular weight heparinoid, in healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1716644/),[ml] / [min],7.1,81150,DB01109,Heparin
,1716644,clearance of anti-Xa activity,"Chlorthalidone produced a slight decrease in clearance of anti-Xa activity from 7.1 +/- 1.0 to 6.6 +/- 0.8 mL/min and a decrease of the volume of distribution from 0.20 +/- 0.05 to 0.16 +/- 0.04 L/kg, whereas the volume of distribution of antithrombin activity increased from 0.14 +/- 0.05 to 0.26 +/- 0.10 L/kg (all differences P less than .05).","Influence of chlorthalidone on the pharmacokinetics and pharmacodynamics of Org 10172 (Lomoparan), a low molecular weight heparinoid, in healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1716644/),[ml] / [min],6.6,81151,DB01109,Heparin
,1716644,volume of distribution,"Chlorthalidone produced a slight decrease in clearance of anti-Xa activity from 7.1 +/- 1.0 to 6.6 +/- 0.8 mL/min and a decrease of the volume of distribution from 0.20 +/- 0.05 to 0.16 +/- 0.04 L/kg, whereas the volume of distribution of antithrombin activity increased from 0.14 +/- 0.05 to 0.26 +/- 0.10 L/kg (all differences P less than .05).","Influence of chlorthalidone on the pharmacokinetics and pharmacodynamics of Org 10172 (Lomoparan), a low molecular weight heparinoid, in healthy volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1716644/),[l] / [kg],0.20,81152,DB01109,Heparin
,1716644,volume of distribution,"Chlorthalidone produced a slight decrease in clearance of anti-Xa activity from 7.1 +/- 1.0 to 6.6 +/- 0.8 mL/min and a decrease of the volume of distribution from 0.20 +/- 0.05 to 0.16 +/- 0.04 L/kg, whereas the volume of distribution of antithrombin activity increased from 0.14 +/- 0.05 to 0.26 +/- 0.10 L/kg (all differences P less than .05).","Influence of chlorthalidone on the pharmacokinetics and pharmacodynamics of Org 10172 (Lomoparan), a low molecular weight heparinoid, in healthy volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1716644/),[l] / [kg],0.16,81153,DB01109,Heparin
,1716644,volume of distribution,"Chlorthalidone produced a slight decrease in clearance of anti-Xa activity from 7.1 +/- 1.0 to 6.6 +/- 0.8 mL/min and a decrease of the volume of distribution from 0.20 +/- 0.05 to 0.16 +/- 0.04 L/kg, whereas the volume of distribution of antithrombin activity increased from 0.14 +/- 0.05 to 0.26 +/- 0.10 L/kg (all differences P less than .05).","Influence of chlorthalidone on the pharmacokinetics and pharmacodynamics of Org 10172 (Lomoparan), a low molecular weight heparinoid, in healthy volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1716644/),[l] / [kg],0.14,81154,DB01109,Heparin
,1716644,volume of distribution,"Chlorthalidone produced a slight decrease in clearance of anti-Xa activity from 7.1 +/- 1.0 to 6.6 +/- 0.8 mL/min and a decrease of the volume of distribution from 0.20 +/- 0.05 to 0.16 +/- 0.04 L/kg, whereas the volume of distribution of antithrombin activity increased from 0.14 +/- 0.05 to 0.26 +/- 0.10 L/kg (all differences P less than .05).","Influence of chlorthalidone on the pharmacokinetics and pharmacodynamics of Org 10172 (Lomoparan), a low molecular weight heparinoid, in healthy volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1716644/),[l] / [kg],0.26,81155,DB01109,Heparin
,8196366,tissue half-life,"EC-SOD C displayed a tissue half-life of about 85 hours, whereas the EC-SOD variants with reduced and absent heparin-affinities displayed half-lives of about 20 and 7 hours, respectively.",Turnover of extracellular-superoxide dismutase in tissues. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8196366/),h,85,81325,DB01109,Heparin
,8196366,half-lives,"EC-SOD C displayed a tissue half-life of about 85 hours, whereas the EC-SOD variants with reduced and absent heparin-affinities displayed half-lives of about 20 and 7 hours, respectively.",Turnover of extracellular-superoxide dismutase in tissues. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8196366/),h,20,81326,DB01109,Heparin
,8196366,half-lives,"EC-SOD C displayed a tissue half-life of about 85 hours, whereas the EC-SOD variants with reduced and absent heparin-affinities displayed half-lives of about 20 and 7 hours, respectively.",Turnover of extracellular-superoxide dismutase in tissues. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8196366/),h,7,81327,DB01109,Heparin
>,24065589,half-life,"DNPH3 showed long circulating properties in vivo (half-life >8 h, more than 60-fold longer than that of parent D) and low reticuloendothelial system (RES) recognition in liver and spleen.",Magnetic targeting of novel heparinized iron oxide nanoparticles evaluated in a 9L-glioma mouse model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24065589/),h,8,81669,DB01109,Heparin
,24065589,maximum loading content,"Protamine, a model cationic protein, was efficiently loaded onto DNPH3 with a maximum loading content of 26.4 μg/mg Fe.",Magnetic targeting of novel heparinized iron oxide nanoparticles evaluated in a 9L-glioma mouse model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24065589/),[μg] / [fe·mg],26.4,81670,DB01109,Heparin
,24065589,targeting time,"Magnetic capture of DNPH3 in tumor site with optimized conditions (I.D. of 12 mg/kg, targeting time of 45 min) was up to 29.42 μg Fe/g tissue (12.26% I.D./g tissue).",Magnetic targeting of novel heparinized iron oxide nanoparticles evaluated in a 9L-glioma mouse model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24065589/),,45,81671,DB01109,Heparin
,24065589,targeting time,"Magnetic capture of DNPH3 in tumor site with optimized conditions (I.D. of 12 mg/kg, targeting time of 45 min) was up to 29.42 μg Fe/g tissue (12.26% I.D./g tissue).",Magnetic targeting of novel heparinized iron oxide nanoparticles evaluated in a 9L-glioma mouse model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24065589/),[fe·μg] / [g·tissue],29.42,81672,DB01109,Heparin
,19954711,area under the curve (,"Bemiparin 3500 IU achieved more anti-Xa activity than enoxaparin 4000 IU, measured by the area under the curve (geometric mean AUC0t) (bemiparin 3.69 vs. enoxaparin 3.33 IU h/ml; p < 0.001).",Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954711/),[h·iu] / [ml],3.69,81759,DB01109,Heparin
,19954711,area under the curve (,"Bemiparin 3500 IU achieved more anti-Xa activity than enoxaparin 4000 IU, measured by the area under the curve (geometric mean AUC0t) (bemiparin 3.69 vs. enoxaparin 3.33 IU h/ml; p < 0.001).",Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954711/),[h·iu] / [ml],3.33,81760,DB01109,Heparin
,19954711,activity half-life,Anti-Xa activity half-life was 5.44 hours for bemiparin and 4.71 hours for enoxaparin.,Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954711/),h,5.44,81761,DB01109,Heparin
,19954711,activity half-life,Anti-Xa activity half-life was 5.44 hours for bemiparin and 4.71 hours for enoxaparin.,Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954711/),h,4.71,81762,DB01109,Heparin
,19954711,anti,"The ""in-vivo"" anti-Xa:IIa ratios were: bemiparin 37.9 (95% CI: 28.0 - 55.3, n = 2) and enoxaparin 16.3 (95% CI: 12.2 - 23.4, n = 8).",Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954711/),,37,81763,DB01109,Heparin
,19954711,anti,"The ""in-vivo"" anti-Xa:IIa ratios were: bemiparin 37.9 (95% CI: 28.0 - 55.3, n = 2) and enoxaparin 16.3 (95% CI: 12.2 - 23.4, n = 8).",Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954711/),,16,81764,DB01109,Heparin
more,9352383,bioavailability,"The s.c. administration of the two Desmin doses had a negligible effect on the activated partial thromboplastin time and a very small effect on the thrombin time, measured with human thrombin; in contrast, Heptest, heparin cofactor II, and anti-Xa activities increased, with a good drug bioavailability (more than 100%).","Bioavailability of Desmin, a low molecular weight dermatan sulfate, after subcutaneous administration to healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9352383/),%,100,81777,DB01109,Heparin
,16364500,distribution half-life,"After intravenous bolus, HB-EGF had a distribution half-life of 0.8 min and an elimination half-life of 26.67 min.",Tissue distribution and plasma clearance of heparin-binding EGF-like growth factor (HB-EGF) in adult and newborn rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16364500/),min,0.8,82730,DB01109,Heparin
,16364500,elimination half-life,"After intravenous bolus, HB-EGF had a distribution half-life of 0.8 min and an elimination half-life of 26.67 min.",Tissue distribution and plasma clearance of heparin-binding EGF-like growth factor (HB-EGF) in adult and newborn rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16364500/),min,26.67,82731,DB01109,Heparin
,16364500,bioavailability,"After gastric administration, the bioavailability was 7.8%, with a 2.38 h half-life in the absorption phase and an 11.13 h half-life in the elimination phase.",Tissue distribution and plasma clearance of heparin-binding EGF-like growth factor (HB-EGF) in adult and newborn rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16364500/),%,7.8,82732,DB01109,Heparin
,16364500,half-life,"After gastric administration, the bioavailability was 7.8%, with a 2.38 h half-life in the absorption phase and an 11.13 h half-life in the elimination phase.",Tissue distribution and plasma clearance of heparin-binding EGF-like growth factor (HB-EGF) in adult and newborn rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16364500/),h,2.38,82733,DB01109,Heparin
,16364500,half-life,"After gastric administration, the bioavailability was 7.8%, with a 2.38 h half-life in the absorption phase and an 11.13 h half-life in the elimination phase.",Tissue distribution and plasma clearance of heparin-binding EGF-like growth factor (HB-EGF) in adult and newborn rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16364500/),h,11.13,82734,DB01109,Heparin
,12532174,bioavailability,"Phase I trials have shown a 100% bioavailability after subcutaneous (s.c.) administration, a rapid onset of action and an approximate half-life of 13.5 h.",Fondaparinux sodium. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12532174/),%,100,83385,DB01109,Heparin
,12532174,half-life,"Phase I trials have shown a 100% bioavailability after subcutaneous (s.c.) administration, a rapid onset of action and an approximate half-life of 13.5 h.",Fondaparinux sodium. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12532174/),h,13.5,83386,DB01109,Heparin
,7487286,half life,Its half life is about three hours when administered intravenously which requires continuous infusion whereas subcutaneous administration can ensure stable plasma concentrations and antithrombotic activity over a period of approximatively 12 hours.,[Subcutaneous recombinant hirudin in the treatment of deep venous thrombosis. A pharmacokinetic study]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7487286/),h,three,84617,DB01109,Heparin
,22770782,half-life,A short half-life (4.30±0.14 min) and a relatively high clearance (3.83±1.46 L/h/kg) were found.,"Development and full validation of an UPLC-MS/MS method for the determination of an anti-allergic indolinone derivative in rat plasma, and application to a preliminary pharmacokinetic study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22770782/),min,4.30,84785,DB01109,Heparin
,22770782,clearance,A short half-life (4.30±0.14 min) and a relatively high clearance (3.83±1.46 L/h/kg) were found.,"Development and full validation of an UPLC-MS/MS method for the determination of an anti-allergic indolinone derivative in rat plasma, and application to a preliminary pharmacokinetic study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22770782/),[l] / [h·kg],3.83,84786,DB01109,Heparin
,27722127,aPTT,An aPTT range of 87.1 sec to 128.7 sec corresponded to anti-Xa levels of 0.3 IU/mL to 0.7 IU/mL for HTR under our laboratory conditions.,Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27722127/),s,87.1,84847,DB01109,Heparin
,27722127,aPTT,An aPTT range of 87.1 sec to 128.7 sec corresponded to anti-Xa levels of 0.3 IU/mL to 0.7 IU/mL for HTR under our laboratory conditions.,Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27722127/),s,128.7,84848,DB01109,Heparin
,27722127,anti-Xa,An aPTT range of 87.1 sec to 128.7 sec corresponded to anti-Xa levels of 0.3 IU/mL to 0.7 IU/mL for HTR under our laboratory conditions.,Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27722127/),i,0.3,84849,DB01109,Heparin
,27722127,anti-Xa,An aPTT range of 87.1 sec to 128.7 sec corresponded to anti-Xa levels of 0.3 IU/mL to 0.7 IU/mL for HTR under our laboratory conditions.,Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27722127/),,0.7,84850,DB01109,Heparin
,30564584,elimination half-life,"The elimination half-life was 1.3 ± 0.2 h, with high protein binding (92-99%).",Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30564584/),h,1.3,84957,DB01109,Heparin
,30564584,protein binding,"The elimination half-life was 1.3 ± 0.2 h, with high protein binding (92-99%).",Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30564584/),%,92-99,84958,DB01109,Heparin
,8894971,Michaelis-Menten,The Michaelis-Menten parameters Vmax and K(m) were 62 +/- 8 micrograms.min-1.kg-1 and 16 +/- 4 micrograms.,"Comparative pharmacokinetic, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894971/),[μg] / [kg·min],62,85482,DB01109,Heparin
,8894971,Vmax,The Michaelis-Menten parameters Vmax and K(m) were 62 +/- 8 micrograms.min-1.kg-1 and 16 +/- 4 micrograms.,"Comparative pharmacokinetic, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894971/),[μg] / [kg·min],62,85483,DB01109,Heparin
,8894971,K(m),The Michaelis-Menten parameters Vmax and K(m) were 62 +/- 8 micrograms.min-1.kg-1 and 16 +/- 4 micrograms.,"Comparative pharmacokinetic, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894971/),μg,16,85484,DB01109,Heparin
,8894971,Clintr,ml-1 (Clintr 3.9 +/- 1.1 ml.min-1.kg-1) and 74 +/- 6 micrograms.min-1.kg-1 and 11 +/- 2 micrograms.,"Comparative pharmacokinetic, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894971/),[ml] / [kg·min],3.9,85485,DB01109,Heparin
,8894971,Clintr,ml-1 (Clintr 3.9 +/- 1.1 ml.min-1.kg-1) and 74 +/- 6 micrograms.min-1.kg-1 and 11 +/- 2 micrograms.,"Comparative pharmacokinetic, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894971/),[μg] / [kg·min],74,85486,DB01109,Heparin
,8894971,Clintr,ml-1 (Clintr 3.9 +/- 1.1 ml.min-1.kg-1) and 74 +/- 6 micrograms.min-1.kg-1 and 11 +/- 2 micrograms.,"Comparative pharmacokinetic, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894971/),μg,11,85487,DB01109,Heparin
,8894971,Clintr,"ml-1 (Clintr 6.7 +/- 1.2 ml.min-1.kg-1) for aconitylated-HSA (Aco-HSA) and succinylated-HSA (Suc-HSA) respectively, using 125I-labelled proteins.","Comparative pharmacokinetic, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894971/),[ml] / [kg·min],6.7,85488,DB01109,Heparin
,8894971,volume of distribution (V),The volume of distribution (V) of both compounds was approximately 60 ml.,"Comparative pharmacokinetic, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894971/),ml,60,85489,DB01109,Heparin
,16411388,anti-Xa,"The objectives of the current study were to determine i) the once daily dose required to achieve anti-Xa levels of 0.5-1.0 IU/mL, ii) the pharmacokinetics and iii) preliminary safety data using tinzaparin.",Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411388/),,0.5-1.0,85994,DB01109,Heparin
,26766749,LOS,"The median (range) LOS was 7 (2-58) days for the compliant group versus 15 days (2-101) for the noncompliant (P = 0.06, Mann-Whitney U test).",Compliance With Enoxaparin Dosing and Monitoring Guidelines and the Impact on Patient Length of Stay: A Pilot Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26766749/),d,7,87329,DB01109,Heparin
,26766749,LOS,"The median (range) LOS was 7 (2-58) days for the compliant group versus 15 days (2-101) for the noncompliant (P = 0.06, Mann-Whitney U test).",Compliance With Enoxaparin Dosing and Monitoring Guidelines and the Impact on Patient Length of Stay: A Pilot Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26766749/),d,15,87330,DB01109,Heparin
,26766749,LOS,"In these patients, the median (range) LOS was 16.5 days (2-101).",Compliance With Enoxaparin Dosing and Monitoring Guidelines and the Impact on Patient Length of Stay: A Pilot Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26766749/),d,16.5,87331,DB01109,Heparin
<,25900127,anti-Xa activities,The clinical study reconfirmed the absence of bioaccumulation of certoparin with anti-Xa activities between <0.01 and 0.02 IU/mL after 24 h.,Pharmacokinetics of Certoparin During In Vitro and In Vivo Dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25900127/),[iu] / [ml],0.,87392,DB01109,Heparin
,25900127,plasma half-life time,A short plasma half-life time of 2.0 ± 0.7 h was determined during hemodialysis.,Pharmacokinetics of Certoparin During In Vitro and In Vivo Dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25900127/),h,2.0,87393,DB01109,Heparin
,25900127,half-life time,"Different from LMWH significantly cleared by the kidneys, the relatively short half-life time of certoparin of only 2 h during hemodialysis allows a more reliable control of the anti-coagulatory effects and decreases the risk of bleeding complications.",Pharmacokinetics of Certoparin During In Vitro and In Vivo Dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25900127/),h,2,87394,DB01109,Heparin
,28302764,half maximal inhibitory concentration,The half maximal inhibitory concentration of 18F-GP1 to GPIIb/IIIa was 20 nM.,"18F-GP1, a Novel PET Tracer Designed for High-Sensitivity, Low-Background Detection of Thrombi. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28302764/),nM,20,87536,DB01109,Heparin
,28302764,clot-to-blood ratio,18F-GP1 bound to thrombi with a mean clot-to-blood ratio of 95.,"18F-GP1, a Novel PET Tracer Designed for High-Sensitivity, Low-Background Detection of Thrombi. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28302764/),,95,87537,DB01109,Heparin
,15085465,peak drug level,Intravenous administration of the same dose resulted in a peak drug level of approximately 1.5 anti-Xa U/mL.,Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15085465/),[u] / [ml],1.5,88757,DB01109,Heparin
,15085465,elimination half-life,The elimination half-life was approximately 1 hour.,Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15085465/),h,1,88758,DB01109,Heparin
,15085465,peak drug concentrations,Intravenous administration of 175 U/kg resulted in peak drug concentrations of almost 5 anti-Xa U/mL.,Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15085465/),[u] / [ml],5,88759,DB01109,Heparin
,21872414,flow-rate,"Tamoxifen, N-desmethyl-tamoxifen, 4-hydroxy-tamoxifen and endoxifen were chromatographically separated on an Acquity UPLC(®) BEH C18 1.7 μm 2.1 mm×100 mm column eluted at a flow-rate of 0.300 ml/min on a gradient of 0.2mM ammonium formate and acetonitrile, both acidified with 0.1% formic acid.",Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21872414/),[ml] / [min],0.300,89948,DB01109,Heparin
,21872414,overall run time,"The overall run time of the method was 10 min, with elution times of 2.9, 3.0, 4.1 and 4.2 min for endoxifen, 4-hydroxy-tamoxifen, N-desmethyl-tamoxifen and tamoxifen, respectively.",Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21872414/),min,10,89949,DB01109,Heparin
,21872414,elution times,"The overall run time of the method was 10 min, with elution times of 2.9, 3.0, 4.1 and 4.2 min for endoxifen, 4-hydroxy-tamoxifen, N-desmethyl-tamoxifen and tamoxifen, respectively.",Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21872414/),min,2.9,89950,DB01109,Heparin
,21872414,elution times,"The overall run time of the method was 10 min, with elution times of 2.9, 3.0, 4.1 and 4.2 min for endoxifen, 4-hydroxy-tamoxifen, N-desmethyl-tamoxifen and tamoxifen, respectively.",Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21872414/),min,3.0,89951,DB01109,Heparin
,21872414,elution times,"The overall run time of the method was 10 min, with elution times of 2.9, 3.0, 4.1 and 4.2 min for endoxifen, 4-hydroxy-tamoxifen, N-desmethyl-tamoxifen and tamoxifen, respectively.",Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21872414/),min,4.1,89952,DB01109,Heparin
,21872414,elution times,"The overall run time of the method was 10 min, with elution times of 2.9, 3.0, 4.1 and 4.2 min for endoxifen, 4-hydroxy-tamoxifen, N-desmethyl-tamoxifen and tamoxifen, respectively.",Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21872414/),min,4.2,89953,DB01109,Heparin
,12172976,CLcr,Median baseline CLcr values were 71.5 ml/min for NRF patients and 44 ml/min for IRF patients.,Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172976/),[ml] / [min],71.5,90257,DB01109,Heparin
,12172976,CLcr,Median baseline CLcr values were 71.5 ml/min for NRF patients and 44 ml/min for IRF patients.,Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172976/),[ml] / [min],44,90258,DB01109,Heparin
,27628785,en,"By incorporation of the negative polymer of enoxaparin sodium (ES), DOX was highly encapsulated into EPNs with an encapsulation efficiency of 92.49%, and ES effectively inhibited the proliferation of HUVEC cell lines.",Novel nanostructured enoxaparin sodium-PLGA hybrid carriers overcome tumor multidrug resistance of doxorubicin hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27628785/),,92,91236,DB01109,Heparin
,18204174,area under the curve (AUC),"Analysis of the anti-FXa activity as a function of the time after administration revealed values of the area under the curve (AUC) of 5.70+/-1.58 U.hour/ml and 8.43+/-1.31 U.hour/ml (mean+/-SD) with interindividual coefficients of variation of 28% and 13% after injection of 3000 IU and inhalation of 9000 IU, respectively.",Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18204174/),[h·u] / [ml],5.70,92174,DB01109,Heparin
,18204174,area under the curve (AUC),"Analysis of the anti-FXa activity as a function of the time after administration revealed values of the area under the curve (AUC) of 5.70+/-1.58 U.hour/ml and 8.43+/-1.31 U.hour/ml (mean+/-SD) with interindividual coefficients of variation of 28% and 13% after injection of 3000 IU and inhalation of 9000 IU, respectively.",Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18204174/),[h·u] / [ml],8.43,92175,DB01109,Heparin
outside,16842391,percentage of,To develop an appropriate dosing strategy for continuous intravenous infusions (CII) of enoxaparin by minimizing the percentage of steady-state anti-Xa concentration (C(ss)) outside the therapeutic range of 0.5-1.2 IU ml(-1).,Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842391/),[iu] / [ml],0.5-1.2,93402,DB01109,Heparin
outside,16842391,steady-state anti-Xa concentration (C(ss)),To develop an appropriate dosing strategy for continuous intravenous infusions (CII) of enoxaparin by minimizing the percentage of steady-state anti-Xa concentration (C(ss)) outside the therapeutic range of 0.5-1.2 IU ml(-1).,Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842391/),[iu] / [ml],0.5-1.2,93403,DB01109,Heparin
,8396956,half-lives,"2. The time courses of the anti-Xa activity of Fragmin, Fraxiparine and Clexane (five subjects) were best fitted by a monoexponential function and had comparable half-lives of 1.9 h, 2.3 h and 2.8 h, respectively.",A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8396956/),h,1.9,94960,DB01109,Heparin
,8396956,half-lives,"2. The time courses of the anti-Xa activity of Fragmin, Fraxiparine and Clexane (five subjects) were best fitted by a monoexponential function and had comparable half-lives of 1.9 h, 2.3 h and 2.8 h, respectively.",A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8396956/),h,2.3,94961,DB01109,Heparin
,8396956,half-lives,"2. The time courses of the anti-Xa activity of Fragmin, Fraxiparine and Clexane (five subjects) were best fitted by a monoexponential function and had comparable half-lives of 1.9 h, 2.3 h and 2.8 h, respectively.",A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8396956/),h,2.8,94962,DB01109,Heparin
,8396956,terminal half-lives,"The time courses of the anti-Xa activity of Orgaran and Clexane (four subjects) were described by a biexponential function with terminal half-lives of 56.8h and 27.7 h, respectively.",A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8396956/),h,56.8,94963,DB01109,Heparin
,8396956,terminal half-lives,"The time courses of the anti-Xa activity of Orgaran and Clexane (four subjects) were described by a biexponential function with terminal half-lives of 56.8h and 27.7 h, respectively.",A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8396956/),h,27.7,94964,DB01109,Heparin
,8396956,'clearance',"Orgaran injection was associated with a significantly smaller 'clearance' (0.8 +/- 0.2 l h-1) of the plasma anti-Xa activity compared with Fragmin (2.0 +/- 0.5), Fraxiparine (1.7 +/- 0.5) and Clexane (1.6 +/- 0.5).",A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8396956/),[l] / [h],0.8,94965,DB01109,Heparin
,8396956,'clearance',"Orgaran injection was associated with a significantly smaller 'clearance' (0.8 +/- 0.2 l h-1) of the plasma anti-Xa activity compared with Fragmin (2.0 +/- 0.5), Fraxiparine (1.7 +/- 0.5) and Clexane (1.6 +/- 0.5).",A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8396956/),[l] / [h],2.0,94966,DB01109,Heparin
,8396956,'clearance',"Orgaran injection was associated with a significantly smaller 'clearance' (0.8 +/- 0.2 l h-1) of the plasma anti-Xa activity compared with Fragmin (2.0 +/- 0.5), Fraxiparine (1.7 +/- 0.5) and Clexane (1.6 +/- 0.5).",A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8396956/),[l] / [h],1.7,94967,DB01109,Heparin
,8396956,'clearance',"Orgaran injection was associated with a significantly smaller 'clearance' (0.8 +/- 0.2 l h-1) of the plasma anti-Xa activity compared with Fragmin (2.0 +/- 0.5), Fraxiparine (1.7 +/- 0.5) and Clexane (1.6 +/- 0.5).",A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8396956/),[l] / [h],1.6,94968,DB01109,Heparin
,8396956,th,4. Orgaran caused the smallest and Fragmin the greatest prolongation of the activated partial thromboplastin time (Orgaran 5.8 +/- 1.2 s vs Fragmin 18.5 +/- 5.2 s) and the thrombin clotting time (Orgaran 2.9 +/- 1.7 s vs Fragmin 47.8 +/- 0.9 s).,A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8396956/),s,2.9,94969,DB01109,Heparin
,25445701,mean residence time,"Compared to the free form of PEG-LHT7, the mean residence time of PEG-LHT7/protamine nanocomplex was found higher (15.9h) with its increased accumulation in tumor.",Functionalized heparin-protamine based self-assembled nanocomplex for efficient anti-angiogenic therapy. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25445701/),h,15.9,95086,DB01109,Heparin
,19272635,peak anti-Xa level,"The average peak anti-Xa level was 0.25 (SD+/-0.11, range 0.08 to 0.59) units/mL.","Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19272635/),[units] / [ml],0.25,97212,DB01109,Heparin
,20298591,AFXa,An AFXa level between 0.1 to 0.3 IU/ml was considered evidence of effective antithrombotic activity.,"Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20298591/),[iu] / [ml],0.1 to 0.3,98134,DB01109,Heparin
,7831664,anti-factor Xa/antithrombin ratio,The anti-factor Xa/antithrombin ratio of these compounds determined in a rabbit plasma system were 2.5 and 1.2 for CY 216 and ACLM respectively while BCLM was devoid of anti-thrombin effect.,Pharmacological properties of CY 216 and of its ACLM and BCLM components in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7831664/),,2.5,99061,DB01109,Heparin
,7831664,anti-factor Xa/antithrombin ratio,The anti-factor Xa/antithrombin ratio of these compounds determined in a rabbit plasma system were 2.5 and 1.2 for CY 216 and ACLM respectively while BCLM was devoid of anti-thrombin effect.,Pharmacological properties of CY 216 and of its ACLM and BCLM components in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7831664/),,1.2,99062,DB01109,Heparin
,12851531,IC(50),"The ETP IC(50) values for melagatran and the low-molecular-weight heparin dalteparin were 0.44 micromol/l and 0.06 IU/ml, respectively.","Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12851531/),[μM] / [l],0.44,99817,DB01109,Heparin
,12851531,IC(50),"The ETP IC(50) values for melagatran and the low-molecular-weight heparin dalteparin were 0.44 micromol/l and 0.06 IU/ml, respectively.","Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12851531/),[iu] / [ml],0.06,99818,DB01109,Heparin
,12536118,K(i),Recombinant nematode anticoagulant protein c2 (rNAPc2) is a potent (K(i) = 10 pM) inhibitor of the factor VIIa/tissue factor complex (fVIIa/TF) that involves the pre-requisite binding to either zymogen or activated factor X (fX) prior to the formation of the final quaternary complex with fVIIa/TF.,Inhibition of factor VIIa/tissue factor with nematode anticoagulant protein c2: from unique mechanism to a promising new clinical anticoagulant. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12536118/),pM,10,101305,DB01109,Heparin
>,12536118,elimination half-life,"The formation of the binary complex with circulating fX governs the pharmacokinetic profile of rNAPc2 in humans, resulting in a prolonged elimination half-life of >50 h.",Inhibition of factor VIIa/tissue factor with nematode anticoagulant protein c2: from unique mechanism to a promising new clinical anticoagulant. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12536118/),h,50,101306,DB01109,Heparin
,9493587,accumulation factors,"1) Between day 1 and day 10, there was an accumulation of the anti-Xa activity for treatment A but not for treatment B (accumulation factors: 1.6 and 1.1 respectively); 2) On day 10, the AUC(0-12 h) were slightly but significantly lower than the AUC(12-24 h) suggesting a circadian effect for anti-Xa and anti-IIa activities; 3) the clearance of the anti-Xa activity was comparable at the 2-dose regimens, while that of the anti-IIa activity was lower in treatment B than in treatment A, indicating a significant dose effect for the pharmacodynamics of the longer heparin chains; 4) On average, the clearance of the anti-IIa activity was twice as high as that of the anti-Xa activity; 5) For treatment B, significant APTT prolongations were noticed at Tmax (prolongation factor: 1.7 +/- 0.25), in relation with the anti-IIa activity (0.3 +/- 0.1 IU x ml(-1)).","Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493587/),,1.6,101438,DB01109,Heparin
,9493587,accumulation factors,"1) Between day 1 and day 10, there was an accumulation of the anti-Xa activity for treatment A but not for treatment B (accumulation factors: 1.6 and 1.1 respectively); 2) On day 10, the AUC(0-12 h) were slightly but significantly lower than the AUC(12-24 h) suggesting a circadian effect for anti-Xa and anti-IIa activities; 3) the clearance of the anti-Xa activity was comparable at the 2-dose regimens, while that of the anti-IIa activity was lower in treatment B than in treatment A, indicating a significant dose effect for the pharmacodynamics of the longer heparin chains; 4) On average, the clearance of the anti-IIa activity was twice as high as that of the anti-Xa activity; 5) For treatment B, significant APTT prolongations were noticed at Tmax (prolongation factor: 1.7 +/- 0.25), in relation with the anti-IIa activity (0.3 +/- 0.1 IU x ml(-1)).","Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493587/),,1.1,101439,DB01109,Heparin
,9493587,Tmax,"1) Between day 1 and day 10, there was an accumulation of the anti-Xa activity for treatment A but not for treatment B (accumulation factors: 1.6 and 1.1 respectively); 2) On day 10, the AUC(0-12 h) were slightly but significantly lower than the AUC(12-24 h) suggesting a circadian effect for anti-Xa and anti-IIa activities; 3) the clearance of the anti-Xa activity was comparable at the 2-dose regimens, while that of the anti-IIa activity was lower in treatment B than in treatment A, indicating a significant dose effect for the pharmacodynamics of the longer heparin chains; 4) On average, the clearance of the anti-IIa activity was twice as high as that of the anti-Xa activity; 5) For treatment B, significant APTT prolongations were noticed at Tmax (prolongation factor: 1.7 +/- 0.25), in relation with the anti-IIa activity (0.3 +/- 0.1 IU x ml(-1)).","Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493587/),[iu] / [ml],0.3,101440,DB01109,Heparin
,16390818,relative bioavailability,"In vivo studies in rats with ardeparin (1,200 IU/kg) and sodium caprate (100 mg/kg) led to a relative bioavailability of 27% with plasma anti-factor Xa levels within the therapeutic range (>0.2 IU/ml).",Oral delivery of low-molecular-weight heparin using sodium caprate as absorption enhancer reaches therapeutic levels. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390818/),%,27,101492,DB01109,Heparin
,26238770,aPTT ratio,"In the first 6 h after PPCI, aPTT ratio was 5.1 for patients with CKD versus 3.4 for those without (p < 0.001).",Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26238770/),,5.1,101644,DB01109,Heparin
,26238770,aPTT ratio,"In the first 6 h after PPCI, aPTT ratio was 5.1 for patients with CKD versus 3.4 for those without (p < 0.001).",Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26238770/),,3.4,101645,DB01109,Heparin
,9544216,relative bioavailability,"Using one of the most effective delivery agents in this series, an estimated relative bioavailability of 8% can be achieved following oral administration to cynomolgus monkeys.",Synthesis and evaluation of compounds that facilitate the gastrointestinal absorption of heparin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9544216/),%,8,101776,DB01109,Heparin
,21437357,Oral bioavailability,"Oral bioavailability of LHD in mice, rats and monkeys were 16.1 ± 3.0, 15.6 ± 6.1, and 15.8 ± 2.5%, respectively.",Pharmacokinetic evaluation of an oral tablet form of low-molecular-weight heparin and deoxycholic acid conjugate as a novel oral anticoagulant. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21437357/),%,16.1,102192,DB01109,Heparin
,21437357,Oral bioavailability,"Oral bioavailability of LHD in mice, rats and monkeys were 16.1 ± 3.0, 15.6 ± 6.1, and 15.8 ± 2.5%, respectively.",Pharmacokinetic evaluation of an oral tablet form of low-molecular-weight heparin and deoxycholic acid conjugate as a novel oral anticoagulant. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21437357/),%,15.6,102193,DB01109,Heparin
,21437357,Oral bioavailability,"Oral bioavailability of LHD in mice, rats and monkeys were 16.1 ± 3.0, 15.6 ± 6.1, and 15.8 ± 2.5%, respectively.",Pharmacokinetic evaluation of an oral tablet form of low-molecular-weight heparin and deoxycholic acid conjugate as a novel oral anticoagulant. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21437357/),%,15.8,102194,DB01109,Heparin
,22291058,flow rate,"The analyte and glimepiride d8 (internal standard, IS) are chromatographed on a C(18) column; the mobile phase is acetonitrile-2 mm ammonium formate (88:12, v/v), with the pH adjusted to 3.5 with formic acid, at a flow rate of 0.5 mL/min.",Rapid and specific approach for direct measurement of glimepiride in human plasma by LC-ESI-MS-MS employing automated 96 well format: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22291058/),[ml] / [min],0.5,103358,DB01109,Heparin
,22291058,retention times,"The retention times of glimepiride and the IS are 0.93 min, and the runtime is 1.6 min per sample.",Rapid and specific approach for direct measurement of glimepiride in human plasma by LC-ESI-MS-MS employing automated 96 well format: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22291058/),min,0.93,103359,DB01109,Heparin
,22291058,runtime,"The retention times of glimepiride and the IS are 0.93 min, and the runtime is 1.6 min per sample.",Rapid and specific approach for direct measurement of glimepiride in human plasma by LC-ESI-MS-MS employing automated 96 well format: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22291058/),[min] / [sample],1.6,103360,DB01109,Heparin
,22291058,m/z,"Selected reaction monitoring of MH(+) at m/z 491.20 and 499.26 result in stable fragment ions with m/z 351.80 and 359.96 for glimepiride and the IS, respectively.",Rapid and specific approach for direct measurement of glimepiride in human plasma by LC-ESI-MS-MS employing automated 96 well format: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22291058/),,351.80,103361,DB01109,Heparin
,22291058,m/z,"Selected reaction monitoring of MH(+) at m/z 491.20 and 499.26 result in stable fragment ions with m/z 351.80 and 359.96 for glimepiride and the IS, respectively.",Rapid and specific approach for direct measurement of glimepiride in human plasma by LC-ESI-MS-MS employing automated 96 well format: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22291058/),,359.96,103362,DB01109,Heparin
,22291058,recovery,The recovery of glimepiride and the IS ranged from 81.91 to 83.36%.,Rapid and specific approach for direct measurement of glimepiride in human plasma by LC-ESI-MS-MS employing automated 96 well format: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22291058/),%,81.91 to 83.36,103363,DB01109,Heparin
,22864018,concentration,"After systemic heparinization, the landiolol concentration was significantly decreased from 0.407±0.251 µg·mL(-1) to 0.232±0.207 µg·mL(-1) (<0.01).",Influence of hemodynamic variations on the pharmacokinetics of landiolol in patients undergoing cardiovascular surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22864018/),[μg] / [ml],0.407,106963,DB01109,Heparin
,22864018,concentration,"After systemic heparinization, the landiolol concentration was significantly decreased from 0.407±0.251 µg·mL(-1) to 0.232±0.207 µg·mL(-1) (<0.01).",Influence of hemodynamic variations on the pharmacokinetics of landiolol in patients undergoing cardiovascular surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22864018/),[μg] / [ml],0.232,106964,DB01109,Heparin
,20637970,T(max),"Avanafil reached a mean T(max) at 0.33 to 0.52 hour after dosing and then declined, with a mean apparent t1/2 of 5.36 to 10.66 hours.","Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637970/),h,0.33 to 0.52,107050,DB01109,Heparin
,20637970,apparent t1/2,"Avanafil reached a mean T(max) at 0.33 to 0.52 hour after dosing and then declined, with a mean apparent t1/2 of 5.36 to 10.66 hours.","Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637970/),h,5.36 to 10.66,107051,DB01109,Heparin
,20637970,accumulation index,"AUC and C(max) were proportional to dose, and the mean accumulation index on day 7 after a single daily dose of avanafil was 0.98.","Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637970/),,0.98,107052,DB01109,Heparin
,10726023,retention times,"The retention times for argatroban and M1-metabolite peaks were found to be 10.5 +/- 0.3 minutes and 3.9 +/- 0.1 minutes, respectively.",Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: potential clinical applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10726023/),min,10.5,107679,DB01109,Heparin
,10726023,retention times,"The retention times for argatroban and M1-metabolite peaks were found to be 10.5 +/- 0.3 minutes and 3.9 +/- 0.1 minutes, respectively.",Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: potential clinical applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10726023/),min,3.9,107680,DB01109,Heparin
,16470916,maximal plasma concentration (C(max)),"The maximal plasma concentration (C(max)) of the three treated groups were 0.51, 0.70 and 0.81 microg/ml, respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[μg] / [ml],0.51,108535,DB01109,Heparin
,16470916,maximal plasma concentration (C(max)),"The maximal plasma concentration (C(max)) of the three treated groups were 0.51, 0.70 and 0.81 microg/ml, respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[μg] / [ml],0.70,108536,DB01109,Heparin
,16470916,maximal plasma concentration (C(max)),"The maximal plasma concentration (C(max)) of the three treated groups were 0.51, 0.70 and 0.81 microg/ml, respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[μg] / [ml],0.81,108537,DB01109,Heparin
,16470916,area under the concentration-time curve (AUC(0-8)),"The area under the concentration-time curve (AUC(0-8)) were 1.81, 2.83 and 3.63 microg/(h.ml(-1)), respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[h·μg] / [ml],1.81,108538,DB01109,Heparin
,16470916,area under the concentration-time curve (AUC(0-8)),"The area under the concentration-time curve (AUC(0-8)) were 1.81, 2.83 and 3.63 microg/(h.ml(-1)), respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[h·μg] / [ml],2.83,108539,DB01109,Heparin
,16470916,area under the concentration-time curve (AUC(0-8)),"The area under the concentration-time curve (AUC(0-8)) were 1.81, 2.83 and 3.63 microg/(h.ml(-1)), respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[h·μg] / [ml],3.63,108540,DB01109,Heparin
,12492611,total,Mean +/- s.d. total and free TFPI increased from 62.9 +/- 9.4/8.3 +/- 2.1 ng ml-1 at baseline to 237.2 +/- 40.9/111.0 +/- 19.9 ng ml-1 after 40 min infusion.,Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],62.9,108641,DB01109,Heparin
,12492611,total,Mean +/- s.d. total and free TFPI increased from 62.9 +/- 9.4/8.3 +/- 2.1 ng ml-1 at baseline to 237.2 +/- 40.9/111.0 +/- 19.9 ng ml-1 after 40 min infusion.,Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],8.3,108642,DB01109,Heparin
,12492611,total,Mean +/- s.d. total and free TFPI increased from 62.9 +/- 9.4/8.3 +/- 2.1 ng ml-1 at baseline to 237.2 +/- 40.9/111.0 +/- 19.9 ng ml-1 after 40 min infusion.,Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],237.2,108643,DB01109,Heparin
,12492611,free,Mean +/- s.d. total and free TFPI increased from 62.9 +/- 9.4/8.3 +/- 2.1 ng ml-1 at baseline to 237.2 +/- 40.9/111.0 +/- 19.9 ng ml-1 after 40 min infusion.,Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],62.9,108644,DB01109,Heparin
,12492611,free,Mean +/- s.d. total and free TFPI increased from 62.9 +/- 9.4/8.3 +/- 2.1 ng ml-1 at baseline to 237.2 +/- 40.9/111.0 +/- 19.9 ng ml-1 after 40 min infusion.,Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],8.3,108645,DB01109,Heparin
,12492611,free,Mean +/- s.d. total and free TFPI increased from 62.9 +/- 9.4/8.3 +/- 2.1 ng ml-1 at baseline to 237.2 +/- 40.9/111.0 +/- 19.9 ng ml-1 after 40 min infusion.,Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],237.2,108646,DB01109,Heparin
,12492611,free,Mean +/- s.d. total and free TFPI increased from 62.9 +/- 9.4/8.3 +/- 2.1 ng ml-1 at baseline to 237.2 +/- 40.9/111.0 +/- 19.9 ng ml-1 after 40 min infusion.,Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],111.0,108647,DB01109,Heparin
,12492611,TFPI,Mean +/- s.d. total and free TFPI increased from 62.9 +/- 9.4/8.3 +/- 2.1 ng ml-1 at baseline to 237.2 +/- 40.9/111.0 +/- 19.9 ng ml-1 after 40 min infusion.,Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],8.3,108648,DB01109,Heparin
,12492611,TFPI,Mean +/- s.d. total and free TFPI increased from 62.9 +/- 9.4/8.3 +/- 2.1 ng ml-1 at baseline to 237.2 +/- 40.9/111.0 +/- 19.9 ng ml-1 after 40 min infusion.,Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],237.2,108649,DB01109,Heparin
,12492611,TFPI,Mean +/- s.d. total and free TFPI increased from 62.9 +/- 9.4/8.3 +/- 2.1 ng ml-1 at baseline to 237.2 +/- 40.9/111.0 +/- 19.9 ng ml-1 after 40 min infusion.,Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],111.0,108650,DB01109,Heparin
,12492611,release rate,The TFPI release rate rapidly increased to maximum of 200 +/- 45 micro g min-1 after 17.5 min heparin infusion but did not increase further although heparin concentrations further doubled.,Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[μg] / [min],200,108651,DB01109,Heparin
,12492611,antigen,"In contrast to TFPI, t-PA antigen decreased from 5.6 +/- 1.0 at baseline to 4.5 +/- 1.0 ng ml-1 at the end of infusion (t = 40 min) (difference of 1.1 ng ml-1 (95% confidence interval; 0.9, 1.3).",Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],5.6,108652,DB01109,Heparin
,12492611,antigen,"In contrast to TFPI, t-PA antigen decreased from 5.6 +/- 1.0 at baseline to 4.5 +/- 1.0 ng ml-1 at the end of infusion (t = 40 min) (difference of 1.1 ng ml-1 (95% confidence interval; 0.9, 1.3).",Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],4.5,108653,DB01109,Heparin
,9690805,anti-FXa activity,An anti-FXa activity of 0.20-0.40 IU/ml 3 h after injection was obtained.,A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690805/),[iu] / [ml],0.20-0.40,109722,DB01109,Heparin
,9690805,Cmax,"The means +/- SD, when comparing morning and evening doses for 5000 IU, were: Cmax 0.21 +/- 0.05 and 0.20 +/- 0.05 IU anti-FXa/ml, AUC 0-24 h 1.97 +/- 0.46 and 1.93 +/- 0.55 IU x h/ml and tmax 3.71 +/- 0.89 and 4.32 +/- 1.60 h, respectively (NS).",A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690805/),[a·anti-f·iu] / [ml],0.21,109723,DB01109,Heparin
,9690805,Cmax,"The means +/- SD, when comparing morning and evening doses for 5000 IU, were: Cmax 0.21 +/- 0.05 and 0.20 +/- 0.05 IU anti-FXa/ml, AUC 0-24 h 1.97 +/- 0.46 and 1.93 +/- 0.55 IU x h/ml and tmax 3.71 +/- 0.89 and 4.32 +/- 1.60 h, respectively (NS).",A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690805/),[a·anti-f·iu] / [ml],0.20,109724,DB01109,Heparin
,9690805,AUC 0-24 h,"The means +/- SD, when comparing morning and evening doses for 5000 IU, were: Cmax 0.21 +/- 0.05 and 0.20 +/- 0.05 IU anti-FXa/ml, AUC 0-24 h 1.97 +/- 0.46 and 1.93 +/- 0.55 IU x h/ml and tmax 3.71 +/- 0.89 and 4.32 +/- 1.60 h, respectively (NS).",A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690805/),[h·iu] / [ml],1.97,109725,DB01109,Heparin
,9690805,AUC 0-24 h,"The means +/- SD, when comparing morning and evening doses for 5000 IU, were: Cmax 0.21 +/- 0.05 and 0.20 +/- 0.05 IU anti-FXa/ml, AUC 0-24 h 1.97 +/- 0.46 and 1.93 +/- 0.55 IU x h/ml and tmax 3.71 +/- 0.89 and 4.32 +/- 1.60 h, respectively (NS).",A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690805/),[h·iu] / [ml],1.93,109726,DB01109,Heparin
,9690805,tmax,"The means +/- SD, when comparing morning and evening doses for 5000 IU, were: Cmax 0.21 +/- 0.05 and 0.20 +/- 0.05 IU anti-FXa/ml, AUC 0-24 h 1.97 +/- 0.46 and 1.93 +/- 0.55 IU x h/ml and tmax 3.71 +/- 0.89 and 4.32 +/- 1.60 h, respectively (NS).",A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690805/),h,3.71,109727,DB01109,Heparin
,9690805,tmax,"The means +/- SD, when comparing morning and evening doses for 5000 IU, were: Cmax 0.21 +/- 0.05 and 0.20 +/- 0.05 IU anti-FXa/ml, AUC 0-24 h 1.97 +/- 0.46 and 1.93 +/- 0.55 IU x h/ml and tmax 3.71 +/- 0.89 and 4.32 +/- 1.60 h, respectively (NS).",A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690805/),h,4.32,109728,DB01109,Heparin
,9690805,half-lives,"The half-lives after a morning and an evening dose of 5000 IU dalteparin were 4.92 +/- 2.80 and 3.87 +/- 1.15 h, respectively (NS).",A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690805/),h,4.92,109729,DB01109,Heparin
,9690805,half-lives,"The half-lives after a morning and an evening dose of 5000 IU dalteparin were 4.92 +/- 2.80 and 3.87 +/- 1.15 h, respectively (NS).",A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690805/),h,3.87,109730,DB01109,Heparin
,16291417,Sc,Mean Sc (for CVVH) or Sa (for CVVHD) values in the in vitro procedures ranged from 0.16 to 0.57.,In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291417/),,0.,109942,DB01109,Heparin
,16291417,Sa,Mean Sc (for CVVH) or Sa (for CVVHD) values in the in vitro procedures ranged from 0.16 to 0.57.,In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291417/),,0.,109943,DB01109,Heparin
,16291417,Sc,"In patients, Sc or Sa achieved values between 0.26 and 0.67.",In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291417/),,0.26,109944,DB01109,Heparin
,16291417,Sa,"In patients, Sc or Sa achieved values between 0.26 and 0.67.",In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291417/),,0.26,109945,DB01109,Heparin
,16291417,Sa,"In patients, Sc or Sa achieved values between 0.26 and 0.67.",In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291417/),,0.67,109946,DB01109,Heparin
,32125889,Cmax,"A significant difference was observed in pharmacokinetic parameters between males and females, as Cmax in males (230 ± 80.2 ng/mL) was significantly higher than in females (224.9 ± 75.5 ng/mL), while [Formula: see text] was also significantly higher (p < 0.05) in males (2102 ± 200.3 ng·h-1·mL-1) compared to females (1825.7 ± 225.4 ng·h-1·mL-1).",The effect of gender and ABCB1 gene polymorphism on the pharmacokinetics of azithromycin in healthy male and female Pakistani subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32125889/),[ng] / [ml],230,111473,DB01109,Heparin
,32125889,Cmax,"A significant difference was observed in pharmacokinetic parameters between males and females, as Cmax in males (230 ± 80.2 ng/mL) was significantly higher than in females (224.9 ± 75.5 ng/mL), while [Formula: see text] was also significantly higher (p < 0.05) in males (2102 ± 200.3 ng·h-1·mL-1) compared to females (1825.7 ± 225.4 ng·h-1·mL-1).",The effect of gender and ABCB1 gene polymorphism on the pharmacokinetics of azithromycin in healthy male and female Pakistani subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32125889/),[ng] / [ml],224.9,111474,DB01109,Heparin
,32125889,Cmax,"A significant difference was observed in pharmacokinetic parameters between males and females, as Cmax in males (230 ± 80.2 ng/mL) was significantly higher than in females (224.9 ± 75.5 ng/mL), while [Formula: see text] was also significantly higher (p < 0.05) in males (2102 ± 200.3 ng·h-1·mL-1) compared to females (1825.7 ± 225.4 ng·h-1·mL-1).",The effect of gender and ABCB1 gene polymorphism on the pharmacokinetics of azithromycin in healthy male and female Pakistani subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32125889/),[ng] / [h·ml],1825.7,111475,DB01109,Heparin
,32125889,[Formula:,"A significant difference was observed in pharmacokinetic parameters between males and females, as Cmax in males (230 ± 80.2 ng/mL) was significantly higher than in females (224.9 ± 75.5 ng/mL), while [Formula: see text] was also significantly higher (p < 0.05) in males (2102 ± 200.3 ng·h-1·mL-1) compared to females (1825.7 ± 225.4 ng·h-1·mL-1).",The effect of gender and ABCB1 gene polymorphism on the pharmacokinetics of azithromycin in healthy male and female Pakistani subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32125889/),[ng] / [h·ml],2102,111476,DB01109,Heparin
,32125889,[Formula:,"A significant difference was observed in pharmacokinetic parameters between males and females, as Cmax in males (230 ± 80.2 ng/mL) was significantly higher than in females (224.9 ± 75.5 ng/mL), while [Formula: see text] was also significantly higher (p < 0.05) in males (2102 ± 200.3 ng·h-1·mL-1) compared to females (1825.7 ± 225.4 ng·h-1·mL-1).",The effect of gender and ABCB1 gene polymorphism on the pharmacokinetics of azithromycin in healthy male and female Pakistani subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32125889/),[ng] / [h·ml],1825.7,111477,DB01109,Heparin
below,21454037,Anti-Xa,Anti-Xa levels below 0.1 IU/mL at any time were considered subtherapeutic.,Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21454037/),[iu] / [ml],0.1,116409,DB01109,Heparin
more,21454037,anti-Xa,Two patients (5.6%) did not attain therapeutic levels defined as anti-Xa more than 0.1 IU/mL at 3 hours post dose.,Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21454037/),[iu] / [ml],0.1,116410,DB01109,Heparin
,21454037,AUC,"Median AUC was 1.84 IU·h/mL (interquartile range, 1.47 IU·h/mL).",Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21454037/),[h·iu] / [ml],1.84,116411,DB01109,Heparin
more,21454037,anti-Xa level,"In the study, prophylactic SC enoxaparin in critically ill patients at the current 30 mg SC twice daily dosage attained an anti-Xa level more than 0.1 U/mL in nearly all patients.",Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21454037/),[u] / [ml],0.1,116412,DB01109,Heparin
,15928099,clearance,Median iohexol clearance was similar with dalteparin (99-103 ml/min) and melagatran in the dialysis fluid (98-100 ml/min).,Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15928099/),[ml] / [min],99-103,118657,DB01109,Heparin
,15928099,clearance,Median iohexol clearance was similar with dalteparin (99-103 ml/min) and melagatran in the dialysis fluid (98-100 ml/min).,Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15928099/),[ml] / [min],98-100,118658,DB01109,Heparin
,15928099,clearance,"While the clearance of melagatran was low in patients with renal failure (mean+/-SD, 0.93+/-0.36 l/h), haemodialysis provided efficient clearance of melagatran (7.20+/-0.76 l/h).",Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15928099/),[l] / [h],0.93,118659,DB01109,Heparin
,15928099,clearance,"While the clearance of melagatran was low in patients with renal failure (mean+/-SD, 0.93+/-0.36 l/h), haemodialysis provided efficient clearance of melagatran (7.20+/-0.76 l/h).",Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15928099/),[l] / [h],7.20,118660,DB01109,Heparin
,15928099,clearance,Melagatran clearance by dialysis (104+/-10 ml/min) was comparable to iohexol clearance.,Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15928099/),[ml] / [min],104,118661,DB01109,Heparin
,16134071,maximal concentration,"High plasma heparin concentrations were observed (maximal concentration = 4.64 +/-1.4 aXa U/mL) and decreased according to a slightly concave-convex pattern on a semilogarithmic curve, but returned to baseline slightly more slowly (t240-t300 minutes) than did APTT.",Pharmacokinetics and pharmacodynamics of a therapeutic dose of unfractionated heparin (200 U/kg) administered subcutaneously or intravenously to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16134071/),[a·a·u] / [ml],4.64,118711,DB01109,Heparin
,16134071,Plasma aXa activity,Plasma aXa activity reached a maximum of 0.56 +/-0.20 aXa U/mL (range 0.42-0.9 U/mL) after 132 +/-26.8 minutes; this lasted for 102 +/-26.8 minutes.,Pharmacokinetics and pharmacodynamics of a therapeutic dose of unfractionated heparin (200 U/kg) administered subcutaneously or intravenously to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16134071/),[a·a·u] / [ml],0.56,118712,DB01109,Heparin
,12383040,terminal half-life,"It has favourable pharmacokinetics including 100% bioavailability, low variability and a mean terminal half-life of 17 hours for young and 21 hours for elderly healthy volunteers, enabling once-daily administration.",Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12383040/),h,17,121095,DB01109,Heparin
,12383040,terminal half-life,"It has favourable pharmacokinetics including 100% bioavailability, low variability and a mean terminal half-life of 17 hours for young and 21 hours for elderly healthy volunteers, enabling once-daily administration.",Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12383040/),h,21,121096,DB01109,Heparin
,12383040,B(max),"The specific binding parameters B(max) (binding capacity) and K(D )(dissociation constant) were similar for human plasma (B(max) = 2072 nmol/L, K(D) = 28 nmol/L) and purified ATIII (B(max) = 1627 nmol/L and K(D) = 32 nmol/L).",Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12383040/),[nM] / [l],2072,121097,DB01109,Heparin
,12383040,K(D),"The specific binding parameters B(max) (binding capacity) and K(D )(dissociation constant) were similar for human plasma (B(max) = 2072 nmol/L, K(D) = 28 nmol/L) and purified ATIII (B(max) = 1627 nmol/L and K(D) = 32 nmol/L).",Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12383040/),[nM] / [l],28,121098,DB01109,Heparin
,12383040,B(max),"The specific binding parameters B(max) (binding capacity) and K(D )(dissociation constant) were similar for human plasma (B(max) = 2072 nmol/L, K(D) = 28 nmol/L) and purified ATIII (B(max) = 1627 nmol/L and K(D) = 32 nmol/L).",Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12383040/),[nM] / [l],1627,121099,DB01109,Heparin
,12383040,K(D),"The specific binding parameters B(max) (binding capacity) and K(D )(dissociation constant) were similar for human plasma (B(max) = 2072 nmol/L, K(D) = 28 nmol/L) and purified ATIII (B(max) = 1627 nmol/L and K(D) = 32 nmol/L).",Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12383040/),[nM] / [l],32,121100,DB01109,Heparin
,7830857,T1/2,"We observed a moderate increase of the elimination half-life of reviparine (T1/2: 5 +/- 1.6 h between dialysis, 3.6 +/- 1.3 during dialysis with an HP membrane and 4.7 +/- 1.8 during dialysis with an LP membrane) versus 3.3 +/- 1 in healthy volunteers.",Pharmacokinetics of a low molecular weight heparin (reviparine) in hemodialyzed patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7830857/),h,5,121263,DB01109,Heparin
,7830857,T1/2,"We observed a moderate increase of the elimination half-life of reviparine (T1/2: 5 +/- 1.6 h between dialysis, 3.6 +/- 1.3 during dialysis with an HP membrane and 4.7 +/- 1.8 during dialysis with an LP membrane) versus 3.3 +/- 1 in healthy volunteers.",Pharmacokinetics of a low molecular weight heparin (reviparine) in hemodialyzed patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7830857/),h,3.6,121264,DB01109,Heparin
,7830857,T1/2,"We observed a moderate increase of the elimination half-life of reviparine (T1/2: 5 +/- 1.6 h between dialysis, 3.6 +/- 1.3 during dialysis with an HP membrane and 4.7 +/- 1.8 during dialysis with an LP membrane) versus 3.3 +/- 1 in healthy volunteers.",Pharmacokinetics of a low molecular weight heparin (reviparine) in hemodialyzed patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7830857/),h,4.7,121265,DB01109,Heparin
,7830857,T1/2,"We observed a moderate increase of the elimination half-life of reviparine (T1/2: 5 +/- 1.6 h between dialysis, 3.6 +/- 1.3 during dialysis with an HP membrane and 4.7 +/- 1.8 during dialysis with an LP membrane) versus 3.3 +/- 1 in healthy volunteers.",Pharmacokinetics of a low molecular weight heparin (reviparine) in hemodialyzed patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7830857/),h,3.3,121266,DB01109,Heparin
,11234669,Anti-Xa,"Anti-Xa and anti-IIa activity levels on day 2 were 0.66 +/- 0.20 IU/mL (range: 0.26-1.04 IU/mL) and 0.33 +/- 0.10 IU/mL (range: 0.18-0.55 IU/mL), respectively.",[Monitoring of tinzaparin in a ten day treatment dose in elderly patients]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11234669/),[iu] / [ml],0.66,121390,DB01109,Heparin
,11234669,anti-IIa activity,"Anti-Xa and anti-IIa activity levels on day 2 were 0.66 +/- 0.20 IU/mL (range: 0.26-1.04 IU/mL) and 0.33 +/- 0.10 IU/mL (range: 0.18-0.55 IU/mL), respectively.",[Monitoring of tinzaparin in a ten day treatment dose in elderly patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11234669/),[iu] / [ml],0.33,121391,DB01109,Heparin
,14980001,duration of action,The reversibility study with dodecanoylsucrose showed that the effect of alkanoylsucroses faded away with time and the duration of action of this agent at the site of administration was 120-140 min.,Alkanoylsucroses in nasal delivery of low molecular weight heparins: in-vivo absorption and reversibility studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14980001/),min,120-140,121404,DB01109,Heparin
,2287554,ACT,We administered a calculated mean +/- SD heparin doses of 85 +/- 14 U/kg to 10 subjects to achieve a mean +/- SD target ACT of 364 +/- 29 seconds.,Evaluation of a rapid monitoring system to study heparin pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287554/),seconds,364,123161,DB01109,Heparin
,2287554,peak ACT,This dose produced a mean +/- SD measured peak ACT of 337 +/- 53 seconds from a mean +/- SD baseline of 121 +/- 10 seconds.,Evaluation of a rapid monitoring system to study heparin pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287554/),seconds,337,123162,DB01109,Heparin
,2287554,peak ACT,This dose produced a mean +/- SD measured peak ACT of 337 +/- 53 seconds from a mean +/- SD baseline of 121 +/- 10 seconds.,Evaluation of a rapid monitoring system to study heparin pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287554/),seconds,121,123163,DB01109,Heparin
,2287554,mean residence time,"Using the ACT values, the average mean residence time for heparin effect was 1.2 hours and half-life was 0.8 +/- 0.2 hours, with all the subjects' values returning to within 10% of baseline by 4 hours after the dose.",Evaluation of a rapid monitoring system to study heparin pharmacokinetics and pharmacodynamics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287554/),h,1.2,123164,DB01109,Heparin
,2287554,half-life,"Using the ACT values, the average mean residence time for heparin effect was 1.2 hours and half-life was 0.8 +/- 0.2 hours, with all the subjects' values returning to within 10% of baseline by 4 hours after the dose.",Evaluation of a rapid monitoring system to study heparin pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287554/),h,0.8,123165,DB01109,Heparin
,2287554,total-body clearance,"Using the protamine-derived heparin concentrations, heparin total-body clearance ranged from 43 to 99 ml/hr/kg (mean +/- SD 73.3 +/- 14.5 ml/hr/kg).",Evaluation of a rapid monitoring system to study heparin pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287554/),[ml] / [h·kg],43 to 99,123166,DB01109,Heparin
,2287554,total-body clearance,"Using the protamine-derived heparin concentrations, heparin total-body clearance ranged from 43 to 99 ml/hr/kg (mean +/- SD 73.3 +/- 14.5 ml/hr/kg).",Evaluation of a rapid monitoring system to study heparin pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287554/),[ml] / [h·kg],73.3,123167,DB01109,Heparin
,8703665,Amax,"The Amax and the AUC(0, 24h) of plasma anti-Xa activity after reviparin administration were both slightly but significantly lower than those observed after enoxaparin administration (difference between treatments of 0.03 95% CI[0.01-0.05] iu ml-1 h and 0.56 95% CI[0.22-0.90] iu ml-1 for Amax and AUC(0, 24h) respectively).",Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703665/),[h·iu] / [ml],0.03,123382,DB01109,Heparin
,8703665,Amax,"The Amax and the AUC(0, 24h) of plasma anti-Xa activity after reviparin administration were both slightly but significantly lower than those observed after enoxaparin administration (difference between treatments of 0.03 95% CI[0.01-0.05] iu ml-1 h and 0.56 95% CI[0.22-0.90] iu ml-1 for Amax and AUC(0, 24h) respectively).",Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703665/),[iu] / [ml],0.56,123383,DB01109,Heparin
,8703665,"AUC(0, 24h)","The Amax and the AUC(0, 24h) of plasma anti-Xa activity after reviparin administration were both slightly but significantly lower than those observed after enoxaparin administration (difference between treatments of 0.03 95% CI[0.01-0.05] iu ml-1 h and 0.56 95% CI[0.22-0.90] iu ml-1 for Amax and AUC(0, 24h) respectively).",Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703665/),[iu] / [ml],0.56,123384,DB01109,Heparin
,8703665,t1/2,"The t1/2 for reviparin did not significantly differ from that of enoxaparin (2.7 +/- 0.7 h vs 3.5 +/- 0.9 h respectively, NS).",Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703665/),h,2.7,123385,DB01109,Heparin
,8703665,t1/2,"The t1/2 for reviparin did not significantly differ from that of enoxaparin (2.7 +/- 0.7 h vs 3.5 +/- 0.9 h respectively, NS).",Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703665/),h,3.5,123386,DB01109,Heparin
,8703665,Amax,"The Amax of the plasma anti-thrombin activity after reviparin administration was also slightly but significantly lower than that observed after enoxaparin administration, (difference between treatments of 0.018 95% CI[0.01-0.025] iu ml-1) whereas the AUC(0, 24h) of anti-thrombin activity vs time was not.",Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703665/),[iu] / [ml],0.018,123387,DB01109,Heparin
,8703665,surface under the thrombin generation curve,"4. The calculated surface under the thrombin generation curve vs time (or thrombin potential) at peak was significantly higher after reviparin than after enoxaparin (367 +/- 53 UA vs 305 +/- 48 UA respectively, P < 0.05).",Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703665/),ua,367,123388,DB01109,Heparin
,8703665,surface under the thrombin generation curve,"4. The calculated surface under the thrombin generation curve vs time (or thrombin potential) at peak was significantly higher after reviparin than after enoxaparin (367 +/- 53 UA vs 305 +/- 48 UA respectively, P < 0.05).",Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703665/),ua,305,123389,DB01109,Heparin
,10211714,peak plasma concentration (C(max)),Early detection of IVM (12 h) with a peak plasma concentration (C(max)) between 33 and 39 ng/mL was observed in pigs.,Bioequivalence of ivermectin formulations in pigs and cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211714/),[ng] / [ml],33 and 39,123739,DB01109,Heparin
,10211714,elimination half-lives,"The drug was detected in plasma up to 20 days post-administration of either formulation, resulting in elimination half-lives between 3.47 and 3.80 days.",Bioequivalence of ivermectin formulations in pigs and cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211714/),d,3.47 and 3.80,123740,DB01109,Heparin
,10211714,C(max),C(max) values (between 40.5 and 46.4 ng/mL) were achieved at 2 days post-administration of both formulations.,Bioequivalence of ivermectin formulations in pigs and cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211714/),[ng] / [ml],40.5 and 46.4,123741,DB01109,Heparin
,10763553,peak plasma heparin activity,"After intravenous application of 25, 50 and 100 anti-fXaU./kg body weight (BW) the mean peak plasma heparin activity of 0.52 +/- 0.12 (x +/- s), 1.08 +/- 0.23 and 1.86 +/- 0.17 anti-fXaU./ml, respectively, was measured.",[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),[anti-f·au] / [ml],0.52,124001,DB01109,Heparin
,10763553,peak plasma heparin activity,"After intravenous application of 25, 50 and 100 anti-fXaU./kg body weight (BW) the mean peak plasma heparin activity of 0.52 +/- 0.12 (x +/- s), 1.08 +/- 0.23 and 1.86 +/- 0.17 anti-fXaU./ml, respectively, was measured.",[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),[anti-f·au] / [ml],1.08,124002,DB01109,Heparin
,10763553,peak plasma heparin activity,"After intravenous application of 25, 50 and 100 anti-fXaU./kg body weight (BW) the mean peak plasma heparin activity of 0.52 +/- 0.12 (x +/- s), 1.08 +/- 0.23 and 1.86 +/- 0.17 anti-fXaU./ml, respectively, was measured.",[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),[anti-f·au] / [ml],1.86,124003,DB01109,Heparin
,10763553,maximum heparin activity,"After subcutaneous application of 50, 100 and 200 anti-fXaU./kg BW maximum heparin activity in the plasma was determined after 144-216 minutes (mean values) of 0.28 +/- 0.01, 0.52 +/- 0.06 or 1.09 +/- 0.20 anti-fXaU./ml.",[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),[anti-f·au] / [ml],0.28,124004,DB01109,Heparin
,10763553,maximum heparin activity,"After subcutaneous application of 50, 100 and 200 anti-fXaU./kg BW maximum heparin activity in the plasma was determined after 144-216 minutes (mean values) of 0.28 +/- 0.01, 0.52 +/- 0.06 or 1.09 +/- 0.20 anti-fXaU./ml.",[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),[anti-f·au] / [ml],0.52,124005,DB01109,Heparin
,10763553,maximum heparin activity,"After subcutaneous application of 50, 100 and 200 anti-fXaU./kg BW maximum heparin activity in the plasma was determined after 144-216 minutes (mean values) of 0.28 +/- 0.01, 0.52 +/- 0.06 or 1.09 +/- 0.20 anti-fXaU./ml.",[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),[anti-f·au] / [ml],1.09,124006,DB01109,Heparin
,10763553,plasma terminal half-life (t50),Intravenous application of LMWH has a short plasma terminal half-life (t50) between 49 and 76 minutes which depended on the dosage.,[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),min,49 and 76,124007,DB01109,Heparin
,10763553,t50,"After injection of 50, 100 and 200 anti-fXaU./kg BW t50 values of 81, 123 and 182 minutes were calculated.",[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),min,81,124008,DB01109,Heparin
,10763553,t50,"After injection of 50, 100 and 200 anti-fXaU./kg BW t50 values of 81, 123 and 182 minutes were calculated.",[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),min,123,124009,DB01109,Heparin
,10763553,t50,"After injection of 50, 100 and 200 anti-fXaU./kg BW t50 values of 81, 123 and 182 minutes were calculated.",[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),min,182,124010,DB01109,Heparin
,10763553,apparent volume of distribution,The apparent volume of distribution after intravenously applicated LMWH ranged between 50 and 70 ml/kg BW.,[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),[ml] / [kg],50 and 70,124011,DB01109,Heparin
,10763553,absolute bioavailability,"The absolute bioavailability calculated for the subcutaneous NMH-injection of 50 and 100 anti-fXaU./kg BW was 107% and 104%, respectively.",[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),%,107,124012,DB01109,Heparin
,10763553,absolute bioavailability,"The absolute bioavailability calculated for the subcutaneous NMH-injection of 50 and 100 anti-fXaU./kg BW was 107% and 104%, respectively.",[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),%,104,124013,DB01109,Heparin
,9268187,absolute bioavailability,The mean absolute bioavailability of ardeparin based on aIIa activity ranged from 62% to 64% and the mean absolute bioavailability based on aXa activity ranged from 88% to 97%.,"Absolute and comparative subcutaneous bioavailability of ardeparin sodium, a low molecular weight heparin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9268187/),%,62,124325,DB01109,Heparin
,9268187,absolute bioavailability,The mean absolute bioavailability of ardeparin based on aIIa activity ranged from 62% to 64% and the mean absolute bioavailability based on aXa activity ranged from 88% to 97%.,"Absolute and comparative subcutaneous bioavailability of ardeparin sodium, a low molecular weight heparin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9268187/),%,64,124326,DB01109,Heparin
,9268187,absolute bioavailability,The mean absolute bioavailability of ardeparin based on aIIa activity ranged from 62% to 64% and the mean absolute bioavailability based on aXa activity ranged from 88% to 97%.,"Absolute and comparative subcutaneous bioavailability of ardeparin sodium, a low molecular weight heparin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9268187/),%,88,124327,DB01109,Heparin
,9268187,absolute bioavailability,The mean absolute bioavailability of ardeparin based on aIIa activity ranged from 62% to 64% and the mean absolute bioavailability based on aXa activity ranged from 88% to 97%.,"Absolute and comparative subcutaneous bioavailability of ardeparin sodium, a low molecular weight heparin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9268187/),%,97,124328,DB01109,Heparin
,11961072,central,"Pericardial fluid volumes of catheter-instrumented rats, derived from (initial) central compartment volumes, ranged between 0.5 and 0.9 ml/kg.",Pharmacokinetic advantage of intrapericardially applied substances in the rat. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11961072/),[ml] / [kg],0.5 and 0.9,124368,DB01109,Heparin
,11961072,per,"After chronic (7 days) intrapericardial infusions with osmotic minipumps, pericardial fluid/plasma concentration ratios (local advantages) were 7 to 10 for the fluorescent proteins and >30 for FITC-heparin.",Pharmacokinetic advantage of intrapericardially applied substances in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11961072/),,7 to 10,124369,DB01109,Heparin
,11961072,fluid/plasma concentration ratios,"After chronic (7 days) intrapericardial infusions with osmotic minipumps, pericardial fluid/plasma concentration ratios (local advantages) were 7 to 10 for the fluorescent proteins and >30 for FITC-heparin.",Pharmacokinetic advantage of intrapericardially applied substances in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11961072/),,7 to 10,124370,DB01109,Heparin
>,11961072,fluid/plasma concentration ratios,"After chronic (7 days) intrapericardial infusions with osmotic minipumps, pericardial fluid/plasma concentration ratios (local advantages) were 7 to 10 for the fluorescent proteins and >30 for FITC-heparin.",Pharmacokinetic advantage of intrapericardially applied substances in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11961072/),,30,124371,DB01109,Heparin
,7995679,peak concentration,"The peak concentration, the elimination half-life and the apparent distribution volume were respectively 3.8 mcg/ml, 275 min and 0.40 ml/g.",Metabolic fate of partially depolymerized shark chondroitin sulfate in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995679/),[mcg] / [ml],3.8,124920,DB01109,Heparin
,7995679,elimination half-life,"The peak concentration, the elimination half-life and the apparent distribution volume were respectively 3.8 mcg/ml, 275 min and 0.40 ml/g.",Metabolic fate of partially depolymerized shark chondroitin sulfate in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995679/),min,275,124921,DB01109,Heparin
,7995679,apparent distribution volume,"The peak concentration, the elimination half-life and the apparent distribution volume were respectively 3.8 mcg/ml, 275 min and 0.40 ml/g.",Metabolic fate of partially depolymerized shark chondroitin sulfate in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995679/),[ml] / [g],0.40,124922,DB01109,Heparin
,7995679,concentration at the peak,"The concentration at the peak, the elimination half-life and the apparent distribution volume were respectively 4.6 mcg/ml, 310 min and 0.44 ml/g.",Metabolic fate of partially depolymerized shark chondroitin sulfate in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995679/),[mcg] / [ml],4.6,124923,DB01109,Heparin
,7995679,elimination half-life,"The concentration at the peak, the elimination half-life and the apparent distribution volume were respectively 4.6 mcg/ml, 310 min and 0.44 ml/g.",Metabolic fate of partially depolymerized shark chondroitin sulfate in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995679/),min,310,124924,DB01109,Heparin
,7995679,apparent distribution volume,"The concentration at the peak, the elimination half-life and the apparent distribution volume were respectively 4.6 mcg/ml, 310 min and 0.44 ml/g.",Metabolic fate of partially depolymerized shark chondroitin sulfate in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995679/),[ml] / [g],0.44,124925,DB01109,Heparin
<,8960425,aPTT,"In 82.5% of the patients, aPTT values were ranged between the highest and the lowest aPTT of < 30 s.",Recombinant hirudin (HBW 023) produces stable anticoagulation unaffected by circadian variation in patients with thrombolysis for acute myocardial infarction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8960425/),s,30,125200,DB01109,Heparin
,1962905,half-life,4. The half-life of LMW heparin was 1.5 to 1.8 hours; unfractionated heparin had 0.68 hours.,Comparative studies on properties of unfractionated and low molecular weight heparin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1962905/),h,1.5 to 1.8,126115,DB01109,Heparin
,1962905,half-life,4. The half-life of LMW heparin was 1.5 to 1.8 hours; unfractionated heparin had 0.68 hours.,Comparative studies on properties of unfractionated and low molecular weight heparin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1962905/),h,0.68,126116,DB01109,Heparin
,30902709,critical micelle concentration (CMC),"Owing both hydrophobic and hydrophilic moieties, the conjugate was successfully self-assembled into artesunate-heparin nanocapsules (ART-HEP-NCPs) with lower critical micelle concentration (CMC) of about 20 µg/mL.",Artesunate-heparin conjugate based nanocapsules with improved pharmacokinetics to combat malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30902709/),[μg] / [ml],20,126184,DB01109,Heparin
,30902709,drug loading efficiency (DLE),"Interestingly, such modification achieved high drug loading efficiency (DLE) of ART (29.3 wt%), which is significantly higher than already reported conventional ART-loaded nanoparticles.",Artesunate-heparin conjugate based nanocapsules with improved pharmacokinetics to combat malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30902709/),wt%,29.3,126185,DB01109,Heparin
,30902709,half-maximal inhibitory concentration (IC50),"Notably, ART-HEP-NCPs has promising internalization into Plasmodium infected red blood cells (iRBCs) and also displayed in vitro inhibitory effect against P. falciparum 3D7 with half-maximal inhibitory concentration (IC50) of 10.16 nM, which was slightly higher than free ART (IC50 6.27 nM).",Artesunate-heparin conjugate based nanocapsules with improved pharmacokinetics to combat malaria. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30902709/),nM,10.16,126186,DB01109,Heparin
,30902709,IC50,"Notably, ART-HEP-NCPs has promising internalization into Plasmodium infected red blood cells (iRBCs) and also displayed in vitro inhibitory effect against P. falciparum 3D7 with half-maximal inhibitory concentration (IC50) of 10.16 nM, which was slightly higher than free ART (IC50 6.27 nM).",Artesunate-heparin conjugate based nanocapsules with improved pharmacokinetics to combat malaria. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30902709/),nM,6.27,126187,DB01109,Heparin
,12134955,peak percentage,"When total body distribution was considered, the recovery of radioactivity was greater for the endothelium than for plasma (peak percentage of the dose was 65% at 15 min, 20% at 3 min, 5% from 20 to 240 min for the vena cava, aortic endothelium, and plasma, respectively).",Tissue distribution of [14C]sucrose octasulfate following oral administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12134955/),%,65,126566,DB01109,Heparin
,12134955,peak percentage,"When total body distribution was considered, the recovery of radioactivity was greater for the endothelium than for plasma (peak percentage of the dose was 65% at 15 min, 20% at 3 min, 5% from 20 to 240 min for the vena cava, aortic endothelium, and plasma, respectively).",Tissue distribution of [14C]sucrose octasulfate following oral administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12134955/),%,20,126567,DB01109,Heparin
,12134955,peak percentage,"When total body distribution was considered, the recovery of radioactivity was greater for the endothelium than for plasma (peak percentage of the dose was 65% at 15 min, 20% at 3 min, 5% from 20 to 240 min for the vena cava, aortic endothelium, and plasma, respectively).",Tissue distribution of [14C]sucrose octasulfate following oral administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12134955/),%,5,126568,DB01109,Heparin
,27980562,drug entrapment efficiency,"The average drug entrapment efficiency for LMWH-ISL-SLN was (99.80 ± 3.27)%, drug loading was (18.68 ± 1.51)%, mean particle size was (217.53 ± 4.86) nm and zeta potential was (-18.24 ± 2.47) mV.","Preparation, Properties and Preclinical Pharmacokinetics of Low Molecular Weight Heparin-modified Isoliquiritigenin-loaded Solid Lipid Nanoparticle. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27980562/),%,99.80,126665,DB01109,Heparin
,27980562,drug loading,"The average drug entrapment efficiency for LMWH-ISL-SLN was (99.80 ± 3.27)%, drug loading was (18.68 ± 1.51)%, mean particle size was (217.53 ± 4.86) nm and zeta potential was (-18.24 ± 2.47) mV.","Preparation, Properties and Preclinical Pharmacokinetics of Low Molecular Weight Heparin-modified Isoliquiritigenin-loaded Solid Lipid Nanoparticle. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27980562/),%,18.68,126666,DB01109,Heparin
,18074760,m/z(+1),Multiple reaction monitoring was used for the measurement of tacrolimus (m/z(+1) 821.49-->4768.35 Th) and sirolimus as internal standard (m/z(+1) 931.69-->864.39 Th).,"Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),th,821.49,127188,DB01109,Heparin
,18074760,m/z(+1),Multiple reaction monitoring was used for the measurement of tacrolimus (m/z(+1) 821.49-->4768.35 Th) and sirolimus as internal standard (m/z(+1) 931.69-->864.39 Th).,"Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),th,4768.35,127189,DB01109,Heparin
,18074760,m/z(+1),Multiple reaction monitoring was used for the measurement of tacrolimus (m/z(+1) 821.49-->4768.35 Th) and sirolimus as internal standard (m/z(+1) 931.69-->864.39 Th).,"Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),th,931.69,127190,DB01109,Heparin
,18074760,m/z(+1),Multiple reaction monitoring was used for the measurement of tacrolimus (m/z(+1) 821.49-->4768.35 Th) and sirolimus as internal standard (m/z(+1) 931.69-->864.39 Th).,"Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),th,864.39,127191,DB01109,Heparin
,18074760,absolute recovery,"Method showed to be accurate, precise and linear over the range from 1 to 80 ng/ml, having an absolute recovery of 94%.","Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),%,94,127192,DB01109,Heparin
,18074760,Total run-time,Total run-time is around 1.5 min.,"Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),min,1.5,127193,DB01109,Heparin
,18074760,maximum blood concentration,"Mean maximum blood concentration was 32.63 +/- 1.74 ng/ml, and was reached at 1 h post-dose; elimination half-life was 14.18 +/- 5.71 h.","Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),[ng] / [ml],32.63,127194,DB01109,Heparin
,18074760,elimination half-life,"Mean maximum blood concentration was 32.63 +/- 1.74 ng/ml, and was reached at 1 h post-dose; elimination half-life was 14.18 +/- 5.71 h.","Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),h,14.18,127195,DB01109,Heparin
,3715820,mw,"The pharmacokinetics of a low molecular weight heparin (LMWH) with a mean mw of 4000-6000 D (KABI 2165, Fragmin) was studied in 6 healthy volunteers after intravenous (iv) and subcutaneous (sc) administration of 120 U (anti FXa)/kg.","Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3715820/),d,4000-6000,127228,DB01109,Heparin
,3715820,half-life,"The half-life in plasma of the anti FXa activity after iv injection was 119 +/- 17 min, the volume of distribution (Vd) 3.4 +/- 0.5 1 and the total clearence 20.5 +/- 2.5 ml/min.","Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3715820/),min,119,127229,DB01109,Heparin
,3715820,volume of distribution (Vd),"The half-life in plasma of the anti FXa activity after iv injection was 119 +/- 17 min, the volume of distribution (Vd) 3.4 +/- 0.5 1 and the total clearence 20.5 +/- 2.5 ml/min.","Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3715820/),1,3.4,127230,DB01109,Heparin
,3715820,total clearence,"The half-life in plasma of the anti FXa activity after iv injection was 119 +/- 17 min, the volume of distribution (Vd) 3.4 +/- 0.5 1 and the total clearence 20.5 +/- 2.5 ml/min.","Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3715820/),[ml] / [min],20.5,127231,DB01109,Heparin
,3715820,maximal anti FXa activity,The maximal anti FXa activity determined 3 min after iv bolus injection amounted to 2.2 +/- 0.3 U (anti FXa)/ml with a corresponding increase of the APTT from 31 +/- 7 sec to 113 +/- 35 sec.,"Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3715820/),[a·anti·f·u] / [ml],2.2,127232,DB01109,Heparin
,3715820,plasma half-life,"After sc administration the plasma half-life of the anti FXa activity was longer than after iv injection, 228 +/- 40 min, corresponding to the absorption rate thus found to be the rate limiting step.","Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3715820/),min,228,127233,DB01109,Heparin
,3715820,peak,After sc administration the peak was reached after 4 hours (0.6 +/- 0.1 U (anti FXa)/ml; APTT increase 5 sec).,"Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3715820/),u,0.6,127234,DB01109,Heparin
,3715820,bioavailability,The bioavailability after sc injection was calculated to be 87 +/- 6%.,"Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3715820/),%,87,127235,DB01109,Heparin
,7824956,sensitivity,A linear relationship of binding was obtained for all three cell lines; the sensitivity was 0.1 microgram/mL for monocytes and lymphocytes and 0.03 microgram/mL for granulocytes without differences between rat and human cells.,Binding of fluorescent-labeled low molecular mass heparin to latex microspheres and to rat and human leukocytes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7824956/),[μg] / [ml],0.1,127272,DB01109,Heparin
,7824956,sensitivity,A linear relationship of binding was obtained for all three cell lines; the sensitivity was 0.1 microgram/mL for monocytes and lymphocytes and 0.03 microgram/mL for granulocytes without differences between rat and human cells.,Binding of fluorescent-labeled low molecular mass heparin to latex microspheres and to rat and human leukocytes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7824956/),[μg] / [ml],0.03,127273,DB01109,Heparin
,666973,clearance,"Heparin removal in normal subjects after 75 u/kg was nearly linear with a clearance of 0.64 ml/min/kg, SD +/- 0.11.",Heparin pharmacokinetics: increased requirements in pulmonary embolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/666973/),[ml] / [kg·min],0.64,127989,DB01109,Heparin
,666973,clearance,"Heparin clearance in pulmonary embolism (0.80 ml/min/kg +/- 0.23) was significantly accelerated compared both to normals (P less than 0.005) and to thrombophlebitis patients (0.55 ml/min/kg +/- 0.19, P less than 0.01); the disappearance was more curvilinear in thrombophlebitis and pulmonary embolism than in normal subjects (P less than 0.025).",Heparin pharmacokinetics: increased requirements in pulmonary embolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/666973/),[ml] / [kg·min],0.80,127990,DB01109,Heparin
,666973,clearance,"Heparin clearance in pulmonary embolism (0.80 ml/min/kg +/- 0.23) was significantly accelerated compared both to normals (P less than 0.005) and to thrombophlebitis patients (0.55 ml/min/kg +/- 0.19, P less than 0.01); the disappearance was more curvilinear in thrombophlebitis and pulmonary embolism than in normal subjects (P less than 0.025).",Heparin pharmacokinetics: increased requirements in pulmonary embolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/666973/),[ml] / [kg·min],0.55,127991,DB01109,Heparin
,666973,clearance,The pattern and rate of disappearance in renal disease was similar to normal subjects; in liver disease clearance was accelerated (0.86 ml/min/kg +/- 0.28) and disappearance curvilinear.,Heparin pharmacokinetics: increased requirements in pulmonary embolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/666973/),[ml] / [kg·min],0.86,127992,DB01109,Heparin
,15821819,half-life,The half-life of intravenous dalteparin is 77 minutes with slight dose-related variation.,High-dose intravenous dalteparin can be monitored effectively using standard coagulation times. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15821819/),min,77,128078,DB01109,Heparin
,16273676,blood loss,Average estimated blood loss during surgery was 36 cc (5-500 cc).,Continuous intravenous heparin infusion prevents peri-operative thromboembolic events in bariatric surgery patients. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16273676/),cc,36,128744,DB01109,Heparin
,7629026,half-life,The half-life of serum EC-SOD after the prompt rise was about 90 min.,Heparin-induced release of extracellular-superoxide dismutase form (V) to plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7629026/),min,90,129303,DB01109,Heparin
,11556655,clearance,The clearance of tinzaparin based on anti-Xa activity ranged from 1.14 to 2.04 L/hr.,Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11556655/),[l] / [h],1.14 to 2.04,129369,DB01109,Heparin
,11556655,volume of distribution,"The volume of distribution was 3.1-5.0 L, suggesting that the molecular entities responsible for anti-Xa and anti-IIa activities are confined to the intravascular space.",Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11556655/),l,3.1-5.0,129370,DB01109,Heparin
,11556655,half-life,The mean half-life of anti-Xa activity after s.c. injection ranged from 3.41 to 4.13 hours and was independent of the dose.,Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11556655/),h,3.41 to 4.13,129371,DB01109,Heparin
,11556655,absolute bioavailability,The mean absolute bioavailability of s.c. tinzaparin was 86.7%.,Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11556655/),%,86.7,129372,DB01109,Heparin
,16631328,T50%s,"The in vitro release study showed that the T50%s were 3.2+/-0.1min for Sylysia 320, 4.6+/-0.2min for Florite RE, 13.7+/-0.1min for Neusilin US(2).",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),min,3.2,129892,DB01109,Heparin
,16631328,T50%s,"The in vitro release study showed that the T50%s were 3.2+/-0.1min for Sylysia 320, 4.6+/-0.2min for Florite RE, 13.7+/-0.1min for Neusilin US(2).",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),min,4.6,129893,DB01109,Heparin
,16631328,T50%s,"The in vitro release study showed that the T50%s were 3.2+/-0.1min for Sylysia 320, 4.6+/-0.2min for Florite RE, 13.7+/-0.1min for Neusilin US(2).",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),min,13.7,129894,DB01109,Heparin
,16631328,C(max),"The in vivo rat absorption study showed that Florite RE system had the highest C(max), 0.42+/-0.01IU/mL and AUC, 0.59+/-0.06IUh/mL, where plasma LMWH levels were measured as anti-Xa activity.",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),[iu] / [ml],0.42,129895,DB01109,Heparin
,16631328,AUC,"The in vivo rat absorption study showed that Florite RE system had the highest C(max), 0.42+/-0.01IU/mL and AUC, 0.59+/-0.06IUh/mL, where plasma LMWH levels were measured as anti-Xa activity.",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),[iuh] / [ml],0.59,129896,DB01109,Heparin
,16631328,C(max),"Other preparations had the C(max) and AUC, 0.12+/-0.01IU/mL and 0.15+/-0.02IUh/mL for Neusilin US(2) and 0.25+/-0.02IU/mL and 0.40+/-0.03IUh/mL for Sylysia 320, respectively.",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),[iu] / [ml],0.12,129897,DB01109,Heparin
,16631328,C(max),"Other preparations had the C(max) and AUC, 0.12+/-0.01IU/mL and 0.15+/-0.02IUh/mL for Neusilin US(2) and 0.25+/-0.02IU/mL and 0.40+/-0.03IUh/mL for Sylysia 320, respectively.",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),[iu] / [ml],0.25,129898,DB01109,Heparin
,16631328,AUC,"Other preparations had the C(max) and AUC, 0.12+/-0.01IU/mL and 0.15+/-0.02IUh/mL for Neusilin US(2) and 0.25+/-0.02IU/mL and 0.40+/-0.03IUh/mL for Sylysia 320, respectively.",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),[iuh] / [ml],0.15,129899,DB01109,Heparin
,16631328,AUC,"Other preparations had the C(max) and AUC, 0.12+/-0.01IU/mL and 0.15+/-0.02IUh/mL for Neusilin US(2) and 0.25+/-0.02IU/mL and 0.40+/-0.03IUh/mL for Sylysia 320, respectively.",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),[iuh] / [ml],0.40,129900,DB01109,Heparin
,16631328,bioavailability (BA),"The bioavailability (BA) of LMWH from the microporous calcium silicate preparation, Florite RE, was 18.8% in rats by comparing the AUC obtained after i.v. injection of LMWH, 40IU/kg to another group of rats.",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),%,18.8,129901,DB01109,Heparin
,16631328,C(max),"High plasma anti-Xa activity levels were obtained, i.e., the C(max) was 0.48+/-0.11IU/mL and AUC was 1.64+/-0.32IUh/mL.",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),[iu] / [ml],0.48,129902,DB01109,Heparin
,16631328,AUC,"High plasma anti-Xa activity levels were obtained, i.e., the C(max) was 0.48+/-0.11IU/mL and AUC was 1.64+/-0.32IUh/mL.",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),[iuh] / [ml],1.64,129903,DB01109,Heparin
<,28510738,ACT,Heparin was administered as an initial bolus of 300 IU kg -1 followed by additional boluses of 5000 IU to maintain ACT <400 s.,Pharmacokinetic/pharmacodynamic model for unfractionated heparin dosing during cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28510738/),s,400,130468,DB01109,Heparin
,11213853,total body clearance,"After administration of the drug, total body clearance was 14.6 ml/minute and there was a 2-fold prolongation in antifactor Xa activity half-life compared with values reported in healthy subjects.",The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11213853/),[ml] / [min],14.6,130714,DB01109,Heparin
,11213853,accumulation ratio,An accumulation ratio of 1.6 was estimated for a dosing interval of every 12 hours based on single-dose pharmacokinetics.,The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11213853/),,1.6,130715,DB01109,Heparin
,21176310,terminal elimination half-life,"Warfarin has a long half-life; following a single dose, the terminal elimination half-life is about one week, with a mean effective half-life of 40 hours.","The ""warfarin window"" in pregnancy: the importance of half-life. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21176310/),week,one,131307,DB01109,Heparin
,21176310,effective half-life,"Warfarin has a long half-life; following a single dose, the terminal elimination half-life is about one week, with a mean effective half-life of 40 hours.","The ""warfarin window"" in pregnancy: the importance of half-life. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21176310/),h,40,131308,DB01109,Heparin
,3164387,elimination half-lives,"The elimination half-lives were similar, 11.7 +/- 3.8 and 13.5 +/- 5.2 min, respectively (N.S.).",Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3164387/),min,11.7,131990,DB01109,Heparin
,3164387,elimination half-lives,"The elimination half-lives were similar, 11.7 +/- 3.8 and 13.5 +/- 5.2 min, respectively (N.S.).",Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3164387/),min,13.5,131991,DB01109,Heparin
,3164387,Cl,"The Cl values were 4.15 +/- 1.11 and 0.58 +/- 0.26 ml/min/kg and the Vd values were 72.1 +/- 38.7 and 9.9 +/- 2.4 ml/kg for the N-deacetylated and N-desulfated heparins, respectively.",Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3164387/),[ml] / [kg·min],4.15,131992,DB01109,Heparin
,3164387,Cl,"The Cl values were 4.15 +/- 1.11 and 0.58 +/- 0.26 ml/min/kg and the Vd values were 72.1 +/- 38.7 and 9.9 +/- 2.4 ml/kg for the N-deacetylated and N-desulfated heparins, respectively.",Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3164387/),[ml] / [kg·min],0.58,131993,DB01109,Heparin
,3164387,Vd,"The Cl values were 4.15 +/- 1.11 and 0.58 +/- 0.26 ml/min/kg and the Vd values were 72.1 +/- 38.7 and 9.9 +/- 2.4 ml/kg for the N-deacetylated and N-desulfated heparins, respectively.",Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3164387/),[ml] / [kg],72.1,131994,DB01109,Heparin
,3164387,Vd,"The Cl values were 4.15 +/- 1.11 and 0.58 +/- 0.26 ml/min/kg and the Vd values were 72.1 +/- 38.7 and 9.9 +/- 2.4 ml/kg for the N-deacetylated and N-desulfated heparins, respectively.",Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3164387/),[ml] / [kg],9.9,131995,DB01109,Heparin
,3164387,elimination half-life,"We have reported previously that after a similar dose of standard heparin the elimination half-life was 69.0 +/- 13.1 min, Cl was 0.64 +/- 0.16 ml/min/kg and Vd was 62.6 +/- 16.7 ml/kg.",Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3164387/),min,69.0,131996,DB01109,Heparin
,3164387,Cl,"We have reported previously that after a similar dose of standard heparin the elimination half-life was 69.0 +/- 13.1 min, Cl was 0.64 +/- 0.16 ml/min/kg and Vd was 62.6 +/- 16.7 ml/kg.",Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3164387/),[ml] / [kg·min],0.64,131997,DB01109,Heparin
,3164387,Vd,"We have reported previously that after a similar dose of standard heparin the elimination half-life was 69.0 +/- 13.1 min, Cl was 0.64 +/- 0.16 ml/min/kg and Vd was 62.6 +/- 16.7 ml/kg.",Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3164387/),[ml] / [kg],62.6,131998,DB01109,Heparin
,9176182,fractional catabolic rate,"The whole body fractional catabolic rate for HCII (jt, 0.43/day, equivalent to t1/2 = 1.61 days) was significantly faster than for AT (jt, 0.37/day; t1/2 = 1.89 days; P < 0.005).",Comparative metabolism and distribution of rabbit heparin cofactor II and rabbit antithrombin in rabbits. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176182/),1/[d],0.43,132152,DB01109,Heparin
,9176182,t1/2,"The whole body fractional catabolic rate for HCII (jt, 0.43/day, equivalent to t1/2 = 1.61 days) was significantly faster than for AT (jt, 0.37/day; t1/2 = 1.89 days; P < 0.005).",Comparative metabolism and distribution of rabbit heparin cofactor II and rabbit antithrombin in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176182/),d,1.61,132153,DB01109,Heparin
,9176182,t1/2,"The whole body fractional catabolic rate for HCII (jt, 0.43/day, equivalent to t1/2 = 1.61 days) was significantly faster than for AT (jt, 0.37/day; t1/2 = 1.89 days; P < 0.005).",Comparative metabolism and distribution of rabbit heparin cofactor II and rabbit antithrombin in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176182/),1/[d],0.37,132154,DB01109,Heparin
,9176182,t1/2,"The whole body fractional catabolic rate for HCII (jt, 0.43/day, equivalent to t1/2 = 1.61 days) was significantly faster than for AT (jt, 0.37/day; t1/2 = 1.89 days; P < 0.005).",Comparative metabolism and distribution of rabbit heparin cofactor II and rabbit antithrombin in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176182/),d,1.89,132155,DB01109,Heparin
,9176182,m,"From the catabolic data and blood concentrations, absolute quantities of HCII and AT catabolized by a 3-kg rabbit amounted to 12.8 and 19.9 mg/day, respectively, equivalent to a molar ratio, AT/HCII, of 1.7.",Comparative metabolism and distribution of rabbit heparin cofactor II and rabbit antithrombin in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176182/),,1,132156,DB01109,Heparin
,9176182,molar ratio,"Both proteins were released from the liver, the molar ratio in the perfusate rising to approximately 1.4 at 2.5 h.",Comparative metabolism and distribution of rabbit heparin cofactor II and rabbit antithrombin in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176182/),,1.4,132157,DB01109,Heparin
,15454859,Ki,"PD-198961, 3-(4-5-[(2R,6S)-2,6-dimethyltetrahydro-1(2H)-pyridinyl]pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl)-4-hydroxybenzenecarboximidamide, is a novel, synthetic factor Xa inhibitor with a Ki of 2.7 nM against human factor Xa.","In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15454859/),nM,2.7,133120,DB01109,Heparin
,15454859,peak plasma concentration,The peak plasma concentration of PD-198961 was 977 +/- 96 ng/ml.,"In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15454859/),[ng] / [ml],977,133121,DB01109,Heparin
,15454859,TTO,"When administered at 3.0 microg/kg/min IV, PD-198961 prolonged TTO from 28 +/- 5 minutes (control) to 120 +/- 0 minutes (P < 0.001) and reduced TW from 9.9 +/- 1.5 mg (control) to 2.8 +/- 0.9 mg (P < 0.01).","In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15454859/),min,28,133122,DB01109,Heparin
,15454859,TTO,"When administered at 3.0 microg/kg/min IV, PD-198961 prolonged TTO from 28 +/- 5 minutes (control) to 120 +/- 0 minutes (P < 0.001) and reduced TW from 9.9 +/- 1.5 mg (control) to 2.8 +/- 0.9 mg (P < 0.01).","In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15454859/),min,120,133123,DB01109,Heparin
,15454859,TW,"When administered at 3.0 microg/kg/min IV, PD-198961 prolonged TTO from 28 +/- 5 minutes (control) to 120 +/- 0 minutes (P < 0.001) and reduced TW from 9.9 +/- 1.5 mg (control) to 2.8 +/- 0.9 mg (P < 0.01).","In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15454859/),mg,9.9,133124,DB01109,Heparin
,15454859,TW,"When administered at 3.0 microg/kg/min IV, PD-198961 prolonged TTO from 28 +/- 5 minutes (control) to 120 +/- 0 minutes (P < 0.001) and reduced TW from 9.9 +/- 1.5 mg (control) to 2.8 +/- 0.9 mg (P < 0.01).","In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15454859/),mg,2.8,133125,DB01109,Heparin
,14717940,plasma concentrations,Mean predialysis PEG-Hirudin plasma concentrations increased up to a maximum of 488 ng/mL in group I (HD8) and up to 536 ng/mL in group II (HD8).,Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14717940/),[ng] / [ml],48,133416,DB01109,Heparin
,14717940,plasma levels,Mean post-dialysis plasma levels ranged from 818 to 995 ng/mL.,Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14717940/),ng,818 to 995,133417,DB01109,Heparin
,14717940,aPTT,"Five minutes after injecting PEG-Hirudin or UFH, mean aPTT was prolonged to a maximum of 85 and 188 seconds, respectively.",Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14717940/),seconds,85,133418,DB01109,Heparin
,14717940,aPTT,"Five minutes after injecting PEG-Hirudin or UFH, mean aPTT was prolonged to a maximum of 85 and 188 seconds, respectively.",Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14717940/),seconds,188,133419,DB01109,Heparin
,14717940,aPTT,Mean post-dialysis aPTT values ranged from 60 to 68 seconds after PEG-Hirudin and 34 to 46 seconds after UFH.,Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14717940/),seconds,60 to 68,133420,DB01109,Heparin
,14717940,aPTT,Mean post-dialysis aPTT values ranged from 60 to 68 seconds after PEG-Hirudin and 34 to 46 seconds after UFH.,Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14717940/),seconds,34 to 46,133421,DB01109,Heparin
,2160414,APTT,"Five to ten min after IV injection, the APTT ranged between 56 and 98 sec (baseline 40 sec), the TCT between 28 and 99 sec (baseline 19 sec) and the anti-factor Xa activity between 1.58 and 2.28 IC U/ml.",Pharmacodynamics of CY 216 in healthy volunteers: inter-individual variations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2160414/),s,56 and 98,133778,DB01109,Heparin
,2160414,TCT,"Five to ten min after IV injection, the APTT ranged between 56 and 98 sec (baseline 40 sec), the TCT between 28 and 99 sec (baseline 19 sec) and the anti-factor Xa activity between 1.58 and 2.28 IC U/ml.",Pharmacodynamics of CY 216 in healthy volunteers: inter-individual variations. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2160414/),se,28 and 99,133779,DB01109,Heparin
,2160414,anti-,"Five to ten min after IV injection, the APTT ranged between 56 and 98 sec (baseline 40 sec), the TCT between 28 and 99 sec (baseline 19 sec) and the anti-factor Xa activity between 1.58 and 2.28 IC U/ml.",Pharmacodynamics of CY 216 in healthy volunteers: inter-individual variations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2160414/),[ic·u] / [ml],1.58 and 2.28,133780,DB01109,Heparin
,2160414,activity half-life,The anti-factor Xa activity half-life ranged between 1.5 and 2.9 h.,Pharmacodynamics of CY 216 in healthy volunteers: inter-individual variations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2160414/),h,1.5 and 2.9,133781,DB01109,Heparin
,2160414,maximum anti-factor Xa activity,"After SC injection, there were no detectable APTT and TCT prolongations; the maximum anti-factor Xa activity ranged between 0.36 and 0.88 IC U/ml and the half life between 1.5 and 6.4 h.",Pharmacodynamics of CY 216 in healthy volunteers: inter-individual variations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2160414/),[ic·u] / [ml],0.36 and 0.88,133782,DB01109,Heparin
,2160414,half life,"After SC injection, there were no detectable APTT and TCT prolongations; the maximum anti-factor Xa activity ranged between 0.36 and 0.88 IC U/ml and the half life between 1.5 and 6.4 h.",Pharmacodynamics of CY 216 in healthy volunteers: inter-individual variations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2160414/),h,1.5 and 6.4,133783,DB01109,Heparin
up to,20390227,peak concentration,"After oral administration, whatever the formulation, sustained anti-Xa and anti-IIa activities were obtained compared to the subcutaneous injection with a peak concentration at 4 hours (up to 0.59 anti-Xa U/ml and 0.11 anti-IIa U/ml for PLGA S 50% / ERS 50% formulation).",Oral administration of a microencapsulated low-molecular-weight heparin to rabbits: anti-Xa and anti-IIa profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20390227/),[u] / [ml],0.59,136483,DB01109,Heparin
,20390227,peak concentration,"After oral administration, whatever the formulation, sustained anti-Xa and anti-IIa activities were obtained compared to the subcutaneous injection with a peak concentration at 4 hours (up to 0.59 anti-Xa U/ml and 0.11 anti-IIa U/ml for PLGA S 50% / ERS 50% formulation).",Oral administration of a microencapsulated low-molecular-weight heparin to rabbits: anti-Xa and anti-IIa profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20390227/),[u] / [ml],0.11,136484,DB01109,Heparin
up to,20390227,relative bioavailabilities,"Anti-Xa and anti-IIa relative bioavailabilities were high, up to 40% (ERS 100% formulation).",Oral administration of a microencapsulated low-molecular-weight heparin to rabbits: anti-Xa and anti-IIa profiles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20390227/),%,40,136485,DB01109,Heparin
,20390227,Anti-Xa/anti-IIa ratios,"Anti-Xa/anti-IIa ratios were within range already obtained for subcutaneous injection, i.e. between 5 and 15.",Oral administration of a microencapsulated low-molecular-weight heparin to rabbits: anti-Xa and anti-IIa profiles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20390227/),,5 and 15,136486,DB01109,Heparin
,12598065,IC(50)s,"Statistically significant concentration (melagatran, the active form of ximelagatran)-response relationships for F1+2 (p = 0.005), TAT (p = 0.005) and beta-TG (p < 0.001) levels, with IC(50)s of 0.376 (F1+2), 0.163 (TAT) and 0.115 (beta-TG) micromol/l, were detected.","Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12598065/),[μM] / [l],0.376,136505,DB01109,Heparin
,12598065,IC(50)s,"Statistically significant concentration (melagatran, the active form of ximelagatran)-response relationships for F1+2 (p = 0.005), TAT (p = 0.005) and beta-TG (p < 0.001) levels, with IC(50)s of 0.376 (F1+2), 0.163 (TAT) and 0.115 (beta-TG) micromol/l, were detected.","Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12598065/),[μM] / [l],0.163,136506,DB01109,Heparin
,12598065,IC(50)s,"Statistically significant concentration (melagatran, the active form of ximelagatran)-response relationships for F1+2 (p = 0.005), TAT (p = 0.005) and beta-TG (p < 0.001) levels, with IC(50)s of 0.376 (F1+2), 0.163 (TAT) and 0.115 (beta-TG) micromol/l, were detected.","Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12598065/),[μM] / [l],0.115,136507,DB01109,Heparin
,26842561,steady state peak,"Based on drug concentrations previously published in pharmacokinetic studies, the expected steady state peak and trough antifactor Xa activity ranges for apixaban are 1.80 to 2.20 IU/mL and 0.70 to 1.10 IU/mL, respectively.",Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26842561/),[iu] / [ml],1.80 to 2.20,137223,DB01109,Heparin
,26842561,trough antifactor Xa activity,"Based on drug concentrations previously published in pharmacokinetic studies, the expected steady state peak and trough antifactor Xa activity ranges for apixaban are 1.80 to 2.20 IU/mL and 0.70 to 1.10 IU/mL, respectively.",Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26842561/),[iu] / [ml],0.70 to 1.10,137224,DB01109,Heparin
,4057042,cumulative urinary recovery,"Even at 5 h after the administration when most radioactivity in plasma disappeared, the cumulative urinary recovery was only 4.8 to 8.4% of dose (1 to 15 microCi/kg), and 61 to 43% of dose was found in liver.",Dose-dependent disposition of fractionated 3H-heparin in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057042/),%,4.8 to 8.4,137629,DB01109,Heparin
,4057042,cumulative urinary recovery,"Even at 5 h after the administration when most radioactivity in plasma disappeared, the cumulative urinary recovery was only 4.8 to 8.4% of dose (1 to 15 microCi/kg), and 61 to 43% of dose was found in liver.",Dose-dependent disposition of fractionated 3H-heparin in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057042/),%,61 to 43,137630,DB01109,Heparin
,27146359,final amount,The final amount released varied from 1.5 to 18% of the amount of bFGF-entrapped.,Entrapment of basic fibroblast growth factor (bFGF) in a succinylated chitosan nanoparticle delivery system and release profile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27146359/),,1,138070,DB01109,Heparin
,1448841,clearance,"The mean heparin clearance in the DVT group was 2,164 +/- 1,024 ml/h at 4 h, 2,591 +/- 1,239 ml/h at 12 h, and 2,795 +/- 1,863 m/h at 24 h.",Altered heparin pharmacodynamics in patients with pulmonary embolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1448841/),[ml] / [h],"2,164",138111,DB01109,Heparin
,1448841,clearance,"The mean heparin clearance in the DVT group was 2,164 +/- 1,024 ml/h at 4 h, 2,591 +/- 1,239 ml/h at 12 h, and 2,795 +/- 1,863 m/h at 24 h.",Altered heparin pharmacodynamics in patients with pulmonary embolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1448841/),[ml] / [h],"2,591",138112,DB01109,Heparin
,1448841,clearance,"The mean heparin clearance in the DVT group was 2,164 +/- 1,024 ml/h at 4 h, 2,591 +/- 1,239 ml/h at 12 h, and 2,795 +/- 1,863 m/h at 24 h.",Altered heparin pharmacodynamics in patients with pulmonary embolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1448841/),[m] / [h],"2,795",138113,DB01109,Heparin
,1448841,clearances,"The PE patients had clearances of 1,775 +/- 494, 2,004 +/- 321, and 2,843 +/- 1,000 ml/h at 4, 12, and 24 h, respectively.",Altered heparin pharmacodynamics in patients with pulmonary embolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1448841/),[ml] / [h],"1,775",138114,DB01109,Heparin
,1448841,clearances,"The PE patients had clearances of 1,775 +/- 494, 2,004 +/- 321, and 2,843 +/- 1,000 ml/h at 4, 12, and 24 h, respectively.",Altered heparin pharmacodynamics in patients with pulmonary embolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1448841/),[ml] / [h],"2,004",138115,DB01109,Heparin
,1448841,clearances,"The PE patients had clearances of 1,775 +/- 494, 2,004 +/- 321, and 2,843 +/- 1,000 ml/h at 4, 12, and 24 h, respectively.",Altered heparin pharmacodynamics in patients with pulmonary embolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1448841/),[ml] / [h],"2,843",138116,DB01109,Heparin
,1448841,EMAX,"The mean EMAX and EC50 for the DVT patients were 130 +/- 40.99 s and 1.01 +/- 0.70 units/ml, respectively.",Altered heparin pharmacodynamics in patients with pulmonary embolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1448841/),s,130,138117,DB01109,Heparin
,1448841,EC50,"The mean EMAX and EC50 for the DVT patients were 130 +/- 40.99 s and 1.01 +/- 0.70 units/ml, respectively.",Altered heparin pharmacodynamics in patients with pulmonary embolism. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1448841/),[units] / [ml],1.01,138118,DB01109,Heparin
,1448841,EMAX,"For the PE patients, the mean EMAX was 418 +/- 200 s and the mean EC50 was 4.32 +/- 2.81 units/ml.",Altered heparin pharmacodynamics in patients with pulmonary embolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1448841/),s,418,138119,DB01109,Heparin
,1448841,EC50,"For the PE patients, the mean EMAX was 418 +/- 200 s and the mean EC50 was 4.32 +/- 2.81 units/ml.",Altered heparin pharmacodynamics in patients with pulmonary embolism. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1448841/),[units] / [ml],4.32,138120,DB01109,Heparin
,7946973,ratio of plasma AUC (0 infinity)s,"Bidirectional inversion also occurred in vivo, with a ratio of plasma AUC (0 infinity)s [S:R] of 8.1:1.",Bidirectional chiral inversion of the enantiomers of the nonsteroidal antiinflammatory drug oxindanac in dogs. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946973/),,8.1,138978,DB01109,Heparin
,7946973,Elimination t1/2s,"Elimination t1/2s of the isomers were the same (R, 12.1 h, S, 13.3 h).",Bidirectional chiral inversion of the enantiomers of the nonsteroidal antiinflammatory drug oxindanac in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946973/),h,12.1,138979,DB01109,Heparin
,7946973,Elimination t1/2s,"Elimination t1/2s of the isomers were the same (R, 12.1 h, S, 13.3 h).",Bidirectional chiral inversion of the enantiomers of the nonsteroidal antiinflammatory drug oxindanac in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946973/),h,13.3,138980,DB01109,Heparin
,9837939,rate constants,"Both heparin cofactor II-heparin and heparin cofactor II-dermatan sulfate had fast bimolecular rate constants of 1.4 x 10(7) M-1 s-1 and 1.3 x 10(7) M-1 s-1, respectively, for reaction with thrombin.",Covalent heparin cofactor II-heparin and heparin cofactor II-dermatan sulfate complexes. Characterization of novel anticoagulants. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9837939/),1/[M·s],1.4 x 10(7),139020,DB01109,Heparin
,9837939,rate constants,"Both heparin cofactor II-heparin and heparin cofactor II-dermatan sulfate had fast bimolecular rate constants of 1.4 x 10(7) M-1 s-1 and 1.3 x 10(7) M-1 s-1, respectively, for reaction with thrombin.",Covalent heparin cofactor II-heparin and heparin cofactor II-dermatan sulfate complexes. Characterization of novel anticoagulants. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9837939/),1/[M·s],1.3 x 10(7),139021,DB01109,Heparin
,9837939,half-life,"The intravenous half-life of the covalent complexes in rabbits was significantly longer than that of free heparin or dermatan sulfate (4.4, 3.4, 0.33, and 0.50 h for heparin cofactor II-heparin, heparin cofactor II-dermatan sulfate, heparin, and dermatan sulfate, respectively).",Covalent heparin cofactor II-heparin and heparin cofactor II-dermatan sulfate complexes. Characterization of novel anticoagulants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9837939/),h,4.4,139022,DB01109,Heparin
,9837939,half-life,"The intravenous half-life of the covalent complexes in rabbits was significantly longer than that of free heparin or dermatan sulfate (4.4, 3.4, 0.33, and 0.50 h for heparin cofactor II-heparin, heparin cofactor II-dermatan sulfate, heparin, and dermatan sulfate, respectively).",Covalent heparin cofactor II-heparin and heparin cofactor II-dermatan sulfate complexes. Characterization of novel anticoagulants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9837939/),h,3.4,139023,DB01109,Heparin
,9837939,half-life,"The intravenous half-life of the covalent complexes in rabbits was significantly longer than that of free heparin or dermatan sulfate (4.4, 3.4, 0.33, and 0.50 h for heparin cofactor II-heparin, heparin cofactor II-dermatan sulfate, heparin, and dermatan sulfate, respectively).",Covalent heparin cofactor II-heparin and heparin cofactor II-dermatan sulfate complexes. Characterization of novel anticoagulants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9837939/),h,0.33,139024,DB01109,Heparin
,9837939,half-life,"The intravenous half-life of the covalent complexes in rabbits was significantly longer than that of free heparin or dermatan sulfate (4.4, 3.4, 0.33, and 0.50 h for heparin cofactor II-heparin, heparin cofactor II-dermatan sulfate, heparin, and dermatan sulfate, respectively).",Covalent heparin cofactor II-heparin and heparin cofactor II-dermatan sulfate complexes. Characterization of novel anticoagulants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9837939/),h,0.50,139025,DB01109,Heparin
,9280370,IC50s,"The 5-lipoxygenase activating protein (FLAP) inhibitors, BAY X 1005 and BAY Y 1015, produced concentration dependent inhibition of ionophore-induced LTB4 synthesis by equine whole blood (mean +/- SEM IC50s n = 5; 6.14 +/- 0.28 microM vs. 12.30 +/- 0.75 microM for BAY Y 1015 and BAY X 1005, respectively) and neutrophils (mean +/- SEM IC50s n = 5; 0.003 +/- 0.001 microM vs. 0.045 +/- 0.021 microM for BAY Y 1015 and BAY X 1005, respectively) and LTC4 synthesis by equine eosinophils (mean +/- SEM IC50s n = 5; 0.0036 +/- 0.0002 microM and 0.108 +/- 0.023 microM for BAY Y 1015 and BAY X 1005, respectively) in vitro.",Pharmacology of the 5-lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280370/),μM,6.14,139190,DB01109,Heparin
,9280370,IC50s,"The 5-lipoxygenase activating protein (FLAP) inhibitors, BAY X 1005 and BAY Y 1015, produced concentration dependent inhibition of ionophore-induced LTB4 synthesis by equine whole blood (mean +/- SEM IC50s n = 5; 6.14 +/- 0.28 microM vs. 12.30 +/- 0.75 microM for BAY Y 1015 and BAY X 1005, respectively) and neutrophils (mean +/- SEM IC50s n = 5; 0.003 +/- 0.001 microM vs. 0.045 +/- 0.021 microM for BAY Y 1015 and BAY X 1005, respectively) and LTC4 synthesis by equine eosinophils (mean +/- SEM IC50s n = 5; 0.0036 +/- 0.0002 microM and 0.108 +/- 0.023 microM for BAY Y 1015 and BAY X 1005, respectively) in vitro.",Pharmacology of the 5-lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280370/),μM,12.30,139191,DB01109,Heparin
,9280370,IC50s,"The 5-lipoxygenase activating protein (FLAP) inhibitors, BAY X 1005 and BAY Y 1015, produced concentration dependent inhibition of ionophore-induced LTB4 synthesis by equine whole blood (mean +/- SEM IC50s n = 5; 6.14 +/- 0.28 microM vs. 12.30 +/- 0.75 microM for BAY Y 1015 and BAY X 1005, respectively) and neutrophils (mean +/- SEM IC50s n = 5; 0.003 +/- 0.001 microM vs. 0.045 +/- 0.021 microM for BAY Y 1015 and BAY X 1005, respectively) and LTC4 synthesis by equine eosinophils (mean +/- SEM IC50s n = 5; 0.0036 +/- 0.0002 microM and 0.108 +/- 0.023 microM for BAY Y 1015 and BAY X 1005, respectively) in vitro.",Pharmacology of the 5-lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280370/),μM,0.003,139192,DB01109,Heparin
,9280370,IC50s,"The 5-lipoxygenase activating protein (FLAP) inhibitors, BAY X 1005 and BAY Y 1015, produced concentration dependent inhibition of ionophore-induced LTB4 synthesis by equine whole blood (mean +/- SEM IC50s n = 5; 6.14 +/- 0.28 microM vs. 12.30 +/- 0.75 microM for BAY Y 1015 and BAY X 1005, respectively) and neutrophils (mean +/- SEM IC50s n = 5; 0.003 +/- 0.001 microM vs. 0.045 +/- 0.021 microM for BAY Y 1015 and BAY X 1005, respectively) and LTC4 synthesis by equine eosinophils (mean +/- SEM IC50s n = 5; 0.0036 +/- 0.0002 microM and 0.108 +/- 0.023 microM for BAY Y 1015 and BAY X 1005, respectively) in vitro.",Pharmacology of the 5-lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280370/),μM,0.045,139193,DB01109,Heparin
,9280370,IC50s,"The 5-lipoxygenase activating protein (FLAP) inhibitors, BAY X 1005 and BAY Y 1015, produced concentration dependent inhibition of ionophore-induced LTB4 synthesis by equine whole blood (mean +/- SEM IC50s n = 5; 6.14 +/- 0.28 microM vs. 12.30 +/- 0.75 microM for BAY Y 1015 and BAY X 1005, respectively) and neutrophils (mean +/- SEM IC50s n = 5; 0.003 +/- 0.001 microM vs. 0.045 +/- 0.021 microM for BAY Y 1015 and BAY X 1005, respectively) and LTC4 synthesis by equine eosinophils (mean +/- SEM IC50s n = 5; 0.0036 +/- 0.0002 microM and 0.108 +/- 0.023 microM for BAY Y 1015 and BAY X 1005, respectively) in vitro.",Pharmacology of the 5-lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280370/),μM,0.0036,139194,DB01109,Heparin
,9280370,IC50s,"The 5-lipoxygenase activating protein (FLAP) inhibitors, BAY X 1005 and BAY Y 1015, produced concentration dependent inhibition of ionophore-induced LTB4 synthesis by equine whole blood (mean +/- SEM IC50s n = 5; 6.14 +/- 0.28 microM vs. 12.30 +/- 0.75 microM for BAY Y 1015 and BAY X 1005, respectively) and neutrophils (mean +/- SEM IC50s n = 5; 0.003 +/- 0.001 microM vs. 0.045 +/- 0.021 microM for BAY Y 1015 and BAY X 1005, respectively) and LTC4 synthesis by equine eosinophils (mean +/- SEM IC50s n = 5; 0.0036 +/- 0.0002 microM and 0.108 +/- 0.023 microM for BAY Y 1015 and BAY X 1005, respectively) in vitro.",Pharmacology of the 5-lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280370/),μM,0.108,139195,DB01109,Heparin
,15217988,dissociation constants (KI),"In vitro, the dissociation constants (KI) for ABT as the P450 mechanism-based inactivator were determined to be 45.6 and 193 microM, and the maximal inactivation rate constants (kinact) were determined to be 0.089 and 0.075 min(-1) for the mouse and guinea pig liver microsomes, respectively.",Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217988/),μM,45.6,139333,DB01109,Heparin
,15217988,dissociation constants (KI),"In vitro, the dissociation constants (KI) for ABT as the P450 mechanism-based inactivator were determined to be 45.6 and 193 microM, and the maximal inactivation rate constants (kinact) were determined to be 0.089 and 0.075 min(-1) for the mouse and guinea pig liver microsomes, respectively.",Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217988/),μM,193,139334,DB01109,Heparin
,15217988,maximal inactivation rate constants (kinact),"In vitro, the dissociation constants (KI) for ABT as the P450 mechanism-based inactivator were determined to be 45.6 and 193 microM, and the maximal inactivation rate constants (kinact) were determined to be 0.089 and 0.075 min(-1) for the mouse and guinea pig liver microsomes, respectively.",Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217988/),1/[min],0.089,139335,DB01109,Heparin
,15217988,maximal inactivation rate constants (kinact),"In vitro, the dissociation constants (KI) for ABT as the P450 mechanism-based inactivator were determined to be 45.6 and 193 microM, and the maximal inactivation rate constants (kinact) were determined to be 0.089 and 0.075 min(-1) for the mouse and guinea pig liver microsomes, respectively.",Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217988/),1/[min],0.075,139336,DB01109,Heparin
,7701550,recovery,"In the Immuninehep-plus crossover study (n = 27), Immuninehep-plus and Bebulin had, respectively, a recovery of 0.90 +/- 0.26 and 0.84 +/- 0.23 IU per dL per IU per kg, a compartmental half-life of 17.11 +/- 6.18 and 15.94 +/- 4.69 hours, and an effective half-life of 16.51 +/- 3.48 and 16.48 +/- 4.26 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),[iu] / [dl·iu·kg],0.90,140250,DB01109,Heparin
,7701550,recovery,"In the Immuninehep-plus crossover study (n = 27), Immuninehep-plus and Bebulin had, respectively, a recovery of 0.90 +/- 0.26 and 0.84 +/- 0.23 IU per dL per IU per kg, a compartmental half-life of 17.11 +/- 6.18 and 15.94 +/- 4.69 hours, and an effective half-life of 16.51 +/- 3.48 and 16.48 +/- 4.26 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),[iu] / [dl·iu·kg],0.84,140251,DB01109,Heparin
,7701550,compartmental half-life,"In the Immuninehep-plus crossover study (n = 27), Immuninehep-plus and Bebulin had, respectively, a recovery of 0.90 +/- 0.26 and 0.84 +/- 0.23 IU per dL per IU per kg, a compartmental half-life of 17.11 +/- 6.18 and 15.94 +/- 4.69 hours, and an effective half-life of 16.51 +/- 3.48 and 16.48 +/- 4.26 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),h,17.11,140252,DB01109,Heparin
,7701550,compartmental half-life,"In the Immuninehep-plus crossover study (n = 27), Immuninehep-plus and Bebulin had, respectively, a recovery of 0.90 +/- 0.26 and 0.84 +/- 0.23 IU per dL per IU per kg, a compartmental half-life of 17.11 +/- 6.18 and 15.94 +/- 4.69 hours, and an effective half-life of 16.51 +/- 3.48 and 16.48 +/- 4.26 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),h,15.94,140253,DB01109,Heparin
,7701550,effective half-life,"In the Immuninehep-plus crossover study (n = 27), Immuninehep-plus and Bebulin had, respectively, a recovery of 0.90 +/- 0.26 and 0.84 +/- 0.23 IU per dL per IU per kg, a compartmental half-life of 17.11 +/- 6.18 and 15.94 +/- 4.69 hours, and an effective half-life of 16.51 +/- 3.48 and 16.48 +/- 4.26 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),h,16.51,140254,DB01109,Heparin
,7701550,effective half-life,"In the Immuninehep-plus crossover study (n = 27), Immuninehep-plus and Bebulin had, respectively, a recovery of 0.90 +/- 0.26 and 0.84 +/- 0.23 IU per dL per IU per kg, a compartmental half-life of 17.11 +/- 6.18 and 15.94 +/- 4.69 hours, and an effective half-life of 16.51 +/- 3.48 and 16.48 +/- 4.26 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),h,16.48,140255,DB01109,Heparin
,7701550,recovery,"In the Immuninehep-minus crossover study (n = 26), Immuninehep-minus and Bebulin had, respectively, a recovery of 0.92 +/- 0.31 and 1.02 +/- 0.36 IU per dL per IU per kg, a compartmental half-life of 17.42 +/- 5.60 and 18.77 +/- 6.27 hours, and an effective half-life of 16.39 +/- 4.44 and 16.48 +/- 4.28 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),[iu] / [dl·iu·kg],0.92,140256,DB01109,Heparin
,7701550,recovery,"In the Immuninehep-minus crossover study (n = 26), Immuninehep-minus and Bebulin had, respectively, a recovery of 0.92 +/- 0.31 and 1.02 +/- 0.36 IU per dL per IU per kg, a compartmental half-life of 17.42 +/- 5.60 and 18.77 +/- 6.27 hours, and an effective half-life of 16.39 +/- 4.44 and 16.48 +/- 4.28 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),[iu] / [dl·iu·kg],1.02,140257,DB01109,Heparin
,7701550,compartmental half-life,"In the Immuninehep-minus crossover study (n = 26), Immuninehep-minus and Bebulin had, respectively, a recovery of 0.92 +/- 0.31 and 1.02 +/- 0.36 IU per dL per IU per kg, a compartmental half-life of 17.42 +/- 5.60 and 18.77 +/- 6.27 hours, and an effective half-life of 16.39 +/- 4.44 and 16.48 +/- 4.28 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),h,17.42,140258,DB01109,Heparin
,7701550,compartmental half-life,"In the Immuninehep-minus crossover study (n = 26), Immuninehep-minus and Bebulin had, respectively, a recovery of 0.92 +/- 0.31 and 1.02 +/- 0.36 IU per dL per IU per kg, a compartmental half-life of 17.42 +/- 5.60 and 18.77 +/- 6.27 hours, and an effective half-life of 16.39 +/- 4.44 and 16.48 +/- 4.28 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),h,18.77,140259,DB01109,Heparin
,7701550,effective half-life,"In the Immuninehep-minus crossover study (n = 26), Immuninehep-minus and Bebulin had, respectively, a recovery of 0.92 +/- 0.31 and 1.02 +/- 0.36 IU per dL per IU per kg, a compartmental half-life of 17.42 +/- 5.60 and 18.77 +/- 6.27 hours, and an effective half-life of 16.39 +/- 4.44 and 16.48 +/- 4.28 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),h,16.39,140260,DB01109,Heparin
,7701550,effective half-life,"In the Immuninehep-minus crossover study (n = 26), Immuninehep-minus and Bebulin had, respectively, a recovery of 0.92 +/- 0.31 and 1.02 +/- 0.36 IU per dL per IU per kg, a compartmental half-life of 17.42 +/- 5.60 and 18.77 +/- 6.27 hours, and an effective half-life of 16.39 +/- 4.44 and 16.48 +/- 4.28 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),h,16.48,140261,DB01109,Heparin
,15236435,run time,"BPU is extracted from plasma into acetonitrile:n-butyl-chloride using paclitaxel as the internal standard and separated on a Waters Symmetry C18 (3.9 x 150 mm, 5 microm) column with acetonitrile-water mobile phase (70:30, v/v) using isocratic flow at 1 mL/min for a run time of 5 min.",A method for determination of dimethyl benzoylphenyl urea (BPU) in human plasma by using LC/UV. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15236435/),min,5,140804,DB01109,Heparin
,15236435,retention times,The retention times were 1.9 min for paclitaxel and 4.1 min for BPU.,A method for determination of dimethyl benzoylphenyl urea (BPU) in human plasma by using LC/UV. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15236435/),min,1.9,140805,DB01109,Heparin
,15236435,retention times,The retention times were 1.9 min for paclitaxel and 4.1 min for BPU.,A method for determination of dimethyl benzoylphenyl urea (BPU) in human plasma by using LC/UV. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15236435/),min,4.1,140806,DB01109,Heparin
,15236435,maximum plasma concentration,"Following administration of BPU 320 mg as a weekly oral dose to a patient with advanced solid tumor malignancies, the maximum plasma concentration was 2 micro g/mL and concentrations were quantifiable up to 168 h after administration.",A method for determination of dimethyl benzoylphenyl urea (BPU) in human plasma by using LC/UV. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15236435/),[μg] / [ml],2,140807,DB01109,Heparin
,10850840,peak plasma concentration,"Mean (+/- SD) peak plasma concentration of BDZ following IV administration (1,316 +/- 216 microg/L) was greater than that following IN administration (448 +/- 41 microg/L).",Comparison of plasma benzodiazepine concentrations following intranasal and intravenous administration of diazepam to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850840/),[μg] / [l],"1,316",141201,DB01109,Heparin
,10850840,peak plasma concentration,"Mean (+/- SD) peak plasma concentration of BDZ following IV administration (1,316 +/- 216 microg/L) was greater than that following IN administration (448 +/- 41 microg/L).",Comparison of plasma benzodiazepine concentrations following intranasal and intravenous administration of diazepam to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850840/),[μg] / [l],448,141202,DB01109,Heparin
< or =,10850840,Time to peak concentration,Time to peak concentration was < or = 3 minutes following IV administration and 4.5 +/- 1.5 minutes following IN administration.,Comparison of plasma benzodiazepine concentrations following intranasal and intravenous administration of diazepam to dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850840/),min,3,141203,DB01109,Heparin
,10850840,Time to peak concentration,Time to peak concentration was < or = 3 minutes following IV administration and 4.5 +/- 1.5 minutes following IN administration.,Comparison of plasma benzodiazepine concentrations following intranasal and intravenous administration of diazepam to dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850840/),min,4.5,141204,DB01109,Heparin
,10850840,bioavailability,Mean bioavailability of BDZ following IN administration was 80 +/- 9%.,Comparison of plasma benzodiazepine concentrations following intranasal and intravenous administration of diazepam to dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850840/),%,80,141205,DB01109,Heparin
,12968985,clearance,"Basic population PK parameters were an enoxaparin clearance of 0.733 l h(-1)[95% confidence interval (CI) 0.698, 0.738], a distribution volume of 5.24 l (95% CI 4.20, 6.28) and an elimination half-life of 5.0 h.",Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968985/),[l] / [h],0.733,141796,DB01109,Heparin
,12968985,distribution volume,"Basic population PK parameters were an enoxaparin clearance of 0.733 l h(-1)[95% confidence interval (CI) 0.698, 0.738], a distribution volume of 5.24 l (95% CI 4.20, 6.28) and an elimination half-life of 5.0 h.",Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968985/),l,5.24,141797,DB01109,Heparin
,12968985,elimination half-life,"Basic population PK parameters were an enoxaparin clearance of 0.733 l h(-1)[95% confidence interval (CI) 0.698, 0.738], a distribution volume of 5.24 l (95% CI 4.20, 6.28) and an elimination half-life of 5.0 h.",Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968985/),h,5.0,141798,DB01109,Heparin
,31463801,Peak plasma anti-FXa activity (Cmax),"Peak plasma anti-FXa activity (Cmax) ranged from 0.14 to 0.30 IU/mL, median Cmax was 0.205 IU/mL.",Prophylactic Use of Enoxaparin in Adolescents During Bariatric Surgery-a Prospective Clinical Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463801/),[iu] / [ml],0.14 to 0.30,142170,DB01109,Heparin
,31463801,Cmax,"Peak plasma anti-FXa activity (Cmax) ranged from 0.14 to 0.30 IU/mL, median Cmax was 0.205 IU/mL.",Prophylactic Use of Enoxaparin in Adolescents During Bariatric Surgery-a Prospective Clinical Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463801/),[iu] / [ml],0.205,142171,DB01109,Heparin
,31463801,Tmax,Median Tmax was 5.67 h (range 3.78-7.52 h).,Prophylactic Use of Enoxaparin in Adolescents During Bariatric Surgery-a Prospective Clinical Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463801/),h,5.67,142172,DB01109,Heparin
,31463801,AUCi,Median AUCi was 1.00 h IU/mL (range 0.42-1.67 h IU/mL).,Prophylactic Use of Enoxaparin in Adolescents During Bariatric Surgery-a Prospective Clinical Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463801/),[h·iu] / [ml],1.00,142173,DB01109,Heparin
,24483951,Maximum plasma concentration,"Maximum plasma concentration, volume of distribution per absorption, and elimination half-life were 0.663 μg/mL, 0.21 L, and 11.4 h, respectively, for females and 0.920 μg/mL, 0.35 L, and 17.8 h, respectively, for males.",Meloxicam pharmacokinetics using nonlinear mixed-effects modeling in ferrets after single subcutaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24483951/),[μg] / [ml],0.663,142514,DB01109,Heparin
,24483951,volume of distribution per absorption,"Maximum plasma concentration, volume of distribution per absorption, and elimination half-life were 0.663 μg/mL, 0.21 L, and 11.4 h, respectively, for females and 0.920 μg/mL, 0.35 L, and 17.8 h, respectively, for males.",Meloxicam pharmacokinetics using nonlinear mixed-effects modeling in ferrets after single subcutaneous administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24483951/),l,0.21,142515,DB01109,Heparin
,24483951,volume of distribution per absorption,"Maximum plasma concentration, volume of distribution per absorption, and elimination half-life were 0.663 μg/mL, 0.21 L, and 11.4 h, respectively, for females and 0.920 μg/mL, 0.35 L, and 17.8 h, respectively, for males.",Meloxicam pharmacokinetics using nonlinear mixed-effects modeling in ferrets after single subcutaneous administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24483951/),[μg] / [ml],0.920,142516,DB01109,Heparin
,24483951,volume of distribution per absorption,"Maximum plasma concentration, volume of distribution per absorption, and elimination half-life were 0.663 μg/mL, 0.21 L, and 11.4 h, respectively, for females and 0.920 μg/mL, 0.35 L, and 17.8 h, respectively, for males.",Meloxicam pharmacokinetics using nonlinear mixed-effects modeling in ferrets after single subcutaneous administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24483951/),l,0.35,142517,DB01109,Heparin
,24483951,elimination half-life,"Maximum plasma concentration, volume of distribution per absorption, and elimination half-life were 0.663 μg/mL, 0.21 L, and 11.4 h, respectively, for females and 0.920 μg/mL, 0.35 L, and 17.8 h, respectively, for males.",Meloxicam pharmacokinetics using nonlinear mixed-effects modeling in ferrets after single subcutaneous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24483951/),h,11.4,142518,DB01109,Heparin
,24483951,elimination half-life,"Maximum plasma concentration, volume of distribution per absorption, and elimination half-life were 0.663 μg/mL, 0.21 L, and 11.4 h, respectively, for females and 0.920 μg/mL, 0.35 L, and 17.8 h, respectively, for males.",Meloxicam pharmacokinetics using nonlinear mixed-effects modeling in ferrets after single subcutaneous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24483951/),h,17.8,142519,DB01109,Heparin
,24483951,Systemic clearance per absorption,Systemic clearance per absorption was not affected by gender and was 13.4 mL/h.,Meloxicam pharmacokinetics using nonlinear mixed-effects modeling in ferrets after single subcutaneous administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24483951/),[ml] / [h],13.4,142520,DB01109,Heparin
,30463865,anti,"Utilizing standard population pharmacokinetic data, the expected antifactor Xa activity without TPE was 0.14 IU/mL.",Effect of plasma exchange on antifactor Xa activity of enoxaparin and serum levetiracetam levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30463865/),[iu] / [ml],0.14,142888,DB01109,Heparin
less,2983432,half-life in,"PF4 has a half-life in plasma of less than 3 minutes, and its rapid clearance appears to be a function of binding to the vascular endothelium.",In vivo studies on the binding of heparin and its fractions with platelet factor 4. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2983432/),min,3,142890,DB01109,Heparin
,2850327,peak levels,"By giving 8000 b.i.d., mean peak levels of .35-.40 U/ml of anti Xa activity were reached in the first day and of .45-.55 U/ml in the following days, a residual activity in the order of .1-.2 U/ml being always detected in the samples drawn immediately before the following injection.",Clinical pharmacology of a new low molecular weight heparin (Alfa LMWH-Fluxum). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2850327/),[u] / [ml],.35-.40,144240,DB01109,Heparin
,2850327,peak levels,"By giving 8000 b.i.d., mean peak levels of .35-.40 U/ml of anti Xa activity were reached in the first day and of .45-.55 U/ml in the following days, a residual activity in the order of .1-.2 U/ml being always detected in the samples drawn immediately before the following injection.",Clinical pharmacology of a new low molecular weight heparin (Alfa LMWH-Fluxum). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2850327/),[u] / [ml],.45-.55,144241,DB01109,Heparin
,2850327,residual activity,"By giving 8000 b.i.d., mean peak levels of .35-.40 U/ml of anti Xa activity were reached in the first day and of .45-.55 U/ml in the following days, a residual activity in the order of .1-.2 U/ml being always detected in the samples drawn immediately before the following injection.",Clinical pharmacology of a new low molecular weight heparin (Alfa LMWH-Fluxum). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2850327/),[u] / [ml],.1-.2,144242,DB01109,Heparin
,23314760,Vessel/muscle ratios,"Vessel/muscle ratios in control, EPO, and AEPO groups were 0.50 ± 0.34, 0.61 ± 0.32, and 2.83 ± 1.13, respectively (p < 0.0001).",Asialoerythropoietin exerts stronger angiogenic activity than erythropoietin via its binding affinity to tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23314760/),,0.50,144253,DB01109,Heparin
,23314760,Vessel/muscle ratios,"Vessel/muscle ratios in control, EPO, and AEPO groups were 0.50 ± 0.34, 0.61 ± 0.32, and 2.83 ± 1.13, respectively (p < 0.0001).",Asialoerythropoietin exerts stronger angiogenic activity than erythropoietin via its binding affinity to tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23314760/),,0.61,144254,DB01109,Heparin
,23314760,Vessel/muscle ratios,"Vessel/muscle ratios in control, EPO, and AEPO groups were 0.50 ± 0.34, 0.61 ± 0.32, and 2.83 ± 1.13, respectively (p < 0.0001).",Asialoerythropoietin exerts stronger angiogenic activity than erythropoietin via its binding affinity to tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23314760/),,2.83,144255,DB01109,Heparin
,18506696,flow rate,"Chromatographic separation was achieved on a C(18) column (250 x 4.6 mm i.d., 5 microm particle size) with a mobile phase of methanol-acetonitrile-water (containing 2 mmol/L ammonium acetate; 42.5:42.5:15, v/v/v) at a flow rate of 0.4 mL/min.",Determination of sodium cromoglycate in human plasma by liquid chromatography with tandem mass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18506696/),[ml] / [min],0.4,144475,DB01109,Heparin
,18506696,recovery,Ions monitored in the multiple reaction monitoring mode were m/z 469.0 (precursor ion) to m/z 245.0 (product ion) for SCG and m/z 447.2 (precursor ion) to m/z327.1 (product ion) for pravastatin sodium (internal standard) The average recovery of SCG from human plasma was 94.88% and the lower limit of quantitation was 0.3 ng/mL.,Determination of sodium cromoglycate in human plasma by liquid chromatography with tandem mass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18506696/),%,94.88,144476,DB01109,Heparin
,20307530,T(max),PM102 rapidly (T(max) 1-2.6min) appeared in plasma after dosing.,"Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20307530/),min,1-2.6,145077,DB01109,Heparin
,20307530,T(1/2),Concentrations of PM102 generally declined rapidly after reaching T(max) with a mean T(1/2) of 4 to 31min.,"Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20307530/),min,4 to 31,145078,DB01109,Heparin
,21166024,flow rate,Topiramate and the topiramate d-12 internal standard (IS) were chromatographed on a Betasil C18 column at a flow rate of 0.5 mL/min.,"A simple, rapid and specific method for measurement of topiramate in human plasma by LC-MS/MS employing automated solid-phase extraction techniques: Application for bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166024/),[ml] / [min],0.5,145469,DB01109,Heparin
,21166024,total run time,The total run time was 1.80 min.,"A simple, rapid and specific method for measurement of topiramate in human plasma by LC-MS/MS employing automated solid-phase extraction techniques: Application for bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166024/),min,1.80,145470,DB01109,Heparin
,21166024,mass,"The mass transition [M-H] ions used for detection were m/z 338.10→78.20 for topiramate, m/z 350.40→90.10 for IS.","A simple, rapid and specific method for measurement of topiramate in human plasma by LC-MS/MS employing automated solid-phase extraction techniques: Application for bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166024/),,338.10,145471,DB01109,Heparin
,21166024,m/z,"The mass transition [M-H] ions used for detection were m/z 338.10→78.20 for topiramate, m/z 350.40→90.10 for IS.","A simple, rapid and specific method for measurement of topiramate in human plasma by LC-MS/MS employing automated solid-phase extraction techniques: Application for bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166024/),,338.10,145472,DB01109,Heparin
,21166024,m/z,"The mass transition [M-H] ions used for detection were m/z 338.10→78.20 for topiramate, m/z 350.40→90.10 for IS.","A simple, rapid and specific method for measurement of topiramate in human plasma by LC-MS/MS employing automated solid-phase extraction techniques: Application for bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166024/),,78.20,145473,DB01109,Heparin
,21166024,m/z,"The mass transition [M-H] ions used for detection were m/z 338.10→78.20 for topiramate, m/z 350.40→90.10 for IS.","A simple, rapid and specific method for measurement of topiramate in human plasma by LC-MS/MS employing automated solid-phase extraction techniques: Application for bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166024/),,350.40,145474,DB01109,Heparin
,21166024,m/z,"The mass transition [M-H] ions used for detection were m/z 338.10→78.20 for topiramate, m/z 350.40→90.10 for IS.","A simple, rapid and specific method for measurement of topiramate in human plasma by LC-MS/MS employing automated solid-phase extraction techniques: Application for bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166024/),,90.10,145475,DB01109,Heparin
,21166024,Recovery,Recovery of topiramate and IS ranged from 78.20 to 87.74%.,"A simple, rapid and specific method for measurement of topiramate in human plasma by LC-MS/MS employing automated solid-phase extraction techniques: Application for bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166024/),%,78.20 to 87.74,145476,DB01109,Heparin
,10702431,fast compartment volume,The fast compartment volume was 41.1 mL/kg and the volume of distribution was 115.4 mL/kg.,Pharmacokinetics of recombinant transgenic antithrombin in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702431/),[ml] / [kg],41.1,146089,DB01109,Heparin
,10702431,volume of distribution,The fast compartment volume was 41.1 mL/kg and the volume of distribution was 115.4 mL/kg.,Pharmacokinetics of recombinant transgenic antithrombin in volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702431/),[ml] / [kg],115.4,146090,DB01109,Heparin
,10702431,Intercompartmental clearance,Intercompartmental clearance was 0. 0763 mL. kg(-1).,Pharmacokinetics of recombinant transgenic antithrombin in volunteers. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702431/),[ml] / [kg],0. 0763,146091,DB01109,Heparin
,10702431,elimination clearance,min(-1) and elimination clearance was 0.0383 mL. kg(-1). min(-1).,Pharmacokinetics of recombinant transgenic antithrombin in volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702431/),[ml] / [kg·min],0.0383,146092,DB01109,Heparin
,10702431,distribution half-life,These variables are equivalent to a distribution half-life of 196 min and an elimination half-life of 2568 min.,Pharmacokinetics of recombinant transgenic antithrombin in volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702431/),min,196,146093,DB01109,Heparin
,10702431,elimination half-life,These variables are equivalent to a distribution half-life of 196 min and an elimination half-life of 2568 min.,Pharmacokinetics of recombinant transgenic antithrombin in volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702431/),min,2568,146094,DB01109,Heparin
,10954342,V,The mean value of V (8.41) in the normal-weight patients was similar to that reported in the literature.,The effect of body weight on dalteparin pharmacokinetics. A preliminary study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954342/),,8.41,146240,DB01109,Heparin
,1359056,clearance,"The average clearance in control rats (male and female) was 36 mL min-1 kg-1, the initial volume of distribution 1.4 L kg-1, the volume of distribution at steady state 2.3 L kg-1 and the terminal half-life 59 min.","Pharmacokinetics of moclobemide in male, virgin female, pregnant and nursing rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1359056/),[ml] / [kg·min],36,146709,DB01109,Heparin
,1359056,initial volume of distribution,"The average clearance in control rats (male and female) was 36 mL min-1 kg-1, the initial volume of distribution 1.4 L kg-1, the volume of distribution at steady state 2.3 L kg-1 and the terminal half-life 59 min.","Pharmacokinetics of moclobemide in male, virgin female, pregnant and nursing rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1359056/),[l] / [kg],1.4,146710,DB01109,Heparin
,1359056,volume of distribution at steady state,"The average clearance in control rats (male and female) was 36 mL min-1 kg-1, the initial volume of distribution 1.4 L kg-1, the volume of distribution at steady state 2.3 L kg-1 and the terminal half-life 59 min.","Pharmacokinetics of moclobemide in male, virgin female, pregnant and nursing rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1359056/),[l] / [kg],2.3,146711,DB01109,Heparin
,1359056,terminal half-life,"The average clearance in control rats (male and female) was 36 mL min-1 kg-1, the initial volume of distribution 1.4 L kg-1, the volume of distribution at steady state 2.3 L kg-1 and the terminal half-life 59 min.","Pharmacokinetics of moclobemide in male, virgin female, pregnant and nursing rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1359056/),min,59,146712,DB01109,Heparin
,1359056,blood-to-plasma concentration ratio,The blood-to-plasma concentration ratio of moclobemide was 0.84 giving rise to an average blood clearance of 30 mL min-1 kg-1.,"Pharmacokinetics of moclobemide in male, virgin female, pregnant and nursing rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1359056/),,0.84,146713,DB01109,Heparin
,1359056,blood clearance,The blood-to-plasma concentration ratio of moclobemide was 0.84 giving rise to an average blood clearance of 30 mL min-1 kg-1.,"Pharmacokinetics of moclobemide in male, virgin female, pregnant and nursing rats. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1359056/),[ml] / [kg·min],30,146714,DB01109,Heparin
,27317305,maximum concentration (C max),"Following single doses of peramivir (150, 300 and 600 mg), the maximum concentration (C max) values were 12,416 ± 3078, 23,147 ± 3668 and 44,113 ± 3787 µg/L, respectively, and the area under the plasma concentration-time curve (AUC) from 0 h to infinity post-dose (AUC∞) values were 24.68 ± 6.48, 47.33 ± 9.22 and 92.43 ± 12.72 mg·h/L, respectively.",Pharmacokinetic Properties of Peramivir After Single and Multiple Intravenous Infusions in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27317305/),[μg] / [l],"12,416",146894,DB01109,Heparin
,27317305,maximum concentration (C max),"Following single doses of peramivir (150, 300 and 600 mg), the maximum concentration (C max) values were 12,416 ± 3078, 23,147 ± 3668 and 44,113 ± 3787 µg/L, respectively, and the area under the plasma concentration-time curve (AUC) from 0 h to infinity post-dose (AUC∞) values were 24.68 ± 6.48, 47.33 ± 9.22 and 92.43 ± 12.72 mg·h/L, respectively.",Pharmacokinetic Properties of Peramivir After Single and Multiple Intravenous Infusions in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27317305/),[μg] / [l],"23,147",146895,DB01109,Heparin
,27317305,maximum concentration (C max),"Following single doses of peramivir (150, 300 and 600 mg), the maximum concentration (C max) values were 12,416 ± 3078, 23,147 ± 3668 and 44,113 ± 3787 µg/L, respectively, and the area under the plasma concentration-time curve (AUC) from 0 h to infinity post-dose (AUC∞) values were 24.68 ± 6.48, 47.33 ± 9.22 and 92.43 ± 12.72 mg·h/L, respectively.",Pharmacokinetic Properties of Peramivir After Single and Multiple Intravenous Infusions in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27317305/),[μg] / [l],"44,113",146896,DB01109,Heparin
,27317305,area under the plasma concentration-time curve (AUC) from 0 h to infinity post-dose (AUC∞),"Following single doses of peramivir (150, 300 and 600 mg), the maximum concentration (C max) values were 12,416 ± 3078, 23,147 ± 3668 and 44,113 ± 3787 µg/L, respectively, and the area under the plasma concentration-time curve (AUC) from 0 h to infinity post-dose (AUC∞) values were 24.68 ± 6.48, 47.33 ± 9.22 and 92.43 ± 12.72 mg·h/L, respectively.",Pharmacokinetic Properties of Peramivir After Single and Multiple Intravenous Infusions in Healthy Chinese Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27317305/),[h·mg] / [l],24.68,146897,DB01109,Heparin
,27317305,area under the plasma concentration-time curve (AUC) from 0 h to infinity post-dose (AUC∞),"Following single doses of peramivir (150, 300 and 600 mg), the maximum concentration (C max) values were 12,416 ± 3078, 23,147 ± 3668 and 44,113 ± 3787 µg/L, respectively, and the area under the plasma concentration-time curve (AUC) from 0 h to infinity post-dose (AUC∞) values were 24.68 ± 6.48, 47.33 ± 9.22 and 92.43 ± 12.72 mg·h/L, respectively.",Pharmacokinetic Properties of Peramivir After Single and Multiple Intravenous Infusions in Healthy Chinese Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27317305/),[h·mg] / [l],47.33,146898,DB01109,Heparin
,27317305,area under the plasma concentration-time curve (AUC) from 0 h to infinity post-dose (AUC∞),"Following single doses of peramivir (150, 300 and 600 mg), the maximum concentration (C max) values were 12,416 ± 3078, 23,147 ± 3668 and 44,113 ± 3787 µg/L, respectively, and the area under the plasma concentration-time curve (AUC) from 0 h to infinity post-dose (AUC∞) values were 24.68 ± 6.48, 47.33 ± 9.22 and 92.43 ± 12.72 mg·h/L, respectively.",Pharmacokinetic Properties of Peramivir After Single and Multiple Intravenous Infusions in Healthy Chinese Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27317305/),[h·mg] / [l],92.43,146899,DB01109,Heparin
,26774588,half-life,"In vitro incubations with heparin stabilized plasma showed that PYY3-36 was degraded with a half-life of 175 min, whereas incubations with PYY3-35 (half-life of 6 min) showed a rapid formation of PYY3-34.",Metabolism of peptide YY 3-36 in Göttingen mini-pig and rhesus monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26774588/),min,175,146945,DB01109,Heparin
,26774588,half-life,"In vitro incubations with heparin stabilized plasma showed that PYY3-36 was degraded with a half-life of 175 min, whereas incubations with PYY3-35 (half-life of 6 min) showed a rapid formation of PYY3-34.",Metabolism of peptide YY 3-36 in Göttingen mini-pig and rhesus monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26774588/),min,6,146946,DB01109,Heparin
,3801083,Mr avg,"The decasaccharides (dp = 10, Mr avg = 2,800) were the smallest oligosaccharides which resulted in substantial lipase release.",Effect of very low molecular weight heparin-derived oligosaccharides on lipoprotein lipase release in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3801083/),,"2,800",147171,DB01109,Heparin
,27044828,polydispersity index,"The polydispersity index of NG-LMWH was 1.052, which was lower than heparin (1.5) and enoxaparin (1.279).",Preparation and evaluation a new generation of low molecular weight heparin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044828/),,1.052,147575,DB01109,Heparin
,27044828,polydispersity index,"The polydispersity index of NG-LMWH was 1.052, which was lower than heparin (1.5) and enoxaparin (1.279).",Preparation and evaluation a new generation of low molecular weight heparin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044828/),,1.5,147576,DB01109,Heparin
,27044828,polydispersity index,"The polydispersity index of NG-LMWH was 1.052, which was lower than heparin (1.5) and enoxaparin (1.279).",Preparation and evaluation a new generation of low molecular weight heparin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044828/),,1.279,147577,DB01109,Heparin
,2847460,clearance half-life,After intravenous and sub-cutaneous injection the clearance half-life of the different LMW heparins is about 3 to 4 hours.,Pharmacokinetics of low molecular weight heparins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2847460/),h,3 to 4,149278,DB01109,Heparin
≥,27281580,Recoveries,Recoveries of indirubin and I.S. were consistent and ≥75.5%.,Development and full validation of an UPLC-MS/MS method for the quantification of the plant-derived alkaloid indirubin in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27281580/),%,75.5,150196,DB01109,Heparin
,27281580,half-life (t1/2),"Indirubin had a half-life (t1/2) of 35min, and a relatively high clearance (CL) of 2.71L/h/kg.",Development and full validation of an UPLC-MS/MS method for the quantification of the plant-derived alkaloid indirubin in rat plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27281580/),min,35,150197,DB01109,Heparin
,27281580,clearance (CL),"Indirubin had a half-life (t1/2) of 35min, and a relatively high clearance (CL) of 2.71L/h/kg.",Development and full validation of an UPLC-MS/MS method for the quantification of the plant-derived alkaloid indirubin in rat plasma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27281580/),[l] / [h·kg],2.71,150198,DB01109,Heparin
,25087072,anti-Xa,The primary objective was to determine if modified enoxaparin treatment doses would achieve therapeutic anti-Xa levels (goal range 0.6-1.0 IU/mL) in morbidly obese patients.,Assessing an enoxaparin dosing protocol in morbidly obese patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25087072/),i,0.6-1.0,150465,DB01109,Heparin
,25087072,anti-Xa level,The initial peak anti-Xa levels were in therapeutic range in 15 of 31 patients (48 %) with an initial mean anti-Xa level of 0.92 IU/mL.,Assessing an enoxaparin dosing protocol in morbidly obese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25087072/),[iu] / [ml],0.92,150466,DB01109,Heparin
,22097340,recoveries,"The mean recoveries were (99.3 +/- 1.4)%, (92.8 +/- 1.8)%, (98.4 +/- 2.0)% for high, middle, low concentrations of the samples respectively.",[Studies on pharmacokinetics of hydroxysafflor yellow A in Carthamus tinctorius and its compound preparation in rat]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22097340/),%,99.3,151161,DB01109,Heparin
,22097340,recoveries,"The mean recoveries were (99.3 +/- 1.4)%, (92.8 +/- 1.8)%, (98.4 +/- 2.0)% for high, middle, low concentrations of the samples respectively.",[Studies on pharmacokinetics of hydroxysafflor yellow A in Carthamus tinctorius and its compound preparation in rat]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22097340/),%,92.8,151162,DB01109,Heparin
,22097340,recoveries,"The mean recoveries were (99.3 +/- 1.4)%, (92.8 +/- 1.8)%, (98.4 +/- 2.0)% for high, middle, low concentrations of the samples respectively.",[Studies on pharmacokinetics of hydroxysafflor yellow A in Carthamus tinctorius and its compound preparation in rat]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22097340/),%,98.4,151163,DB01109,Heparin
,2595781,total-body clearance,"Mean +/- SE total-body clearance and elimination half-life were 887 +/- 159 ml/min and 1.4 +/- 0.2 hr, respectively, in the i.v. bolus study, indicating that 6-MP is rapidly cleared from the systemic circulation.",The pharmacokinetic advantage of local 6-mercaptopurine infusion in a canine renal transplant model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595781/),[ml] / [min],887,152842,DB01109,Heparin
,2595781,elimination half-life,"Mean +/- SE total-body clearance and elimination half-life were 887 +/- 159 ml/min and 1.4 +/- 0.2 hr, respectively, in the i.v. bolus study, indicating that 6-MP is rapidly cleared from the systemic circulation.",The pharmacokinetic advantage of local 6-mercaptopurine infusion in a canine renal transplant model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595781/),h,1.4,152843,DB01109,Heparin
,667338,half-life,Under these conditions the half-life of heparin-35S increased from 1.6 h in control animals to 2.35 h in the animals after intravenous injection of a threshold dose of thrombin causing activation of the anticoagulation system.,[Heparin clearance during activation of the anticoagulation system in animals]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/667338/),h,1.6,153263,DB01109,Heparin
,667338,half-life,Under these conditions the half-life of heparin-35S increased from 1.6 h in control animals to 2.35 h in the animals after intravenous injection of a threshold dose of thrombin causing activation of the anticoagulation system.,[Heparin clearance during activation of the anticoagulation system in animals]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/667338/),h,2.35,153264,DB01109,Heparin
,15632219,aPTT,"Among the 4 hemodialysis patients, aPTT, ACT, and plasma argatroban concentrations remained stable during RRT, with respective mean +/- SD values of 74.3 +/- 34.2 seconds, 198 +/- 23 seconds, and 499 +/- 353 ng/mL before RRT, and 70.6 +/- 21.4 seconds, 181 +/- 12 seconds, and 453 +/- 295 ng/mL 2 hours after starting RRT (p values NS).",Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15632219/),seconds,74.3,153351,DB01109,Heparin
,15632219,ACT,"Among the 4 hemodialysis patients, aPTT, ACT, and plasma argatroban concentrations remained stable during RRT, with respective mean +/- SD values of 74.3 +/- 34.2 seconds, 198 +/- 23 seconds, and 499 +/- 353 ng/mL before RRT, and 70.6 +/- 21.4 seconds, 181 +/- 12 seconds, and 453 +/- 295 ng/mL 2 hours after starting RRT (p values NS).",Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15632219/),[ng] / [ml],499,153352,DB01109,Heparin
,15632219,ACT,"Among the 4 hemodialysis patients, aPTT, ACT, and plasma argatroban concentrations remained stable during RRT, with respective mean +/- SD values of 74.3 +/- 34.2 seconds, 198 +/- 23 seconds, and 499 +/- 353 ng/mL before RRT, and 70.6 +/- 21.4 seconds, 181 +/- 12 seconds, and 453 +/- 295 ng/mL 2 hours after starting RRT (p values NS).",Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15632219/),[ng] / [ml],453,153353,DB01109,Heparin
,15632219,Systemic clearance,Systemic clearance was 17.7 +/- 12.8 L/h before hemodialysis and 17.0 +/- 9.5 L/h during hemodialysis (n = 2).,Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15632219/),[l] / [h],17.7,153354,DB01109,Heparin
,15632219,Systemic clearance,Systemic clearance was 17.7 +/- 12.8 L/h before hemodialysis and 17.0 +/- 9.5 L/h during hemodialysis (n = 2).,Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15632219/),[l] / [h],17.0,153355,DB01109,Heparin
,15632219,clearance,The dialyzer clearance (dialysate recovery method) was 1.5 +/- 0.4 L/h (n = 4).,Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15632219/),[l] / [h],1.5,153356,DB01109,Heparin
,15632219,clearance,Generally similar responses occurred in the CVVH patient: systemic argatroban clearance was 4.8 L/h before CVVH and 4 L/h during CVVH.,Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15632219/),[l] / [h],4.8,153357,DB01109,Heparin
,15632219,clearance,Generally similar responses occurred in the CVVH patient: systemic argatroban clearance was 4.8 L/h before CVVH and 4 L/h during CVVH.,Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15632219/),[l] / [h],4,153358,DB01109,Heparin
,15632219,clearance,The hemofilter argatroban clearance was 0.9 L/h.,Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15632219/),[l] / [h],0.9,153359,DB01109,Heparin
,2653017,activity half-lives,"After SK, activator activity half-lives were 184 minutes (group B) and 169 minutes (group C), and after APSAC 188 minutes (group D).","Pharmacokinetics, thrombolytic efficacy and hemorrhagic risk of different streptokinase regimens in heparin-treated acute myocardial infarction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2653017/),min,184,155238,DB01109,Heparin
,2653017,activity half-lives,"After SK, activator activity half-lives were 184 minutes (group B) and 169 minutes (group C), and after APSAC 188 minutes (group D).","Pharmacokinetics, thrombolytic efficacy and hemorrhagic risk of different streptokinase regimens in heparin-treated acute myocardial infarction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2653017/),min,169,155239,DB01109,Heparin
,2653017,activity half-lives,"After SK, activator activity half-lives were 184 minutes (group B) and 169 minutes (group C), and after APSAC 188 minutes (group D).","Pharmacokinetics, thrombolytic efficacy and hemorrhagic risk of different streptokinase regimens in heparin-treated acute myocardial infarction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2653017/),min,188,155240,DB01109,Heparin
,630740,t 1/2,"This was noted to decay relatively slowly, the mean t 1/2 of heparin in the peritoneal cavity being 10.8 +/- 0.93 hr.",Activity of intraperitoneal heparin during peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/630740/),h,10.8,155294,DB01109,Heparin
,2550047,t1/2,"Pharmacokinetic parameters based on the anti-Xa activity measurements after the i.v. dose were as follows (mean +/- s.d.): t1/2, 1.82 +/- 0.23 h; V, 4.34 +/- 0.651; and CL, 28.0 +/- 6.2 ml min-1.",Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550047/),h,1.82,155621,DB01109,Heparin
,2550047,V,"Pharmacokinetic parameters based on the anti-Xa activity measurements after the i.v. dose were as follows (mean +/- s.d.): t1/2, 1.82 +/- 0.23 h; V, 4.34 +/- 0.651; and CL, 28.0 +/- 6.2 ml min-1.",Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550047/),,4.34,155622,DB01109,Heparin
,2550047,CL,"Pharmacokinetic parameters based on the anti-Xa activity measurements after the i.v. dose were as follows (mean +/- s.d.): t1/2, 1.82 +/- 0.23 h; V, 4.34 +/- 0.651; and CL, 28.0 +/- 6.2 ml min-1.",Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550047/),[ml] / [min],28.0,155623,DB01109,Heparin
,2550047,Half-life,"Half-life values based on the anti-IIa and APTT activities were 1.63 +/- 0.43 and 1.09 +/- 0.51 h, respectively.",Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550047/),h,1.63,155624,DB01109,Heparin
,2550047,Half-life,"Half-life values based on the anti-IIa and APTT activities were 1.63 +/- 0.43 and 1.09 +/- 0.51 h, respectively.",Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550047/),h,1.09,155625,DB01109,Heparin
,4085634,specific,The quaternary salt of 1-14C-polymetacryloyl lupinine with a specific activity of 1 microCi/mM has been synthesized.,[Synthesis and pharmacokinetic characteristics of 14CH3-polymethacryloyl lupinine--a heparin antagonist]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4085634/),,1,155677,DB01109,Heparin
,21425940,deformability,"Flexosomes had similar particle size compared with ethosomes, but their deformability was higher than that of ethosomes (76.7% vs. 46.8%).",Transdermal delivery of low molecular weight heparin loaded in flexible liposomes with bioavailability enhancement: comparison with ethosomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21425940/),%,76.7,155765,DB01109,Heparin
,21425940,deformability,"Flexosomes had similar particle size compared with ethosomes, but their deformability was higher than that of ethosomes (76.7% vs. 46.8%).",Transdermal delivery of low molecular weight heparin loaded in flexible liposomes with bioavailability enhancement: comparison with ethosomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21425940/),%,46.8,155766,DB01109,Heparin
,21425940,[anti-Xa](max),"In vivo, after the topical application of flexosome to hairless mouse, [anti-Xa](max) was 1.11 IU/mL, while ethosomes showed only 0.32 IU/mL.",Transdermal delivery of low molecular weight heparin loaded in flexible liposomes with bioavailability enhancement: comparison with ethosomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21425940/),[iu] / [ml],1.11,155767,DB01109,Heparin
,21425940,[anti-Xa](max),"In vivo, after the topical application of flexosome to hairless mouse, [anti-Xa](max) was 1.11 IU/mL, while ethosomes showed only 0.32 IU/mL.",Transdermal delivery of low molecular weight heparin loaded in flexible liposomes with bioavailability enhancement: comparison with ethosomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21425940/),[iu] / [ml],0.32,155768,DB01109,Heparin
,6693537,MCR,"The mean OT MCR in these women was 17.4 +/- 9.2 (+/- SEM) ml/kg X min, similar to the MCR in normal men (17.6 +/- 2.1 ml/kg X min).",Studies of oxytocin in plasma of women during hypocontractile labor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6693537/),[ml] / [kg·min],17.4,155798,DB01109,Heparin
,6693537,MCR,"The mean OT MCR in these women was 17.4 +/- 9.2 (+/- SEM) ml/kg X min, similar to the MCR in normal men (17.6 +/- 2.1 ml/kg X min).",Studies of oxytocin in plasma of women during hypocontractile labor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6693537/),[ml] / [kg·min],17.6,155799,DB01109,Heparin
,16187968,CL,"Mean population parameters (intersubject variability, %) were CL 1.2 l h(-1) (33), V 2.9 l (30) and zero-order input 0.25 h (24).",Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187968/),[l] / [h],1.2,156480,DB01109,Heparin
,16187968,V,"Mean population parameters (intersubject variability, %) were CL 1.2 l h(-1) (33), V 2.9 l (30) and zero-order input 0.25 h (24).",Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187968/),l,2.9,156481,DB01109,Heparin
,16187968,zero-order input,"Mean population parameters (intersubject variability, %) were CL 1.2 l h(-1) (33), V 2.9 l (30) and zero-order input 0.25 h (24).",Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187968/),h,0.25,156482,DB01109,Heparin
>,16187968,anti-Xa,"With a single bolus of 0.5 mg kg(-1), the totality of the patients reached an effective anticoagulation level (anti-Xa >0.5 IU ml(-1)) and only 2.5% reached levels above 1.5 IU ml(-1).",Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187968/),[iu] / [ml],0.5,156483,DB01109,Heparin
,8772222,half-lives (t 1/2),Cmax were reached between 1 h and 3 h after the injection and the half-lives (t 1/2) were remarkably constant (13.1 h to 13.9 h).,Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772222/),h,13.1,156647,DB01109,Heparin
,8772222,half-lives (t 1/2),Cmax were reached between 1 h and 3 h after the injection and the half-lives (t 1/2) were remarkably constant (13.1 h to 13.9 h).,Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772222/),h,13.9,156648,DB01109,Heparin
,32952511,Cmax,"Significant pharmacokinetic differences were observed between the quetiapine-alone and quetiapine plus probenecid groups in terms of Cmax (392 ± 209 vs. 1323 ± 343 ug/L, respectively, P = 0.004), AUC0-∞ (P = 0.04) and Tmax (P = 0.004).",Role of Glucuronidation Pathway in Quetiapine Metabolism: An In vivo Drug-Drug Interaction Study between Quetiapine and Probenecid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32952511/),[ug] / [l],392,156842,DB01109,Heparin
,32952511,Cmax,"Significant pharmacokinetic differences were observed between the quetiapine-alone and quetiapine plus probenecid groups in terms of Cmax (392 ± 209 vs. 1323 ± 343 ug/L, respectively, P = 0.004), AUC0-∞ (P = 0.04) and Tmax (P = 0.004).",Role of Glucuronidation Pathway in Quetiapine Metabolism: An In vivo Drug-Drug Interaction Study between Quetiapine and Probenecid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32952511/),[ug] / [l],1323,156843,DB01109,Heparin
,32952511,drug clearance (CL/F),"Further, in the combined drug group, there was a decrease in drug clearance (CL/F) (from 27 ± 11 to 16 ± 3 L/h/kg; P = 0.005) and an increase in the volume of distribution (Vd) (P = 0.01), but there was no significant difference between both groups in terms of half-lives (P = 0.27).",Role of Glucuronidation Pathway in Quetiapine Metabolism: An In vivo Drug-Drug Interaction Study between Quetiapine and Probenecid. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32952511/),[l] / [h·kg],27,156844,DB01109,Heparin
,32952511,drug clearance (CL/F),"Further, in the combined drug group, there was a decrease in drug clearance (CL/F) (from 27 ± 11 to 16 ± 3 L/h/kg; P = 0.005) and an increase in the volume of distribution (Vd) (P = 0.01), but there was no significant difference between both groups in terms of half-lives (P = 0.27).",Role of Glucuronidation Pathway in Quetiapine Metabolism: An In vivo Drug-Drug Interaction Study between Quetiapine and Probenecid. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32952511/),[l] / [h·kg],16,156845,DB01109,Heparin
,10102460,mean plasma concentrations,"The mean plasma concentrations in the low, medium and high dose groups were 0.17, 0.31 and 0.53 micromol/l, respectively.","Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10102460/),[μM] / [l],0.17,158176,DB01109,Heparin
,10102460,mean plasma concentrations,"The mean plasma concentrations in the low, medium and high dose groups were 0.17, 0.31 and 0.53 micromol/l, respectively.","Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10102460/),[μM] / [l],0.31,158177,DB01109,Heparin
,10102460,mean plasma concentrations,"The mean plasma concentrations in the low, medium and high dose groups were 0.17, 0.31 and 0.53 micromol/l, respectively.","Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10102460/),[μM] / [l],0.53,158178,DB01109,Heparin
,2402751,half-life time,"125I-radiolabeled intact PF4, reduced PF4 and C-terminal PF4 peptides injected into rabbits were cleared from the circulation in a biphasic pattern with components having half-life time of 1-2 min and 20-140 min.",Human platelet factor 4 and its C-terminal peptides: heparin binding and clearance from the circulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2402751/),min,1-2,158323,DB01109,Heparin
,2402751,half-life time,"125I-radiolabeled intact PF4, reduced PF4 and C-terminal PF4 peptides injected into rabbits were cleared from the circulation in a biphasic pattern with components having half-life time of 1-2 min and 20-140 min.",Human platelet factor 4 and its C-terminal peptides: heparin binding and clearance from the circulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2402751/),min,20-140,158324,DB01109,Heparin
,3378803,maximal plasma levels,Two cases of severe salicylate poisoning with maximal plasma levels of 6.9 and 8.9 mmol/l are described.,Haemodialysis or haemoperfusion in severe salicylate poisoning? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378803/),[mM] / [l],6.9,158689,DB01109,Heparin
,3378803,maximal plasma levels,Two cases of severe salicylate poisoning with maximal plasma levels of 6.9 and 8.9 mmol/l are described.,Haemodialysis or haemoperfusion in severe salicylate poisoning? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378803/),[mM] / [l],8.9,158690,DB01109,Heparin
,3378803,dial,"There was a non-significant higher dialysance (mean 86 ml/min, s.d. +/- 8) than haemoperfusion clearance (mean 81 ml/min s.d. +/- 17) at a blood flow of 200 ml/min.",Haemodialysis or haemoperfusion in severe salicylate poisoning? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378803/),[ml] / [min],86,158691,DB01109,Heparin
,3378803,clearance,"There was a non-significant higher dialysance (mean 86 ml/min, s.d. +/- 8) than haemoperfusion clearance (mean 81 ml/min s.d. +/- 17) at a blood flow of 200 ml/min.",Haemodialysis or haemoperfusion in severe salicylate poisoning? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378803/),[ml] / [min],81,158692,DB01109,Heparin
,3378803,blood flow,"There was a non-significant higher dialysance (mean 86 ml/min, s.d. +/- 8) than haemoperfusion clearance (mean 81 ml/min s.d. +/- 17) at a blood flow of 200 ml/min.",Haemodialysis or haemoperfusion in severe salicylate poisoning? ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378803/),[ml] / [min],200,158693,DB01109,Heparin
,18431408,Clearance,"Clearance of the drug was higher in the pregnant women throughout pregnancy when compared with nonpregnant women (0.78 +/- 0.03 l/h vs. 0.52 +/- 0.03 l/h, respectively P < 0.001) with the stage of the pregnancy having no influence.",Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18431408/),[l] / [h],0.78,160244,DB01109,Heparin
,18431408,Clearance,"Clearance of the drug was higher in the pregnant women throughout pregnancy when compared with nonpregnant women (0.78 +/- 0.03 l/h vs. 0.52 +/- 0.03 l/h, respectively P < 0.001) with the stage of the pregnancy having no influence.",Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18431408/),[l] / [h],0.52,160245,DB01109,Heparin
,32581516,IC50,Voriconazole inhibited the metabolism of vonoprazan at an IC50 of 2.93 μM and showed mixed inhibition.,Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32581516/),μM,2.93,160874,DB01109,Heparin
,26507836,elimination half-life,Mean elimination half-life was 71.9-118 h over the dose range from 0.3 to 3 mg/kg.,"Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26507836/),h,71.9-118,161040,DB01109,Heparin
,25015542,last detectable plasma concentration (tmax),The last detectable plasma concentration (tmax) of paste formulation was significantly earlier (36.00 h) compared with granule formulation (46.29 h).,"Plasma pharmacokinetics, faecal excretion and efficacy of pyrantel pamoate paste and granule formulations following per os administration in donkeys naturally infected with intestinal strongylidae. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25015542/),h,36.00,161667,DB01109,Heparin
,25015542,last detectable plasma concentration (tmax),The last detectable plasma concentration (tmax) of paste formulation was significantly earlier (36.00 h) compared with granule formulation (46.29 h).,"Plasma pharmacokinetics, faecal excretion and efficacy of pyrantel pamoate paste and granule formulations following per os administration in donkeys naturally infected with intestinal strongylidae. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25015542/),h,46.29,161668,DB01109,Heparin
,25015542,terminal half lives (t1/2,"Although, there was no significant difference on terminal half lives (t1/2: 12.39 h vs. 14.86 h), tmax (14.86 h vs. 14.00) and MRT (24.80 h vs. 25.44 h) values; the Cmax (0.09 μg/ml) AUC (2.65 μgh/ml) values of paste formulation were significantly lower and smaller compared with those of granule formulation (0.21 μg/ml and 5.60 μgh/ml), respectively.","Plasma pharmacokinetics, faecal excretion and efficacy of pyrantel pamoate paste and granule formulations following per os administration in donkeys naturally infected with intestinal strongylidae. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25015542/),h,12.39,161669,DB01109,Heparin
,25015542,terminal half lives (t1/2,"Although, there was no significant difference on terminal half lives (t1/2: 12.39 h vs. 14.86 h), tmax (14.86 h vs. 14.00) and MRT (24.80 h vs. 25.44 h) values; the Cmax (0.09 μg/ml) AUC (2.65 μgh/ml) values of paste formulation were significantly lower and smaller compared with those of granule formulation (0.21 μg/ml and 5.60 μgh/ml), respectively.","Plasma pharmacokinetics, faecal excretion and efficacy of pyrantel pamoate paste and granule formulations following per os administration in donkeys naturally infected with intestinal strongylidae. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25015542/),h,14.86,161670,DB01109,Heparin
,25015542,tmax,"Although, there was no significant difference on terminal half lives (t1/2: 12.39 h vs. 14.86 h), tmax (14.86 h vs. 14.00) and MRT (24.80 h vs. 25.44 h) values; the Cmax (0.09 μg/ml) AUC (2.65 μgh/ml) values of paste formulation were significantly lower and smaller compared with those of granule formulation (0.21 μg/ml and 5.60 μgh/ml), respectively.","Plasma pharmacokinetics, faecal excretion and efficacy of pyrantel pamoate paste and granule formulations following per os administration in donkeys naturally infected with intestinal strongylidae. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25015542/),h,14.86,161671,DB01109,Heparin
,25015542,tmax,"Although, there was no significant difference on terminal half lives (t1/2: 12.39 h vs. 14.86 h), tmax (14.86 h vs. 14.00) and MRT (24.80 h vs. 25.44 h) values; the Cmax (0.09 μg/ml) AUC (2.65 μgh/ml) values of paste formulation were significantly lower and smaller compared with those of granule formulation (0.21 μg/ml and 5.60 μgh/ml), respectively.","Plasma pharmacokinetics, faecal excretion and efficacy of pyrantel pamoate paste and granule formulations following per os administration in donkeys naturally infected with intestinal strongylidae. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25015542/),,14.00,161672,DB01109,Heparin
,25015542,MRT,"Although, there was no significant difference on terminal half lives (t1/2: 12.39 h vs. 14.86 h), tmax (14.86 h vs. 14.00) and MRT (24.80 h vs. 25.44 h) values; the Cmax (0.09 μg/ml) AUC (2.65 μgh/ml) values of paste formulation were significantly lower and smaller compared with those of granule formulation (0.21 μg/ml and 5.60 μgh/ml), respectively.","Plasma pharmacokinetics, faecal excretion and efficacy of pyrantel pamoate paste and granule formulations following per os administration in donkeys naturally infected with intestinal strongylidae. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25015542/),h,24.80,161673,DB01109,Heparin
,25015542,MRT,"Although, there was no significant difference on terminal half lives (t1/2: 12.39 h vs. 14.86 h), tmax (14.86 h vs. 14.00) and MRT (24.80 h vs. 25.44 h) values; the Cmax (0.09 μg/ml) AUC (2.65 μgh/ml) values of paste formulation were significantly lower and smaller compared with those of granule formulation (0.21 μg/ml and 5.60 μgh/ml), respectively.","Plasma pharmacokinetics, faecal excretion and efficacy of pyrantel pamoate paste and granule formulations following per os administration in donkeys naturally infected with intestinal strongylidae. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25015542/),h,25.44,161674,DB01109,Heparin
,25015542,Cmax,"Although, there was no significant difference on terminal half lives (t1/2: 12.39 h vs. 14.86 h), tmax (14.86 h vs. 14.00) and MRT (24.80 h vs. 25.44 h) values; the Cmax (0.09 μg/ml) AUC (2.65 μgh/ml) values of paste formulation were significantly lower and smaller compared with those of granule formulation (0.21 μg/ml and 5.60 μgh/ml), respectively.","Plasma pharmacokinetics, faecal excretion and efficacy of pyrantel pamoate paste and granule formulations following per os administration in donkeys naturally infected with intestinal strongylidae. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25015542/),[μg] / [ml],0.09,161675,DB01109,Heparin
,25015542,AUC,"Although, there was no significant difference on terminal half lives (t1/2: 12.39 h vs. 14.86 h), tmax (14.86 h vs. 14.00) and MRT (24.80 h vs. 25.44 h) values; the Cmax (0.09 μg/ml) AUC (2.65 μgh/ml) values of paste formulation were significantly lower and smaller compared with those of granule formulation (0.21 μg/ml and 5.60 μgh/ml), respectively.","Plasma pharmacokinetics, faecal excretion and efficacy of pyrantel pamoate paste and granule formulations following per os administration in donkeys naturally infected with intestinal strongylidae. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25015542/),[μgh] / [ml],2.65,161676,DB01109,Heparin
,25015542,AUC,"Although, there was no significant difference on terminal half lives (t1/2: 12.39 h vs. 14.86 h), tmax (14.86 h vs. 14.00) and MRT (24.80 h vs. 25.44 h) values; the Cmax (0.09 μg/ml) AUC (2.65 μgh/ml) values of paste formulation were significantly lower and smaller compared with those of granule formulation (0.21 μg/ml and 5.60 μgh/ml), respectively.","Plasma pharmacokinetics, faecal excretion and efficacy of pyrantel pamoate paste and granule formulations following per os administration in donkeys naturally infected with intestinal strongylidae. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25015542/),[μg] / [ml],0.21,161677,DB01109,Heparin
,25015542,AUC,"Although, there was no significant difference on terminal half lives (t1/2: 12.39 h vs. 14.86 h), tmax (14.86 h vs. 14.00) and MRT (24.80 h vs. 25.44 h) values; the Cmax (0.09 μg/ml) AUC (2.65 μgh/ml) values of paste formulation were significantly lower and smaller compared with those of granule formulation (0.21 μg/ml and 5.60 μgh/ml), respectively.","Plasma pharmacokinetics, faecal excretion and efficacy of pyrantel pamoate paste and granule formulations following per os administration in donkeys naturally infected with intestinal strongylidae. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25015542/),[μgh] / [ml],5.60,161678,DB01109,Heparin
,25015542,dry faecal concentrations,"The highest dry faecal concentrations were 710.46 μg/g and 537.21 μg/g and were determined at 48 h for both paste and granule formulation of PYR in donkeys, respectively.","Plasma pharmacokinetics, faecal excretion and efficacy of pyrantel pamoate paste and granule formulations following per os administration in donkeys naturally infected with intestinal strongylidae. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25015542/),[μg] / [g],710.46,161679,DB01109,Heparin
,25015542,dry faecal concentrations,"The highest dry faecal concentrations were 710.46 μg/g and 537.21 μg/g and were determined at 48 h for both paste and granule formulation of PYR in donkeys, respectively.","Plasma pharmacokinetics, faecal excretion and efficacy of pyrantel pamoate paste and granule formulations following per os administration in donkeys naturally infected with intestinal strongylidae. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25015542/),[μg] / [g],537.21,161680,DB01109,Heparin
,29464007,attenuation,Results:99mTc attenuation by LVAD titanium (1 mm) was 23%.,Diagnosis of LVAD Thrombus using a High-Avidity Fibrin-Specific 99mTc Probe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29464007/),%,23,161861,DB01109,Heparin
,29464007,Kd,"99mTc-F1A affinity to fibrin was Kd ~10 µM, whereas, the bound 99mTc-F4A probe was not displaced by F1A (120,000:1).",Diagnosis of LVAD Thrombus using a High-Avidity Fibrin-Specific 99mTc Probe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29464007/),μM,10,161862,DB01109,Heparin
,29464007,half-life,The pharmacokinetic half-life of 99mTc-F4A was 28% faster (124±41 min) than 99mTc-F1A (176±26 min) with both being bioeliminated through the urinary system with negligible liver or spleen biodistribution.,Diagnosis of LVAD Thrombus using a High-Avidity Fibrin-Specific 99mTc Probe. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29464007/),min,124,161863,DB01109,Heparin
,29464007,half-life,The pharmacokinetic half-life of 99mTc-F4A was 28% faster (124±41 min) than 99mTc-F1A (176±26 min) with both being bioeliminated through the urinary system with negligible liver or spleen biodistribution.,Diagnosis of LVAD Thrombus using a High-Avidity Fibrin-Specific 99mTc Probe. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29464007/),min,176,161864,DB01109,Heparin
,8067830,activated clotting time,"At a 0.5 mg.kg-1.min-1 dose, the activated clotting time rose with aptamer infusion from 106 +/- 12 seconds to 187 +/- 8 seconds (+/- 1 standard deviation) (p = 0.014), increased further with hemodilution (to 259 +/- 41 seconds; p = 0.017), and was even more prolonged during total CPB (> 1,500 seconds; p < 0.001).",Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067830/),seconds,106,162469,DB01109,Heparin
,8067830,activated clotting time,"At a 0.5 mg.kg-1.min-1 dose, the activated clotting time rose with aptamer infusion from 106 +/- 12 seconds to 187 +/- 8 seconds (+/- 1 standard deviation) (p = 0.014), increased further with hemodilution (to 259 +/- 41 seconds; p = 0.017), and was even more prolonged during total CPB (> 1,500 seconds; p < 0.001).",Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067830/),seconds,187,162470,DB01109,Heparin
,8067830,activated clotting time,"At a 0.5 mg.kg-1.min-1 dose, the activated clotting time rose with aptamer infusion from 106 +/- 12 seconds to 187 +/- 8 seconds (+/- 1 standard deviation) (p = 0.014), increased further with hemodilution (to 259 +/- 41 seconds; p = 0.017), and was even more prolonged during total CPB (> 1,500 seconds; p < 0.001).",Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067830/),seconds,259,162471,DB01109,Heparin
,6543145,T1,"In vivo, after I.V. infusion of the drug, there was no difference in the same animal between anticoagulant activity measurements and radioactive countings, both displaying a plasmatic biexponential pattern (T1 = 2.9 minutes, T2 = 76 minutes).",Technetium labelled heparin: potential value as a tracer of heparin activity in pharmacokinetic and biodistribution studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6543145/),min,2.9,165419,DB01109,Heparin
,6543145,T2,"In vivo, after I.V. infusion of the drug, there was no difference in the same animal between anticoagulant activity measurements and radioactive countings, both displaying a plasmatic biexponential pattern (T1 = 2.9 minutes, T2 = 76 minutes).",Technetium labelled heparin: potential value as a tracer of heparin activity in pharmacokinetic and biodistribution studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6543145/),min,76,165420,DB01109,Heparin
,1514168,bleeding time,"Mean (range) bleeding time values were 8.4 min (7.5-9.7) during heparin/placebo, 12.1 min (9.2-18.6) (GR32191/placebo) and 16.3 min (11.5-21.4) (GR32191/heparin) in the 40 mg study, while these values were 8.7 min (5.5-15.5), 16.0 min (9.3 - greater than 36.0) and 23.8 min (10.7 - greater than 36.0), respectively in the 80 mg study.",Pronounced effects of the combination of a new thromboxane antagonist (GR32191) and heparin on bleeding time in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1514168/),min,8.4,165555,DB01109,Heparin
,1514168,bleeding time,"Mean (range) bleeding time values were 8.4 min (7.5-9.7) during heparin/placebo, 12.1 min (9.2-18.6) (GR32191/placebo) and 16.3 min (11.5-21.4) (GR32191/heparin) in the 40 mg study, while these values were 8.7 min (5.5-15.5), 16.0 min (9.3 - greater than 36.0) and 23.8 min (10.7 - greater than 36.0), respectively in the 80 mg study.",Pronounced effects of the combination of a new thromboxane antagonist (GR32191) and heparin on bleeding time in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1514168/),min,12.1,165556,DB01109,Heparin
,1514168,bleeding time,"Mean (range) bleeding time values were 8.4 min (7.5-9.7) during heparin/placebo, 12.1 min (9.2-18.6) (GR32191/placebo) and 16.3 min (11.5-21.4) (GR32191/heparin) in the 40 mg study, while these values were 8.7 min (5.5-15.5), 16.0 min (9.3 - greater than 36.0) and 23.8 min (10.7 - greater than 36.0), respectively in the 80 mg study.",Pronounced effects of the combination of a new thromboxane antagonist (GR32191) and heparin on bleeding time in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1514168/),min,16.3,165557,DB01109,Heparin
,1514168,bleeding time,"Mean (range) bleeding time values were 8.4 min (7.5-9.7) during heparin/placebo, 12.1 min (9.2-18.6) (GR32191/placebo) and 16.3 min (11.5-21.4) (GR32191/heparin) in the 40 mg study, while these values were 8.7 min (5.5-15.5), 16.0 min (9.3 - greater than 36.0) and 23.8 min (10.7 - greater than 36.0), respectively in the 80 mg study.",Pronounced effects of the combination of a new thromboxane antagonist (GR32191) and heparin on bleeding time in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1514168/),min,8.7,165558,DB01109,Heparin
,1514168,bleeding time,"Mean (range) bleeding time values were 8.4 min (7.5-9.7) during heparin/placebo, 12.1 min (9.2-18.6) (GR32191/placebo) and 16.3 min (11.5-21.4) (GR32191/heparin) in the 40 mg study, while these values were 8.7 min (5.5-15.5), 16.0 min (9.3 - greater than 36.0) and 23.8 min (10.7 - greater than 36.0), respectively in the 80 mg study.",Pronounced effects of the combination of a new thromboxane antagonist (GR32191) and heparin on bleeding time in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1514168/),min,16.0,165559,DB01109,Heparin
,1514168,bleeding time,"Mean (range) bleeding time values were 8.4 min (7.5-9.7) during heparin/placebo, 12.1 min (9.2-18.6) (GR32191/placebo) and 16.3 min (11.5-21.4) (GR32191/heparin) in the 40 mg study, while these values were 8.7 min (5.5-15.5), 16.0 min (9.3 - greater than 36.0) and 23.8 min (10.7 - greater than 36.0), respectively in the 80 mg study.",Pronounced effects of the combination of a new thromboxane antagonist (GR32191) and heparin on bleeding time in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1514168/),min,23.8,165560,DB01109,Heparin
,8026028,clearance,The clearance of DSPA (2.3 to 3.5 mL.min-1.kg-1) was lower compared with TPA (11.4 to 20 mL.min-1.kg-1) due to a prolonged terminal half-life.,Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8026028/),[ml] / [kg·min],2.3 to 3.5,166931,DB01109,Heparin
,8026028,clearance,The clearance of DSPA (2.3 to 3.5 mL.min-1.kg-1) was lower compared with TPA (11.4 to 20 mL.min-1.kg-1) due to a prolonged terminal half-life.,Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8026028/),[ml] / [kg·min],11.4 to 20,166932,DB01109,Heparin
,11748110,maximum activated partial thromboplastin times,"After oral administration of 100 mg/kg of heparin-DOCA, the maximum activated partial thromboplastin times of the LMWH(3 kDa)-DOCA, LMWH(6 kDa)-DOCA, and UFH-DOCA were 31.0+/-6.0, 87.8+/-11.1, and 51.0+/-8.7 seconds, respectively.",Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748110/),seconds,31.0,167388,DB01109,Heparin
,11748110,maximum activated partial thromboplastin times,"After oral administration of 100 mg/kg of heparin-DOCA, the maximum activated partial thromboplastin times of the LMWH(3 kDa)-DOCA, LMWH(6 kDa)-DOCA, and UFH-DOCA were 31.0+/-6.0, 87.8+/-11.1, and 51.0+/-8.7 seconds, respectively.",Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748110/),seconds,87.8,167389,DB01109,Heparin
,11748110,maximum activated partial thromboplastin times,"After oral administration of 100 mg/kg of heparin-DOCA, the maximum activated partial thromboplastin times of the LMWH(3 kDa)-DOCA, LMWH(6 kDa)-DOCA, and UFH-DOCA were 31.0+/-6.0, 87.8+/-11.1, and 51.0+/-8.7 seconds, respectively.",Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748110/),seconds,51.0,167390,DB01109,Heparin
,11748110,peak plasma concentrations,"The peak plasma concentrations of LMWH(3 kDa)-DOCA, LMWH(6 kDa)-DOCA, and UFH-DOCA were 0.06+/-0.02, 0.76+/-0.15, and 0.41+/-0.13 IU/mL, respectively.",Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748110/),[iu] / [ml],0.06,167391,DB01109,Heparin
,11748110,peak plasma concentrations,"The peak plasma concentrations of LMWH(3 kDa)-DOCA, LMWH(6 kDa)-DOCA, and UFH-DOCA were 0.06+/-0.02, 0.76+/-0.15, and 0.41+/-0.13 IU/mL, respectively.",Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748110/),[iu] / [ml],0.76,167392,DB01109,Heparin
,11748110,peak plasma concentrations,"The peak plasma concentrations of LMWH(3 kDa)-DOCA, LMWH(6 kDa)-DOCA, and UFH-DOCA were 0.06+/-0.02, 0.76+/-0.15, and 0.41+/-0.13 IU/mL, respectively.",Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748110/),[iu] / [ml],0.41,167393,DB01109,Heparin
,11748110,bioavailability,The bioavailability of LMWH(6 kDa)-DOCA at the 20-mg/kg dosage was calculated to be 7.8%.,Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748110/),%,7.8,167394,DB01109,Heparin
,32165317,AUC,"The AUC values for rhMK after IM and intra-articular (IA) administration were 1523.3 ± 35.2 h × ng/mL and 872.0 ± 36.1 h × ng/mL, whereas the apparent volumes of distribution (Vd/f) were 0.184 ± 0.067 L/kg and 11.6 ± 0.8 L/kg, respectively, suggesting that rhMK was distributed more locally after IA injection than after IM injection as Vd/f magnitude gives a general idea of extent distribution in the body and higher Vd/f represents more locally distribution.",Pharmacokinetics of midkine with different N-terminal structures in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32165317/),[h·ng] / [ml],1523.3,167467,DB01109,Heparin
,32165317,AUC,"The AUC values for rhMK after IM and intra-articular (IA) administration were 1523.3 ± 35.2 h × ng/mL and 872.0 ± 36.1 h × ng/mL, whereas the apparent volumes of distribution (Vd/f) were 0.184 ± 0.067 L/kg and 11.6 ± 0.8 L/kg, respectively, suggesting that rhMK was distributed more locally after IA injection than after IM injection as Vd/f magnitude gives a general idea of extent distribution in the body and higher Vd/f represents more locally distribution.",Pharmacokinetics of midkine with different N-terminal structures in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32165317/),[h·ng] / [ml],872.0,167468,DB01109,Heparin
,32165317,apparent volumes of distribution (Vd/f),"The AUC values for rhMK after IM and intra-articular (IA) administration were 1523.3 ± 35.2 h × ng/mL and 872.0 ± 36.1 h × ng/mL, whereas the apparent volumes of distribution (Vd/f) were 0.184 ± 0.067 L/kg and 11.6 ± 0.8 L/kg, respectively, suggesting that rhMK was distributed more locally after IA injection than after IM injection as Vd/f magnitude gives a general idea of extent distribution in the body and higher Vd/f represents more locally distribution.",Pharmacokinetics of midkine with different N-terminal structures in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32165317/),[l] / [kg],0.184,167469,DB01109,Heparin
,32165317,apparent volumes of distribution (Vd/f),"The AUC values for rhMK after IM and intra-articular (IA) administration were 1523.3 ± 35.2 h × ng/mL and 872.0 ± 36.1 h × ng/mL, whereas the apparent volumes of distribution (Vd/f) were 0.184 ± 0.067 L/kg and 11.6 ± 0.8 L/kg, respectively, suggesting that rhMK was distributed more locally after IA injection than after IM injection as Vd/f magnitude gives a general idea of extent distribution in the body and higher Vd/f represents more locally distribution.",Pharmacokinetics of midkine with different N-terminal structures in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32165317/),[l] / [kg],11.6,167470,DB01109,Heparin
,512841,bolus half-life,"It is shown that, even though both models exhibit a bolus half-life of from 1 to 2 hr, over 2 days can be required for true steady-state conditions to be achieved in these models when a constant intravenous infusion of drug is given.",Pharmacokinetic modeling of heparin and its clinical implications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512841/),h,1 to 2,170429,DB01109,Heparin
,12420244,elimination half-life,Pharmacokinetic data compared with those of a control group without AHAb administration revealed that r-hirudin elimination half-life was significantly prolonged (59 +/- 25 minutes versus 142 +/- 25 minutes).,Biological relevance of anti-recombinant hirudin antibodies--results from in vitro and in vivo studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12420244/),min,59,170699,DB01109,Heparin
,12420244,elimination half-life,Pharmacokinetic data compared with those of a control group without AHAb administration revealed that r-hirudin elimination half-life was significantly prolonged (59 +/- 25 minutes versus 142 +/- 25 minutes).,Biological relevance of anti-recombinant hirudin antibodies--results from in vitro and in vivo studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12420244/),min,142,170700,DB01109,Heparin
,12420244,volume of distribution,"The volume of distribution of r-hirudin was significantly decreased (275 +/- 112 mL/kg versus 35 +/- 3 mL/kg), indicating that r-hirudin bound by AHAb is mainly distributed to the intravascular compartment.",Biological relevance of anti-recombinant hirudin antibodies--results from in vitro and in vivo studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12420244/),[ml] / [kg],275,170701,DB01109,Heparin
,12420244,volume of distribution,"The volume of distribution of r-hirudin was significantly decreased (275 +/- 112 mL/kg versus 35 +/- 3 mL/kg), indicating that r-hirudin bound by AHAb is mainly distributed to the intravascular compartment.",Biological relevance of anti-recombinant hirudin antibodies--results from in vitro and in vivo studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12420244/),[ml] / [kg],35,170702,DB01109,Heparin
>,16931658,ACT+,An ACT+ value of >300 s was the target.,"Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: results of the ""EVOLUTION OFF"" trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16931658/),s,300,171275,DB01109,Heparin
,7997890,aXa activity,Lipophilically modified heparin had an aXa activity ranging from 52 to 168 U/mg (unfractionated) and 60 to 108 U/mg (LMMH) and antithrombin activity ranging from 31 to 270 U/mg (unfractionated) and 5 to 15 U/mg (LMMH).,Semisynthesis and analysis of lipophilically modified unfractionated and low molecular mass heparins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997890/),[u] / [mg],52 to 168,171937,DB01109,Heparin
,7997890,aXa activity,Lipophilically modified heparin had an aXa activity ranging from 52 to 168 U/mg (unfractionated) and 60 to 108 U/mg (LMMH) and antithrombin activity ranging from 31 to 270 U/mg (unfractionated) and 5 to 15 U/mg (LMMH).,Semisynthesis and analysis of lipophilically modified unfractionated and low molecular mass heparins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997890/),[u] / [mg],60 to 108,171938,DB01109,Heparin
,7997890,antithrombin activity,Lipophilically modified heparin had an aXa activity ranging from 52 to 168 U/mg (unfractionated) and 60 to 108 U/mg (LMMH) and antithrombin activity ranging from 31 to 270 U/mg (unfractionated) and 5 to 15 U/mg (LMMH).,Semisynthesis and analysis of lipophilically modified unfractionated and low molecular mass heparins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997890/),[u] / [mg],31 to 270,171939,DB01109,Heparin
,7997890,antithrombin activity,Lipophilically modified heparin had an aXa activity ranging from 52 to 168 U/mg (unfractionated) and 60 to 108 U/mg (LMMH) and antithrombin activity ranging from 31 to 270 U/mg (unfractionated) and 5 to 15 U/mg (LMMH).,Semisynthesis and analysis of lipophilically modified unfractionated and low molecular mass heparins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997890/),[u] / [mg],5 to 15,171940,DB01109,Heparin
,9610757,Blood elimination,Blood elimination in the rabbit was 18.5 minutes which decreased to 7.5 minutes when followed by the injection of protamine.,"Indium-111 DTPA-heparin: radiolabeling, pharmacokinetics, and biodistribution following intravenous administration in rat and rabbit. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9610757/),min,18.5,174607,DB01109,Heparin
,9610757,Blood elimination,Blood elimination in the rabbit was 18.5 minutes which decreased to 7.5 minutes when followed by the injection of protamine.,"Indium-111 DTPA-heparin: radiolabeling, pharmacokinetics, and biodistribution following intravenous administration in rat and rabbit. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9610757/),min,7.5,174608,DB01109,Heparin
,9610757,half-time,"Radioactivity cleared from the liver and lungs as a single exponential with a half-time of 30 minutes, but there was very rapid increase of radioactivity in the lungs, peaking at 1-2 minutes, following the injection of protamine.","Indium-111 DTPA-heparin: radiolabeling, pharmacokinetics, and biodistribution following intravenous administration in rat and rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9610757/),min,30,174609,DB01109,Heparin
,1379967,elimination half-lives,"In humans, widely different pharmacokinetic profiles for various biological effects were observed, with relatively short elimination half-lives for the anti-IIa and IIaGI activities of 4.3 +/- 3.5 and 6.7 +/- 3.2 h, respectively, but a relatively long elimination half-life of anti-Xa activity of 24.5 +/- 9.6 h.",Pharmacokinetic considerations on Orgaran (Org 10172) therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1379967/),h,4.3,174918,DB01109,Heparin
,1379967,elimination half-lives,"In humans, widely different pharmacokinetic profiles for various biological effects were observed, with relatively short elimination half-lives for the anti-IIa and IIaGI activities of 4.3 +/- 3.5 and 6.7 +/- 3.2 h, respectively, but a relatively long elimination half-life of anti-Xa activity of 24.5 +/- 9.6 h.",Pharmacokinetic considerations on Orgaran (Org 10172) therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1379967/),h,6.7,174919,DB01109,Heparin
,1379967,elimination half-life,"In humans, widely different pharmacokinetic profiles for various biological effects were observed, with relatively short elimination half-lives for the anti-IIa and IIaGI activities of 4.3 +/- 3.5 and 6.7 +/- 3.2 h, respectively, but a relatively long elimination half-life of anti-Xa activity of 24.5 +/- 9.6 h.",Pharmacokinetic considerations on Orgaran (Org 10172) therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1379967/),h,24.5,174920,DB01109,Heparin
,1379967,Absorption,"Absorption from subcutaneous tissues was found to be close to 100%, which is significantly higher than of heparin; a finding which indicates that the subcutaneous route is reliable for the administration of Orgaran.",Pharmacokinetic considerations on Orgaran (Org 10172) therapy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1379967/),%,100,174921,DB01109,Heparin
,27514823,Area under the concentration-time curve from 0 to 360 min (AUC0-t ),"Area under the concentration-time curve from 0 to 360 min (AUC0-t ) of EP, PEP and MEP were 666.99, 650.76 and 632.37 µg·min/mL, respectively.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),[min·μg] / [ml],666.99,175709,DB01109,Heparin
,27514823,Area under the concentration-time curve from 0 to 360 min (AUC0-t ),"Area under the concentration-time curve from 0 to 360 min (AUC0-t ) of EP, PEP and MEP were 666.99, 650.76 and 632.37 µg·min/mL, respectively.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),[min·μg] / [ml],650.76,175710,DB01109,Heparin
,27514823,Area under the concentration-time curve from 0 to 360 min (AUC0-t ),"Area under the concentration-time curve from 0 to 360 min (AUC0-t ) of EP, PEP and MEP were 666.99, 650.76 and 632.37 µg·min/mL, respectively.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),[min·μg] / [ml],632.37,175711,DB01109,Heparin
,27514823,Maximum plasma concentration (C max),"Maximum plasma concentration (C max) of EP, PEP and MEP were 4.15, 4.08 and 3.59 μg/mL, respectively.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),[μg] / [ml],4.15,175712,DB01109,Heparin
,27514823,Maximum plasma concentration (C max),"Maximum plasma concentration (C max) of EP, PEP and MEP were 4.15, 4.08 and 3.59 μg/mL, respectively.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),[μg] / [ml],4.08,175713,DB01109,Heparin
,27514823,Maximum plasma concentration (C max),"Maximum plasma concentration (C max) of EP, PEP and MEP were 4.15, 4.08 and 3.59 μg/mL, respectively.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),[μg] / [ml],3.59,175714,DB01109,Heparin
,27514823,Mean residence time (MRT),"Mean residence time (MRT) of EP, PEP and MEP were 197.00, 173.97 and 183.87 min, respectively, when the rats were treated with EP-PEP-MEP.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),min,197.00,175715,DB01109,Heparin
,27514823,Mean residence time (MRT),"Mean residence time (MRT) of EP, PEP and MEP were 197.00, 173.97 and 183.87 min, respectively, when the rats were treated with EP-PEP-MEP.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),min,173.97,175716,DB01109,Heparin
,27514823,Mean residence time (MRT),"Mean residence time (MRT) of EP, PEP and MEP were 197.00, 173.97 and 183.87 min, respectively, when the rats were treated with EP-PEP-MEP.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),min,183.87,175717,DB01109,Heparin
,14987920,total clearance,The total clearance (16.0-21.0 ml/h/kg) and half-life (4-6 h) of C3 were also dose-independent.,"Pharmacodynamics and pharmacokinetics of C3, a heparin-derived oligosaccharide mixture, in non-human primates. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14987920/),[ml] / [h·kg],16.0-21.0,175890,DB01109,Heparin
,14987920,half-life,The total clearance (16.0-21.0 ml/h/kg) and half-life (4-6 h) of C3 were also dose-independent.,"Pharmacodynamics and pharmacokinetics of C3, a heparin-derived oligosaccharide mixture, in non-human primates. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14987920/),h,4-6,175891,DB01109,Heparin
,33538636,peak concentrations (Cmax,"After IM administration, CHE and DHCHE rapidly reached peak concentrations (Cmax, 69.79 ± 15.41 and 3.47 ± 1.23 ng/ml) at 0.42 ± 0.13 and 0.33 ± 0.13 h, respectively.",Pharmacokinetics of Chelerythrine and Its Metabolite after Oral and Intramuscular Administrations in Pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33538636/),[ng] / [ml],69.79,176888,DB01109,Heparin
,33538636,peak concentrations (Cmax,"After IM administration, CHE and DHCHE rapidly reached peak concentrations (Cmax, 69.79 ± 15.41 and 3.47 ± 1.23 ng/ml) at 0.42 ± 0.13 and 0.33 ± 0.13 h, respectively.",Pharmacokinetics of Chelerythrine and Its Metabolite after Oral and Intramuscular Administrations in Pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33538636/),[ng] / [ml],3.47,176889,DB01109,Heparin
,33538636,Cmax,"After single oral administration, CHE and DHCHE rapidly increased to reach Cmax of 5.04 ± 1.00 and 1.21 ± 0.35 ng/ml at 1.83 ± 0.26 and 1.67 ± 0.26 h, respectively.",Pharmacokinetics of Chelerythrine and Its Metabolite after Oral and Intramuscular Administrations in Pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33538636/),[ng] / [ml],5.04,176890,DB01109,Heparin
,33538636,Cmax,"After single oral administration, CHE and DHCHE rapidly increased to reach Cmax of 5.04 ± 1.00 and 1.21 ± 0.35 ng/ml at 1.83 ± 0.26 and 1.67 ± 0.26 h, respectively.",Pharmacokinetics of Chelerythrine and Its Metabolite after Oral and Intramuscular Administrations in Pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33538636/),[ng] / [ml],1.21,176891,DB01109,Heparin
,33538636,half-life (T1/2),"The half-life (T1/2) was 2.03 ± 0.26 and 2.56 ± 1.00 h for CHE and DHCHE, respectively.",Pharmacokinetics of Chelerythrine and Its Metabolite after Oral and Intramuscular Administrations in Pigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33538636/),h,2.03,176892,DB01109,Heparin
,33538636,half-life (T1/2),"The half-life (T1/2) was 2.03 ± 0.26 and 2.56 ± 1.00 h for CHE and DHCHE, respectively.",Pharmacokinetics of Chelerythrine and Its Metabolite after Oral and Intramuscular Administrations in Pigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33538636/),h,2.56,176893,DB01109,Heparin
,33538636,steady-state concentrations (Css),"After multiple oral administration, the average steady-state concentrations (Css) of CHE and DHCHE were 2.51 ± 0.40 and 0.6 ± 0.06 ng/ml, respectively.",Pharmacokinetics of Chelerythrine and Its Metabolite after Oral and Intramuscular Administrations in Pigs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33538636/),[ng] / [ml],2.51,176894,DB01109,Heparin
,33538636,steady-state concentrations (Css),"After multiple oral administration, the average steady-state concentrations (Css) of CHE and DHCHE were 2.51 ± 0.40 and 0.6 ± 0.06 ng/ml, respectively.",Pharmacokinetics of Chelerythrine and Its Metabolite after Oral and Intramuscular Administrations in Pigs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33538636/),[ng] / [ml],0.6,176895,DB01109,Heparin
,12235452,Time to maximum anti-Xa activity,"Time to maximum anti-Xa activity was 1 hour longer in obese volunteers, but maximum anti-Xa activity was similar in both groups.",The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235452/),h,1,178920,DB01109,Heparin
,3277474,half-life,"Heparin pharmacokinetics are poorly understood, but when the usual doses are given intravenously, heparin is rapidly removed from the blood and has a half-life of approximately 90 minutes.",Anticoagulation: a surgical perspective. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3277474/),min,90,181021,DB01109,Heparin
,19616095,particle size,The mean particle size of the liposomes was 104.8+/-20.7 nm and the drug entrapment efficiency was 90.3+/-0.1%.,Cationic liposomes as carriers for aerosolized formulations of an anionic drug: safety and efficacy study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19616095/),nm,104.8,182210,DB01109,Heparin
,19616095,drug,The mean particle size of the liposomes was 104.8+/-20.7 nm and the drug entrapment efficiency was 90.3+/-0.1%.,Cationic liposomes as carriers for aerosolized formulations of an anionic drug: safety and efficacy study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19616095/),%,90.3,182211,DB01109,Heparin
,19616095,entrapment efficiency,The mean particle size of the liposomes was 104.8+/-20.7 nm and the drug entrapment efficiency was 90.3+/-0.1%.,Cationic liposomes as carriers for aerosolized formulations of an anionic drug: safety and efficacy study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19616095/),%,90.3,182212,DB01109,Heparin
,19616095,half-life,"The half-life of the cationic liposomal formulation was 10.6+/-0.2h, a 2.2-fold increase compared to low molecular weight heparin formulated in saline, and the relative bioavailability was approximately 73.4+/-19.1% when compared to subcutaneously administered drug.",Cationic liposomes as carriers for aerosolized formulations of an anionic drug: safety and efficacy study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19616095/),h,10.6,182213,DB01109,Heparin
,19616095,relative bioavailability,"The half-life of the cationic liposomal formulation was 10.6+/-0.2h, a 2.2-fold increase compared to low molecular weight heparin formulated in saline, and the relative bioavailability was approximately 73.4+/-19.1% when compared to subcutaneously administered drug.",Cationic liposomes as carriers for aerosolized formulations of an anionic drug: safety and efficacy study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19616095/),%,73.4,182214,DB01109,Heparin
,25668796,flow rate,"Analyses were performed on a liquid chromatography system employing a Kromasil 60-5CN column (2.1 mm × 100 mm, 5 μm) and an isocratic elution with mixed solution of acetonitrile-20mM ammonium formate containing 0.3% formic acid (40:60, v/v), at a flow rate of 0.35 mL/min.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),[ml] / [min],0.35,182760,DB01109,Heparin
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,452.1,182761,DB01109,Heparin
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,344.3,182762,DB01109,Heparin
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,338.3,182763,DB01109,Heparin
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,77.9,182764,DB01109,Heparin
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,355.0,182765,DB01109,Heparin
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,41.9,182766,DB01109,Heparin
,1851342,elimination half life,"For the AXa the following parameters were estimated in a 1-compartment model (mean and 95% confidence limits in brackets): elimination half life 82 minutes (60-127 min), absorption half life (s.c. inj.) 200 minutes (137-368 min), bioavailability 90% (24-156%), and apparent volume of distribution 3.9 l (3.1-5.2 l).","Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1851342/),min,82,182767,DB01109,Heparin
,1851342,absorption half life,"For the AXa the following parameters were estimated in a 1-compartment model (mean and 95% confidence limits in brackets): elimination half life 82 minutes (60-127 min), absorption half life (s.c. inj.) 200 minutes (137-368 min), bioavailability 90% (24-156%), and apparent volume of distribution 3.9 l (3.1-5.2 l).","Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1851342/),min,200,182768,DB01109,Heparin
,1851342,bioavailability,"For the AXa the following parameters were estimated in a 1-compartment model (mean and 95% confidence limits in brackets): elimination half life 82 minutes (60-127 min), absorption half life (s.c. inj.) 200 minutes (137-368 min), bioavailability 90% (24-156%), and apparent volume of distribution 3.9 l (3.1-5.2 l).","Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1851342/),%,90,182769,DB01109,Heparin
,1851342,apparent volume of distribution,"For the AXa the following parameters were estimated in a 1-compartment model (mean and 95% confidence limits in brackets): elimination half life 82 minutes (60-127 min), absorption half life (s.c. inj.) 200 minutes (137-368 min), bioavailability 90% (24-156%), and apparent volume of distribution 3.9 l (3.1-5.2 l).","Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1851342/),l,3.9,182770,DB01109,Heparin
,1851342,elimination half life,"For the AIIa the parameters estimated in a 1-compartment model were: elimination half life 71 minutes (52-115 min), absorption half life 257 minutes (133-3442 min), bioavailability 67% (44-90%), and apparent volume of distribution 10.1 l (7.2-16.7 l).","Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1851342/),min,71,182771,DB01109,Heparin
,1851342,absorption half life,"For the AIIa the parameters estimated in a 1-compartment model were: elimination half life 71 minutes (52-115 min), absorption half life 257 minutes (133-3442 min), bioavailability 67% (44-90%), and apparent volume of distribution 10.1 l (7.2-16.7 l).","Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1851342/),min,257,182772,DB01109,Heparin
,1851342,bioavailability,"For the AIIa the parameters estimated in a 1-compartment model were: elimination half life 71 minutes (52-115 min), absorption half life 257 minutes (133-3442 min), bioavailability 67% (44-90%), and apparent volume of distribution 10.1 l (7.2-16.7 l).","Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1851342/),%,67,182773,DB01109,Heparin
,1851342,apparent volume of distribution,"For the AIIa the parameters estimated in a 1-compartment model were: elimination half life 71 minutes (52-115 min), absorption half life 257 minutes (133-3442 min), bioavailability 67% (44-90%), and apparent volume of distribution 10.1 l (7.2-16.7 l).","Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1851342/),l,10.1,182774,DB01109,Heparin
,8311274,elimination half-time (t1/2 beta,"Compared to the pre-CPB period as well as to patients not exposed to CPB, CABG patients after CPB exhibited an increased elimination half-time (t1/2 beta = 180 +/- 55 min SD), central distribution volume (Vc = 0.25 +/- 0.07 L/kg), and total volume of distribution (Vdss 0.63 +/- 0.08 L/kg; Vd area 0.92 +/- 0.23 L/kg) which reflected a 33%-50% decrease in alpha 1-acid glycoprotein, the principal plasma protein to which alfentanil is bound.",Alfentanil pharmacokinetics in cardiac surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8311274/),min,180,182815,DB01109,Heparin
,8311274,central distribution volume (Vc,"Compared to the pre-CPB period as well as to patients not exposed to CPB, CABG patients after CPB exhibited an increased elimination half-time (t1/2 beta = 180 +/- 55 min SD), central distribution volume (Vc = 0.25 +/- 0.07 L/kg), and total volume of distribution (Vdss 0.63 +/- 0.08 L/kg; Vd area 0.92 +/- 0.23 L/kg) which reflected a 33%-50% decrease in alpha 1-acid glycoprotein, the principal plasma protein to which alfentanil is bound.",Alfentanil pharmacokinetics in cardiac surgical patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8311274/),[l] / [kg],0.25,182816,DB01109,Heparin
,8311274,total volume of distribution (Vdss,"Compared to the pre-CPB period as well as to patients not exposed to CPB, CABG patients after CPB exhibited an increased elimination half-time (t1/2 beta = 180 +/- 55 min SD), central distribution volume (Vc = 0.25 +/- 0.07 L/kg), and total volume of distribution (Vdss 0.63 +/- 0.08 L/kg; Vd area 0.92 +/- 0.23 L/kg) which reflected a 33%-50% decrease in alpha 1-acid glycoprotein, the principal plasma protein to which alfentanil is bound.",Alfentanil pharmacokinetics in cardiac surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8311274/),[l] / [kg],0.63,182817,DB01109,Heparin
,8311274,Vd area,"Compared to the pre-CPB period as well as to patients not exposed to CPB, CABG patients after CPB exhibited an increased elimination half-time (t1/2 beta = 180 +/- 55 min SD), central distribution volume (Vc = 0.25 +/- 0.07 L/kg), and total volume of distribution (Vdss 0.63 +/- 0.08 L/kg; Vd area 0.92 +/- 0.23 L/kg) which reflected a 33%-50% decrease in alpha 1-acid glycoprotein, the principal plasma protein to which alfentanil is bound.",Alfentanil pharmacokinetics in cardiac surgical patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8311274/),[l] / [kg],0.92,182818,DB01109,Heparin
,683118,area under curve,"The area under curve of iron increase was 531 +/- 329 (SD) after A, 415 +/- 327 And 414 +/- 390 after B and C respectively without significant changes.",[Bioavailability of Ce-Ferro forte. Comparative iron load test (author's transl)]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/683118/),,531,183497,DB01109,Heparin
,683118,area under curve,"The area under curve of iron increase was 531 +/- 329 (SD) after A, 415 +/- 327 And 414 +/- 390 after B and C respectively without significant changes.",[Bioavailability of Ce-Ferro forte. Comparative iron load test (author's transl)]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/683118/),,415,183498,DB01109,Heparin
,683118,area under curve,"The area under curve of iron increase was 531 +/- 329 (SD) after A, 415 +/- 327 And 414 +/- 390 after B and C respectively without significant changes.",[Bioavailability of Ce-Ferro forte. Comparative iron load test (author's transl)]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/683118/),,414,183499,DB01109,Heparin
,26820168,maximum concentration of EPM in plasma (Cmax),"The maximum concentration of EPM in plasma (Cmax) and the time to reach Cmax were both greater after S/C administration (59.70 (SD 12.90) ng/mL and 1.30 (SD 0.27) days, respectively) than after topical administration (20.73 (SD 4.04) ng/mL and 4.40 (SD 0.89) days, respectively) (p<0.001).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),[ng] / [ml],59.70,183536,DB01109,Heparin
,26820168,maximum concentration of EPM in plasma (Cmax),"The maximum concentration of EPM in plasma (Cmax) and the time to reach Cmax were both greater after S/C administration (59.70 (SD 12.90) ng/mL and 1.30 (SD 0.27) days, respectively) than after topical administration (20.73 (SD 4.04) ng/mL and 4.40 (SD 0.89) days, respectively) (p<0.001).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),[ng] / [ml],20.73,183537,DB01109,Heparin
,26820168,time to reach Cmax,"The maximum concentration of EPM in plasma (Cmax) and the time to reach Cmax were both greater after S/C administration (59.70 (SD 12.90) ng/mL and 1.30 (SD 0.27) days, respectively) than after topical administration (20.73 (SD 4.04) ng/mL and 4.40 (SD 0.89) days, respectively) (p<0.001).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),d,1.30,183538,DB01109,Heparin
,26820168,time to reach Cmax,"The maximum concentration of EPM in plasma (Cmax) and the time to reach Cmax were both greater after S/C administration (59.70 (SD 12.90) ng/mL and 1.30 (SD 0.27) days, respectively) than after topical administration (20.73 (SD 4.04) ng/mL and 4.40 (SD 0.89) days, respectively) (p<0.001).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),d,4.40,183539,DB01109,Heparin
,26820168,area under the curve; AUC,"In addition, S/C administration resulted in greater plasma availability (area under the curve; AUC), and a shorter terminal half-life and mean residence time (295.9 (SD 61.47) ng.day/mL; 2.95 (SD 0.74) days and 4.69 (SD 1.01) days, respectively) compared with topical administration (168.2 (SD15.67) ng.day/mL; 4.63 (SD 0.32) days, and 8.23 (SD 0.57) days, respectively) (p<0.01).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),[d·ng] / [ml],295.9,183540,DB01109,Heparin
,26820168,terminal half-life,"In addition, S/C administration resulted in greater plasma availability (area under the curve; AUC), and a shorter terminal half-life and mean residence time (295.9 (SD 61.47) ng.day/mL; 2.95 (SD 0.74) days and 4.69 (SD 1.01) days, respectively) compared with topical administration (168.2 (SD15.67) ng.day/mL; 4.63 (SD 0.32) days, and 8.23 (SD 0.57) days, respectively) (p<0.01).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),[d·ng] / [ml],295.9,183541,DB01109,Heparin
,26820168,terminal half-life,"In addition, S/C administration resulted in greater plasma availability (area under the curve; AUC), and a shorter terminal half-life and mean residence time (295.9 (SD 61.47) ng.day/mL; 2.95 (SD 0.74) days and 4.69 (SD 1.01) days, respectively) compared with topical administration (168.2 (SD15.67) ng.day/mL; 4.63 (SD 0.32) days, and 8.23 (SD 0.57) days, respectively) (p<0.01).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),d,2.95,183542,DB01109,Heparin
,26820168,terminal half-life,"In addition, S/C administration resulted in greater plasma availability (area under the curve; AUC), and a shorter terminal half-life and mean residence time (295.9 (SD 61.47) ng.day/mL; 2.95 (SD 0.74) days and 4.69 (SD 1.01) days, respectively) compared with topical administration (168.2 (SD15.67) ng.day/mL; 4.63 (SD 0.32) days, and 8.23 (SD 0.57) days, respectively) (p<0.01).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),[d·ng] / [ml],168.2,183543,DB01109,Heparin
,26820168,mean residence time,"In addition, S/C administration resulted in greater plasma availability (area under the curve; AUC), and a shorter terminal half-life and mean residence time (295.9 (SD 61.47) ng.day/mL; 2.95 (SD 0.74) days and 4.69 (SD 1.01) days, respectively) compared with topical administration (168.2 (SD15.67) ng.day/mL; 4.63 (SD 0.32) days, and 8.23 (SD 0.57) days, respectively) (p<0.01).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),d,2.95,183544,DB01109,Heparin
,26820168,mean residence time,"In addition, S/C administration resulted in greater plasma availability (area under the curve; AUC), and a shorter terminal half-life and mean residence time (295.9 (SD 61.47) ng.day/mL; 2.95 (SD 0.74) days and 4.69 (SD 1.01) days, respectively) compared with topical administration (168.2 (SD15.67) ng.day/mL; 4.63 (SD 0.32) days, and 8.23 (SD 0.57) days, respectively) (p<0.01).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),d,4.69,183545,DB01109,Heparin
,26820168,mean residence time,"In addition, S/C administration resulted in greater plasma availability (area under the curve; AUC), and a shorter terminal half-life and mean residence time (295.9 (SD 61.47) ng.day/mL; 2.95 (SD 0.74) days and 4.69 (SD 1.01) days, respectively) compared with topical administration (168.2 (SD15.67) ng.day/mL; 4.63 (SD 0.32) days, and 8.23 (SD 0.57) days, respectively) (p<0.01).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),[d·ng] / [ml],168.2,183546,DB01109,Heparin
,26820168,mean residence time,"In addition, S/C administration resulted in greater plasma availability (area under the curve; AUC), and a shorter terminal half-life and mean residence time (295.9 (SD 61.47) ng.day/mL; 2.95 (SD 0.74) days and 4.69 (SD 1.01) days, respectively) compared with topical administration (168.2 (SD15.67) ng.day/mL; 4.63 (SD 0.32) days, and 8.23 (SD 0.57) days, respectively) (p<0.01).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),d,4.63,183547,DB01109,Heparin
,26820168,mean residence time,"In addition, S/C administration resulted in greater plasma availability (area under the curve; AUC), and a shorter terminal half-life and mean residence time (295.9 (SD 61.47) ng.day/mL; 2.95 (SD 0.74) days and 4.69 (SD 1.01) days, respectively) compared with topical administration (168.2 (SD15.67) ng.day/mL; 4.63 (SD 0.32) days, and 8.23 (SD 0.57) days, respectively) (p<0.01).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),d,8.23,183548,DB01109,Heparin
,26820168,AUC,"Subcutaneous administration resulted in greater faecal excretion than topical administration, expressed as AUC adjusted for dose (1188.9 (SD 491.64) vs. 311.5 (SD 46.90) ng.day/g; p<0.05).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),[d·ng] / [g],1188.9,183549,DB01109,Heparin
,26820168,AUC,"Subcutaneous administration resulted in greater faecal excretion than topical administration, expressed as AUC adjusted for dose (1188.9 (SD 491.64) vs. 311.5 (SD 46.90) ng.day/g; p<0.05).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),[d·ng] / [g],311.5,183550,DB01109,Heparin
,26820168,Maximum concentration,Maximum concentration in faeces was also higher following S/C than topical administration (223.0 (SD 63.96) vs. 99.47 (SD 43.24) ng/g; p<0.01).,Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),[ng] / [g],223.0,183551,DB01109,Heparin
,26820168,Maximum concentration,Maximum concentration in faeces was also higher following S/C than topical administration (223.0 (SD 63.96) vs. 99.47 (SD 43.24) ng/g; p<0.01).,Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),[ng] / [g],99.47,183552,DB01109,Heparin
,28962537,anti,"A median of 3 (IQR = 1-5) anti-factor Xa levels were sampled at 4.4 ± 1.3 hours after a dose, with a mean anti-factor Xa level of 0.52 ± 0.23 U/mL.",Population Pharmacokinetics of Enoxaparin in Pediatric Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28962537/),u,0.52,183740,DB01109,Heparin
,27378205,AUC,"Pharmacokinetic parameters were also determined in blood after IV administration of HEP NPs: AUC, Cmax, MRT, and Tmax values are 6096.075 ± 5.90 μg h/mL, 144.38 ± 1.52 μg/L, 58.71 ± 0.25 h, 96 ± 0.50 h, respectively and 117.92 ± 1.78, 45.35 ± 3.00, 1.2 ± 0.25, 0.5 ± 0.02 in plain 5-FU solution.",Heparin-appended polycaprolactone core/corona nanoparticles for site specific delivery of 5-fluorouracil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27378205/),[h·μg] / [ml],6096.075,183753,DB01109,Heparin
,27378205,Cmax,"Pharmacokinetic parameters were also determined in blood after IV administration of HEP NPs: AUC, Cmax, MRT, and Tmax values are 6096.075 ± 5.90 μg h/mL, 144.38 ± 1.52 μg/L, 58.71 ± 0.25 h, 96 ± 0.50 h, respectively and 117.92 ± 1.78, 45.35 ± 3.00, 1.2 ± 0.25, 0.5 ± 0.02 in plain 5-FU solution.",Heparin-appended polycaprolactone core/corona nanoparticles for site specific delivery of 5-fluorouracil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27378205/),[μg] / [l],144.38,183754,DB01109,Heparin
,27378205,Cmax,"Pharmacokinetic parameters were also determined in blood after IV administration of HEP NPs: AUC, Cmax, MRT, and Tmax values are 6096.075 ± 5.90 μg h/mL, 144.38 ± 1.52 μg/L, 58.71 ± 0.25 h, 96 ± 0.50 h, respectively and 117.92 ± 1.78, 45.35 ± 3.00, 1.2 ± 0.25, 0.5 ± 0.02 in plain 5-FU solution.",Heparin-appended polycaprolactone core/corona nanoparticles for site specific delivery of 5-fluorouracil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27378205/),h,58.71,183755,DB01109,Heparin
,27378205,MRT,"Pharmacokinetic parameters were also determined in blood after IV administration of HEP NPs: AUC, Cmax, MRT, and Tmax values are 6096.075 ± 5.90 μg h/mL, 144.38 ± 1.52 μg/L, 58.71 ± 0.25 h, 96 ± 0.50 h, respectively and 117.92 ± 1.78, 45.35 ± 3.00, 1.2 ± 0.25, 0.5 ± 0.02 in plain 5-FU solution.",Heparin-appended polycaprolactone core/corona nanoparticles for site specific delivery of 5-fluorouracil. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27378205/),[μg] / [l],144.38,183756,DB01109,Heparin
,27378205,MRT,"Pharmacokinetic parameters were also determined in blood after IV administration of HEP NPs: AUC, Cmax, MRT, and Tmax values are 6096.075 ± 5.90 μg h/mL, 144.38 ± 1.52 μg/L, 58.71 ± 0.25 h, 96 ± 0.50 h, respectively and 117.92 ± 1.78, 45.35 ± 3.00, 1.2 ± 0.25, 0.5 ± 0.02 in plain 5-FU solution.",Heparin-appended polycaprolactone core/corona nanoparticles for site specific delivery of 5-fluorouracil. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27378205/),h,58.71,183757,DB01109,Heparin
,27378205,Tmax,"Pharmacokinetic parameters were also determined in blood after IV administration of HEP NPs: AUC, Cmax, MRT, and Tmax values are 6096.075 ± 5.90 μg h/mL, 144.38 ± 1.52 μg/L, 58.71 ± 0.25 h, 96 ± 0.50 h, respectively and 117.92 ± 1.78, 45.35 ± 3.00, 1.2 ± 0.25, 0.5 ± 0.02 in plain 5-FU solution.",Heparin-appended polycaprolactone core/corona nanoparticles for site specific delivery of 5-fluorouracil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27378205/),h,96,183758,DB01109,Heparin
,2379386,clearance,Heparin clearance was 1.6 +/- 0.5 ml/kg/min in the patient and 2.1 +/- 0.8 ml/kg/min in the separated circuit.,Inactivation of heparin during extracorporeal circulation in infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379386/),[ml] / [kg·min],1.6,184823,DB01109,Heparin
,2379386,clearance,Heparin clearance was 1.6 +/- 0.5 ml/kg/min in the patient and 2.1 +/- 0.8 ml/kg/min in the separated circuit.,Inactivation of heparin during extracorporeal circulation in infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379386/),[ml] / [kg·min],2.1,184824,DB01109,Heparin
,2379386,clearances,"In each patient, the total of heparin clearances in the patient and circuit, 3.7 +/- 1.0 ml/kg/min, was virtually identical with the heparin clearance during the procedure, 3.8 +/- 1.9 ml/kg/min (r = 0.94, p less than 0.01).",Inactivation of heparin during extracorporeal circulation in infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379386/),[ml] / [kg·min],3.7,184825,DB01109,Heparin
,2379386,clearance,"In each patient, the total of heparin clearances in the patient and circuit, 3.7 +/- 1.0 ml/kg/min, was virtually identical with the heparin clearance during the procedure, 3.8 +/- 1.9 ml/kg/min (r = 0.94, p less than 0.01).",Inactivation of heparin during extracorporeal circulation in infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379386/),[ml] / [kg·min],3.8,184826,DB01109,Heparin
,20663996,Clearance (CL),"Clearance (CL) and distribution volumes (V1 and V2) were 21 L/h, 9.2 L, and 6.6 L, respectively.",Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of coagulation parameters. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20663996/),[l] / [h],21,186032,DB01109,Heparin
,20663996,V1,"Clearance (CL) and distribution volumes (V1 and V2) were 21 L/h, 9.2 L, and 6.6 L, respectively.",Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of coagulation parameters. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20663996/),l,9.2,186033,DB01109,Heparin
,20663996,V2,"Clearance (CL) and distribution volumes (V1 and V2) were 21 L/h, 9.2 L, and 6.6 L, respectively.",Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of coagulation parameters. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20663996/),l,6.6,186034,DB01109,Heparin
,3164149,t1/2,"The t1/2 values were 30, 35, and 50 min for the 23,000, 13,300, and 5,100 MW fractions, respectively.",Pharmacokinetics of heparins differing in mean molecular weight using a Xa amidolytic and Heptest clotting method. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3164149/),min,30,186319,DB01109,Heparin
,3164149,t1/2,"The t1/2 values were 30, 35, and 50 min for the 23,000, 13,300, and 5,100 MW fractions, respectively.",Pharmacokinetics of heparins differing in mean molecular weight using a Xa amidolytic and Heptest clotting method. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3164149/),min,35,186320,DB01109,Heparin
,3164149,t1/2,"The t1/2 values were 30, 35, and 50 min for the 23,000, 13,300, and 5,100 MW fractions, respectively.",Pharmacokinetics of heparins differing in mean molecular weight using a Xa amidolytic and Heptest clotting method. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3164149/),min,50,186321,DB01109,Heparin
,3164149,t1/2,"The t1/2 values were 30, 35, and 50 min for the 23,000, 13,300, and 5,100 MW fractions, respectively.",Pharmacokinetics of heparins differing in mean molecular weight using a Xa amidolytic and Heptest clotting method. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3164149/),,"13,",186322,DB01109,Heparin
,7254945,half life (T1/2),"In comparison with the adult data (mean adult plasma heparin half life (T1/2) = 63.3 min), the newborn infants demonstrated a significantly shorter plasma heparin half life (T1/2 = 35.5 min in group I, 33 to 36 wk gestation; 35.5 min in group II, 29 to 32 wk gestation; and 41.6 min in group III, 25 to 28 wk gestation), as demonstrated by a chromogenic heparin assay.",Heparin clearance in the newborn. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7254945/),min,63.3,186704,DB01109,Heparin
,7254945,half life (T1/2,"In comparison with the adult data (mean adult plasma heparin half life (T1/2) = 63.3 min), the newborn infants demonstrated a significantly shorter plasma heparin half life (T1/2 = 35.5 min in group I, 33 to 36 wk gestation; 35.5 min in group II, 29 to 32 wk gestation; and 41.6 min in group III, 25 to 28 wk gestation), as demonstrated by a chromogenic heparin assay.",Heparin clearance in the newborn. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7254945/),min,35.5,186705,DB01109,Heparin
,7254945,half life (T1/2,"In comparison with the adult data (mean adult plasma heparin half life (T1/2) = 63.3 min), the newborn infants demonstrated a significantly shorter plasma heparin half life (T1/2 = 35.5 min in group I, 33 to 36 wk gestation; 35.5 min in group II, 29 to 32 wk gestation; and 41.6 min in group III, 25 to 28 wk gestation), as demonstrated by a chromogenic heparin assay.",Heparin clearance in the newborn. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7254945/),min,41.6,186706,DB01109,Heparin
,7254945,Vd,"The newborn groups, had a larger volume of distribution (Vd) of heparin which varied inversely with gestational age (Vd =36.6 ml/kg in the adults, 57.8 ml/kg in group I, 73.3 ml/kg in group II, and 81.0 ml/kg in group III babies.",Heparin clearance in the newborn. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7254945/),[ml] / [kg],36.6,186707,DB01109,Heparin
,7254945,Vd,"The newborn groups, had a larger volume of distribution (Vd) of heparin which varied inversely with gestational age (Vd =36.6 ml/kg in the adults, 57.8 ml/kg in group I, 73.3 ml/kg in group II, and 81.0 ml/kg in group III babies.",Heparin clearance in the newborn. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7254945/),[ml] / [kg],57.8,186708,DB01109,Heparin
,7254945,Vd,"The newborn groups, had a larger volume of distribution (Vd) of heparin which varied inversely with gestational age (Vd =36.6 ml/kg in the adults, 57.8 ml/kg in group I, 73.3 ml/kg in group II, and 81.0 ml/kg in group III babies.",Heparin clearance in the newborn. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7254945/),[ml] / [kg],73.3,186709,DB01109,Heparin
,7254945,Vd,"The newborn groups, had a larger volume of distribution (Vd) of heparin which varied inversely with gestational age (Vd =36.6 ml/kg in the adults, 57.8 ml/kg in group I, 73.3 ml/kg in group II, and 81.0 ml/kg in group III babies.",Heparin clearance in the newborn. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7254945/),[ml] / [kg],81.0,186710,DB01109,Heparin
,7254945,CIadult,Heparin clearance (CI) was significantly greater in all newborn groups when compared with the adult (CIadult = 0.43 ml/kg/min; ClGrIII = 1.49 ml/kg/min).,Heparin clearance in the newborn. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7254945/),[ml] / [kg·min],0.43,186711,DB01109,Heparin
,7254945,ClGrIII,Heparin clearance (CI) was significantly greater in all newborn groups when compared with the adult (CIadult = 0.43 ml/kg/min; ClGrIII = 1.49 ml/kg/min).,Heparin clearance in the newborn. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7254945/),[ml] / [kg·min],1.49,186712,DB01109,Heparin
,31116389,peak aFXa levels,"Primary outcome: in-range peak aFXa levels (goal range, 0.3-0.5 IU/mL) with enoxaparin, 40 mg per day.",Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31116389/),[iu] / [ml],0.3-0.5,187182,DB01109,Heparin
,31116389,trough aFXa,"Secondary outcomes: (1) in-range trough aFXa levels (goal range, 0.1-0.2 IU/mL) and (2) the proportion of patients with in-range peak aFXa levels from enoxaparin, 40 mg once daily, vs the real-time enoxaparin dose adjustment protocol.",Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31116389/),[iu] / [ml],0.1-0.2,187183,DB01109,Heparin
<,31116389,aFXa,"Among 106 patients (91.4%) whose peak aFXa level was appropriately drawn, 72 (67.9%) received inadequate anticoagulation (aFXa < 0.3 IU/mL) with enoxaparin, 40 mg per day.",Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31116389/),[iu] / [ml],0.3,187184,DB01109,Heparin
,9449562,detection limits,The detection limits were 10 ng/ml for roc and 50 ng/ml for 17OH-roc.,Quantification of the neuromuscular blocking agent rocuronium and its putative metabolite 17-desacetylrocuronium in heparinized plasma by capillary gas chromatography using a nitrogen sensitive detector. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449562/),[ng] / [ml],10,188474,DB01109,Heparin
,9449562,detection limits,The detection limits were 10 ng/ml for roc and 50 ng/ml for 17OH-roc.,Quantification of the neuromuscular blocking agent rocuronium and its putative metabolite 17-desacetylrocuronium in heparinized plasma by capillary gas chromatography using a nitrogen sensitive detector. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449562/),[ng] / [ml],50,188475,DB01109,Heparin
,19929210,relative bioavailabilities,"Enoxaparin pellets showed fast in vitro release in phosphate buffer (pH 7.4) and prolonged in vivo drug absorption after a single oral dose of 600 anti-Xa IU/ kg of body weight, leading to relative bioavailabilities ranging from 9.7 +/- 1.9% to 12.8 +/- 2.7% and anti-Xa activity over the curative dose.",Pellets for oral administration of low-molecular-weight heparin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19929210/),%,9.7,189138,DB01109,Heparin
,19929210,relative bioavailabilities,"Enoxaparin pellets showed fast in vitro release in phosphate buffer (pH 7.4) and prolonged in vivo drug absorption after a single oral dose of 600 anti-Xa IU/ kg of body weight, leading to relative bioavailabilities ranging from 9.7 +/- 1.9% to 12.8 +/- 2.7% and anti-Xa activity over the curative dose.",Pellets for oral administration of low-molecular-weight heparin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19929210/),%,12.8,189139,DB01109,Heparin
,2741797,effective refractory period,"Following heparin administration during electrophysiologic testing in 10 patients receiving quinidine, there were significant increases in the mean (+/- SD) right ventricular effective refractory period (266 +/- 24 versus 279 +/- 23; p less than 0.025), free fatty acid concentration (515 +/- 213 versus 1071 +/- 359 mmol/L; p less than 0.001), and unbound quinidine concentration (0.3 +/- 0.1 to 0.6 +/- 0.1 microgram/ml; p less than 0.001) but no changes in heart rate, corrected QT interval, or total plasma quinidine concentration.",The clinical implication of changing unbound quinidine levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741797/),,266,189266,DB01109,Heparin
,2741797,effective refractory period,"Following heparin administration during electrophysiologic testing in 10 patients receiving quinidine, there were significant increases in the mean (+/- SD) right ventricular effective refractory period (266 +/- 24 versus 279 +/- 23; p less than 0.025), free fatty acid concentration (515 +/- 213 versus 1071 +/- 359 mmol/L; p less than 0.001), and unbound quinidine concentration (0.3 +/- 0.1 to 0.6 +/- 0.1 microgram/ml; p less than 0.001) but no changes in heart rate, corrected QT interval, or total plasma quinidine concentration.",The clinical implication of changing unbound quinidine levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741797/),,279,189267,DB01109,Heparin
,2741797,free fatty acid concentration,"Following heparin administration during electrophysiologic testing in 10 patients receiving quinidine, there were significant increases in the mean (+/- SD) right ventricular effective refractory period (266 +/- 24 versus 279 +/- 23; p less than 0.025), free fatty acid concentration (515 +/- 213 versus 1071 +/- 359 mmol/L; p less than 0.001), and unbound quinidine concentration (0.3 +/- 0.1 to 0.6 +/- 0.1 microgram/ml; p less than 0.001) but no changes in heart rate, corrected QT interval, or total plasma quinidine concentration.",The clinical implication of changing unbound quinidine levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741797/),[mM] / [l],515,189268,DB01109,Heparin
,2741797,free fatty acid concentration,"Following heparin administration during electrophysiologic testing in 10 patients receiving quinidine, there were significant increases in the mean (+/- SD) right ventricular effective refractory period (266 +/- 24 versus 279 +/- 23; p less than 0.025), free fatty acid concentration (515 +/- 213 versus 1071 +/- 359 mmol/L; p less than 0.001), and unbound quinidine concentration (0.3 +/- 0.1 to 0.6 +/- 0.1 microgram/ml; p less than 0.001) but no changes in heart rate, corrected QT interval, or total plasma quinidine concentration.",The clinical implication of changing unbound quinidine levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741797/),[mM] / [l],1071,189269,DB01109,Heparin
,2741797,unbound quinidine concentration,"Following heparin administration during electrophysiologic testing in 10 patients receiving quinidine, there were significant increases in the mean (+/- SD) right ventricular effective refractory period (266 +/- 24 versus 279 +/- 23; p less than 0.025), free fatty acid concentration (515 +/- 213 versus 1071 +/- 359 mmol/L; p less than 0.001), and unbound quinidine concentration (0.3 +/- 0.1 to 0.6 +/- 0.1 microgram/ml; p less than 0.001) but no changes in heart rate, corrected QT interval, or total plasma quinidine concentration.",The clinical implication of changing unbound quinidine levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741797/),[μg] / [ml],0.3,189270,DB01109,Heparin
,2741797,unbound quinidine concentration,"Following heparin administration during electrophysiologic testing in 10 patients receiving quinidine, there were significant increases in the mean (+/- SD) right ventricular effective refractory period (266 +/- 24 versus 279 +/- 23; p less than 0.025), free fatty acid concentration (515 +/- 213 versus 1071 +/- 359 mmol/L; p less than 0.001), and unbound quinidine concentration (0.3 +/- 0.1 to 0.6 +/- 0.1 microgram/ml; p less than 0.001) but no changes in heart rate, corrected QT interval, or total plasma quinidine concentration.",The clinical implication of changing unbound quinidine levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741797/),[μg] / [ml],0.,189271,DB01109,Heparin
,2741797,half-life,"Eleven patients studied on day 3 (+/- 1) and day 10 (+/- 3) during an acute myocardial infarction showed a significant decrease in unbound quinidine fraction (12 +/- 4% versus 9 +/- 4%; p less than 0.02) accompanied by a decrease, rather than the predicted increase, in half-life (7.1 +/- 2.7 versus 6.3 +/- 2.1 hours; p less than 0.02).",The clinical implication of changing unbound quinidine levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741797/),h,7.1,189272,DB01109,Heparin
,2741797,half-life,"Eleven patients studied on day 3 (+/- 1) and day 10 (+/- 3) during an acute myocardial infarction showed a significant decrease in unbound quinidine fraction (12 +/- 4% versus 9 +/- 4%; p less than 0.02) accompanied by a decrease, rather than the predicted increase, in half-life (7.1 +/- 2.7 versus 6.3 +/- 2.1 hours; p less than 0.02).",The clinical implication of changing unbound quinidine levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741797/),h,6.3,189273,DB01109,Heparin
,1501359,V-H,"To facilitate therapy of central venous catheter-related Gram-positive bacterial infection in patients who require total parenteral nutrition (TPN) therapy, we studied the stability of vancomycin in a commonly used TPN solution (V-TPN) at final concentrations of 0.5 mg/mL and 1.0 mg/mL and in heparin (100 U/mL in 0.9% NaCl) at 25 micrograms/mL (V-H).",Vancomycin stability in heparin and total parenteral nutrition solutions: novel approach to therapy of central venous catheter-related infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501359/),,25,189516,DB01109,Heparin
,34288257,MTD,The MTD was 10 g daily.,"First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34288257/),g,10,189930,DB01109,Heparin
,12817900,absolute bioavailability,For tablets being based on the thiomer/GSH system an absolute bioavailability of 19.9 +/- 9.3% (means +/- SD; n = 5) vs. intravenous injection could be achieved.,Development and in vivo evaluation of an oral delivery system for low molecular weight heparin based on thiolated polycarbophil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12817900/),%,19.9,194455,DB01109,Heparin
,7919374,antifactor Xa/antithrombin ratio,"They were devoid of antithrombin activity, whereas the antifactor Xa/antithrombin ratio of CY216 was 3.8.",Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7919374/),,3.8,195197,DB01109,Heparin
,7919374,clearance,"After bolus intravenous administration, the clearance (mL/kg/h) of CY216 decreased from 91 +/- 27 for the dose of 12.5 U/kg to 49 +/- 14 for the dose of 50 U/kg and then remained constant up to the highest dose tested (500 U/kg).",Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7919374/),[ml] / [h·kg],91,195198,DB01109,Heparin
,7919374,clearance,"After bolus intravenous administration, the clearance (mL/kg/h) of CY216 decreased from 91 +/- 27 for the dose of 12.5 U/kg to 49 +/- 14 for the dose of 50 U/kg and then remained constant up to the highest dose tested (500 U/kg).",Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7919374/),[ml] / [h·kg],49,195199,DB01109,Heparin
,7919374,plasma activities,"Two hours after the injection, the three compounds provided a thrombus prevention of greater than 95% and mean plasma activities of 0.8, 0.9, and 1.9 U/mL for CY216, NPS, and SPS, respectively.",Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7919374/),[u] / [ml],0.8,195200,DB01109,Heparin
,7919374,plasma activities,"Two hours after the injection, the three compounds provided a thrombus prevention of greater than 95% and mean plasma activities of 0.8, 0.9, and 1.9 U/mL for CY216, NPS, and SPS, respectively.",Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7919374/),[u] / [ml],0.9,195201,DB01109,Heparin
,7919374,plasma activities,"Two hours after the injection, the three compounds provided a thrombus prevention of greater than 95% and mean plasma activities of 0.8, 0.9, and 1.9 U/mL for CY216, NPS, and SPS, respectively.",Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7919374/),[u] / [ml],1.9,195202,DB01109,Heparin
less,7919374,plasma anti-Xa activities,"At that time, the plasma anti-Xa activities were less than 0.06 U/mL for CY216 and NPS, but 1.1 U/mL for SPS.",Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7919374/),[u] / [ml],0.06,195203,DB01109,Heparin
,7919374,plasma anti-Xa activities,"At that time, the plasma anti-Xa activities were less than 0.06 U/mL for CY216 and NPS, but 1.1 U/mL for SPS.",Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7919374/),[u] / [ml],1.1,195204,DB01109,Heparin
,7919374,maximum inhibitory effect,"The lowest total doses providing the maximum inhibitory effect were 3,125, 1,428, and 62 micrograms/kg for CY216, NPS, and SPS, respectively.",Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7919374/),,1,195205,DB01109,Heparin
,7919374,maximum inhibitory effect,"The lowest total doses providing the maximum inhibitory effect were 3,125, 1,428, and 62 micrograms/kg for CY216, NPS, and SPS, respectively.",Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7919374/),,428,195206,DB01109,Heparin
,7919374,maximum inhibitory effect,"The lowest total doses providing the maximum inhibitory effect were 3,125, 1,428, and 62 micrograms/kg for CY216, NPS, and SPS, respectively.",Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7919374/),,62,195207,DB01109,Heparin
,7919374,steady state antifactor Xa activities,"These doses generated mean steady state antifactor Xa activities of 1.06, 1.5, and 1.2 anti-Xa U/mL, respectively.",Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7919374/),anti,1.06,195208,DB01109,Heparin
,7919374,steady state antifactor Xa activities,"These doses generated mean steady state antifactor Xa activities of 1.06, 1.5, and 1.2 anti-Xa U/mL, respectively.",Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7919374/),anti,1.5,195209,DB01109,Heparin
,7919374,steady state antifactor Xa activities,"These doses generated mean steady state antifactor Xa activities of 1.06, 1.5, and 1.2 anti-Xa U/mL, respectively.",Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7919374/),anti,1.2,195210,DB01109,Heparin
,24704454,extraction recoveries,The extraction recoveries ranged from 80.7% to 86.7%.,Development of a sensitive LC-MS/MS method for the determination of bilobalide in rat plasma with special consideration of ex vivo bilobalide stability: application to a preclinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24704454/),%,80.7,195305,DB01109,Heparin
,24704454,extraction recoveries,The extraction recoveries ranged from 80.7% to 86.7%.,Development of a sensitive LC-MS/MS method for the determination of bilobalide in rat plasma with special consideration of ex vivo bilobalide stability: application to a preclinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24704454/),%,86.7,195306,DB01109,Heparin
,12221700,Distribution volume,"Distribution volume was 51.81 mL, clearance was about 2 mL/min, and half-life was 94 min, giving a total elimination time of 11 h.","Pharmacological studies of RGTA(11), a heparan sulfate mimetic polymer, efficient on muscle regeneration. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12221700/),ml,51.81,195386,DB01109,Heparin
,12221700,clearance,"Distribution volume was 51.81 mL, clearance was about 2 mL/min, and half-life was 94 min, giving a total elimination time of 11 h.","Pharmacological studies of RGTA(11), a heparan sulfate mimetic polymer, efficient on muscle regeneration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12221700/),[ml] / [min],2,195387,DB01109,Heparin
,12221700,half-life,"Distribution volume was 51.81 mL, clearance was about 2 mL/min, and half-life was 94 min, giving a total elimination time of 11 h.","Pharmacological studies of RGTA(11), a heparan sulfate mimetic polymer, efficient on muscle regeneration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12221700/),min,94,195388,DB01109,Heparin
,12221700,total elimination time,"Distribution volume was 51.81 mL, clearance was about 2 mL/min, and half-life was 94 min, giving a total elimination time of 11 h.","Pharmacological studies of RGTA(11), a heparan sulfate mimetic polymer, efficient on muscle regeneration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12221700/),h,11,195389,DB01109,Heparin
,1905070,c,"Deletion of the finger and growth factor domains in rt-PA (rt-PA-delta FE) was not associated with marked alteration of the thrombolytic potency (c = 90 +/- 30%, b = 0.34 +/- 0.35 mg/kg, and z = 54 +/- 14% per mg/kg), but was associated with a significant reduction of the specific thrombolytic activity.","Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905070/),%,90,195494,DB01109,Heparin
,1905070,b,"Deletion of the finger and growth factor domains in rt-PA (rt-PA-delta FE) was not associated with marked alteration of the thrombolytic potency (c = 90 +/- 30%, b = 0.34 +/- 0.35 mg/kg, and z = 54 +/- 14% per mg/kg), but was associated with a significant reduction of the specific thrombolytic activity.","Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905070/),[mg] / [kg],0.34,195495,DB01109,Heparin
,1905070,z,"Deletion of the finger and growth factor domains in rt-PA (rt-PA-delta FE) was not associated with marked alteration of the thrombolytic potency (c = 90 +/- 30%, b = 0.34 +/- 0.35 mg/kg, and z = 54 +/- 14% per mg/kg), but was associated with a significant reduction of the specific thrombolytic activity.","Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905070/),[%] / [kg·mg],54,195496,DB01109,Heparin
,16875889,limit of detection,"The limit of detection was 0.01microg/mL, which was more than 40-fold lower than that of conventional plasma protein precipitation using ammonium sulfate.",A simple and rapid determination of biapenem in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16875889/),[μg] / [ml],0.01,195825,DB01109,Heparin
,7706485,initial plasma half-life,The initial plasma half-life of 125I-TFPI was approximately 30 s whereas the half-life of 125I-TFPI-160 was approximately 4 min.,The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7706485/),s,30,195914,DB01109,Heparin
,7706485,half-life,The initial plasma half-life of 125I-TFPI was approximately 30 s whereas the half-life of 125I-TFPI-160 was approximately 4 min.,The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7706485/),min,4,195915,DB01109,Heparin
,9816254,response rates,"Paclitaxel has clinical activity in non-small cell lung cancer, with response rates of 21 and 24% in a 24-h infusion.",Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816254/),%,21,195947,DB01109,Heparin
,9816254,response rates,"Paclitaxel has clinical activity in non-small cell lung cancer, with response rates of 21 and 24% in a 24-h infusion.",Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816254/),%,24,195948,DB01109,Heparin
,11304721,T(max),"Significant treatment differences seen for naproxen T(max) (0.3 h, males only) and diphenhydramine t(1/2,z) (0.8 h, females only) were minor and are unlikely to have therapeutic consequences.",Absence of pharmacokinetic interaction between orally co-administered naproxen sodium and diphenhydramine hydrochloride. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304721/),h,0.3,196206,DB01109,Heparin
,11304721,"t(1/2,z)","Significant treatment differences seen for naproxen T(max) (0.3 h, males only) and diphenhydramine t(1/2,z) (0.8 h, females only) were minor and are unlikely to have therapeutic consequences.",Absence of pharmacokinetic interaction between orally co-administered naproxen sodium and diphenhydramine hydrochloride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304721/),h,0.8,196207,DB01109,Heparin
,24522199,CL/F,The CL/F value in a male patient with the ABCB1 3435CC or CT genotype is 28.8 L/h.,ABCB1 polymorphism and gender affect the pharmacokinetics of amlodipine in Chinese patients with essential hypertension: a population analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24522199/),[l] / [h],28.8,196487,DB01109,Heparin
,20586920,clearance,"Body weight proved to be the most predictive covariate for clearance and central volume of distribution: clearance 15 mL h⁻¹ kg⁻¹, central volume of distribution 169 mL kg⁻¹, intercompartmental clearance 58 mL h⁻¹, peripheral volume of distribution 10 L and absorption rate 0.414 h⁻¹.","Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20586920/),h⁻¹·kg⁻¹·ml,15,196788,DB01109,Heparin
,20586920,central volume of distribution,"Body weight proved to be the most predictive covariate for clearance and central volume of distribution: clearance 15 mL h⁻¹ kg⁻¹, central volume of distribution 169 mL kg⁻¹, intercompartmental clearance 58 mL h⁻¹, peripheral volume of distribution 10 L and absorption rate 0.414 h⁻¹.","Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20586920/),kg⁻¹·ml,169,196789,DB01109,Heparin
,20586920,intercompartmental clearance,"Body weight proved to be the most predictive covariate for clearance and central volume of distribution: clearance 15 mL h⁻¹ kg⁻¹, central volume of distribution 169 mL kg⁻¹, intercompartmental clearance 58 mL h⁻¹, peripheral volume of distribution 10 L and absorption rate 0.414 h⁻¹.","Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20586920/),h⁻¹·ml,58,196790,DB01109,Heparin
,20586920,peripheral volume of distribution,"Body weight proved to be the most predictive covariate for clearance and central volume of distribution: clearance 15 mL h⁻¹ kg⁻¹, central volume of distribution 169 mL kg⁻¹, intercompartmental clearance 58 mL h⁻¹, peripheral volume of distribution 10 L and absorption rate 0.414 h⁻¹.","Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20586920/),l,10,196791,DB01109,Heparin
,20586920,absorption rate,"Body weight proved to be the most predictive covariate for clearance and central volume of distribution: clearance 15 mL h⁻¹ kg⁻¹, central volume of distribution 169 mL kg⁻¹, intercompartmental clearance 58 mL h⁻¹, peripheral volume of distribution 10 L and absorption rate 0.414 h⁻¹.","Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20586920/),h⁻¹,0.414,196792,DB01109,Heparin
above,20586920,24 h,In 53.2% of the patients the median 24 h trough level was above the desired range of 0.1 IU mL⁻¹ anti-FXa activity for prophylaxis therapy.,"Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20586920/),iu·ml⁻¹,0.1,196793,DB01109,Heparin
above,20586920,trough level,In 53.2% of the patients the median 24 h trough level was above the desired range of 0.1 IU mL⁻¹ anti-FXa activity for prophylaxis therapy.,"Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20586920/),iu·ml⁻¹,0.1,196794,DB01109,Heparin
,26245359,flow rate,"Chromatographic separation used an Acquity UPLC BEH C18 column (2.1mm×50mm, 1.7μm) and acetonitrile-0.1% formic acid (20:80, v/v) as mobile phase, at a flow rate of 0.25mL/min.",An LC-MS/MS method for simultaneous determination of trantinterol and its major metabolite in rat plasma and its application to a comparative pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26245359/),[ml] / [min],0.25,197500,DB01109,Heparin
,2022012,elimination half-life,Steady-state plasma concentrations were achieved at 1 hour and declined exponentially with an elimination half-life of 24 +/- 4 minutes.,Combined administration of aspirin and a specific thrombin inhibitor in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2022012/),min,24,199765,DB01109,Heparin
,8045504,equilibrium dissociation constant,"Because hepatocyte growth factor is known to have affinity for heparin, we studied the binding isotherm and found that hepatocyte growth factor has a high-affinity binding site for 35S-heparin with an equilibrium dissociation constant of approximately 0.6 nmol/L.",Heparin-hepatocyte growth factor complex with low plasma clearance and retained hepatocyte proliferating activity. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8045504/),[nM] / [l],0.6,200069,DB01109,Heparin
,15487653,half-life,Zinc levels in the plasma declined in a steady fashion (half-life = 7.6 d).,Diagnosis and treatment of zinc poisoning in a dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15487653/),d,7.6,201996,DB01109,Heparin
,12904065,K(i),"We conducted optimization of a highly efficacious benzamidine-based thrombin inhibitor LB30812 (3, K(i) = 3 pM) to improve oral bioavailability.","Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12904065/),pM,3,202105,DB01109,Heparin
,12904065,K(i),"The present work culminated in the discovery of the N-carboxymethyl- and 2,5-thienylamidine-containing compound 22 that exhibits the most favorable profiles of anticoagulant and antithrombotic activities as well as oral bioavilability (K(i) = 15 pM; F = 43%, 42%, and 15% in rats, dogs, and monkeys, respectively).","Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12904065/),pM,15,202106,DB01109,Heparin
,12904065,F,"The present work culminated in the discovery of the N-carboxymethyl- and 2,5-thienylamidine-containing compound 22 that exhibits the most favorable profiles of anticoagulant and antithrombotic activities as well as oral bioavilability (K(i) = 15 pM; F = 43%, 42%, and 15% in rats, dogs, and monkeys, respectively).","Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12904065/),%,43,202107,DB01109,Heparin
,12904065,F,"The present work culminated in the discovery of the N-carboxymethyl- and 2,5-thienylamidine-containing compound 22 that exhibits the most favorable profiles of anticoagulant and antithrombotic activities as well as oral bioavilability (K(i) = 15 pM; F = 43%, 42%, and 15% in rats, dogs, and monkeys, respectively).","Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12904065/),%,42,202108,DB01109,Heparin
,12904065,F,"The present work culminated in the discovery of the N-carboxymethyl- and 2,5-thienylamidine-containing compound 22 that exhibits the most favorable profiles of anticoagulant and antithrombotic activities as well as oral bioavilability (K(i) = 15 pM; F = 43%, 42%, and 15% in rats, dogs, and monkeys, respectively).","Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12904065/),%,15,202109,DB01109,Heparin
,12416871,maximum plasma concentration,The maximum plasma concentration of enrofloxacin and the time to reach that maximum were 2.91 +/- 0.39 microg/ml and 2.9 +/- 0.51 h. respectively.,Pharmacokinetic disposition of subcutaneously administered enrofloxacin in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12416871/),[μg] / [ml],2.91,202159,DB01109,Heparin
,12416871,time to reach that maximum,The maximum plasma concentration of enrofloxacin and the time to reach that maximum were 2.91 +/- 0.39 microg/ml and 2.9 +/- 0.51 h. respectively.,Pharmacokinetic disposition of subcutaneously administered enrofloxacin in goats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12416871/),h,2.9,202160,DB01109,Heparin
,12416871,elimination half-life,"The elimination half-life and mean residence time of enrofloxacin were 2.84 +/- 0.57 and 5.74 +/- 0.28 h, respectively.",Pharmacokinetic disposition of subcutaneously administered enrofloxacin in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12416871/),h,2.84,202161,DB01109,Heparin
,12416871,mean residence time,"The elimination half-life and mean residence time of enrofloxacin were 2.84 +/- 0.57 and 5.74 +/- 0.28 h, respectively.",Pharmacokinetic disposition of subcutaneously administered enrofloxacin in goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12416871/),h,5.74,202162,DB01109,Heparin
,27693677,droplet size,"The average droplet size of chosen LC-SEDDS, MC-SEDDS and NL-SEDDS ranged between 30 and 40nm.","Development, in vitro and in vivo evaluation of a self-emulsifying drug delivery system (SEDDS) for oral enoxaparin administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27693677/),nm,30 and 40,202337,DB01109,Heparin
,27693677,bioavailability,"Furthermore, orally administrated MC-SEDDS and NL-SEDDS yielded an absolute enoxaparin bioavailability of 2.02% and 2.25%, respectively.","Development, in vitro and in vivo evaluation of a self-emulsifying drug delivery system (SEDDS) for oral enoxaparin administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27693677/),%,2.02,202338,DB01109,Heparin
,27693677,bioavailability,"Furthermore, orally administrated MC-SEDDS and NL-SEDDS yielded an absolute enoxaparin bioavailability of 2.02% and 2.25%, respectively.","Development, in vitro and in vivo evaluation of a self-emulsifying drug delivery system (SEDDS) for oral enoxaparin administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27693677/),%,2.25,202339,DB01109,Heparin
,26790731,Peak plasma concentrations,"Peak plasma concentrations were within a range between 13.8 and 90ng/ml, which guarantee milk drug concentrations below the maximum residues level.",Eprinomectin accumulation in Rhipicephalus (Boophilus) microplus: Pharmacokinetic and efficacy assessment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26790731/),[ng] / [ml],13.8 and 90,202342,DB01109,Heparin
,15925422,coupling ratios,"The coupling ratios of DOCA to LMWH for LD1 and LD2 were 1.33 and 2.37, respectively.",Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15925422/),,1.33,202343,DB01109,Heparin
,15925422,coupling ratios,"The coupling ratios of DOCA to LMWH for LD1 and LD2 were 1.33 and 2.37, respectively.",Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15925422/),,2.37,202344,DB01109,Heparin
up to,15925422,bioavailability,"Pharmacokinetic parameters of LMWH were not significantly changed by conjugation with DOCA; however, when LMWH-DOCA in tricaprylin microemulsion was orally administered in mice, its bioavailability was increased up to 1.5%.",Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15925422/),%,1.5,202345,DB01109,Heparin
,2483703,elimination half-life,The anti FXa elimination half-life was close to 3 hours.,Study of a new low molecular weight heparin (LU 47311) administered to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2483703/),h,3,203029,DB01109,Heparin
,32055590,m,"Mass spectrometric detection and quantitation were conducted by selected reaction-monitoring on a negative electrospray ionization mode with the following transitions: m/z 521.11 → 361.10, 477.03 → 361.10, and 269.00 → 169.60 for ticagrelor, AR-C124910XX, and tolbutamide, respectively.","Simultaneous quantification of ticagrelor and its active metabolite, AR-C124910XX, in human plasma by liquid chromatography-tandem mass spectrometry: Applications in steady-state pharmacokinetics in patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055590/),,521.11,203077,DB01109,Heparin
,32055590,m,"Mass spectrometric detection and quantitation were conducted by selected reaction-monitoring on a negative electrospray ionization mode with the following transitions: m/z 521.11 → 361.10, 477.03 → 361.10, and 269.00 → 169.60 for ticagrelor, AR-C124910XX, and tolbutamide, respectively.","Simultaneous quantification of ticagrelor and its active metabolite, AR-C124910XX, in human plasma by liquid chromatography-tandem mass spectrometry: Applications in steady-state pharmacokinetics in patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055590/),,477.03,203078,DB01109,Heparin
,32055590,m,"Mass spectrometric detection and quantitation were conducted by selected reaction-monitoring on a negative electrospray ionization mode with the following transitions: m/z 521.11 → 361.10, 477.03 → 361.10, and 269.00 → 169.60 for ticagrelor, AR-C124910XX, and tolbutamide, respectively.","Simultaneous quantification of ticagrelor and its active metabolite, AR-C124910XX, in human plasma by liquid chromatography-tandem mass spectrometry: Applications in steady-state pharmacokinetics in patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055590/),,269.00,203079,DB01109,Heparin
,32140914,time,The median time (inter-quartile range) to therapeutic activated partial thromboplastin times' for obese patients was 39 (21.5-56) h.,Unfractionated heparin dosing in obese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32140914/),h,39,204935,DB01109,Heparin
,12407644,antifactor Xa activities,"Mean antifactor Xa activities 4 hours postinjection were 0.2 +/- 0.035 (SEM), 0.38 +/- 0.028, and 0.54 +/- 0.051 U/mL week 1 and 0.26 +/- 0.038, 0.40 +/- 0.055, and 0.64 +/- 0.050 U/mL week 4 for dalteparin, enoxaparin, and danaparoid, respectively.","Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407644/),[u] / [ml],0.2,205686,DB01109,Heparin
,12407644,antifactor Xa activities,"Mean antifactor Xa activities 4 hours postinjection were 0.2 +/- 0.035 (SEM), 0.38 +/- 0.028, and 0.54 +/- 0.051 U/mL week 1 and 0.26 +/- 0.038, 0.40 +/- 0.055, and 0.64 +/- 0.050 U/mL week 4 for dalteparin, enoxaparin, and danaparoid, respectively.","Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407644/),[u] / [ml],0.38,205687,DB01109,Heparin
,12407644,antifactor Xa activities,"Mean antifactor Xa activities 4 hours postinjection were 0.2 +/- 0.035 (SEM), 0.38 +/- 0.028, and 0.54 +/- 0.051 U/mL week 1 and 0.26 +/- 0.038, 0.40 +/- 0.055, and 0.64 +/- 0.050 U/mL week 4 for dalteparin, enoxaparin, and danaparoid, respectively.","Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407644/),[u] / [ml],0.54,205688,DB01109,Heparin
,12407644,antifactor Xa activities,"Mean antifactor Xa activities 4 hours postinjection were 0.2 +/- 0.035 (SEM), 0.38 +/- 0.028, and 0.54 +/- 0.051 U/mL week 1 and 0.26 +/- 0.038, 0.40 +/- 0.055, and 0.64 +/- 0.050 U/mL week 4 for dalteparin, enoxaparin, and danaparoid, respectively.","Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407644/),[u] / [ml],0.26,205689,DB01109,Heparin
,12407644,antifactor Xa activities,"Mean antifactor Xa activities 4 hours postinjection were 0.2 +/- 0.035 (SEM), 0.38 +/- 0.028, and 0.54 +/- 0.051 U/mL week 1 and 0.26 +/- 0.038, 0.40 +/- 0.055, and 0.64 +/- 0.050 U/mL week 4 for dalteparin, enoxaparin, and danaparoid, respectively.","Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407644/),[u] / [ml],0.40,205690,DB01109,Heparin
,12407644,antifactor Xa activities,"Mean antifactor Xa activities 4 hours postinjection were 0.2 +/- 0.035 (SEM), 0.38 +/- 0.028, and 0.54 +/- 0.051 U/mL week 1 and 0.26 +/- 0.038, 0.40 +/- 0.055, and 0.64 +/- 0.050 U/mL week 4 for dalteparin, enoxaparin, and danaparoid, respectively.","Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407644/),[u] / [ml],0.64,205691,DB01109,Heparin
,19624460,adjusted,"After the first dose, adjusted anti-Xa levels were 3.5 (2.6-5.0), 4.8 (3.3-5.5), 4.5 (3.7-7.5) x 10(-3) for the groups A, B, C; P = 0.26.",Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19624460/),1/[(10)^3],3.5,205891,DB01109,Heparin
,19624460,anti-Xa,"After the first dose, adjusted anti-Xa levels were 3.5 (2.6-5.0), 4.8 (3.3-5.5), 4.5 (3.7-7.5) x 10(-3) for the groups A, B, C; P = 0.26.",Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19624460/),1/[(10)^3],3.5,205892,DB01109,Heparin
,19624460,anti-Xa,"After the first dose, adjusted anti-Xa levels were 3.5 (2.6-5.0), 4.8 (3.3-5.5), 4.5 (3.7-7.5) x 10(-3) for the groups A, B, C; P = 0.26.",Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19624460/),1/[(10)^3],4.8,205893,DB01109,Heparin
,19624460,anti-Xa,"After the first dose, adjusted anti-Xa levels were 3.5 (2.6-5.0), 4.8 (3.3-5.5), 4.5 (3.7-7.5) x 10(-3) for the groups A, B, C; P = 0.26.",Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19624460/),1/[(10)^3],4.5,205894,DB01109,Heparin
,15459586,anti-Xa level,The mean +/- SD [95% CI] anti-Xa level 4 hours after the third dose was 0.65 +/- 0.19 [0.59 to 0.70] IU/mL for the severe group and 0.82 +/- 0.18 [0.79 to 0.85] IU/mL for the moderate group (P <.001).,Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15459586/),[iu] / [ml],0.65,206345,DB01109,Heparin
,15459586,anti-Xa level,The mean +/- SD [95% CI] anti-Xa level 4 hours after the third dose was 0.65 +/- 0.19 [0.59 to 0.70] IU/mL for the severe group and 0.82 +/- 0.18 [0.79 to 0.85] IU/mL for the moderate group (P <.001).,Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15459586/),[iu] / [ml],0.82,206346,DB01109,Heparin
,15081569,lag phase,"Ximelagatran (30 mg, 3.79 min, 3.52-4.08 at 2 h), r-hirudin (6.23 min, 4.93-7.86 at 2 h), and enoxaparin (4.68 min, 3.30-6.64 at 2 h) also delayed the lag phase before the thrombin generation burst compared to placebo (2.92 min, 2.71-3.25 at 2 h).","The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15081569/),min,2.92,206793,DB01109,Heparin
,15752373,fraction of drug excreted unchanged (Fu),The fraction of drug excreted unchanged (Fu) was estimated at 71%.,Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752373/),%,71,207439,DB01109,Heparin
,8399075,half-lives,"In saline controls the clearance of both chylomicron triglycerides and retinyl esters seemed to follow exponential courses, with half-lives of about 5 and 10 minutes, respectively.",Biphasic effects of low-molecular-weight and conventional heparins on chylomicron clearance in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8399075/),min,5,207442,DB01109,Heparin
,8399075,half-lives,"In saline controls the clearance of both chylomicron triglycerides and retinyl esters seemed to follow exponential courses, with half-lives of about 5 and 10 minutes, respectively.",Biphasic effects of low-molecular-weight and conventional heparins on chylomicron clearance in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8399075/),min,10,207443,DB01109,Heparin
,7245123,halflife,The halflife of the drug averaged 2.13 h in the obese subjects and 1.36 h in the normal subjects (P less than 0.02).,Pharmacokinetics of heparin in healthy and obese subjects and in combination with dihydroergotamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7245123/),h,2.13,208818,DB01109,Heparin
,7245123,halflife,The halflife of the drug averaged 2.13 h in the obese subjects and 1.36 h in the normal subjects (P less than 0.02).,Pharmacokinetics of heparin in healthy and obese subjects and in combination with dihydroergotamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7245123/),h,1.36,208819,DB01109,Heparin
,18064314,Peak anti-Xa activity,"Peak anti-Xa activity increased from 0.61 +/- 0.14 microg/l after the first dose to 0.89 +/- 0.24 microg/l after dose 9 (P < 0.001), whereas predialysis anti-Xa activity steadily rose to 0.32 +/- 0.09 microg/l (P < 0.001).",Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18064314/),[μg] / [l],0.61,210311,DB01109,Heparin
,18064314,Peak anti-Xa activity,"Peak anti-Xa activity increased from 0.61 +/- 0.14 microg/l after the first dose to 0.89 +/- 0.24 microg/l after dose 9 (P < 0.001), whereas predialysis anti-Xa activity steadily rose to 0.32 +/- 0.09 microg/l (P < 0.001).",Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18064314/),[μg] / [l],0.89,210312,DB01109,Heparin
,18064314,anti-Xa activity,"Peak anti-Xa activity increased from 0.61 +/- 0.14 microg/l after the first dose to 0.89 +/- 0.24 microg/l after dose 9 (P < 0.001), whereas predialysis anti-Xa activity steadily rose to 0.32 +/- 0.09 microg/l (P < 0.001).",Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18064314/),[μg] / [l],0.32,210313,DB01109,Heparin
,18064314,SQCS,"A sufficient but slightly less effective anticoagulation with a mean SQCS of 1.19 +/- 0.71 (n = 121) was obtained by fondaparinux as compared with 0.65 +/- 0.58 (n = 60, P < 0.005) by 4,825 +/- 1,703 U of unfractionated heparin.",Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18064314/),,1.19,210314,DB01109,Heparin
,18064314,SQCS,"A sufficient but slightly less effective anticoagulation with a mean SQCS of 1.19 +/- 0.71 (n = 121) was obtained by fondaparinux as compared with 0.65 +/- 0.58 (n = 60, P < 0.005) by 4,825 +/- 1,703 U of unfractionated heparin.",Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18064314/),,0.65,210315,DB01109,Heparin
,18064314,digital compression time,"Mean digital compression time rose slightly during fondaparinux from 23.7 +/- 7.4 minutes to 24.8 +/- 7.5 minutes (P < 0.05) and, more important, six of the 12 patients reported minor bleeding problems during the interdialytic interval.",Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18064314/),min,23.7,210316,DB01109,Heparin
,18064314,digital compression time,"Mean digital compression time rose slightly during fondaparinux from 23.7 +/- 7.4 minutes to 24.8 +/- 7.5 minutes (P < 0.05) and, more important, six of the 12 patients reported minor bleeding problems during the interdialytic interval.",Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18064314/),min,24.8,210317,DB01109,Heparin
,7778068,maximal anti-FXa effect,"After the intravenous injection, a maximal anti-FXa effect of 1.30 +/- 0.18 IU/ml was measured at 0.05 h and was not measurable after 12 h.",Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11)--a three way cross-over study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7778068/),[iu] / [ml],1.30,210656,DB01109,Heparin
,7778068,maximal anti-FXa effect,"After the subcutaneous injection of 30 and 60 mg, the maximal anti-FXa effect (0.34 +/- 0.08 IU/ml and 0.54 +/- 0.06 IU/ml) was reached after 2-4 h, and was not measurable after 12-18 h.",Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11)--a three way cross-over study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7778068/),[iu] / [ml],0.34,210657,DB01109,Heparin
,7778068,maximal anti-FXa effect,"After the subcutaneous injection of 30 and 60 mg, the maximal anti-FXa effect (0.34 +/- 0.08 IU/ml and 0.54 +/- 0.06 IU/ml) was reached after 2-4 h, and was not measurable after 12-18 h.",Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11)--a three way cross-over study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7778068/),[iu] / [ml],0.54,210658,DB01109,Heparin
,7778068,biological half-life,RO-11 showed a biological half-life of about 5 h and a high subcutaneous bioavailability (96%).,Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11)--a three way cross-over study in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7778068/),h,5,210659,DB01109,Heparin
,7778068,subcutaneous bioavailability,RO-11 showed a biological half-life of about 5 h and a high subcutaneous bioavailability (96%).,Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11)--a three way cross-over study in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7778068/),%,96,210660,DB01109,Heparin
less,2483702,bioavailability,"After SC injection, the bioavailability was less than 50% for U-DS and at least 100% for LMW-DS.","Pharmacological properties of dermatan sulfate, of a low molecular weight dermatan sulfate and of two oversulfated derivatives. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2483702/),%,50,211873,DB01109,Heparin
at,2483702,bioavailability,"After SC injection, the bioavailability was less than 50% for U-DS and at least 100% for LMW-DS.","Pharmacological properties of dermatan sulfate, of a low molecular weight dermatan sulfate and of two oversulfated derivatives. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2483702/),%,100,211874,DB01109,Heparin
,24861792,time to peak level,"The direct thrombin inhibitor, dabigatran, as well as the direct factor Xa inhibtors rivaroxaban, apixaban, and edoxaban, display pharmacodynamic features quite similar to low-molecular-weight heparins, with a time to peak level of 1-4 hours after oral administration, and a half-life between 5 and 14 hours.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),h,1-4,211970,DB01109,Heparin
,24861792,half-life,"The direct thrombin inhibitor, dabigatran, as well as the direct factor Xa inhibtors rivaroxaban, apixaban, and edoxaban, display pharmacodynamic features quite similar to low-molecular-weight heparins, with a time to peak level of 1-4 hours after oral administration, and a half-life between 5 and 14 hours.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),h,5 and 14,211971,DB01109,Heparin
,24861792,re,"Major differences are the extent of renal elimination (with 80% or more for dabigatran, 66% for rivaroxaban [33% unchanged, active drug, and 33% inactive metabolites], 33% for edoxaban, and finally, 25% for apixaban), and bioavailability, which determines the amount of drug required for attaining the target plasma concentration of the drug.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),%,66,211972,DB01109,Heparin
,24861792,re,"Major differences are the extent of renal elimination (with 80% or more for dabigatran, 66% for rivaroxaban [33% unchanged, active drug, and 33% inactive metabolites], 33% for edoxaban, and finally, 25% for apixaban), and bioavailability, which determines the amount of drug required for attaining the target plasma concentration of the drug.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),%,33,211973,DB01109,Heparin
,24861792,re,"Major differences are the extent of renal elimination (with 80% or more for dabigatran, 66% for rivaroxaban [33% unchanged, active drug, and 33% inactive metabolites], 33% for edoxaban, and finally, 25% for apixaban), and bioavailability, which determines the amount of drug required for attaining the target plasma concentration of the drug.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),%,25,211974,DB01109,Heparin
,6612697,peak plasma levels,"Subcutaneously administered dihydroergotamine (DHE) becomes rapidly and completely available to the human systemic circulation, with peak plasma levels of 1.4-3.5 ng/mL/mg achieved in less than 1 h.","The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6612697/),[ng] / [mg·ml],1.4-3.5,212053,DB01109,Heparin
,6612697,t 1/2 alpha,"The elimination of DHE from plasma is biphasic, t 1/2 alpha = 1h, t 1/2 beta = 4-5 h.","The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6612697/),h,1,212054,DB01109,Heparin
,6612697,t 1/2 beta,"The elimination of DHE from plasma is biphasic, t 1/2 alpha = 1h, t 1/2 beta = 4-5 h.","The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6612697/),h,4-5,212055,DB01109,Heparin
,6612697,peak plasma levels,"Heparin peak plasma levels (0.3 I.U./mL by activated factor X, 0.1 I.U./mL by protamine titration with a 15,000 I.U. s.c. bolus) are achieved in 3.6 h.","The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6612697/),[i·u] / [ml],0.3,212056,DB01109,Heparin
,6612697,peak plasma levels,"Heparin peak plasma levels (0.3 I.U./mL by activated factor X, 0.1 I.U./mL by protamine titration with a 15,000 I.U. s.c. bolus) are achieved in 3.6 h.","The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6612697/),[i·u] / [ml],0.1,212057,DB01109,Heparin
,7229928,sensitivities,"Specific, sensitive, reversed-phase high-pressure liquid chromatographic assays of nafronyl (I) and its acidic metabolite and hydrolysis product (II) were developed in aqueous solutions and in biological fluids with sensitivities of 100 ng/ml using butacaine as the internal standard and spectrophotometric detection of 224 nm.",Prediction of stability in pharmaceutical preparations XVIII: application of high-pressure liquid chromatographic assays to study of nafronyl stability and bioanalysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229928/),[ng] / [ml],100,212080,DB01109,Heparin
,7229928,pH of maximum stability,"The pH of maximum stability is 3.0, and pH 5.4 is the maximum that can be tolerated at 30 degrees, with a 10% solvolysis in 3 years.",Prediction of stability in pharmaceutical preparations XVIII: application of high-pressure liquid chromatographic assays to study of nafronyl stability and bioanalysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229928/),,3.0,212081,DB01109,Heparin
,7229928,half-life,"The half-life of nafronyl at 30 degrees was 7 days at pH 7, 12 hr at pH 10, and 21 min in 0.5 N NaOH.",Prediction of stability in pharmaceutical preparations XVIII: application of high-pressure liquid chromatographic assays to study of nafronyl stability and bioanalysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229928/),d,7,212082,DB01109,Heparin
,7229928,half-life,"The half-life of nafronyl at 30 degrees was 7 days at pH 7, 12 hr at pH 10, and 21 min in 0.5 N NaOH.",Prediction of stability in pharmaceutical preparations XVIII: application of high-pressure liquid chromatographic assays to study of nafronyl stability and bioanalysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229928/),h,12,212083,DB01109,Heparin
,7229928,half-life,"The half-life of nafronyl at 30 degrees was 7 days at pH 7, 12 hr at pH 10, and 21 min in 0.5 N NaOH.",Prediction of stability in pharmaceutical preparations XVIII: application of high-pressure liquid chromatographic assays to study of nafronyl stability and bioanalysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229928/),min,21,212084,DB01109,Heparin
,7229928,half-life,"Since nafronyl has a half-life of 3.2 hr in heparinized dog plasma at 25 degrees, blood samples for pharmacokinetic studies of nafronyl must be assayed immediately after sampling.",Prediction of stability in pharmaceutical preparations XVIII: application of high-pressure liquid chromatographic assays to study of nafronyl stability and bioanalysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229928/),h,3.2,212085,DB01109,Heparin
,21819539,accumulation ratio,No significant accumulation was detected: the mean accumulation ratio was 1.06 (90% CI 1.01-1.11).,No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: the IRIS substudy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21819539/),,1.06,212099,DB01109,Heparin
,28404243,Volume of distribution at steady state,"Volume of distribution at steady state after IV administration of butorphanol was 1.27 ± 0.73 L kg-1, and ClTB was 0.0096 ± 0.0024 L kg-1 minute-1.",Pharmacokinetics and selected behavioral responses to butorphanol and its metabolites in goats following intravenous and intramuscular administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404243/),[l] / [kg],1.27,214142,DB01109,Heparin
,28404243,ClTB,"Volume of distribution at steady state after IV administration of butorphanol was 1.27 ± 0.73 L kg-1, and ClTB was 0.0096 ± 0.0024 L kg-1 minute-1.",Pharmacokinetics and selected behavioral responses to butorphanol and its metabolites in goats following intravenous and intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404243/),[l] / [kg·min],0.0096,214143,DB01109,Heparin
,28404243,C0,Extrapolated C0 of butorphanol after IV administration was 146.5 ± 49.8 ng mL-1.,Pharmacokinetics and selected behavioral responses to butorphanol and its metabolites in goats following intravenous and intramuscular administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404243/),[ng] / [ml],146.5,214144,DB01109,Heparin
,28404243,CMAX,"Estimated CMAX after IM administration of butorphanol was 54.98 ± 14.60 ng mL-1, and TMAX was 16.2 ± 5.2 minutes; bioavailability was 82 ± 41%.",Pharmacokinetics and selected behavioral responses to butorphanol and its metabolites in goats following intravenous and intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404243/),[ng] / [ml],54.98,214145,DB01109,Heparin
,28404243,TMAX,"Estimated CMAX after IM administration of butorphanol was 54.98 ± 14.60 ng mL-1, and TMAX was 16.2 ± 5.2 minutes; bioavailability was 82 ± 41%.",Pharmacokinetics and selected behavioral responses to butorphanol and its metabolites in goats following intravenous and intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404243/),min,16.2,214146,DB01109,Heparin
,28404243,bioavailability,"Estimated CMAX after IM administration of butorphanol was 54.98 ± 14.60 ng mL-1, and TMAX was 16.2 ± 5.2 minutes; bioavailability was 82 ± 41%.",Pharmacokinetics and selected behavioral responses to butorphanol and its metabolites in goats following intravenous and intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404243/),%,82,214147,DB01109,Heparin
,28404243,Elimination half-life,"Elimination half-life of butorphanol was 1.87 ± 1.49 and 2.75 ± 1.93 hours for IV and IM administration, respectively.",Pharmacokinetics and selected behavioral responses to butorphanol and its metabolites in goats following intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404243/),h,1.87,214148,DB01109,Heparin
,28404243,Elimination half-life,"Elimination half-life of butorphanol was 1.87 ± 1.49 and 2.75 ± 1.93 hours for IV and IM administration, respectively.",Pharmacokinetics and selected behavioral responses to butorphanol and its metabolites in goats following intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404243/),h,2.75,214149,DB01109,Heparin
,28404243,elimination half-life,"The dose of butorphanol (0.1 mg kg-1, IV or IM) being used clinically to treat postoperative pain in goats has an elimination half-life of 1.87 and 2.75 hours, respectively.",Pharmacokinetics and selected behavioral responses to butorphanol and its metabolites in goats following intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404243/),h,1.87,214150,DB01109,Heparin
,28404243,elimination half-life,"The dose of butorphanol (0.1 mg kg-1, IV or IM) being used clinically to treat postoperative pain in goats has an elimination half-life of 1.87 and 2.75 hours, respectively.",Pharmacokinetics and selected behavioral responses to butorphanol and its metabolites in goats following intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404243/),h,2.75,214151,DB01109,Heparin
,2176903,bioavailability,"After subcutaneous injection, the bioavailability of the anti-factor Xa activity increases with the dose delivered and tends toward 100% at high doses.",Pharmacokinetics of heparin and low molecular weight heparin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2176903/),%,100,214163,DB01109,Heparin
,18447800,terminal half-life,"Mean +/- SD terminal half-life was 10.06 +/- 4.05 hours, and mean peak plasma concentration was 3.30 +/- 1.55 microg/mL.",Pharmacokinetics of cetirizine in healthy cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447800/),h,10.06,215041,DB01109,Heparin
,18447800,peak plasma concentration,"Mean +/- SD terminal half-life was 10.06 +/- 4.05 hours, and mean peak plasma concentration was 3.30 +/- 1.55 microg/mL.",Pharmacokinetics of cetirizine in healthy cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447800/),[μg] / [ml],3.30,215042,DB01109,Heparin
,18447800,volume of distribution,"Mean volume of distribution and clearance (per fraction absorbed) were 0.24 +/- 0.09 L/kg and 0.30 +/- 0.09 mL/kg/min, respectively.",Pharmacokinetics of cetirizine in healthy cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447800/),[l] / [kg],0.24,215043,DB01109,Heparin
,18447800,clearance (per fraction absorbed),"Mean volume of distribution and clearance (per fraction absorbed) were 0.24 +/- 0.09 L/kg and 0.30 +/- 0.09 mL/kg/min, respectively.",Pharmacokinetics of cetirizine in healthy cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447800/),[ml] / [kg·min],0.30,215044,DB01109,Heparin
,18447800,Protein binding,Protein binding was approximately 88%.,Pharmacokinetics of cetirizine in healthy cats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447800/),%,88,215045,DB01109,Heparin
,17063975,Cl(crea),"The pharmacokinetics of the low-molecular weight heparin (LMWH), dalteparin, was evaluated after a single intravenous bolus injection of 50 IU anti-Xa/kg in 8 healthy volunteers, 8 patients with moderate/severe renal failure (Cl(crea) 13.1-56.5 ml/min) and 8 hemodialysis patients.",Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063975/),m,13.1-56.5,215258,DB01109,Heparin
,23585314,initial infusion rate,Group 1 received a bolus of 80 U/Kg/h and an initial infusion rate of 17 U/Kg/h.,Comparison of two nomograms of unfractionated heparin in patients with acute coronary syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585314/),[u] / [h·kg],17,215538,DB01109,Heparin
,23585314,time to pass threshold,The time to pass threshold was on average 7.63±3.95 h for nomogram 1 and 11.05±4.41 h for the second nomogram (P&lt;0.001).,Comparison of two nomograms of unfractionated heparin in patients with acute coronary syndrome. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585314/),h,7.63,215539,DB01109,Heparin
,23585314,time to pass threshold,The time to pass threshold was on average 7.63±3.95 h for nomogram 1 and 11.05±4.41 h for the second nomogram (P&lt;0.001).,Comparison of two nomograms of unfractionated heparin in patients with acute coronary syndrome. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585314/),h,11.05,215540,DB01109,Heparin
,17372680,relative bioavailability,"For tablets based on heparin/papain/HEC, a relative bioavailability of 9.1% vs. subcutaneous injection was obtained, whereas the relative bioavailability of control was 2.4%.",Papain: an effective permeation enhancer for orally administered low molecular weight heparin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17372680/),%,9.1,215971,DB01109,Heparin
,17372680,relative bioavailability,"For tablets based on heparin/papain/HEC, a relative bioavailability of 9.1% vs. subcutaneous injection was obtained, whereas the relative bioavailability of control was 2.4%.",Papain: an effective permeation enhancer for orally administered low molecular weight heparin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17372680/),%,2.4,215972,DB01109,Heparin
,12706637,peak,The pharmacokinetic study demonstrated that 80% of anti-factor Xa levels were within the target range with both patient groups having similar peak (average=0.26 U/ml) and trough (average=0.13 U/ml) levels.,Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12706637/),[u] / [ml],0.26,216305,DB01109,Heparin
,12706637,trough,The pharmacokinetic study demonstrated that 80% of anti-factor Xa levels were within the target range with both patient groups having similar peak (average=0.26 U/ml) and trough (average=0.13 U/ml) levels.,Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12706637/),[u] / [ml],0.13,216306,DB01109,Heparin
,12706637,Peak anti-factor Xa levels,Peak anti-factor Xa levels (0.1-0.3 U/ml) using reviparin-sodium are achieved by administering 50 IU/kg in children greater than 3 months of age and 30 U/kg in children less than 3 months of age.,Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12706637/),[u] / [ml],0.1-0.3,216307,DB01109,Heparin
,32699622,plasma flow rate,"In this in vitro study, 18 anti-infective drugs were administered to human donor plasma and pumped through the heparin-coated pathogen adsorber (Seraph® 100 Microbind®Affinity Blood Filter; ExThera Medical Corp., Martinez, CA, USA) at a plasma flow rate of 250 mL/min for 60 min.",In vitro elimination of anti-infective drugs by the Seraph® 100 Microbind® affinity blood filter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32699622/),[ml] / [min],250,216539,DB01109,Heparin
,32699622,plasma clearance rates,Mean plasma clearance rates ranged between -11.93 mL/min (fluconazole) and 4.86 mL/min (clindamycin).,In vitro elimination of anti-infective drugs by the Seraph® 100 Microbind® affinity blood filter. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32699622/),[ml] / [min],-11.93,216540,DB01109,Heparin
,32699622,plasma clearance rates,Mean plasma clearance rates ranged between -11.93 mL/min (fluconazole) and 4.86 mL/min (clindamycin).,In vitro elimination of anti-infective drugs by the Seraph® 100 Microbind® affinity blood filter. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32699622/),[ml] / [min],4.86,216541,DB01109,Heparin
,20109123,alveolar half-life,"The local alveolar anticoagulant effect was detectable up to 72 h, and the alveolar half-life was estimated at 28 h.",Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109123/),h,28,216707,DB01109,Heparin
,22164964,Cmax,"For the test and reference formulation, mean Cmax values were 2257.3 (ng/ml) and 2156 (ng/ml), respectively.",Comparative in vitro dissolution and in vivo bioequivalence of two diclofenac enteric coated formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22164964/),[ng] / [ml],2257.3,217633,DB01109,Heparin
,22164964,Cmax,"For the test and reference formulation, mean Cmax values were 2257.3 (ng/ml) and 2156 (ng/ml), respectively.",Comparative in vitro dissolution and in vivo bioequivalence of two diclofenac enteric coated formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22164964/),[ng] / [ml],2156,217634,DB01109,Heparin
,22164964,AUC(0)tau,"The mean AUC(0)tau and AUC(0)infinity were 5726.1 (ng x h/ml) and 5917.8 (ng x h/ml) for the test and 5689.9 (ng x h/ml) and 5967.4 (ng x h/ml) for the reference formulation, respectively.",Comparative in vitro dissolution and in vivo bioequivalence of two diclofenac enteric coated formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22164964/),[h·ng] / [ml],5726.1,217635,DB01109,Heparin
,22164964,AUC(0)tau,"The mean AUC(0)tau and AUC(0)infinity were 5726.1 (ng x h/ml) and 5917.8 (ng x h/ml) for the test and 5689.9 (ng x h/ml) and 5967.4 (ng x h/ml) for the reference formulation, respectively.",Comparative in vitro dissolution and in vivo bioequivalence of two diclofenac enteric coated formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22164964/),[h·ng] / [ml],5689.9,217636,DB01109,Heparin
,22164964,AUC(0)infinity,"The mean AUC(0)tau and AUC(0)infinity were 5726.1 (ng x h/ml) and 5917.8 (ng x h/ml) for the test and 5689.9 (ng x h/ml) and 5967.4 (ng x h/ml) for the reference formulation, respectively.",Comparative in vitro dissolution and in vivo bioequivalence of two diclofenac enteric coated formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22164964/),[h·ng] / [ml],5917.8,217637,DB01109,Heparin
,22164964,AUC(0)infinity,"The mean AUC(0)tau and AUC(0)infinity were 5726.1 (ng x h/ml) and 5917.8 (ng x h/ml) for the test and 5689.9 (ng x h/ml) and 5967.4 (ng x h/ml) for the reference formulation, respectively.",Comparative in vitro dissolution and in vivo bioequivalence of two diclofenac enteric coated formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22164964/),[h·ng] / [ml],5967.4,217638,DB01109,Heparin
,19034631,entrapment efficiency,The entrapment efficiency of LMWH in PEG-dendrimer micelles was about 40%.,Synthesis and evaluation of pegylated dendrimeric nanocarrier for pulmonary delivery of low molecular weight heparin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034631/),%,40,218342,DB01109,Heparin
,19034631,relative bioavailability,LMWH entrapped in PEG-dendrimer produced a significant increase in pulmonary absorption and the relative bioavailability of the formulation was 60.6% compared to subcutaneous LMWH.,Synthesis and evaluation of pegylated dendrimeric nanocarrier for pulmonary delivery of low molecular weight heparin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034631/),%,60.6,218343,DB01109,Heparin
,19034631,half-life,"The half-life of the PEG-dendrimer-based formulation was 11.9 h, which is 2.4-fold greater than the half-life of LMWH in a saline control formulation.",Synthesis and evaluation of pegylated dendrimeric nanocarrier for pulmonary delivery of low molecular weight heparin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034631/),h,11.9,218344,DB01109,Heparin
higher,14551364,anti-Xa activity,"A single injection of enoxaparin at 60 U IU/kg (4000 +/- 455 IU) led to an anti-Xa activity higher than 1.2 IU/ml during the first 2 h of the session, and between 0.4 and 1.2 IU during the third and fourth hours.",Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14551364/),[iu] / [ml],1.2,218874,DB01109,Heparin
,14551364,anti-Xa activity,"A single injection of enoxaparin at 60 U IU/kg (4000 +/- 455 IU) led to an anti-Xa activity higher than 1.2 IU/ml during the first 2 h of the session, and between 0.4 and 1.2 IU during the third and fourth hours.",Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14551364/),iu,0.4 and 1.2,218875,DB01109,Heparin
higher,14551364,anti-Xa activity,"After the end of the session, anti-Xa activity remained higher than 0.4 IU/ml up to 10 h after injection, and higher than 0.1 IU/ml up to 24 h.",Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14551364/),[iu] / [ml],0.4,218876,DB01109,Heparin
higher,14551364,anti-Xa activity,"After the end of the session, anti-Xa activity remained higher than 0.4 IU/ml up to 10 h after injection, and higher than 0.1 IU/ml up to 24 h.",Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14551364/),[iu] / [ml],0.1,218877,DB01109,Heparin
>,14551364,anti-Xa activity,"Whatever the procedure, anti-Xa activity remained high (>0.22 +/- 0.99 UI/ml) up to 12 h after the start of the dialysis session.",Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14551364/),[ui] / [ml],0.22,218878,DB01109,Heparin
,8837315,half-life,"Therefore, we examined the half-life of proteogly can-associated h-rTFPI/factor Xa and determined it to be 51 min, which was significantly shorter than that of h-rTFPI by itself (107 min).",The clearance of proteoglycan-associated human recombinant tissue factor pathway inhibitor (h-rTFPI) in rabbits: a complex formation of h-rTFPI with factor Xa promotes a clearance rate of h-rTFPI. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8837315/),min,51,219067,DB01109,Heparin
,8837315,half-life,"Therefore, we examined the half-life of proteogly can-associated h-rTFPI/factor Xa and determined it to be 51 min, which was significantly shorter than that of h-rTFPI by itself (107 min).",The clearance of proteoglycan-associated human recombinant tissue factor pathway inhibitor (h-rTFPI) in rabbits: a complex formation of h-rTFPI with factor Xa promotes a clearance rate of h-rTFPI. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8837315/),min,107,219068,DB01109,Heparin
,16269276,minimum quantifiable limit,The method was linear from 10 to 750 ng/ml with a minimum quantifiable limit of 10 ng/ml when 250 microl aliquots were analyzed.,Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269276/),[ng] / [ml],10,219677,DB01109,Heparin
,1423948,maximal APTT,"Contrary to expectations, the increase of anti-Xa activity, anti-IIa activity, and APTT compared with baseline (predrug) levels was very small, with an average maximal APTT of 42.6 seconds (SD, 12.4 seconds; range, 30.4-70.7 seconds).","Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1423948/),seconds,42.6,220015,DB01109,Heparin
,1423948,maximal APTT,"The majority of volunteers had minimal prolongation of the APTT, but very strong prolongation was also seen (maximal APTT, 163 seconds).","Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1423948/),seconds,163,220016,DB01109,Heparin
,3420106,activities,"As expressed in micromoles fatty acid released/hr/ml plasma, the activities of LPL in CuD and CuA were 32.6 +/- 1.9 and 45.6 +/- 1.3, respectively.","Effect of copper deficiency on the lymphatic absorption of cholesterol, plasma chylomicron clearance, and postheparin lipase activities. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3420106/),,32,222290,DB01109,Heparin
,3420106,activities,"As expressed in micromoles fatty acid released/hr/ml plasma, the activities of LPL in CuD and CuA were 32.6 +/- 1.9 and 45.6 +/- 1.3, respectively.","Effect of copper deficiency on the lymphatic absorption of cholesterol, plasma chylomicron clearance, and postheparin lipase activities. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3420106/),,45.6,222291,DB01109,Heparin
,3263884,apparent t1/2,"Native alpha 1-antichymotrypsin cleared with an apparent t1/2 of 85 min, but alpha 1-antichymotrypsin in complex with chymotrypsin or cathepsin G cleared with a t1/2 of 12 min.","In vivo catabolism of alpha 1-antichymotrypsin is mediated by the Serpin receptor which binds alpha 1-proteinase inhibitor, antithrombin III and heparin cofactor II. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3263884/),min,85,223820,DB01109,Heparin
,3263884,t1/2,"Native alpha 1-antichymotrypsin cleared with an apparent t1/2 of 85 min, but alpha 1-antichymotrypsin in complex with chymotrypsin or cathepsin G cleared with a t1/2 of 12 min.","In vivo catabolism of alpha 1-antichymotrypsin is mediated by the Serpin receptor which binds alpha 1-proteinase inhibitor, antithrombin III and heparin cofactor II. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3263884/),min,12,223821,DB01109,Heparin
,6737238,Plasma protein binding,Plasma protein binding of II by ultrafiltration was 76.4% and was not concentration dependent.,Bioanalyses and pharmacokinetics of nafronyl in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),%,76.4,224547,DB01109,Heparin
,6737238,apparent red blood cell-plasma partition coefficients,"The apparent red blood cell-plasma partition coefficients for I and II were 2.00 and 0.49, respectively, with almost all anticoagulants; the red blood cell-plasma water partition coefficient for II was 2.08 when corrected for plasma protein binding.",Bioanalyses and pharmacokinetics of nafronyl in the dog. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),,2.00,224548,DB01109,Heparin
,6737238,apparent red blood cell-plasma partition coefficients,"The apparent red blood cell-plasma partition coefficients for I and II were 2.00 and 0.49, respectively, with almost all anticoagulants; the red blood cell-plasma water partition coefficient for II was 2.08 when corrected for plasma protein binding.",Bioanalyses and pharmacokinetics of nafronyl in the dog. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),,0.49,224549,DB01109,Heparin
,6737238,red blood cell-plasma water partition coefficient,"The apparent red blood cell-plasma partition coefficients for I and II were 2.00 and 0.49, respectively, with almost all anticoagulants; the red blood cell-plasma water partition coefficient for II was 2.08 when corrected for plasma protein binding.",Bioanalyses and pharmacokinetics of nafronyl in the dog. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),,2.08,224550,DB01109,Heparin
,6737238,total body clearance,The total body clearance of nafronyl (I) referenced to total plasma concentration [1295 +/- 65 (SEM) mL/min] was dose independent (35-70-mg range) and showed biphasic plasma half-lives (intravenous) of 12 and 100 min.,Bioanalyses and pharmacokinetics of nafronyl in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),[ml] / [min],1295,224551,DB01109,Heparin
,6737238,plasma half-lives,The total body clearance of nafronyl (I) referenced to total plasma concentration [1295 +/- 65 (SEM) mL/min] was dose independent (35-70-mg range) and showed biphasic plasma half-lives (intravenous) of 12 and 100 min.,Bioanalyses and pharmacokinetics of nafronyl in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),min,12,224552,DB01109,Heparin
,6737238,plasma half-lives,The total body clearance of nafronyl (I) referenced to total plasma concentration [1295 +/- 65 (SEM) mL/min] was dose independent (35-70-mg range) and showed biphasic plasma half-lives (intravenous) of 12 and 100 min.,Bioanalyses and pharmacokinetics of nafronyl in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),min,100,224553,DB01109,Heparin
,6737238,Apparent volumes of distribution,"Apparent volumes of distribution similarly referenced were 39.8 and 163 L for the central compartment and total body, respectively.",Bioanalyses and pharmacokinetics of nafronyl in the dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),l,39.8,224554,DB01109,Heparin
,6737238,Apparent volumes of distribution,"Apparent volumes of distribution similarly referenced were 39.8 and 163 L for the central compartment and total body, respectively.",Bioanalyses and pharmacokinetics of nafronyl in the dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),l,163,224555,DB01109,Heparin
,6737238,Renal clearances,"Renal clearances referenced to total plasma concentration were 8.3 and 0.18 mL/m for I and II, respectively.",Bioanalyses and pharmacokinetics of nafronyl in the dog. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),[ml] / [m],8.3,224556,DB01109,Heparin
,6737238,Renal clearances,"Renal clearances referenced to total plasma concentration were 8.3 and 0.18 mL/m for I and II, respectively.",Bioanalyses and pharmacokinetics of nafronyl in the dog. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),[ml] / [m],0.18,224557,DB01109,Heparin
,6737238,total urinary excretions,"The respective total urinary excretions of I, II, and the glucuronide of II (III) were 0.48, 0.021, and 0.32% of the administered intravenous doses.",Bioanalyses and pharmacokinetics of nafronyl in the dog. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),%,0.48,224558,DB01109,Heparin
,6737238,total urinary excretions,"The respective total urinary excretions of I, II, and the glucuronide of II (III) were 0.48, 0.021, and 0.32% of the administered intravenous doses.",Bioanalyses and pharmacokinetics of nafronyl in the dog. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),%,0.021,224559,DB01109,Heparin
,6737238,total urinary excretions,"The respective total urinary excretions of I, II, and the glucuronide of II (III) were 0.48, 0.021, and 0.32% of the administered intravenous doses.",Bioanalyses and pharmacokinetics of nafronyl in the dog. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),%,0.32,224560,DB01109,Heparin
,6737238,total urinary excretions,"The respective total urinary excretions of I, II, and III for a bile-cannulated dog were 0.005, 0.16, and 0.40%.",Bioanalyses and pharmacokinetics of nafronyl in the dog. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),%,0.005,224561,DB01109,Heparin
,6737238,total urinary excretions,"The respective total urinary excretions of I, II, and III for a bile-cannulated dog were 0.005, 0.16, and 0.40%.",Bioanalyses and pharmacokinetics of nafronyl in the dog. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),%,0.16,224562,DB01109,Heparin
,6737238,total urinary excretions,"The respective total urinary excretions of I, II, and III for a bile-cannulated dog were 0.005, 0.16, and 0.40%.",Bioanalyses and pharmacokinetics of nafronyl in the dog. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),%,0.40,224563,DB01109,Heparin
,6737238,total body clearance,"The total body clearance of intravenously administered II was 225 mL/min, with a renal clearance of 0.057 mL/min referenced to total plasma concentration.",Bioanalyses and pharmacokinetics of nafronyl in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),[ml] / [min],225,224564,DB01109,Heparin
,6737238,renal clearance,"The total body clearance of intravenously administered II was 225 mL/min, with a renal clearance of 0.057 mL/min referenced to total plasma concentration.",Bioanalyses and pharmacokinetics of nafronyl in the dog. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),[ml] / [min],0.057,224565,DB01109,Heparin
,6737238,total urinary excretions,The respective total urinary excretions of II and III were 0.027 and 0.44% of the intravenous dose of II.,Bioanalyses and pharmacokinetics of nafronyl in the dog. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),%,0.027,224566,DB01109,Heparin
,6737238,total urinary excretions,The respective total urinary excretions of II and III were 0.027 and 0.44% of the intravenous dose of II.,Bioanalyses and pharmacokinetics of nafronyl in the dog. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),%,0.44,224567,DB01109,Heparin
,6737238,plasma half-lives,"Respective plasma half-lives of II (intravenous) were 2.5, 10.9, and 225 min.",Bioanalyses and pharmacokinetics of nafronyl in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),min,2.5,224568,DB01109,Heparin
,6737238,plasma half-lives,"Respective plasma half-lives of II (intravenous) were 2.5, 10.9, and 225 min.",Bioanalyses and pharmacokinetics of nafronyl in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),min,10.9,224569,DB01109,Heparin
,6737238,plasma half-lives,"Respective plasma half-lives of II (intravenous) were 2.5, 10.9, and 225 min.",Bioanalyses and pharmacokinetics of nafronyl in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),min,225,224570,DB01109,Heparin
,6737238,apparent volume of distribution,The apparent volume of distribution referenced to total plasma concentration was 2.2 L (9.1 L referenced to plasma water concentration).,Bioanalyses and pharmacokinetics of nafronyl in the dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),l,2.2,224571,DB01109,Heparin
,6737238,apparent volume of distribution,The apparent volume of distribution referenced to total plasma concentration was 2.2 L (9.1 L referenced to plasma water concentration).,Bioanalyses and pharmacokinetics of nafronyl in the dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),l,9.1,224572,DB01109,Heparin
,6737238,apparent overall volume of distribution,The apparent overall volume of distribution referenced to plasma concentration was 73 L.(ABSTRACT TRUNCATED AT 400 WORDS),Bioanalyses and pharmacokinetics of nafronyl in the dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737238/),l,73,224573,DB01109,Heparin
,20369796,maximum plasma concentration,The maximum plasma concentration attained after the administration of formulation 1 (containing gelatin) was 7.56 +/- 0.835 microg/mL (the mean +/- SEM) and of formulation 2 (containing starch) was 3.4417 +/- 1.16 microg/mL (the mean +/- SEM).,The effect of binders on the bioavailability of ofloxacin tablets in animal model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20369796/),[μg] / [ml],7.56,225065,DB01109,Heparin
,20369796,maximum plasma concentration,The maximum plasma concentration attained after the administration of formulation 1 (containing gelatin) was 7.56 +/- 0.835 microg/mL (the mean +/- SEM) and of formulation 2 (containing starch) was 3.4417 +/- 1.16 microg/mL (the mean +/- SEM).,The effect of binders on the bioavailability of ofloxacin tablets in animal model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20369796/),[μg] / [ml],3.4417,225066,DB01109,Heparin
,10556136,driving flow rate,"Fifteen healthy subjects (5 male, 10 female) inhaled heparin from a jet nebulizer loaded with 90,000 IU of (99m)Tc-heparin, driving flow rate 10 L/min.",Lung deposition and clearance of inhaled (99m)Tc-heparin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10556136/),[l] / [min],10,225843,DB01109,Heparin
,10556136,Jet ne,"Jet nebulizer residual was 48 +/- 6% (mean 43,000 IU), 32 +/- 4% (mean 29,000) was found on exhalation filters, and 5 +/- 2% in the tubing.",Lung deposition and clearance of inhaled (99m)Tc-heparin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10556136/),%,48,225844,DB01109,Heparin
,10556136,Jet ne,"Jet nebulizer residual was 48 +/- 6% (mean 43,000 IU), 32 +/- 4% (mean 29,000) was found on exhalation filters, and 5 +/- 2% in the tubing.",Lung deposition and clearance of inhaled (99m)Tc-heparin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10556136/),%,32,225845,DB01109,Heparin
,10556136,Jet ne,"Jet nebulizer residual was 48 +/- 6% (mean 43,000 IU), 32 +/- 4% (mean 29,000) was found on exhalation filters, and 5 +/- 2% in the tubing.",Lung deposition and clearance of inhaled (99m)Tc-heparin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10556136/),%,5,225846,DB01109,Heparin
,10556136,residual,"Jet nebulizer residual was 48 +/- 6% (mean 43,000 IU), 32 +/- 4% (mean 29,000) was found on exhalation filters, and 5 +/- 2% in the tubing.",Lung deposition and clearance of inhaled (99m)Tc-heparin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10556136/),%,48,225847,DB01109,Heparin
,10556136,residual,"Jet nebulizer residual was 48 +/- 6% (mean 43,000 IU), 32 +/- 4% (mean 29,000) was found on exhalation filters, and 5 +/- 2% in the tubing.",Lung deposition and clearance of inhaled (99m)Tc-heparin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10556136/),%,32,225848,DB01109,Heparin
,10556136,residual,"Jet nebulizer residual was 48 +/- 6% (mean 43,000 IU), 32 +/- 4% (mean 29,000) was found on exhalation filters, and 5 +/- 2% in the tubing.",Lung deposition and clearance of inhaled (99m)Tc-heparin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10556136/),,"29,000",225849,DB01109,Heparin
,10556136,residual,"Jet nebulizer residual was 48 +/- 6% (mean 43,000 IU), 32 +/- 4% (mean 29,000) was found on exhalation filters, and 5 +/- 2% in the tubing.",Lung deposition and clearance of inhaled (99m)Tc-heparin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10556136/),%,5,225850,DB01109,Heparin
,11867368,volume of distribution at steady state,"Model-independent pharmacokinetic analysis revealed median (range) values as follows: volume of distribution at steady state, 12.3 (6.9--63.1) L; clearance, 2.2 (1.1--12.1) L/min; and t1/2, 7.4 (5.9--9.3) min.",The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11867368/),l,12.3,226386,DB01109,Heparin
,11867368,clearance,"Model-independent pharmacokinetic analysis revealed median (range) values as follows: volume of distribution at steady state, 12.3 (6.9--63.1) L; clearance, 2.2 (1.1--12.1) L/min; and t1/2, 7.4 (5.9--9.3) min.",The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11867368/),[l] / [min],2.2,226387,DB01109,Heparin
,11867368,t1/2,"Model-independent pharmacokinetic analysis revealed median (range) values as follows: volume of distribution at steady state, 12.3 (6.9--63.1) L; clearance, 2.2 (1.1--12.1) L/min; and t1/2, 7.4 (5.9--9.3) min.",The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11867368/),min,7.4,226388,DB01109,Heparin
,11867368,half-life,"The rapid disappearance of protamine from the circulation, as defined by a median half-life of 7.4 min, could contribute to cases of ""heparin rebound"" after initial adequate reversal of heparin.",The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11867368/),min,7.4,226389,DB01109,Heparin
,32202190,AUC0-24,"The AUC0-24 of tofacitinib was increased from 1222.81 ± 222.07 to 2016.27 ± 481.62 ng/mL/h, and the difference was significant (p < 0.05).",Effects of naringenin on the pharmacokinetics of tofacitinib in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32202190/),[ng] / [h·ml],1222.81,227341,DB01109,Heparin
,32202190,AUC0-24,"The AUC0-24 of tofacitinib was increased from 1222.81 ± 222.07 to 2016.27 ± 481.62 ng/mL/h, and the difference was significant (p < 0.05).",Effects of naringenin on the pharmacokinetics of tofacitinib in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32202190/),[ng] / [h·ml],2016.27,227342,DB01109,Heparin
,32202190,Tmax,"Compared with the control group, the Tmax was increased from 0.75 ± 0.29 to 3.00 ± 0.00 h (p < 0.05), and the MRT(0-24) was increased from 4.90 ± 0.51 to 6.57 ± 0.66 h (p < 0.05), but the clearance was obviously decreased from 4.10 ± 0.72 to 2.42 ± 0.70 L/h/kg (p < 0.05) in experimental group.",Effects of naringenin on the pharmacokinetics of tofacitinib in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32202190/),h,0.75,227343,DB01109,Heparin
,32202190,Tmax,"Compared with the control group, the Tmax was increased from 0.75 ± 0.29 to 3.00 ± 0.00 h (p < 0.05), and the MRT(0-24) was increased from 4.90 ± 0.51 to 6.57 ± 0.66 h (p < 0.05), but the clearance was obviously decreased from 4.10 ± 0.72 to 2.42 ± 0.70 L/h/kg (p < 0.05) in experimental group.",Effects of naringenin on the pharmacokinetics of tofacitinib in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32202190/),h,3.00,227344,DB01109,Heparin
,32202190,MRT(0-24),"Compared with the control group, the Tmax was increased from 0.75 ± 0.29 to 3.00 ± 0.00 h (p < 0.05), and the MRT(0-24) was increased from 4.90 ± 0.51 to 6.57 ± 0.66 h (p < 0.05), but the clearance was obviously decreased from 4.10 ± 0.72 to 2.42 ± 0.70 L/h/kg (p < 0.05) in experimental group.",Effects of naringenin on the pharmacokinetics of tofacitinib in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32202190/),h,4.90,227345,DB01109,Heparin
,32202190,MRT(0-24),"Compared with the control group, the Tmax was increased from 0.75 ± 0.29 to 3.00 ± 0.00 h (p < 0.05), and the MRT(0-24) was increased from 4.90 ± 0.51 to 6.57 ± 0.66 h (p < 0.05), but the clearance was obviously decreased from 4.10 ± 0.72 to 2.42 ± 0.70 L/h/kg (p < 0.05) in experimental group.",Effects of naringenin on the pharmacokinetics of tofacitinib in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32202190/),h,6.57,227346,DB01109,Heparin
,32202190,clearance,"Compared with the control group, the Tmax was increased from 0.75 ± 0.29 to 3.00 ± 0.00 h (p < 0.05), and the MRT(0-24) was increased from 4.90 ± 0.51 to 6.57 ± 0.66 h (p < 0.05), but the clearance was obviously decreased from 4.10 ± 0.72 to 2.42 ± 0.70 L/h/kg (p < 0.05) in experimental group.",Effects of naringenin on the pharmacokinetics of tofacitinib in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32202190/),[l] / [h·kg],4.10,227347,DB01109,Heparin
,32202190,clearance,"Compared with the control group, the Tmax was increased from 0.75 ± 0.29 to 3.00 ± 0.00 h (p < 0.05), and the MRT(0-24) was increased from 4.90 ± 0.51 to 6.57 ± 0.66 h (p < 0.05), but the clearance was obviously decreased from 4.10 ± 0.72 to 2.42 ± 0.70 L/h/kg (p < 0.05) in experimental group.",Effects of naringenin on the pharmacokinetics of tofacitinib in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32202190/),[l] / [h·kg],2.42,227348,DB01109,Heparin
,4074405,urinary recovery,The compound is well eliminated by urinary route; the urinary recovery was 50% in 24 h and 67% 48 h after administration.,"Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. Part I: Pharmacokinetics in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4074405/),%,50,229377,DB01109,Heparin
,4074405,urinary recovery,The compound is well eliminated by urinary route; the urinary recovery was 50% in 24 h and 67% 48 h after administration.,"Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. Part I: Pharmacokinetics in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4074405/),%,67,229378,DB01109,Heparin
,17552440,anti-Xa activity,"Mean anti-Xa activity 4 hours after enoxaparin (0.48 U/mL) approached the human therapeutic target (0.5-1.0 U/mL); however, mean trough anti-Xa activity was below detection limits.",Anticoagulant effects of low-molecular-weight heparins in healthy cats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17552440/),[u] / [ml],0.48,231882,DB01109,Heparin
,17552440,anti-Xa activity,"Mean anti-Xa activity 4 hours after enoxaparin (0.48 U/mL) approached the human therapeutic target (0.5-1.0 U/mL); however, mean trough anti-Xa activity was below detection limits.",Anticoagulant effects of low-molecular-weight heparins in healthy cats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17552440/),[u] / [ml],0.5-1.0,231883,DB01109,Heparin
,15793802,relative bioavailability,"With the delivery system containing 3 kDa LMWH (279 IU) a relative bioavailability of 19.1% was achieved, offering a significantly (p < 0.05) better bioavailability than the control system displaying a relative bioavailability of 8.1% The 6 kDa LMWH (300 IU) formulation displayed a relative bioavailability of 10.7% in contrast to the control displaying a relative bioavailability of 2.1%.",Oral heparin delivery: design and in vivo evaluation of a stomach-targeted mucoadhesive delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793802/),%,19.1,232105,DB01109,Heparin
,15793802,relative bioavailability,"With the delivery system containing 3 kDa LMWH (279 IU) a relative bioavailability of 19.1% was achieved, offering a significantly (p < 0.05) better bioavailability than the control system displaying a relative bioavailability of 8.1% The 6 kDa LMWH (300 IU) formulation displayed a relative bioavailability of 10.7% in contrast to the control displaying a relative bioavailability of 2.1%.",Oral heparin delivery: design and in vivo evaluation of a stomach-targeted mucoadhesive delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793802/),%,8.1,232106,DB01109,Heparin
,15793802,relative bioavailability,"With the delivery system containing 3 kDa LMWH (279 IU) a relative bioavailability of 19.1% was achieved, offering a significantly (p < 0.05) better bioavailability than the control system displaying a relative bioavailability of 8.1% The 6 kDa LMWH (300 IU) formulation displayed a relative bioavailability of 10.7% in contrast to the control displaying a relative bioavailability of 2.1%.",Oral heparin delivery: design and in vivo evaluation of a stomach-targeted mucoadhesive delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793802/),%,10.7,232107,DB01109,Heparin
,15793802,relative bioavailability,"With the delivery system containing 3 kDa LMWH (279 IU) a relative bioavailability of 19.1% was achieved, offering a significantly (p < 0.05) better bioavailability than the control system displaying a relative bioavailability of 8.1% The 6 kDa LMWH (300 IU) formulation displayed a relative bioavailability of 10.7% in contrast to the control displaying a relative bioavailability of 2.1%.",Oral heparin delivery: design and in vivo evaluation of a stomach-targeted mucoadhesive delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793802/),%,2.1,232108,DB01109,Heparin
,18572651,entrapment efficiency,"The mean diameter was 388 and 357 nm for coated and uncoated nanoparticles, respectively, and the entrapment efficiency ranged from 20 to 32%.",Increase in the vascular residence time of propranolol-loaded nanoparticles coated with heparin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18572651/),%,20 to 32,232195,DB01109,Heparin
,26311056,plasmafiltrate volume,"As for the efficiency of plasmafiltration, the plasmafiltrate volume (from 17 to 20 mL/kg/day) was not significantly different among the groups.",Citrate pharmacokinetics at high levels of circuit citratemia during coupled plasma filtration adsorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26311056/),[ml] / [d·kg],17 to 20,232283,DB01109,Heparin
,15271419,Peak concentrations,"Peak concentrations in tissue and washes of stomach, duodenum, jejunum, ileum and colon were at 6-30, 15-30, 30 min, 2 and 4 h, respectively.","Tissue distribution of the low molecular weight heparin, tinzaparin, following administration to rats by the oral route. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15271419/),h,6-30,232480,DB01109,Heparin
,15271419,Peak concentrations,"Peak concentrations in tissue and washes of stomach, duodenum, jejunum, ileum and colon were at 6-30, 15-30, 30 min, 2 and 4 h, respectively.","Tissue distribution of the low molecular weight heparin, tinzaparin, following administration to rats by the oral route. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15271419/),h,15-30,232481,DB01109,Heparin
,15271419,Peak concentrations,"Peak concentrations in tissue and washes of stomach, duodenum, jejunum, ileum and colon were at 6-30, 15-30, 30 min, 2 and 4 h, respectively.","Tissue distribution of the low molecular weight heparin, tinzaparin, following administration to rats by the oral route. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15271419/),h,30,232482,DB01109,Heparin
,15271419,Amounts,"Amounts found at peak times in combined tissue and washes accounted for 46% and 0.5% in stomach (15 min) and colon (4 h), respectively.","Tissue distribution of the low molecular weight heparin, tinzaparin, following administration to rats by the oral route. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15271419/),,15,232483,DB01109,Heparin
,15271419,Amounts,"Amounts found at peak times in combined tissue and washes accounted for 46% and 0.5% in stomach (15 min) and colon (4 h), respectively.","Tissue distribution of the low molecular weight heparin, tinzaparin, following administration to rats by the oral route. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15271419/),,4,232484,DB01109,Heparin
,3841420,fractional catabolic rate,"The mean values of fractional catabolic rate, intravascular fraction and half-life of the elimination phase were respectively: 0.44 d-1, 0.60 and 2.53 d.",Turnover study of heparin cofactor II in healthy man. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841420/),1/[d],0.44,233423,DB01109,Heparin
,3841420,intravascular fraction,"The mean values of fractional catabolic rate, intravascular fraction and half-life of the elimination phase were respectively: 0.44 d-1, 0.60 and 2.53 d.",Turnover study of heparin cofactor II in healthy man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841420/),d,0.60,233424,DB01109,Heparin
,3841420,half-life of the elimination phase,"The mean values of fractional catabolic rate, intravascular fraction and half-life of the elimination phase were respectively: 0.44 d-1, 0.60 and 2.53 d.",Turnover study of heparin cofactor II in healthy man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841420/),d,2.53,233425,DB01109,Heparin
,3841420,absolute catabolic rate,"Accordingly, the absolute catabolic rate ranged from 1.17 to 1.36 mg X kg-1 X d-1.",Turnover study of heparin cofactor II in healthy man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841420/),[mg] / [d·kg],1.17 to 1.36,233426,DB01109,Heparin
,8033296,binding,Centrifugal ultrafiltration of rat plasma spiked in vitro with MTX (1-100 microM) revealed a mean binding to plasma proteins of 21%.,Evaluation of methotrexate tissue exposure by in situ microdialysis in a rat model. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8033296/),%,21,233570,DB01109,Heparin
,8033296,plasma protein binding,"In rats receiving MTX, plasma protein binding was 23% and the relative drug recovery as assessed with venous microdialysis probes was 18%.",Evaluation of methotrexate tissue exposure by in situ microdialysis in a rat model. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8033296/),%,23,233571,DB01109,Heparin
,8033296,relative drug recovery,"In rats receiving MTX, plasma protein binding was 23% and the relative drug recovery as assessed with venous microdialysis probes was 18%.",Evaluation of methotrexate tissue exposure by in situ microdialysis in a rat model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8033296/),%,18,233572,DB01109,Heparin
,15167633,clearance (CL/F),"The mean clearance (CL/F) and distribution volume (V/F) were 0.72 L/h and 6.65 L, respectively.",Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167633/),[l] / [h],0.72,235107,DB01109,Heparin
,15167633,distribution volume (V/F),"The mean clearance (CL/F) and distribution volume (V/F) were 0.72 L/h and 6.65 L, respectively.",Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167633/),l,6.65,235108,DB01109,Heparin
,15167633,elimination half-life,"The elimination half-life was thus estimated to be 6.4 and 9.2 hours in male and female patients, respectively.",Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167633/),h,6.4,235109,DB01109,Heparin
,15167633,elimination half-life,"The elimination half-life was thus estimated to be 6.4 and 9.2 hours in male and female patients, respectively.",Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167633/),h,9.2,235110,DB01109,Heparin
above,15167633,Maximal anti-Xa activity,Maximal anti-Xa activity was predicted to rise above 1.5 IU/mL in case of mild elevation of serum creatinine according to gender and body weight.,Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167633/),[iu] / [ml],1.5,235111,DB01109,Heparin
,19161457,half life of absorption,Absorption of butorphanol after IM administration was very rapid (half life of absorption of 6 min) but systemic availability after IM injection was low (37%).,Pharmacokinetics of butorphanol in horses after intramuscular injection. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161457/),min,6,235419,DB01109,Heparin
,19161457,Terminal half-life,"Terminal half-life after IV administration was much longer than half-life after IM administration (0.57 h and 7.7 h, respectively).",Pharmacokinetics of butorphanol in horses after intramuscular injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161457/),h,0.57,235420,DB01109,Heparin
,19161457,Terminal half-life,"Terminal half-life after IV administration was much longer than half-life after IM administration (0.57 h and 7.7 h, respectively).",Pharmacokinetics of butorphanol in horses after intramuscular injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161457/),h,7.7,235421,DB01109,Heparin
,19161457,half-life,"Terminal half-life after IV administration was much longer than half-life after IM administration (0.57 h and 7.7 h, respectively).",Pharmacokinetics of butorphanol in horses after intramuscular injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161457/),h,0.57,235422,DB01109,Heparin
,19161457,half-life,"Terminal half-life after IV administration was much longer than half-life after IM administration (0.57 h and 7.7 h, respectively).",Pharmacokinetics of butorphanol in horses after intramuscular injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161457/),h,7.7,235423,DB01109,Heparin
,32045583,peak anti-factor Xa,"Weight-tiered enoxaparin was not significantly more likely to produce adequate anticoagulation (peak anti-factor Xa 0.3 IU/mL or greater) when compared with fixed-dose enoxaparin (44.3% vs 48.2%, P = .67).",Fixed or Weight-Tiered Enoxaparin After Thoracic Surgery for Venous Thromboembolism Prevention. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32045583/),[iu] / [ml],0.3,235506,DB01109,Heparin
,32045583,peak anti-factor Xa,"Weight-tiered enoxaparin was not more likely to avoid over-anticoagulation (peak anti-factor Xa 0.5 IU/mL or greater) when compared with fixed-dose enoxaparin (3.3% vs 3.6%, P = 1.00).",Fixed or Weight-Tiered Enoxaparin After Thoracic Surgery for Venous Thromboembolism Prevention. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32045583/),[iu] / [ml],0.5,235507,DB01109,Heparin
,8758479,time of viability,The mean time of viability of the device is 13 weeks (SD: 10 weeks).,[Model of a miniature pig catheterized for pharmacokinetic and pharmacodynamic studies of anti-infective agents]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8758479/),weeks,13,235978,DB01109,Heparin
,10192753,oral bioavailability,Point estimates for the oral bioavailability of PPS were in the range of 0% with small confidence intervals (CIs).,The oral bioavailability of pentosan polysulphate sodium in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10192753/),%,0,236214,DB01109,Heparin
,22398784,peak pharmacodynamic effect,"Average peak pharmacodynamic effect, measured by anti-Xa activity, was 1.36 U/ml after administration of apixaban and was 0.42 U/ml after enoxaparin.","A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22398784/),[u] / [ml],1.36,238163,DB01109,Heparin
,22398784,peak pharmacodynamic effect,"Average peak pharmacodynamic effect, measured by anti-Xa activity, was 1.36 U/ml after administration of apixaban and was 0.42 U/ml after enoxaparin.","A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22398784/),[u] / [ml],0.42,238164,DB01109,Heparin
,24218420,Time to therapeutic range,"Time to therapeutic range was categorised into 0-12, 13-24 and >24 hours.",Monitoring of unfractionated heparin in critically ill patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24218420/),h,0-12,238538,DB01109,Heparin
,24218420,Time to therapeutic range,"Time to therapeutic range was categorised into 0-12, 13-24 and >24 hours.",Monitoring of unfractionated heparin in critically ill patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24218420/),h,13-24,238539,DB01109,Heparin
,24218420,time to therapeutic range,"In 101 patients admitted to the ICU and MCU, time to therapeutic range was 24 hours in 56% of the population, whereas in 10% of the patients no therapeutic APTT was achieved during UFH treatment.",Monitoring of unfractionated heparin in critically ill patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24218420/),h,24,238540,DB01109,Heparin
,24218420,time to therapeutic range,"In 101 patients admitted to the ICU and MCU, time to therapeutic range was 24 hours in 56% of the population, whereas in 10% of the patients no therapeutic APTT was achieved during UFH treatment.",Monitoring of unfractionated heparin in critically ill patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24218420/),h,56,238541,DB01109,Heparin
,2790187,terminal half-life,"In contrast, the clearance decreased with dose and the terminal half-life ranged from 0.45 +/- 0.08 hours at 0.5 mg/kg to 0.72 +/- 0.11 hours (mean +/- SD) at 2 mg/kg.",Pharmacodynamics and pharmacokinetics of dermatan sulfate in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2790187/),h,0.45,239424,DB01109,Heparin
,2790187,terminal half-life,"In contrast, the clearance decreased with dose and the terminal half-life ranged from 0.45 +/- 0.08 hours at 0.5 mg/kg to 0.72 +/- 0.11 hours (mean +/- SD) at 2 mg/kg.",Pharmacodynamics and pharmacokinetics of dermatan sulfate in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2790187/),h,0.72,239425,DB01109,Heparin
,2790187,bioavailabilities,The respective bioavailabilities were 24.7% +/- 12.9% and 12.4% +/- 9.2% for SC and IM administration.,Pharmacodynamics and pharmacokinetics of dermatan sulfate in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2790187/),%,24.7,239426,DB01109,Heparin
,2790187,bioavailabilities,The respective bioavailabilities were 24.7% +/- 12.9% and 12.4% +/- 9.2% for SC and IM administration.,Pharmacodynamics and pharmacokinetics of dermatan sulfate in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2790187/),%,12.4,239427,DB01109,Heparin
,2790187,peak concentrations,"The average peak concentrations were 0.7 +/- 0.3 and 0.4 +/- 0.2 mg/L after SC and IM injections, respectively.",Pharmacodynamics and pharmacokinetics of dermatan sulfate in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2790187/),[mg] / [l],0.7,239428,DB01109,Heparin
,2790187,peak concentrations,"The average peak concentrations were 0.7 +/- 0.3 and 0.4 +/- 0.2 mg/L after SC and IM injections, respectively.",Pharmacodynamics and pharmacokinetics of dermatan sulfate in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2790187/),[mg] / [l],0.4,239429,DB01109,Heparin
,2790187,half-lives,The half-lives of DS were 7.9 +/- 6.5 hours (SC) and 6.3 +/- 7.4 hours (IM).,Pharmacodynamics and pharmacokinetics of dermatan sulfate in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2790187/),h,7.9,239430,DB01109,Heparin
,2790187,half-lives,The half-lives of DS were 7.9 +/- 6.5 hours (SC) and 6.3 +/- 7.4 hours (IM).,Pharmacodynamics and pharmacokinetics of dermatan sulfate in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2790187/),h,6.3,239431,DB01109,Heparin
,10907966,effect half-life,"Furthermore, upon cessation of infusion, anticoagulant effects dissipated faster for argatroban (effect half-life 18-41 min) than for heparin (effect half-life 23-134 min).",Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10907966/),min,18-41,241473,DB01109,Heparin
,10907966,effect half-life,"Furthermore, upon cessation of infusion, anticoagulant effects dissipated faster for argatroban (effect half-life 18-41 min) than for heparin (effect half-life 23-134 min).",Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10907966/),min,23-134,241474,DB01109,Heparin
,6993082,half-life,"Heparin has a very short half-life, about 1.5 hours, which is dose-dependent and varies with the assay method employed for its measurements.",Clinical pharmacokinetics of heparin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6993082/),h,1.5,242118,DB01109,Heparin
up to,26612099,AUC(0-96 h) (area under the curve),The results of the PK studies showed reduced organ accumulation in mice and the AUC(0-96 h) (area under the curve) was increased up to 1485 ± 125 h × μg/ml.,Safety studies on intravenous infusion of a potent angiogenesis inhibitor: taurocholate-conjugated low molecular weight heparin derivative LHT7 in preclinical models. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612099/),[h·μg] / [ml],1485,242129,DB01109,Heparin
,8409044,Plasma clearance,Plasma clearance was between 1.5 and 1.7 ml/min per kg.,Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8409044/),[ml] / [kg·min],1.5 and 1.7,243679,DB01109,Heparin
,11156732,plasma clearance,"In patients with normal renal function, the intravenous pharmacokinetics of bivalirudin are dose proportional (linear) and are characterized by rapid plasma clearance (4.58 ml/minute/kg), a small volume of distribution (0.2 L/kg), and an elimination half-life of about 30 minutes.",The use of bivalirudin in patients with renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11156732/),[ml] / [kg·min],4.58,245307,DB01109,Heparin
,11156732,volume of distribution,"In patients with normal renal function, the intravenous pharmacokinetics of bivalirudin are dose proportional (linear) and are characterized by rapid plasma clearance (4.58 ml/minute/kg), a small volume of distribution (0.2 L/kg), and an elimination half-life of about 30 minutes.",The use of bivalirudin in patients with renal impairment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11156732/),[l] / [kg],0.2,245308,DB01109,Heparin
,11156732,elimination half-life,"In patients with normal renal function, the intravenous pharmacokinetics of bivalirudin are dose proportional (linear) and are characterized by rapid plasma clearance (4.58 ml/minute/kg), a small volume of distribution (0.2 L/kg), and an elimination half-life of about 30 minutes.",The use of bivalirudin in patients with renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11156732/),min,30,245309,DB01109,Heparin
,11156732,clearance,"A study comparing the pharmacokinetics and pharmacodynamics of bivalirudin with normal renal function (GFR greater than or = 90 ml/minute; n = 8), mild (GFR 60-89 ml/minute; n = 8), moderate (GFR 30-59 ml/minute; n = 7), or severe (GFR < 30 ml/minute; n = 10) renal impairment showed that while clearance was similar in the normal (4.58 ml/minute/kg) and mildly impaired (4.94 ml/minute/kg) groups, the clearance rate was reduced 45% in the moderate impairment (2.50 ml/minute/kg) group and about 68% in the severe impairment (1.46 ml/minute/kg) group.",The use of bivalirudin in patients with renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11156732/),[ml] / [kg·min],4.58,245310,DB01109,Heparin
,11156732,clearance,"A study comparing the pharmacokinetics and pharmacodynamics of bivalirudin with normal renal function (GFR greater than or = 90 ml/minute; n = 8), mild (GFR 60-89 ml/minute; n = 8), moderate (GFR 30-59 ml/minute; n = 7), or severe (GFR < 30 ml/minute; n = 10) renal impairment showed that while clearance was similar in the normal (4.58 ml/minute/kg) and mildly impaired (4.94 ml/minute/kg) groups, the clearance rate was reduced 45% in the moderate impairment (2.50 ml/minute/kg) group and about 68% in the severe impairment (1.46 ml/minute/kg) group.",The use of bivalirudin in patients with renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11156732/),[ml] / [kg·min],4.94,245311,DB01109,Heparin
,11156732,Clearance,Clearance was further reduced (77%) in a group of 12 dialysis dependent patients (1.04 ml/minute/kg).,The use of bivalirudin in patients with renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11156732/),[ml] / [kg·min],1.04,245312,DB01109,Heparin
,11156732,maximal effect (Emax),"The derived maximal effect (Emax) was similar for the normal (58.3 seconds), mildly impaired (44.7 seconds) and moderately impaired (56.8 seconds) groups, but prolonged in the severely renally impaired (79.4 seconds) and dialysis dependent (84.4 seconds) patients.",The use of bivalirudin in patients with renal impairment. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11156732/),seconds,58.3,245313,DB01109,Heparin
,11156732,maximal effect (Emax),"The derived maximal effect (Emax) was similar for the normal (58.3 seconds), mildly impaired (44.7 seconds) and moderately impaired (56.8 seconds) groups, but prolonged in the severely renally impaired (79.4 seconds) and dialysis dependent (84.4 seconds) patients.",The use of bivalirudin in patients with renal impairment. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11156732/),seconds,44.7,245314,DB01109,Heparin
,11156732,maximal effect (Emax),"The derived maximal effect (Emax) was similar for the normal (58.3 seconds), mildly impaired (44.7 seconds) and moderately impaired (56.8 seconds) groups, but prolonged in the severely renally impaired (79.4 seconds) and dialysis dependent (84.4 seconds) patients.",The use of bivalirudin in patients with renal impairment. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11156732/),seconds,56.8,245315,DB01109,Heparin
,11156732,maximal effect (Emax),"The derived maximal effect (Emax) was similar for the normal (58.3 seconds), mildly impaired (44.7 seconds) and moderately impaired (56.8 seconds) groups, but prolonged in the severely renally impaired (79.4 seconds) and dialysis dependent (84.4 seconds) patients.",The use of bivalirudin in patients with renal impairment. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11156732/),seconds,79.4,245316,DB01109,Heparin
,11156732,maximal effect (Emax),"The derived maximal effect (Emax) was similar for the normal (58.3 seconds), mildly impaired (44.7 seconds) and moderately impaired (56.8 seconds) groups, but prolonged in the severely renally impaired (79.4 seconds) and dialysis dependent (84.4 seconds) patients.",The use of bivalirudin in patients with renal impairment. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11156732/),seconds,84.4,245317,DB01109,Heparin
,11156732,ACT,"The mean 45-minute ACT values were similar (350-400 seconds) in the normal, mild and moderately impaired groups, but elevated in the severely impaired group (450 seconds).",The use of bivalirudin in patients with renal impairment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11156732/),seconds,350-400,245318,DB01109,Heparin
,11156732,ACT,"The mean 45-minute ACT values were similar (350-400 seconds) in the normal, mild and moderately impaired groups, but elevated in the severely impaired group (450 seconds).",The use of bivalirudin in patients with renal impairment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11156732/),seconds,450,245319,DB01109,Heparin
,11248285,anti-Xa/anti-IIa ratios,"The anti-Xa/anti-IIa ratios of the drug substances were comparable at 1.5 and 1.7 for tinzaparin and the tinzaparin-like LMWH, respectively.",Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11248285/),,1.5,245557,DB01109,Heparin
,11248285,anti-Xa/anti-IIa ratios,"The anti-Xa/anti-IIa ratios of the drug substances were comparable at 1.5 and 1.7 for tinzaparin and the tinzaparin-like LMWH, respectively.",Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11248285/),,1.7,245558,DB01109,Heparin
,11248285,maximum plasma anti-Xa activity (A(max)),Mean maximum plasma anti-Xa activity (A(max)) was approximately 0.818 IU/ml at 4 h following tinzaparin injection.,Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11248285/),[iu] / [ml],0.818,245559,DB01109,Heparin
,11248285,maximum plasma anti-IIa activity,Mean maximum plasma anti-IIa activity was 0.308 IU/ml at 5 h postdose.,Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11248285/),[iu] / [ml],0.308,245560,DB01109,Heparin
,28820026,heparin to protamine,Patients who had protamine dosing according to the algorithm demonstrated a lower protamine requirement post-bypass relative to empirical management as measured by absolute dose (243 ± 49mg vs. 305 ± 34.7mg; p<0.001) and the heparin to protamine ratio (0.79 ± 0.12 vs. 1.1 ± 0.15; p<0.001).,Pilot validation of an individualised pharmacokinetic algorithm for protamine dosing after systemic heparinisation for cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28820026/),,0.79,245879,DB01109,Heparin
,28820026,heparin to protamine,Patients who had protamine dosing according to the algorithm demonstrated a lower protamine requirement post-bypass relative to empirical management as measured by absolute dose (243 ± 49mg vs. 305 ± 34.7mg; p<0.001) and the heparin to protamine ratio (0.79 ± 0.12 vs. 1.1 ± 0.15; p<0.001).,Pilot validation of an individualised pharmacokinetic algorithm for protamine dosing after systemic heparinisation for cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28820026/),,1.1,245880,DB01109,Heparin
,28820026,ratio,Patients who had protamine dosing according to the algorithm demonstrated a lower protamine requirement post-bypass relative to empirical management as measured by absolute dose (243 ± 49mg vs. 305 ± 34.7mg; p<0.001) and the heparin to protamine ratio (0.79 ± 0.12 vs. 1.1 ± 0.15; p<0.001).,Pilot validation of an individualised pharmacokinetic algorithm for protamine dosing after systemic heparinisation for cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28820026/),,0.79,245881,DB01109,Heparin
,28820026,ratio,Patients who had protamine dosing according to the algorithm demonstrated a lower protamine requirement post-bypass relative to empirical management as measured by absolute dose (243 ± 49mg vs. 305 ± 34.7mg; p<0.001) and the heparin to protamine ratio (0.79 ± 0.12 vs. 1.1 ± 0.15; p<0.001).,Pilot validation of an individualised pharmacokinetic algorithm for protamine dosing after systemic heparinisation for cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28820026/),,1.1,245882,DB01109,Heparin
,28820026,activated clotting time (ACT) ratio,There was no difference in the pre- to post-bypass activated clotting time (ACT) ratio (1.05 ± 0.12 vs. 1.02 ± 0.15; p=0.9).,Pilot validation of an individualised pharmacokinetic algorithm for protamine dosing after systemic heparinisation for cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28820026/),,1.05,245883,DB01109,Heparin
,28820026,activated clotting time (ACT) ratio,There was no difference in the pre- to post-bypass activated clotting time (ACT) ratio (1.05 ± 0.12 vs. 1.02 ± 0.15; p=0.9).,Pilot validation of an individualised pharmacokinetic algorithm for protamine dosing after systemic heparinisation for cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28820026/),,1.02,245884,DB01109,Heparin
,23227470,plasma activity,"The anti-FXa plasma activity increased significantly after enoxaparin administration, with peak levels at 3 h after treatment, but was comparable between the ICU and medical ward groups (median 0.16 IU ml-1 [IQR 0-0.22 IU ml-1] vs. 0.2 IU ml-1 [IQR 0.15-0.27 IU ml-1],respectively, P = 0.13).",Bioactivity of enoxaparin in critically ill patients with normal renal function. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23227470/),[iu] / [ml],0.16,246944,DB01109,Heparin
,23227470,plasma activity,"The anti-FXa plasma activity increased significantly after enoxaparin administration, with peak levels at 3 h after treatment, but was comparable between the ICU and medical ward groups (median 0.16 IU ml-1 [IQR 0-0.22 IU ml-1] vs. 0.2 IU ml-1 [IQR 0.15-0.27 IU ml-1],respectively, P = 0.13).",Bioactivity of enoxaparin in critically ill patients with normal renal function. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23227470/),[iu] / [ml],0.2,246945,DB01109,Heparin
,23227470,area under the anti-FXa activity curve from 0–12 h,"The area under the anti-FXa activity curve from 0–12 h was similar between the groups (median 0.97 IU ml-1 h [IQR0.59-2.1] and 1.48 IU ml-1 h1 [IQR 0.83-1.62], P = 0.42 for the ICU group compared with the control group, respectively).",Bioactivity of enoxaparin in critically ill patients with normal renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23227470/),[h·iu] / [ml],0.97,246946,DB01109,Heparin
,23227470,area under the anti-FXa activity curve from 0–12 h,"The area under the anti-FXa activity curve from 0–12 h was similar between the groups (median 0.97 IU ml-1 h [IQR0.59-2.1] and 1.48 IU ml-1 h1 [IQR 0.83-1.62], P = 0.42 for the ICU group compared with the control group, respectively).",Bioactivity of enoxaparin in critically ill patients with normal renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23227470/),[h1·iu] / [ml],1.48,246947,DB01109,Heparin
,16616629,Maximum anti-Xa activity,"Maximum anti-Xa activity (ie, 0.42 +/- 0.13 IU/mL) was achieved 4 hours after administration (in 8 of 10 patients).",Monitoring of subcutaneous dalteparin in patients with renal insufficiency under intensive care: an observational study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16616629/),[iu] / [ml],0.42,247951,DB01109,Heparin
,28822164,flow rates,"The effects of different flow rates (0.50, 1.0, 1.5, 2.0，3.0 μL•min⁻¹) on recovery in vitro were determined by incremental method and decrement method.",[Analysis on microdialysis probe recovery of baicalin in vitro and in vivo based on LC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28822164/),min⁻¹·μl,1.0,248935,DB01109,Heparin
,28822164,flow rates,"The effects of different flow rates (0.50, 1.0, 1.5, 2.0，3.0 μL•min⁻¹) on recovery in vitro were determined by incremental method and decrement method.",[Analysis on microdialysis probe recovery of baicalin in vitro and in vivo based on LC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28822164/),min⁻¹·μl,1.5,248936,DB01109,Heparin
,28822164,flow rates,"The effects of different flow rates (0.50, 1.0, 1.5, 2.0，3.0 μL•min⁻¹) on recovery in vitro were determined by incremental method and decrement method.",[Analysis on microdialysis probe recovery of baicalin in vitro and in vivo based on LC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28822164/),min⁻¹·μl,2.,248937,DB01109,Heparin
,23879789,AUC,"The AUC of diclofenac from DICCIC (53.7± 5.8 ug/mL.min) was significantly less (Mann Whitney test, p<0.05) than that of diclofenac from diclofenac administration (885.9 ± 124,8 ug/mL.min).",Pharmacokinetic profile of a new diclofenac prodrug without gastroulcerogenic effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23879789/),[ug] / [min·ml],53.7,249456,DB01109,Heparin
,23879789,AUC,"The AUC of diclofenac from DICCIC (53.7± 5.8 ug/mL.min) was significantly less (Mann Whitney test, p<0.05) than that of diclofenac from diclofenac administration (885.9 ± 124,8 ug/mL.min).",Pharmacokinetic profile of a new diclofenac prodrug without gastroulcerogenic effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23879789/),[ug] / [min·ml],885.9,249457,DB01109,Heparin
,23879789,Terminal half-life,"Terminal half-life of diclofenac from DICCIC (50.1 ± 17.2 min) was significantly less (Mann Whitney test, p<0.05) than that of diclofenac from diclofenac administration (247.4 ± 100.9 min).",Pharmacokinetic profile of a new diclofenac prodrug without gastroulcerogenic effect. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23879789/),min,50.1,249458,DB01109,Heparin
,23879789,Terminal half-life,"Terminal half-life of diclofenac from DICCIC (50.1 ± 17.2 min) was significantly less (Mann Whitney test, p<0.05) than that of diclofenac from diclofenac administration (247.4 ± 100.9 min).",Pharmacokinetic profile of a new diclofenac prodrug without gastroulcerogenic effect. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23879789/),min,247.4,249459,DB01109,Heparin
,23879789,clearance,"Still the parameters clearance and distribution volume were calculated for diclofenac from diclofenac, whose results were 9.2 ±1.2 mL/min.kg and 3.3 ±1.2 L/kg, respectively.",Pharmacokinetic profile of a new diclofenac prodrug without gastroulcerogenic effect. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23879789/),[ml] / [kg·min],9.2,249460,DB01109,Heparin
,23879789,distribution volume,"Still the parameters clearance and distribution volume were calculated for diclofenac from diclofenac, whose results were 9.2 ±1.2 mL/min.kg and 3.3 ±1.2 L/kg, respectively.",Pharmacokinetic profile of a new diclofenac prodrug without gastroulcerogenic effect. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23879789/),[l] / [kg],3.3,249461,DB01109,Heparin
,23879789,DICCIC,"The results of DICCIC from DICCIC administration were 108.9 ± 19.6 mL/min.kg and 7.8 ± 2.4 L/kg for clearance and distribution volume, respectively.",Pharmacokinetic profile of a new diclofenac prodrug without gastroulcerogenic effect. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23879789/),[l] / [kg],7.8,249462,DB01109,Heparin
,23879789,clearance,"The results of DICCIC from DICCIC administration were 108.9 ± 19.6 mL/min.kg and 7.8 ± 2.4 L/kg for clearance and distribution volume, respectively.",Pharmacokinetic profile of a new diclofenac prodrug without gastroulcerogenic effect. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23879789/),[ml] / [kg·min],108.9,249463,DB01109,Heparin
,23879789,clearance,"The results of DICCIC from DICCIC administration were 108.9 ± 19.6 mL/min.kg and 7.8 ± 2.4 L/kg for clearance and distribution volume, respectively.",Pharmacokinetic profile of a new diclofenac prodrug without gastroulcerogenic effect. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23879789/),[l] / [kg],7.8,249464,DB01109,Heparin
,23879789,distribution volume,"The results of DICCIC from DICCIC administration were 108.9 ± 19.6 mL/min.kg and 7.8 ± 2.4 L/kg for clearance and distribution volume, respectively.",Pharmacokinetic profile of a new diclofenac prodrug without gastroulcerogenic effect. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23879789/),[l] / [kg],7.8,249465,DB01109,Heparin
,4042156,half-life (t 1/2,"Following discontinuation of infusion, APTT declined with a relatively constant half-life (t 1/2 of 2.4 +/- 0.08 hr, suggesting elimination by first-order kinetics.",Heparin elimination following continuous infusion during intra-aortic balloon counterpulsation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042156/),h,2.4,249904,DB01109,Heparin
,4042156,t 1/2,"In comparison, the t 1/2 following single bolus doses has been shown to be markedly dose dependent, increasing from 30 min at low doses to 2 hr at very high doses.",Heparin elimination following continuous infusion during intra-aortic balloon counterpulsation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042156/),min,30,249905,DB01109,Heparin
,4042156,t 1/2,"In comparison, the t 1/2 following single bolus doses has been shown to be markedly dose dependent, increasing from 30 min at low doses to 2 hr at very high doses.",Heparin elimination following continuous infusion during intra-aortic balloon counterpulsation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042156/),h,2,249906,DB01109,Heparin
,12440613,volume of distribution,"Model-independent pharmacokinetic analysis revealed median (range) values as follows: volume of distribution, 5.4 L (0.82 to 34 L); clearance, 1.4 L/min (0.61 to 3.8 L/min); and half-life, 4.5 min (1.9 to 18 min).",Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12440613/),l,5.4,250230,DB01109,Heparin
,12440613,clearance,"Model-independent pharmacokinetic analysis revealed median (range) values as follows: volume of distribution, 5.4 L (0.82 to 34 L); clearance, 1.4 L/min (0.61 to 3.8 L/min); and half-life, 4.5 min (1.9 to 18 min).",Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12440613/),[l] / [min],1.4,250231,DB01109,Heparin
,12440613,half-life,"Model-independent pharmacokinetic analysis revealed median (range) values as follows: volume of distribution, 5.4 L (0.82 to 34 L); clearance, 1.4 L/min (0.61 to 3.8 L/min); and half-life, 4.5 min (1.9 to 18 min).",Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12440613/),min,4.5,250232,DB01109,Heparin
,12440613,half-life,Protamine has a very short (approximately 5 minutes) half-life after a single 250-mg dose in adult patients.,Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12440613/),min,5,250233,DB01109,Heparin
,2476054,peak plasma concentrations,"In contrast, after the intravenous dose of 225 mg, peak plasma concentrations by competitive binding assay were 26 to 35 micrograms/mL (median, 28 micrograms/mL); 25% to 29% (median, 25%) of the dose was recovered in the urine; the APTT increased to 3.5 to 9.2 times the baseline value (median increase, 6.9 times), and the plasma lipolytic activity increased by 185 to 548 times the baseline value (median increase, 438 times).",Dextran sulfate is poorly absorbed after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2476054/),[μg] / [ml],26 to 35,250662,DB01109,Heparin
,2476054,peak plasma concentrations,"In contrast, after the intravenous dose of 225 mg, peak plasma concentrations by competitive binding assay were 26 to 35 micrograms/mL (median, 28 micrograms/mL); 25% to 29% (median, 25%) of the dose was recovered in the urine; the APTT increased to 3.5 to 9.2 times the baseline value (median increase, 6.9 times), and the plasma lipolytic activity increased by 185 to 548 times the baseline value (median increase, 438 times).",Dextran sulfate is poorly absorbed after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2476054/),[μg] / [ml],28,250663,DB01109,Heparin
,7997983,half-lives,"The decay in plasma could be described by a three-compartment model with half-lives of the two distributive phases and the terminal elimination phase of 15 min, 90 min, and 37 hrs, respectively.",Pharmacokinetics of tinzaparin (Logiparin)--a low molecular weight heparin--after single and repeated intravenous administration in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997983/),min,15,251953,DB01109,Heparin
,7997983,half-lives,"The decay in plasma could be described by a three-compartment model with half-lives of the two distributive phases and the terminal elimination phase of 15 min, 90 min, and 37 hrs, respectively.",Pharmacokinetics of tinzaparin (Logiparin)--a low molecular weight heparin--after single and repeated intravenous administration in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997983/),min,90,251954,DB01109,Heparin
,7997983,terminal elimination phase,"The decay in plasma could be described by a three-compartment model with half-lives of the two distributive phases and the terminal elimination phase of 15 min, 90 min, and 37 hrs, respectively.",Pharmacokinetics of tinzaparin (Logiparin)--a low molecular weight heparin--after single and repeated intravenous administration in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997983/),min,15,251955,DB01109,Heparin
,7997983,terminal elimination phase,"The decay in plasma could be described by a three-compartment model with half-lives of the two distributive phases and the terminal elimination phase of 15 min, 90 min, and 37 hrs, respectively.",Pharmacokinetics of tinzaparin (Logiparin)--a low molecular weight heparin--after single and repeated intravenous administration in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997983/),min,90,251956,DB01109,Heparin
,7997983,terminal elimination phase,"The decay in plasma could be described by a three-compartment model with half-lives of the two distributive phases and the terminal elimination phase of 15 min, 90 min, and 37 hrs, respectively.",Pharmacokinetics of tinzaparin (Logiparin)--a low molecular weight heparin--after single and repeated intravenous administration in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997983/),h,37,251957,DB01109,Heparin
,7997983,accumulation ratios,"Drug-related radioactivity accumulated gradually with repeated dosing, reaching accumulation ratios between 5 and 9, when based on trough concentrations.",Pharmacokinetics of tinzaparin (Logiparin)--a low molecular weight heparin--after single and repeated intravenous administration in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997983/),,5 and 9,251958,DB01109,Heparin
,12040334,apparent clearance,"The mean apparent clearance, distribution volume, and plasma half-life were 0.733 L/h, 5.24 L, and 5 hours, respectively.",Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12040334/),[l] / [h],0.733,252945,DB01109,Heparin
,12040334,distribution volume,"The mean apparent clearance, distribution volume, and plasma half-life were 0.733 L/h, 5.24 L, and 5 hours, respectively.",Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12040334/),l,5.24,252946,DB01109,Heparin
,12040334,plasma half-life,"The mean apparent clearance, distribution volume, and plasma half-life were 0.733 L/h, 5.24 L, and 5 hours, respectively.",Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12040334/),h,5,252947,DB01109,Heparin
,25602360,half-life,"Owing to the long elimination of inclacumab (half-life of approximately 18 days), a 2-period, one-sequence study design was used.",Absence of pharmacodynamic interaction between inclacumab and heparin in healthy smokers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25602360/),d,18,253599,DB01109,Heparin
,16982783,half-life,"The results of both the SAD and the MAD studies indicated that there was a dose dependency in the half-life of itraconazole from the novel formulation, increasing from 44 h (100 mg) to more than 150 h (300 mg) once steady state was achieved.",Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16982783/),h,44,255340,DB01109,Heparin
more,16982783,half-life,"The results of both the SAD and the MAD studies indicated that there was a dose dependency in the half-life of itraconazole from the novel formulation, increasing from 44 h (100 mg) to more than 150 h (300 mg) once steady state was achieved.",Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16982783/),h,150,255341,DB01109,Heparin
,24810867,Cmax,Following the single SC injection Cmax was 0.83 ± 0.08 anti-Xa IU/mL and in 5/6 cats was detected after 2 h (Tmax = 110 ± 25 min).,Enoxaparin: pharmacokinetics and treatment schedule for cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24810867/),[iu] / [ml],0.83,255769,DB01109,Heparin
,24810867,Tmax,Following the single SC injection Cmax was 0.83 ± 0.08 anti-Xa IU/mL and in 5/6 cats was detected after 2 h (Tmax = 110 ± 25 min).,Enoxaparin: pharmacokinetics and treatment schedule for cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24810867/),min,110,255770,DB01109,Heparin
,24810867,total clearance,The total clearance was 23.4 ± 4.8 mL/h/kg and the terminal half-life was 2.27 ± 0.4 h.,Enoxaparin: pharmacokinetics and treatment schedule for cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24810867/),[ml] / [h·kg],23.4,255771,DB01109,Heparin
,24810867,terminal half-life,The total clearance was 23.4 ± 4.8 mL/h/kg and the terminal half-life was 2.27 ± 0.4 h.,Enoxaparin: pharmacokinetics and treatment schedule for cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24810867/),h,2.27,255772,DB01109,Heparin
,24810867,peak,"All cats receiving repeated injections reached the defined target peak range of 0.5-1.0 IU/mL by 2 h after the second injection (0.54 [0.50-0.61]; median, [minimum - maximum]) and there was no considerable accumulation subsequently.",Enoxaparin: pharmacokinetics and treatment schedule for cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24810867/),[iu] / [ml],0.5-1.0,255773,DB01109,Heparin
,24810867,activated partial thromboplastin time ratio,"With the exception of thromboelastometry (especially non-activated), ratio values of coagulation times increased significantly although only slightly (e.g., the maximal value of median activated partial thromboplastin time ratio was 1.27).",Enoxaparin: pharmacokinetics and treatment schedule for cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24810867/),,1.27,255774,DB01109,Heparin
,4000042,half-life,"The plasma warfarin level fell rapidly (half-life, 21.7 h), and there was no convincing evidence for dose-dependency in its disposition.",Plasma warfarin concentrations after a massive overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4000042/),h,21.7,256626,DB01109,Heparin
,12199669,recovery,The recovery of vWF: RCo was significantly lower in patients with type 3 vWD (1.4 +/- 0.05% U(-1) kg(-1)) compared with that of the patients with types 1 (2.3 +/- 0.52% U(-1) kg(-1)) or 2A (2.0 +/- 0.06% U(-1) kg(-1)) vWD (P = 0.015).,"Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12199669/),[%] / [kg·u],1.4,256978,DB01109,Heparin
,12199669,recovery,The recovery of vWF: RCo was significantly lower in patients with type 3 vWD (1.4 +/- 0.05% U(-1) kg(-1)) compared with that of the patients with types 1 (2.3 +/- 0.52% U(-1) kg(-1)) or 2A (2.0 +/- 0.06% U(-1) kg(-1)) vWD (P = 0.015).,"Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12199669/),[%] / [kg·u],2.3,256979,DB01109,Heparin
,12199669,recovery,The recovery of vWF: RCo was significantly lower in patients with type 3 vWD (1.4 +/- 0.05% U(-1) kg(-1)) compared with that of the patients with types 1 (2.3 +/- 0.52% U(-1) kg(-1)) or 2A (2.0 +/- 0.06% U(-1) kg(-1)) vWD (P = 0.015).,"Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12199669/),[%] / [kg·u],2.0,256980,DB01109,Heparin
,12199669,clearance,Type 3 vWD patients exhibited significantly higher vWF:RCo clearance (5.1 +/- 1.1 mL kg(-1) h(-1)) compared with that of patients with type 2A (2.8 +/- 0.7 mL kg(-1) h(-1)) and type 1 (2.6 +/- 1.0 mL kg(-1) h(-1)) vWD (P = 0.028).,"Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12199669/),[ml] / [h·kg],5.1,256981,DB01109,Heparin
,12199669,clearance,Type 3 vWD patients exhibited significantly higher vWF:RCo clearance (5.1 +/- 1.1 mL kg(-1) h(-1)) compared with that of patients with type 2A (2.8 +/- 0.7 mL kg(-1) h(-1)) and type 1 (2.6 +/- 1.0 mL kg(-1) h(-1)) vWD (P = 0.028).,"Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12199669/),[ml] / [h·kg],2.8,256982,DB01109,Heparin
,12199669,clearance,Type 3 vWD patients exhibited significantly higher vWF:RCo clearance (5.1 +/- 1.1 mL kg(-1) h(-1)) compared with that of patients with type 2A (2.8 +/- 0.7 mL kg(-1) h(-1)) and type 1 (2.6 +/- 1.0 mL kg(-1) h(-1)) vWD (P = 0.028).,"Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12199669/),[ml] / [h·kg],2.6,256983,DB01109,Heparin
,12199669,terminal half-life,"Accordingly, terminal half-life was lower in patients with type 3 vWD (8.0 +/- 0.6 h(-1)) compared with type 2A (12.7 +/- 5.9 h(-1)) or type 1 (14 +/- 1.2 h(-1)) vWD patients.","Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12199669/),1/[h],8.0,256984,DB01109,Heparin
,12199669,terminal half-life,"Accordingly, terminal half-life was lower in patients with type 3 vWD (8.0 +/- 0.6 h(-1)) compared with type 2A (12.7 +/- 5.9 h(-1)) or type 1 (14 +/- 1.2 h(-1)) vWD patients.","Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12199669/),1/[h],12.7,256985,DB01109,Heparin
,12199669,terminal half-life,"Accordingly, terminal half-life was lower in patients with type 3 vWD (8.0 +/- 0.6 h(-1)) compared with type 2A (12.7 +/- 5.9 h(-1)) or type 1 (14 +/- 1.2 h(-1)) vWD patients.","Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12199669/),1/[h],14,256986,DB01109,Heparin
,29423936,clearance (CLTYP,"Parameter estimates were CLi = CLTYP * (BWPREOP /70)3/4 ; Vi = VTYP * (BW(t)/70)1 ; where typical clearance (CLTYP ) and typical volume of distribution (VTYP ) were 1.23 l h-1 and 14.6 l, respectively.",Population pharmacokinetics of enoxaparin in early stage of paediatric liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29423936/),[l] / [h],1.23,257078,DB01109,Heparin
,29423936,volume of distribution (VTYP ),"Parameter estimates were CLi = CLTYP * (BWPREOP /70)3/4 ; Vi = VTYP * (BW(t)/70)1 ; where typical clearance (CLTYP ) and typical volume of distribution (VTYP ) were 1.23 l h-1 and 14.6 l, respectively.",Population pharmacokinetics of enoxaparin in early stage of paediatric liver transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29423936/),l,14.6,257079,DB01109,Heparin
,29423936,anti-,More than 100 IU kg-1 12 h-1 are suggested to reach the target range of anti-Xa activity of 0.2-0.4 IU ml-1 from the first day.,Population pharmacokinetics of enoxaparin in early stage of paediatric liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29423936/),i,0.2-0.4,257080,DB01109,Heparin
,12147872,peak anti-Xa level,"The peak anti-Xa level was 1.30 0.18 IU/ml (range, 1.03 1.69 IU/ml).",Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12147872/),[iu] / [ml],1.30,257917,DB01109,Heparin
,12147872,minimum anti-Xa level,The minimum anti-Xa level was 0.55 IU/ml 4 hours after enoxaparin.,Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12147872/),[iu] / [ml],0.55,257918,DB01109,Heparin
,1963020,half-life,"After intravenous administration, unfractionated heparin was cleared with a half-life of 35 min, irrespective of assay methods.",Comparison of the pharmacokinetics of enoxaparin (Clexane) and unfractionated heparin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1963020/),min,35,257924,DB01109,Heparin
,1963020,half-life,"However, the concentration of enoxaparin, measured by competitive binding assay, declined with the longer half-life of 60 min, and its anti-Factor IIa and anti-Factor Xa activities had half-lives of 40 and 275 min, respectively.",Comparison of the pharmacokinetics of enoxaparin (Clexane) and unfractionated heparin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1963020/),min,60,257925,DB01109,Heparin
,1963020,half-lives,"However, the concentration of enoxaparin, measured by competitive binding assay, declined with the longer half-life of 60 min, and its anti-Factor IIa and anti-Factor Xa activities had half-lives of 40 and 275 min, respectively.",Comparison of the pharmacokinetics of enoxaparin (Clexane) and unfractionated heparin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1963020/),min,40,257926,DB01109,Heparin
,1963020,half-lives,"However, the concentration of enoxaparin, measured by competitive binding assay, declined with the longer half-life of 60 min, and its anti-Factor IIa and anti-Factor Xa activities had half-lives of 40 and 275 min, respectively.",Comparison of the pharmacokinetics of enoxaparin (Clexane) and unfractionated heparin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1963020/),min,275,257927,DB01109,Heparin
,2595748,half-life,"Mean first-order pharmacokinetic parameters were: half-life, 117 min; heparin volume of distribution (V), 68 ml/kg; clearance, 28 ml/min.",Heparin pharmacokinetics during hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595748/),min,117,258254,DB01109,Heparin
,2595748,volume of distribution (V),"Mean first-order pharmacokinetic parameters were: half-life, 117 min; heparin volume of distribution (V), 68 ml/kg; clearance, 28 ml/min.",Heparin pharmacokinetics during hemodialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595748/),[ml] / [kg],68,258255,DB01109,Heparin
,2595748,clearance,"Mean first-order pharmacokinetic parameters were: half-life, 117 min; heparin volume of distribution (V), 68 ml/kg; clearance, 28 ml/min.",Heparin pharmacokinetics during hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595748/),[ml] / [min],28,258256,DB01109,Heparin
,1719279,re,Comparison with infusion experiments showed that intravenous bolus injection of 140 kU/kg of BM 06.022 was equieffective to a 90-min infusion of 800 kU/kg (= 1 mg/kg) of alteplase as a standard treatment regarding reperfusion rate (66%) and time to reperfusion (15 +/- 6 vs. 18 +/- 8 min).,Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1719279/),,66,258779,DB01109,Heparin
,1719279,time to reperfusion,Comparison with infusion experiments showed that intravenous bolus injection of 140 kU/kg of BM 06.022 was equieffective to a 90-min infusion of 800 kU/kg (= 1 mg/kg) of alteplase as a standard treatment regarding reperfusion rate (66%) and time to reperfusion (15 +/- 6 vs. 18 +/- 8 min).,Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1719279/),min,15,258780,DB01109,Heparin
,1719279,time to reperfusion,Comparison with infusion experiments showed that intravenous bolus injection of 140 kU/kg of BM 06.022 was equieffective to a 90-min infusion of 800 kU/kg (= 1 mg/kg) of alteplase as a standard treatment regarding reperfusion rate (66%) and time to reperfusion (15 +/- 6 vs. 18 +/- 8 min).,Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1719279/),min,18,258781,DB01109,Heparin
,1719279,total plasma clearance,Pharmacokinetic analysis for functionally active BM 06.022 or alteplase in plasma revealed a total plasma clearance of 4.1-6.6 ml/min/kg for BM 06.022 and of 12.6-42.3 ml/min/kg for alteplase.,Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1719279/),[ml] / [kg·min],4.1-6.6,258782,DB01109,Heparin
,1719279,total plasma clearance,Pharmacokinetic analysis for functionally active BM 06.022 or alteplase in plasma revealed a total plasma clearance of 4.1-6.6 ml/min/kg for BM 06.022 and of 12.6-42.3 ml/min/kg for alteplase.,Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1719279/),[ml] / [kg·min],12.6-42.3,258783,DB01109,Heparin
,15886289,aPTT,The infusion was initiated at 2.0 microg/kg/min and was titrated to a goal aPTT of 60-80 seconds.,"Extensive prolongation of aPTT with argatroban in an elderly patient with improving renal function, normal hepatic enzymes, and metastatic lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15886289/),seconds,60-80,259081,DB01109,Heparin
,1964665,ratio of,"These preparations have a ratio of anti-Xa activity to anti-II activity of approximately 4, while it is 1 for unfractionated heparin.",Heparin and thrombosis: a seventy year long story. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1964665/),,4,259745,DB01109,Heparin
,1964665,ratio of,"These preparations have a ratio of anti-Xa activity to anti-II activity of approximately 4, while it is 1 for unfractionated heparin.",Heparin and thrombosis: a seventy year long story. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1964665/),,1,259746,DB01109,Heparin
,28335025,m,"The analyte detection was performed on a triple quadrupole tandem mass spectrometer equipped with positive-ion electrospray ionization by multiple reaction ion monitoring mode of the transitions at m/z [M + H]+ 175.1 → 77.1 for edaravone, and m/z [M + H]+ 180.2 → 110.0 for phenacetin.","A Novel LC-MS-MS Method With an Effective Antioxidant for the Determination of Edaravone, a Free-Radical Scavenger in Dog Plasma and its Application to a Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28335025/),,77,260639,DB01109,Heparin
,28335025,m/,"The analyte detection was performed on a triple quadrupole tandem mass spectrometer equipped with positive-ion electrospray ionization by multiple reaction ion monitoring mode of the transitions at m/z [M + H]+ 175.1 → 77.1 for edaravone, and m/z [M + H]+ 180.2 → 110.0 for phenacetin.","A Novel LC-MS-MS Method With an Effective Antioxidant for the Determination of Edaravone, a Free-Radical Scavenger in Dog Plasma and its Application to a Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28335025/),,180.,260640,DB01109,Heparin
,28335025,m/,"The analyte detection was performed on a triple quadrupole tandem mass spectrometer equipped with positive-ion electrospray ionization by multiple reaction ion monitoring mode of the transitions at m/z [M + H]+ 175.1 → 77.1 for edaravone, and m/z [M + H]+ 180.2 → 110.0 for phenacetin.","A Novel LC-MS-MS Method With an Effective Antioxidant for the Determination of Edaravone, a Free-Radical Scavenger in Dog Plasma and its Application to a Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28335025/),,110.0,260641,DB01109,Heparin
,31578015,Peak anti-Xa,Peak anti-Xa was significantly higher in the IV group 0.42 (0.39-0.43) IU/mL than in the SC group 0.16 (0.09-0.18) IU/mL (p < 0.001).,Pharmacokinetic Comparison of Subcutaneous and Intravenous Nadroparin Administration for Thromboprophylaxis in Critically Ill Patients on Vasopressors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31578015/),[iu] / [ml],0.42,261293,DB01109,Heparin
,31578015,Peak anti-Xa,Peak anti-Xa was significantly higher in the IV group 0.42 (0.39-0.43) IU/mL than in the SC group 0.16 (0.09-0.18) IU/mL (p < 0.001).,Pharmacokinetic Comparison of Subcutaneous and Intravenous Nadroparin Administration for Thromboprophylaxis in Critically Ill Patients on Vasopressors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31578015/),[iu] / [ml],0.16,261294,DB01109,Heparin
,31578015,area under the curve (AUC),There was a trend towards higher area under the curve (AUC) of anti-Xa in the SC group 1.41 (0.41-1.80) IU/mL × h than in the IV group 1.04 (0.93-1.13) IU/mL × h (p = 0.08).,Pharmacokinetic Comparison of Subcutaneous and Intravenous Nadroparin Administration for Thromboprophylaxis in Critically Ill Patients on Vasopressors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31578015/),[iu] / [h·ml],1.41,261295,DB01109,Heparin
,31578015,area under the curve (AUC),There was a trend towards higher area under the curve (AUC) of anti-Xa in the SC group 1.41 (0.41-1.80) IU/mL × h than in the IV group 1.04 (0.93-1.13) IU/mL × h (p = 0.08).,Pharmacokinetic Comparison of Subcutaneous and Intravenous Nadroparin Administration for Thromboprophylaxis in Critically Ill Patients on Vasopressors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31578015/),[iu] / [h·ml],1.04,261296,DB01109,Heparin
,31578015,decrease half-life,"In the IV group, anti-Xa decrease half-life was 1.6 (1.4-2.0) h.",Pharmacokinetic Comparison of Subcutaneous and Intravenous Nadroparin Administration for Thromboprophylaxis in Critically Ill Patients on Vasopressors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31578015/),h,1.6,261297,DB01109,Heparin
higher,18779469,trough anti-Xa level,"Bioaccumulation was defined by a trough anti-Xa level higher than 0.40 IU/mL, measured twice weekly.",Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18779469/),[iu] / [ml],0.40,262311,DB01109,Heparin
<,18779469,trough anti-Xa level,"In 120 patients who had at least 1 trough anti-Xa level (427 total measurements), no patient had bioaccumulation (0%; 95% confidence interval [CI]: 0%-3.0%); the median (IQR) trough anti-Xa level was undetectable (<0.10 IU/mL [<0.10 to <0.10 IU/mL]).",Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18779469/),[iu] / [ml],0.10,262312,DB01109,Heparin
,18779469,peak anti-Xa,"Based on serial measurements, peak anti-Xa levels were 0.29 to 0.34 IU/mL and trough levels were lower than 0.06 IU/mL.",Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18779469/),[iu] / [ml],0.29 to 0.34,262313,DB01109,Heparin
lower,18779469,trough levels,"Based on serial measurements, peak anti-Xa levels were 0.29 to 0.34 IU/mL and trough levels were lower than 0.06 IU/mL.",Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18779469/),[iu] / [ml],0.06,262314,DB01109,Heparin
,18779469,trough anti-Xa,"Deep vein thrombosis occurred in 7 of 138 patients (5.1%; 95% CI, 2.5%-10.1%); major bleeding occurred in 10 patients (7.2%; 95% CI, 4.0%-12.8%), all with trough anti-Xa levels of 0.18 IU/mL or lower.",Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18779469/),[iu] / [ml],0.18,262315,DB01109,Heparin
,2508258,peak plasma concentration,"Ten mg rt-PA were infused in 2 minutes resulting in a peak plasma concentration (mean +/- SD) of 3310 +/- 950 ng/ml, followed by 50 mg in 1 h and 30 mg in 1.5 h yielding steady state plasma levels of 2210 +/- 470 ng/ml and 930 +/- 200 ng/ml, respectively.",Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2508258/),[ng] / [ml],3310,264754,DB01109,Heparin
,2508258,steady state plasma levels,"Ten mg rt-PA were infused in 2 minutes resulting in a peak plasma concentration (mean +/- SD) of 3310 +/- 950 ng/ml, followed by 50 mg in 1 h and 30 mg in 1.5 h yielding steady state plasma levels of 2210 +/- 470 ng/ml and 930 +/- 200 ng/ml, respectively.",Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2508258/),[ng] / [ml],2210,264755,DB01109,Heparin
,2508258,steady state plasma levels,"Ten mg rt-PA were infused in 2 minutes resulting in a peak plasma concentration (mean +/- SD) of 3310 +/- 950 ng/ml, followed by 50 mg in 1 h and 30 mg in 1.5 h yielding steady state plasma levels of 2210 +/- 470 ng/ml and 930 +/- 200 ng/ml, respectively.",Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2508258/),[ng] / [ml],930,264756,DB01109,Heparin
,2508258,Total clearance,"Total clearance of rt-PA was 380 +/- 74 ml/min, t1/2 alpha was 3.6 +/- 0.9 min and t1/2 beta was 16 +/- 5.4 min.",Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2508258/),[ml] / [min],380,264757,DB01109,Heparin
,2508258,t1/2 alpha,"Total clearance of rt-PA was 380 +/- 74 ml/min, t1/2 alpha was 3.6 +/- 0.9 min and t1/2 beta was 16 +/- 5.4 min.",Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2508258/),min,3.6,264758,DB01109,Heparin
,2508258,t1/2 beta,"Total clearance of rt-PA was 380 +/- 74 ml/min, t1/2 alpha was 3.6 +/- 0.9 min and t1/2 beta was 16 +/- 5.4 min.",Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2508258/),min,16,264759,DB01109,Heparin
,21978598,maximum plasma heparin activities (C(max)),"Following IV injection, maximum plasma heparin activities (C(max)) were 0.67 ± 0.14, 1.44 ± 0.22 and 2.87 ± 0.38 IU anti-FXa/mL, respectively.",Pharmacokinetics of the low molecular weight heparin dalteparin in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21978598/),iu,0.67,265116,DB01109,Heparin
,21978598,maximum plasma heparin activities (C(max)),"Following IV injection, maximum plasma heparin activities (C(max)) were 0.67 ± 0.14, 1.44 ± 0.22 and 2.87 ± 0.38 IU anti-FXa/mL, respectively.",Pharmacokinetics of the low molecular weight heparin dalteparin in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21978598/),iu,1.44,265117,DB01109,Heparin
,21978598,maximum plasma heparin activities (C(max)),"Following IV injection, maximum plasma heparin activities (C(max)) were 0.67 ± 0.14, 1.44 ± 0.22 and 2.87 ± 0.38 IU anti-FXa/mL, respectively.",Pharmacokinetics of the low molecular weight heparin dalteparin in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21978598/),iu,2.87,265118,DB01109,Heparin
,21978598,half-life (t(½)),The calculated mean half-life (t(½)) was between 39 and 57 min and was not significantly dose-dependent (P=0.139).,Pharmacokinetics of the low molecular weight heparin dalteparin in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21978598/),min,39 and 57,265119,DB01109,Heparin
,21978598,volume of distribution,The volume of distribution (35-39 mL/kg) was almost equivalent to the plasma volume.,Pharmacokinetics of the low molecular weight heparin dalteparin in cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21978598/),[ml] / [kg],35-39,265120,DB01109,Heparin
,21978598,C(max),"After SC injection, C(max) values of 0.41 ± 0.10, 0.86 ± 0.17 or 1.91 ± 0.16 IU anti-FXa/mL, respectively, were calculated at 91-110 min post-injection.",Pharmacokinetics of the low molecular weight heparin dalteparin in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21978598/),[a·anti-f·iu] / [ml],0.41,265121,DB01109,Heparin
,21978598,C(max),"After SC injection, C(max) values of 0.41 ± 0.10, 0.86 ± 0.17 or 1.91 ± 0.16 IU anti-FXa/mL, respectively, were calculated at 91-110 min post-injection.",Pharmacokinetics of the low molecular weight heparin dalteparin in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21978598/),[a·anti-f·iu] / [ml],0.86,265122,DB01109,Heparin
,21978598,C(max),"After SC injection, C(max) values of 0.41 ± 0.10, 0.86 ± 0.17 or 1.91 ± 0.16 IU anti-FXa/mL, respectively, were calculated at 91-110 min post-injection.",Pharmacokinetics of the low molecular weight heparin dalteparin in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21978598/),[a·anti-f·iu] / [ml],1.91,265123,DB01109,Heparin
,21978598,t(½),The t(½) values were between 106 and 122 min and were not significantly influenced by dose (P=0.784).,Pharmacokinetics of the low molecular weight heparin dalteparin in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21978598/),min,106 and 122,265124,DB01109,Heparin
,21978598,bioavailability,The bioavailability after SC injection was approximately 100%.,Pharmacokinetics of the low molecular weight heparin dalteparin in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21978598/),%,100,265125,DB01109,Heparin
,7482431,recovery rates,The recovery rates of the native LDL particles ranged between 75% and 85% of the injected dose.,The injection of heparin prolongs the plasma clearance of oxidized low density lipoprotein in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482431/),%,75,266357,DB01109,Heparin
,7482431,recovery rates,The recovery rates of the native LDL particles ranged between 75% and 85% of the injected dose.,The injection of heparin prolongs the plasma clearance of oxidized low density lipoprotein in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482431/),%,85,266358,DB01109,Heparin
,7482431,alpha half-life,Oxidized-LDL tracer particles disappeared from blood with an alpha half-life of 5 minutes and a beta half-life of 7.5 minutes.,The injection of heparin prolongs the plasma clearance of oxidized low density lipoprotein in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482431/),min,5,266359,DB01109,Heparin
,7482431,beta half-life,Oxidized-LDL tracer particles disappeared from blood with an alpha half-life of 5 minutes and a beta half-life of 7.5 minutes.,The injection of heparin prolongs the plasma clearance of oxidized low density lipoprotein in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482431/),min,7.5,266360,DB01109,Heparin
,7482431,alpha half-life,After receptor blocking with unfractionated heparin the alpha half-life of the oxidized-LDL tracer was prolonged to 17.5 minutes and the beta half-life to 27.5 minutes.,The injection of heparin prolongs the plasma clearance of oxidized low density lipoprotein in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482431/),min,17.5,266361,DB01109,Heparin
,7482431,beta half-life,After receptor blocking with unfractionated heparin the alpha half-life of the oxidized-LDL tracer was prolonged to 17.5 minutes and the beta half-life to 27.5 minutes.,The injection of heparin prolongs the plasma clearance of oxidized low density lipoprotein in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482431/),min,27.5,266362,DB01109,Heparin
,10670739,total chromatographic run time,"The total chromatographic run time was 3 min per injection, with retention times of 1.5, 1.9 and 2.4 min for MOR, M6G, and M3G, respectively.","Simultaneous assay of morphine, morphine-3-glucuronide and morphine-6-glucuronide in human plasma using normal-phase liquid chromatography-tandem mass spectrometry with a silica column and an aqueous organic mobile phase. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10670739/),[min] / [injection],3,266721,DB01109,Heparin
,10670739,retention times,"The total chromatographic run time was 3 min per injection, with retention times of 1.5, 1.9 and 2.4 min for MOR, M6G, and M3G, respectively.","Simultaneous assay of morphine, morphine-3-glucuronide and morphine-6-glucuronide in human plasma using normal-phase liquid chromatography-tandem mass spectrometry with a silica column and an aqueous organic mobile phase. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10670739/),min,1.5,266722,DB01109,Heparin
,10670739,retention times,"The total chromatographic run time was 3 min per injection, with retention times of 1.5, 1.9 and 2.4 min for MOR, M6G, and M3G, respectively.","Simultaneous assay of morphine, morphine-3-glucuronide and morphine-6-glucuronide in human plasma using normal-phase liquid chromatography-tandem mass spectrometry with a silica column and an aqueous organic mobile phase. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10670739/),min,1.9,266723,DB01109,Heparin
,10670739,retention times,"The total chromatographic run time was 3 min per injection, with retention times of 1.5, 1.9 and 2.4 min for MOR, M6G, and M3G, respectively.","Simultaneous assay of morphine, morphine-3-glucuronide and morphine-6-glucuronide in human plasma using normal-phase liquid chromatography-tandem mass spectrometry with a silica column and an aqueous organic mobile phase. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10670739/),min,2.4,266724,DB01109,Heparin
,1780093,half-lives,The half-lives of the alpha and beta plasmatic phases were found to be equal at 3.79 and 41.4 min in dialysed subjects and at 1.13 and 16.54 in healthy volunteers.,[Pharmacokinetics of defibrotide in uremic patients undergoing hemodialysis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1780093/),min,3.79,266815,DB01109,Heparin
,1780093,half-lives,The half-lives of the alpha and beta plasmatic phases were found to be equal at 3.79 and 41.4 min in dialysed subjects and at 1.13 and 16.54 in healthy volunteers.,[Pharmacokinetics of defibrotide in uremic patients undergoing hemodialysis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1780093/),min,41.4,266816,DB01109,Heparin
,1780093,half-lives,The half-lives of the alpha and beta plasmatic phases were found to be equal at 3.79 and 41.4 min in dialysed subjects and at 1.13 and 16.54 in healthy volunteers.,[Pharmacokinetics of defibrotide in uremic patients undergoing hemodialysis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1780093/),,1.13,266817,DB01109,Heparin
,1780093,half-lives,The half-lives of the alpha and beta plasmatic phases were found to be equal at 3.79 and 41.4 min in dialysed subjects and at 1.13 and 16.54 in healthy volunteers.,[Pharmacokinetics of defibrotide in uremic patients undergoing hemodialysis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1780093/),min,16.54,266818,DB01109,Heparin
,21784595,overall extraction recovery,The overall extraction recovery of the analyte from the dried blood spots was determined to be about 90%.,Application of automated serial blood sampling and dried blood spot technique with liquid chromatography-tandem mass spectrometry for pharmacokinetic studies in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21784595/),%,90,267195,DB01109,Heparin
,23587152,apparent elimination half-life,"After s.c. injection, the apparent elimination half-life of the dalteparin was about 4 hours, longer than that reported after intravenous (i.v.) injection, indicating a ""flip-flop"" phenomenon.",Low-molecular-weight heparin pharmacokinetics: a dual absorption model approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23587152/),h,4,267272,DB01109,Heparin
,11011804,MW,"The mean MW of these compounds ranges from 3,600 to 6,500 daltons.",Comparative pharmacokinetics of LMWHs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),daltons,"3,600 to 6,500",267803,DB01109,Heparin
,11011804,retention time,"The mean retention time of aXa activity varies from 5.2 (dalteparin) to approximately 7 h (enoxaparin, nadroparin).",Comparative pharmacokinetics of LMWHs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),h,5.2,267804,DB01109,Heparin
,11011804,retention time,"The mean retention time of aXa activity varies from 5.2 (dalteparin) to approximately 7 h (enoxaparin, nadroparin).",Comparative pharmacokinetics of LMWHs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),h,7,267805,DB01109,Heparin
,11011804,Bioavailability,"Bioavailability of prophylactic doses of LMWHs ranges from 86% (dalteparin) to 98% (enoxaparin, nadroparin).",Comparative pharmacokinetics of LMWHs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),%,86,267806,DB01109,Heparin
,11011804,Bioavailability,"Bioavailability of prophylactic doses of LMWHs ranges from 86% (dalteparin) to 98% (enoxaparin, nadroparin).",Comparative pharmacokinetics of LMWHs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),%,98,267807,DB01109,Heparin
,11011804,Clplasma,"The Clplasma is different for each LMWH: 16 mL/min enoxaparin, 21 mL/min nadroparin, 33 mL/min dalteparin, 19 mL/min reviparin, and 22 mL/min tinzaparin.",Comparative pharmacokinetics of LMWHs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),[ml] / [min],16,267808,DB01109,Heparin
,11011804,Clplasma,"The Clplasma is different for each LMWH: 16 mL/min enoxaparin, 21 mL/min nadroparin, 33 mL/min dalteparin, 19 mL/min reviparin, and 22 mL/min tinzaparin.",Comparative pharmacokinetics of LMWHs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),[ml] / [min],21,267809,DB01109,Heparin
,11011804,Clplasma,"The Clplasma is different for each LMWH: 16 mL/min enoxaparin, 21 mL/min nadroparin, 33 mL/min dalteparin, 19 mL/min reviparin, and 22 mL/min tinzaparin.",Comparative pharmacokinetics of LMWHs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),[ml] / [min],33,267810,DB01109,Heparin
,11011804,Clplasma,"The Clplasma is different for each LMWH: 16 mL/min enoxaparin, 21 mL/min nadroparin, 33 mL/min dalteparin, 19 mL/min reviparin, and 22 mL/min tinzaparin.",Comparative pharmacokinetics of LMWHs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),[ml] / [min],19,267811,DB01109,Heparin
,11011804,Clplasma,"The Clplasma is different for each LMWH: 16 mL/min enoxaparin, 21 mL/min nadroparin, 33 mL/min dalteparin, 19 mL/min reviparin, and 22 mL/min tinzaparin.",Comparative pharmacokinetics of LMWHs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),[ml] / [min],22,267812,DB01109,Heparin
,11790706,peak concentration,"A peak concentration of 0.16+/-0.01 IU/mL and an average aPTT of 24 seconds (2-fold increase) were obtained 7 hours after oral dosing of Eudragit RL/PCL NPs containing heparin, exhibiting an absolute bioavailability of 23%.",In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11790706/),[iu] / [ml],0.16,268417,DB01109,Heparin
,11790706,aPTT,"A peak concentration of 0.16+/-0.01 IU/mL and an average aPTT of 24 seconds (2-fold increase) were obtained 7 hours after oral dosing of Eudragit RL/PCL NPs containing heparin, exhibiting an absolute bioavailability of 23%.",In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11790706/),seconds,24,268418,DB01109,Heparin
,11790706,absolute bioavailability,"A peak concentration of 0.16+/-0.01 IU/mL and an average aPTT of 24 seconds (2-fold increase) were obtained 7 hours after oral dosing of Eudragit RL/PCL NPs containing heparin, exhibiting an absolute bioavailability of 23%.",In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11790706/),%,23,268419,DB01109,Heparin
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,96.0,268604,DB01109,Heparin
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,94.9,268605,DB01109,Heparin
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,98.7,268606,DB01109,Heparin
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,9.5,268607,DB01109,Heparin
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,14.0,268608,DB01109,Heparin
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,16.0,268609,DB01109,Heparin
,11307804,BT,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,9.5,268610,DB01109,Heparin
,11307804,BT,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,14.0,268611,DB01109,Heparin
,11307804,BT,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,16.0,268612,DB01109,Heparin
,11307804,inhibition,"At 1 h post-infusion, mean inhibition of PA was 36.2 +/- 39.2, 20.7 +/- 25.9 and 40.7 +/- 36.7% respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,36.2,268613,DB01109,Heparin
,11307804,inhibition,"At 1 h post-infusion, mean inhibition of PA was 36.2 +/- 39.2, 20.7 +/- 25.9 and 40.7 +/- 36.7% respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,20.7,268614,DB01109,Heparin
,11307804,inhibition,"At 1 h post-infusion, mean inhibition of PA was 36.2 +/- 39.2, 20.7 +/- 25.9 and 40.7 +/- 36.7% respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,40.7,268615,DB01109,Heparin
<,11307804,plasma half-life,90% patients had a plasma half-life for AR-C69931XX of <9 min.,"Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,9,268616,DB01109,Heparin
,21950147,maximum serum concentrations,"Mean maximum serum concentrations of 124.5 +/- 34.8 microg/ml and 134.2 +/- 31.1 microg/ml were obtained for the test and reference products, respectively.",Fasted state bioavailability of two delayed release formulations of divalproex sodium in healthy Iranian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950147/),[μg] / [ml],124.5,268996,DB01109,Heparin
,21950147,maximum serum concentrations,"Mean maximum serum concentrations of 124.5 +/- 34.8 microg/ml and 134.2 +/- 31.1 microg/ml were obtained for the test and reference products, respectively.",Fasted state bioavailability of two delayed release formulations of divalproex sodium in healthy Iranian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950147/),[μg] / [ml],134.2,268997,DB01109,Heparin
,21950147,AULo(t),"The AULo(t) and AUCo(infinity) were 2023.8 +/- 578.8 1 microg h/ml and 2705.3 +/- 792.1 microg h/ml for the test and 2068.2 +/- 526.4 microg h/ml and 2729.6 +/- 698.2 microg h/ml for the reference formulation, respectively.",Fasted state bioavailability of two delayed release formulations of divalproex sodium in healthy Iranian volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950147/),[1·h·μg] / [ml],2023.8,268998,DB01109,Heparin
,21950147,AULo(t),"The AULo(t) and AUCo(infinity) were 2023.8 +/- 578.8 1 microg h/ml and 2705.3 +/- 792.1 microg h/ml for the test and 2068.2 +/- 526.4 microg h/ml and 2729.6 +/- 698.2 microg h/ml for the reference formulation, respectively.",Fasted state bioavailability of two delayed release formulations of divalproex sodium in healthy Iranian volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950147/),[h·μg] / [ml],2068.2,268999,DB01109,Heparin
,21950147,AUCo(infinity),"The AULo(t) and AUCo(infinity) were 2023.8 +/- 578.8 1 microg h/ml and 2705.3 +/- 792.1 microg h/ml for the test and 2068.2 +/- 526.4 microg h/ml and 2729.6 +/- 698.2 microg h/ml for the reference formulation, respectively.",Fasted state bioavailability of two delayed release formulations of divalproex sodium in healthy Iranian volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950147/),[h·μg] / [ml],2705.3,269000,DB01109,Heparin
,21950147,AUCo(infinity),"The AULo(t) and AUCo(infinity) were 2023.8 +/- 578.8 1 microg h/ml and 2705.3 +/- 792.1 microg h/ml for the test and 2068.2 +/- 526.4 microg h/ml and 2729.6 +/- 698.2 microg h/ml for the reference formulation, respectively.",Fasted state bioavailability of two delayed release formulations of divalproex sodium in healthy Iranian volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950147/),[h·μg] / [ml],2729.6,269001,DB01109,Heparin
,11254202,flow-rate,An aliquot of 25 microl of the mixture was injected onto a BDS Hypersil C18 column (50x2 mm; 3 microm) at a flow-rate of 0.3 ml/min.,Quantitation of itraconazole in rat heparinized plasma by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11254202/),[ml] / [min],0.3,269294,DB01109,Heparin
,11254202,extraction recovery,The extraction recovery of ITZ was 96%.,Quantitation of itraconazole in rat heparinized plasma by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11254202/),%,96,269295,DB01109,Heparin
,11716391,half-life,It has a half-life of approximately 4.5 hours providing effective dosing every 12 to 24 hours with rapid antithrombotic action.,Low molecular weight heparin prophylaxis in total knee arthroplasty: the answer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11716391/),h,4.5,269308,DB01109,Heparin
,15995464,peak anti-Xa activity,Mean peak anti-Xa activity was 0.19 +/- 0.09 International Units/mL and mean trough was 0.044 +/- 0.04 International Units/mL.,Optimal dose of enoxaparin in critically ill trauma and surgical patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15995464/),[international·units] / [ml],0.19,269411,DB01109,Heparin
,15995464,trough,Mean peak anti-Xa activity was 0.19 +/- 0.09 International Units/mL and mean trough was 0.044 +/- 0.04 International Units/mL.,Optimal dose of enoxaparin in critically ill trauma and surgical patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15995464/),[international·units] / [ml],0.044,269412,DB01109,Heparin
,8701403,half-life,"A drawback in the use of rFVIIa has been its half-life of only about 2 h, which necessitates very frequent and punctual injections.",Feasibility of using recombinant factor VIIa in continuous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701403/),h,2,270452,DB01109,Heparin
,8701403,clearance,The second patient had a progressive decrease of the clearance from 86.4 to 24.7 ml/h/kg.,Feasibility of using recombinant factor VIIa in continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701403/),[ml] / [h·kg],86.4,270453,DB01109,Heparin
,8701403,clearance,The second patient had a progressive decrease of the clearance from 86.4 to 24.7 ml/h/kg.,Feasibility of using recombinant factor VIIa in continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701403/),[ml] / [h·kg],24.7,270454,DB01109,Heparin
,34311154,clearance,The covariate analysis showed that enoxaparin clearance (typical value 1.1 L.h-1) was related to renal function estimated by the CKD-EPI formula and volume of distribution (typical value 17.9 L) to actual body weight.,Pharmacokinetics of enoxaparin in COVID-19 critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34311154/),[l] / [h],1.1,270534,DB01109,Heparin
,34311154,volume of distribution,The covariate analysis showed that enoxaparin clearance (typical value 1.1 L.h-1) was related to renal function estimated by the CKD-EPI formula and volume of distribution (typical value 17.9 L) to actual body weight.,Pharmacokinetics of enoxaparin in COVID-19 critically ill patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34311154/),l,17.9,270535,DB01109,Heparin
,34311154,peak levels,Simulation of anti-Xa activities with enoxaparin 40 mg qd indicated that 64% of the patients had peak levels within the range 0.2 to 0.5 IU.,Pharmacokinetics of enoxaparin in COVID-19 critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34311154/),iu,0.2 to 0.5,270536,DB01109,Heparin
,7586247,maximal peak activity,The maximal peak activity for aPTT ratio was 1.7.,Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586247/),,1.7,271172,DB01109,Heparin
longer,7586247,Disappearance time,Disappearance time of these activities after the highest dose of both LMWHs was longer than 16 hours.,Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586247/),h,16,271173,DB01109,Heparin
,7586247,activity half-life,Overall mean antifactor Xa activity half-life was 4.6 hours.,Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586247/),h,4.6,271174,DB01109,Heparin
,10215964,plasma levels,FVIIa plasma levels during continuous infusion ranged between 6.3 and 10.4 IU mL(-1).,Postoperative use of rFVIIa by continuous infusion in a haemophilic boy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10215964/),[iu] / [ml],6.3 and 10.4,272420,DB01109,Heparin
,2015807,peak-trough difference,The peak-trough difference amounted to about 50 per cent.,"Low dose calcium heparin in horses: plasma heparin concentrations, effects on red blood cell mass and on coagulation variables. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015807/),%,50,273018,DB01109,Heparin
,8245692,Urinary excretion,Urinary excretion of the lipophilic tracer among the rats in this competition experiment was considerably lower (13.7%) as compared with conventional LMWH (53.0%).,Altered pharmacokinetic properties of a lipophilically derivatized low-molecular-weight heparin in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8245692/),%,13.7,273301,DB01109,Heparin
,8245692,Urinary excretion,Urinary excretion of the lipophilic tracer among the rats in this competition experiment was considerably lower (13.7%) as compared with conventional LMWH (53.0%).,Altered pharmacokinetic properties of a lipophilically derivatized low-molecular-weight heparin in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8245692/),%,53.0,273302,DB01109,Heparin
